

[0826] Additional disorders that are likely to have an autoimmune component that may be treated, prevented, and/or diagnosed with the compositions of the invention include, but are not limited to, type II collagen-induced arthritis, antiphospholipid syndrome, dermatitis, allergic encephalomyelitis, myocarditis, relapsing polychondritis, rheumatic heart disease, neuritis, uveitis ophthalmia, polyendocrinopathies, Reiter's Disease, Stiff-Man Syndrome, autoimmune pulmonary inflammation, autism, Guillain-Barre Syndrome, insulin dependent diabetes mellitus, and autoimmune inflammatory eye disorders.

[0827] Additional disorders that are likely to have an autoimmune component that may be treated, prevented, diagnosed and/or prognosed with the compositions of the invention include, but are not limited to, scleroderma with anti-collagen antibodies (often characterized, e.g., by nucleolar and other nuclear antibodies), mixed connective tissue disease (often characterized, e.g., by antibodies to extractable nuclear antigens (e.g., ribonucleoprotein)), polymyositis (often characterized, e.g., by nonhistone ANA), pernicious anemia (often characterized, e.g., by antiparietal cell, microsomes, and intrinsic factor antibodies), idiopathic Addison's disease (often characterized, e.g., by humoral and cell-mediated adrenal cytotoxicity, infertility (often characterized, e.g., by antispermatozoal antibodies), glomerulonephritis (often characterized, e.g., by glomerular basement membrane antibodies or immune complexes), bullous pemphigoid (often characterized, e.g., by IgG and complement in basement membrane), Sjogren's syndrome (often characterized, e.g., by multiple tissue antibodies, and/or a specific nonhistone ANA (SS-B)), diabetes mellitus (often characterized, e.g., by cell-mediated and humoral islet cell antibodies), and adrenergic drug resistance (including adrenergic drug resistance with asthma or cystic fibrosis) (often characterized, e.g., by beta-adrenergic receptor antibodies).

[0828] Additional disorders that may have an autoimmune component that may be treated, prevented, diagnosed and/or prognosed with the compositions of the invention include, but are not limited to, chronic active hepatitis (often characterized, e.g., by smooth muscle antibodies), primary biliary cirrhosis (often characterized, e.g., by mitochondria antibodies), other endocrine gland failure (often characterized, e.g., by specific tissue antibodies in some cases), vitiligo (often characterized, e.g., by melanocyte antibodies), vasculitis (often characterized, e.g., by Ig and complement in vessel walls and/or low serum complement), post-MI (often characterized, e.g., by myocardial

antibodies), cardiomy syndrome (often characterized, e.g., by myocardial antibodies), urticaria (often characterized, e.g., by IgG and IgM antibodies to IgE), atopic dermatitis (often characterized, e.g., by IgG and IgM antibodies to IgE), asthma (often characterized, e.g., by IgG and IgM antibodies to IgE), and many other inflammatory, granulomatous, degenerative, and atrophic disorders.

[0829] In a preferred embodiment, the autoimmune diseases and disorders and/or conditions associated with the diseases and disorders recited above are treated, prevented, diagnosed and/or prognosed using for example, antagonists or agonists, polypeptides or polynucleotides, or antibodies of the present invention. In a specific preferred embodiment, rheumatoid arthritis is treated, prevented, and/or diagnosed using polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention.

[0830] In another specific preferred embodiment, systemic lupus erythematosus is treated, prevented, and/or diagnosed using polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention. In another specific preferred embodiment, idiopathic thrombocytopenia purpura is treated, prevented, and/or diagnosed using polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention.

[0831] In another specific preferred embodiment IgA nephropathy is treated, prevented, and/or diagnosed using polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention.

[0832] In a preferred embodiment, the autoimmune diseases and disorders and/or conditions associated with the diseases and disorders recited above are treated, prevented, diagnosed and/or prognosed using polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention

[0833] In preferred embodiments, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as a immunosuppressive agent(s).

[0834] Polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in treating, preventing, prognosing, and/or diagnosing diseases, disorders, and/or conditions of hematopoietic cells. Polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention could be used to increase differentiation and proliferation of hematopoietic cells, including the

pluripotent stem cells, in an effort to treat or prevent those diseases, disorders, and/or conditions associated with a decrease in certain (or many) types hematopoietic cells, including but not limited to, leukopenia, neutropenia, anemia, and thrombocytopenia. Alternatively, Polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention could be used to increase differentiation and proliferation of hematopoietic cells, including the pluripotent stem cells, in an effort to treat or prevent those diseases, disorders, and/or conditions associated with an increase in certain (or many) types of hematopoietic cells, including but not limited to, histiocytosis.

[0835] Allergic reactions and conditions, such as asthma (particularly allergic asthma) or other respiratory problems, may also be treated, prevented, diagnosed and/or prognosed using polypeptides, antibodies, or polynucleotides of the invention, and/or agonists or antagonists thereof. Moreover, these molecules can be used to treat, prevent, prognose, and/or diagnose anaphylaxis, hypersensitivity to an antigenic molecule, or blood group incompatibility.

[0836] Additionally, polypeptides or polynucleotides of the invention, and/or agonists or antagonists thereof, may be used to treat, prevent, diagnose and/or prognose IgE-mediated allergic reactions. Such allergic reactions include, but are not limited to, asthma, rhinitis, and eczema. In specific embodiments, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be used to modulate IgE concentrations in vitro or in vivo.

[0837] Moreover, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention have uses in the diagnosis, prognosis, prevention, and/or treatment of inflammatory conditions. For example, since polypeptides, antibodies, or polynucleotides of the invention, and/or agonists or antagonists of the invention may inhibit the activation, proliferation and/or differentiation of cells involved in an inflammatory response, these molecules can be used to prevent and/or treat chronic and acute inflammatory conditions. Such inflammatory conditions include, but are not limited to, for example, inflammation associated with infection (e.g., septic shock, sepsis, or systemic inflammatory response syndrome), ischemia-reperfusion injury, endotoxin lethality, complement-mediated hyperacute rejection, nephritis, cytokine or chemokine induced lung injury, inflammatory bowel disease, Crohn's disease, over production of cytokines (e.g., TNF or IL-1.), respiratory disorders (e.g., asthma and allergy);

gastrointestinal disorders (e.g., inflammatory bowel disease); cancers (e.g., gastric, ovarian, lung, bladder, liver, and breast); CNS disorders (e.g., multiple sclerosis; ischemic brain injury and/or stroke, traumatic brain injury, neurodegenerative disorders (e.g., Parkinson's disease and Alzheimer's disease); AIDS-related dementia; and prion disease); cardiovascular disorders (e.g., atherosclerosis, myocarditis, cardiovascular disease, and cardiopulmonary bypass complications); as well as many additional diseases, conditions, and disorders that are characterized by inflammation (e.g., hepatitis, rheumatoid arthritis, gout, trauma, pancreatitis, sarcoidosis, dermatitis, renal ischemia-reperfusion injury, Grave's disease, systemic lupus erythematosus, diabetes mellitus, and allogenic transplant rejection).

[0838] Because inflammation is a fundamental defense mechanism, inflammatory disorders can effect virtually any tissue of the body. Accordingly, polynucleotides, polypeptides, and antibodies of the invention, as well as agonists or antagonists thereof, have uses in the treatment of tissue-specific inflammatory disorders, including, but not limited to, adenitis, alveolitis, angiocholecystitis, appendicitis, balanitis, blepharitis, bronchitis, bursitis, carditis, cellulitis, cervicitis, cholecystitis, chondritis, cochitis, colitis, conjunctivitis, cystitis, dermatitis, diverticulitis, encephalitis, endocarditis, esophagitis, eustachitis, fibrositis, folliculitis, gastritis, gastroenteritis, gingivitis, glossitis, hepatosplenitis, keratitis, labyrinthitis, laryngitis, lymphangitis, mastitis, media otitis, meningitis, metritis, mucitis, myocarditis, myositis, myringitis, nephritis, neuritis, orchitis, osteochondritis, otitis, pericarditis, peritendonitis, peritonitis, pharyngitis, phlebitis, poliomyelitis, prostatitis, pulpitis, retinitis, rhinitis, salpingitis, scleritis, sclerochoroiditis, scrotitis, sinusitis, spondylitis, steatitis, stomatitis, synovitis, syringitis, tendonitis, tonsillitis, urethritis, and vaginitis.

[0839] In specific embodiments, polypeptides, antibodies, or polynucleotides of the invention, and/or agonists or antagonists thereof, are useful to diagnose, prognose, prevent, and/or treat organ transplant rejections and graft-versus-host disease. Organ rejection occurs by host immune cell destruction of the transplanted tissue through an immune response. Similarly, an immune response is also involved in GVHD, but, in this case, the foreign transplanted immune cells destroy the host tissues. Polypeptides, antibodies, or polynucleotides of the invention, and/or agonists or antagonists thereof, that inhibit an immune response, particularly the activation, proliferation, differentiation, or

chemotaxis of T-cells, may be an effective therapy in preventing organ rejection or GVHD. In specific embodiments, polypeptides, antibodies, or polynucleotides of the invention, and/or agonists or antagonists thereof, that inhibit an immune response, particularly the activation, proliferation, differentiation, or chemotaxis of T-cells, may be an effective therapy in preventing experimental allergic and hyperacute xenograft rejection.

[0840] In other embodiments, polypeptides, antibodies, or polynucleotides of the invention, and/or agonists or antagonists thereof, are useful to diagnose, prognose, prevent, and/or treat immune complex diseases, including, but not limited to, serum sickness, post streptococcal glomerulonephritis, polyarteritis nodosa, and immune complex-induced vasculitis.

[0841] Polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the invention can be used to treat, detect, and/or prevent infectious agents. For example, by increasing the immune response, particularly increasing the proliferation activation and/or differentiation of B and/or T cells, infectious diseases may be treated, detected, and/or prevented. The immune response may be increased by either enhancing an existing immune response, or by initiating a new immune response. Alternatively, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may also directly inhibit the infectious agent (refer to section of application listing infectious agents, etc), without necessarily eliciting an immune response.

[0842] In another embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as a vaccine adjuvant that enhances immune responsiveness to an antigen. In a specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as an adjuvant to enhance tumor-specific immune responses.

[0843] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as an adjuvant to enhance anti-viral immune responses. Anti-viral immune responses that may be enhanced using the compositions of the invention as an adjuvant, include virus and virus associated diseases or symptoms described herein or otherwise known in the art. In specific embodiments, the compositions of the invention are used as an adjuvant to enhance an immune response to a virus, disease, or symptom selected from the group consisting of:

AIDS, meningitis, Dengue, EBV, and hepatitis (e.g., hepatitis B). In another specific embodiment, the compositions of the invention are used as an adjuvant to enhance an immune response to a virus, disease, or symptom selected from the group consisting of: HIV/AIDS, respiratory syncytial virus, Dengue, rotavirus, Japanese B encephalitis, influenza A and B, parainfluenza, measles, cytomegalovirus, rabies, Junin, Chikungunya, Rift Valley Fever, herpes simplex, and yellow fever.

[0844] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as an adjuvant to enhance anti-bacterial or anti-fungal immune responses. Anti-bacterial or anti-fungal immune responses that may be enhanced using the compositions of the invention as an adjuvant, include bacteria or fungus and bacteria or fungus associated diseases or symptoms described herein or otherwise known in the art. In specific embodiments, the compositions of the invention are used as an adjuvant to enhance an immune response to a bacteria or fungus, disease, or symptom selected from the group consisting of: tetanus, Diphtheria, botulism, and meningitis type B.

[0845] In another specific embodiment, the compositions of the invention are used as an adjuvant to enhance an immune response to a bacteria or fungus, disease, or symptom selected from the group consisting of: *Vibrio cholerae*, *Mycobacterium leprae*, *Salmonella typhi*, *Salmonella paratyphi*, *Meissneria meningitidis*, *Streptococcus pneumoniae*, Group B streptococcus, *Shigella spp.*, Enterotoxigenic *Escherichia coli*, Enterohemorrhagic *E. coli*, and *Borrelia burgdorferi*.

[0846] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as an adjuvant to enhance anti-parasitic immune responses. Anti-parasitic immune responses that may be enhanced using the compositions of the invention as an adjuvant, include parasite and parasite associated diseases or symptoms described herein or otherwise known in the art. In specific embodiments, the compositions of the invention are used as an adjuvant to enhance an immune response to a parasite. In another specific embodiment, the compositions of the invention are used as an adjuvant to enhance an immune response to Plasmodium (malaria) or Leishmania.

[0847] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention may also be employed to treat

infectious diseases including silicosis, sarcoidosis, and idiopathic pulmonary fibrosis; for example, by preventing the recruitment and activation of mononuclear phagocytes.

[0848] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as an antigen for the generation of antibodies to inhibit or enhance immune mediated responses against polypeptides of the invention.

[0849] In one embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are administered to an animal (e.g., mouse, rat, rabbit, hamster, guinea pig, pigs, micro-pig, chicken, camel, goat, horse, cow, sheep, dog, cat, non-human primate, and human, most preferably human) to boost the immune system to produce increased quantities of one or more antibodies (e.g., IgG, IgA, IgM, and IgE), to induce higher affinity antibody production and immunoglobulin class switching (e.g., IgG, IgA, IgM, and IgE), and/or to increase an immune response.

[0850] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as a stimulator of B cell responsiveness to pathogens.

[0851] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as an activator of T cells.

[0852] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as an agent that elevates the immune status of an individual prior to their receipt of immunosuppressive therapies.

[0853] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as an agent to induce higher affinity antibodies.

[0854] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as an agent to increase serum immunoglobulin concentrations.

[0855] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as an agent to accelerate recovery of immunocompromised individuals.

[0856] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as an agent to boost immunoresponsiveness among aged populations and/or neonates.

[0857] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as an immune system enhancer prior to, during, or after bone marrow transplant and/or other transplants (e.g., allogeneic or xenogeneic organ transplantation). With respect to transplantation, compositions of the invention may be administered prior to, concomitant with, and/or after transplantation. In a specific embodiment, compositions of the invention are administered after transplantation, prior to the beginning of recovery of T-cell populations. In another specific embodiment, compositions of the invention are first administered after transplantation after the beginning of recovery of T cell populations, but prior to full recovery of B cell populations.

[0858] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as an agent to boost immunoresponsiveness among individuals having an acquired loss of B cell function. Conditions resulting in an acquired loss of B cell function that may be ameliorated or treated by administering the polypeptides, antibodies, polynucleotides and/or agonists or antagonists thereof, include, but are not limited to, HIV Infection, AIDS, bone marrow transplant, and B cell chronic lymphocytic leukemia (CLL).

[0859] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as an agent to boost immunoresponsiveness among individuals having a temporary immune deficiency. Conditions resulting in a temporary immune deficiency that may be ameliorated or treated by administering the polypeptides, antibodies, polynucleotides and/or agonists or antagonists thereof, include, but are not limited to, recovery from viral infections (e.g., influenza), conditions associated with malnutrition, recovery from infectious mononucleosis, or conditions associated with stress, recovery from measles, recovery from blood transfusion, and recovery from surgery.

[0860] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as a regulator of antigen presentation by monocytes, dendritic cells, and/or B-cells. In one embodiment,

polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention enhance antigen presentation or antagonizes antigen presentation in vitro or in vivo. Moreover, in related embodiments, said enhancement or antagonism of antigen presentation may be useful as an anti-tumor treatment or to modulate the immune system.

[0861] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as an agent to direct an individual's immune system towards development of a humoral response (i.e. TH2) as opposed to a TH1 cellular response.

[0862] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as a means to induce tumor proliferation and thus make it more susceptible to anti-neoplastic agents. For example, multiple myeloma is a slowly dividing disease and is thus refractory to virtually all anti-neoplastic regimens. If these cells were forced to proliferate more rapidly their susceptibility profile would likely change.

[0863] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as a stimulator of B cell production in pathologies such as AIDS, chronic lymphocyte disorder and/or Common Variable Immunodeficiency.

[0864] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as a therapy for generation and/or regeneration of lymphoid tissues following surgery, trauma or genetic defect. In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used in the pretreatment of bone marrow samples prior to transplant.

[0865] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as a gene-based therapy for genetically inherited disorders resulting in immuno-incompetence/immunodeficiency such as observed among SCID patients.

[0866] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as a means of activating monocytes/macrophages to defend against parasitic diseases that effect monocytes such as Leishmania.

[0867] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as a means of regulating secreted cytokines that are elicited by polypeptides of the invention.

[0868] In another embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used in one or more of the applications described herein, as they may apply to veterinary medicine.

[0869] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as a means of blocking various aspects of immune responses to foreign agents or self. Examples of diseases or conditions in which blocking of certain aspects of immune responses may be desired include autoimmune disorders such as lupus, and arthritis, as well as immunoresponsiveness to skin allergies, inflammation, bowel disease, injury and diseases/disorders associated with pathogens.

[0870] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as a therapy for preventing the B cell proliferation and Ig secretion associated with autoimmune diseases such as idiopathic thrombocytopenic purpura, systemic lupus erythematosus and multiple sclerosis.

[0871] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as a inhibitor of B and/or T cell migration in endothelial cells. This activity disrupts tissue architecture or cognate responses and is useful, for example in disrupting immune responses, and blocking sepsis.

[0872] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as a therapy for chronic hypergammaglobulinemia evident in such diseases as monoclonal gammopathy of undetermined significance (MGUS), Waldenstrom's disease, related idiopathic monoclonal gammopathies, and plasmacytomas.

[0873] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention may be employed for instance to inhibit polypeptide chemotaxis and activation of macrophages and their precursors, and of neutrophils, basophils, B lymphocytes and some T-cell subsets, e.g., activated and CD8 cytotoxic T cells and natural killer cells, in certain autoimmune and chronic inflammatory

and infective diseases. Examples of autoimmune diseases are described herein and include multiple sclerosis, and insulin-dependent diabetes.

[0874] The polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention may also be employed to treat idiopathic hyper-eosinophilic syndrome by, for example, preventing eosinophil production and migration.

[0875] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used to enhance or inhibit complement mediated cell lysis.

[0876] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used to enhance or inhibit antibody dependent cellular cytotoxicity.

[0877] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention may also be employed for treating atherosclerosis, for example, by preventing monocyte infiltration in the artery wall.

[0878] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention may be employed to treat adult respiratory distress syndrome (ARDS).

[0879] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention may be useful for stimulating wound and tissue repair, stimulating angiogenesis, and/or stimulating the repair of vascular or lymphatic diseases or disorders. Additionally, agonists and antagonists of the invention may be used to stimulate the regeneration of mucosal surfaces.

[0880] In a specific embodiment, polynucleotides or polypeptides, and/or agonists thereof are used to diagnose, prognose, treat, and/or prevent a disorder characterized by primary or acquired immunodeficiency, deficient serum immunoglobulin production, recurrent infections, and/or immune system dysfunction. Moreover, polynucleotides or polypeptides, and/or agonists thereof may be used to treat or prevent infections of the joints, bones, skin, and/or parotid glands, blood-borne infections (e.g., sepsis, meningitis, septic arthritis, and/or osteomyelitis), autoimmune diseases (e.g., those disclosed herein), inflammatory disorders, and malignancies, and/or any disease or disorder or condition associated with these infections, diseases, disorders and/or malignancies) including, but not limited to, CVID, other primary immune deficiencies, HIV disease, CLL, recurrent

bronchitis, sinusitis, otitis media, conjunctivitis, pneumonia, hepatitis, meningitis, herpes zoster (e.g., severe herpes zoster), and/or pneumocystis carinii. Other diseases and disorders that may be prevented, diagnosed, prognosed, and/or treated with polynucleotides or polypeptides, and/or agonists of the present invention include, but are not limited to, HIV infection, HTLV-BLV infection, lymphopenia, phagocyte bactericidal dysfunction anemia, thrombocytopenia, and hemoglobinuria.

[0881] In another embodiment, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention are used to treat, and/or diagnose an individual having common variable immunodeficiency disease ("CVID"; also known as "acquired agammaglobulinemia" and "acquired hypogammaglobulinemia") or a subset of this disease.

[0882] In a specific embodiment, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be used to diagnose, prognose, prevent, and/or treat cancers or neoplasms including immune cell or immune tissue-related cancers or neoplasms. Examples of cancers or neoplasms that may be prevented, diagnosed, or treated by polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention include, but are not limited to, acute myelogenous leukemia, chronic myelogenous leukemia, Hodgkin's disease, non-Hodgkin's lymphoma, acute lymphocytic anemia (ALL) Chronic lymphocyte leukemia, plasmacytomas, multiple myeloma, Burkitt's lymphoma, EBV-transformed diseases, and/or diseases and disorders described in the section entitled "Hyperproliferative Disorders" elsewhere herein.

[0883] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as a therapy for decreasing cellular proliferation of Large B-cell Lymphomas.

[0884] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as a means of decreasing the involvement of B cells and Ig associated with Chronic Myelogenous Leukemia.

[0885] In specific embodiments, the compositions of the invention are used as an agent to boost immunoresponsiveness among B cell immunodeficient individuals, such as, for example, an individual who has undergone a partial or complete splenectomy.

[0886] Antagonists of the invention include, for example, binding and/or inhibitory antibodies, antisense nucleic acids, ribozymes or soluble forms of the polypeptides of the

present invention (e.g., Fc fusion protein; see, e.g., Example 9). Agonists of the invention include, for example, binding or stimulatory antibodies, and soluble forms of the polypeptides (e.g., Fc fusion proteins; see, e.g., Example 9). polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention may be employed in a composition with a pharmaceutically acceptable carrier, e.g., as described herein.

[0887] In another embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are administered to an animal (including, but not limited to, those listed above, and also including transgenic animals) incapable of producing functional endogenous antibody molecules or having an otherwise compromised endogenous immune system, but which is capable of producing human immunoglobulin molecules by means of a reconstituted or partially reconstituted immune system from another animal (see, e.g., published PCT Application Nos. WO98/24893, WO/9634096, WO/9633735, and WO/9110741). Administration of polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention to such animals is useful for the generation of monoclonal antibodies against the polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention.

Blood-Related Disorders

[0888] The polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be used to modulate hemostatic (the stopping of bleeding) or thrombolytic (clot dissolving) activity. For example, by increasing hemostatic or thrombolytic activity, polynucleotides or polypeptides, and/or agonists or antagonists of the present invention could be used to treat or prevent blood coagulation diseases, disorders, and/or conditions (e.g., afibrinogenemia, factor deficiencies, hemophilia), blood platelet diseases, disorders, and/or conditions (e.g., thrombocytopenia), or wounds resulting from trauma, surgery, or other causes. Alternatively, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention that can decrease hemostatic or thrombolytic activity could be used to inhibit or dissolve clotting. These molecules could be important in the treatment or prevention of heart attacks (infarction), strokes, or scarring.

[0889] In specific embodiments, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be used to prevent, diagnose, prognose, and/or treat thrombosis, arterial thrombosis, venous thrombosis, thromboembolism, pulmonary embolism, atherosclerosis, myocardial infarction, transient ischemic attack, unstable angina. In specific embodiments, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be used for the prevention of occlusion of saphenous grafts, for reducing the risk of periprocedural thrombosis as might accompany angioplasty procedures, for reducing the risk of stroke in patients with atrial fibrillation including nonrheumatic atrial fibrillation, for reducing the risk of embolism associated with mechanical heart valves and or mitral valves disease. Other uses for the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention, include, but are not limited to, the prevention of occlusions in extracorporeal devices (e.g., intravascular canulas, vascular access shunts in hemodialysis patients, hemodialysis machines, and cardiopulmonary bypass machines).

[0890] In another embodiment, a polypeptide of the invention, or polynucleotides, antibodies, agonists, or antagonists corresponding to that polypeptide, may be used to prevent, diagnose, prognose, and/or treat diseases and disorders of the blood and/or blood forming organs associated with the tissue(s) in which the polypeptide of the invention is expressed, including one, two, three, four, five, or more tissues disclosed in Table 3, column 2 (Library Code).

[0891] The polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be used to modulate hematopoietic activity (the formation of blood cells). For example, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be used to increase the quantity of all or subsets of blood cells, such as, for example, erythrocytes, lymphocytes (B or T cells), myeloid cells (e.g., basophils, eosinophils, neutrophils, mast cells, macrophages) and platelets. The ability to decrease the quantity of blood cells or subsets of blood cells may be useful in the prevention, detection, diagnosis and/or treatment of anemias and leukopenias described below. Alternatively, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be used to decrease the quantity of all or subsets of blood cells, such as, for example, erythrocytes, lymphocytes

(B or T cells), myeloid cells (e.g., basophils, eosinophils, neutrophils, mast cells, macrophages) and platelets. The ability to decrease the quantity of blood cells or subsets of blood cells may be useful in the prevention, detection, diagnosis and/or treatment of leukocytoses, such as, for example eosinophilia.

[0892] The polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be used to prevent, treat, or diagnose blood dyscrasia.

[0893] Anemias are conditions in which the number of red blood cells or amount of hemoglobin (the protein that carries oxygen) in them is below normal. Anemia may be caused by excessive bleeding, decreased red blood cell production, or increased red blood cell destruction (hemolysis). The polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in treating, preventing, and/or diagnosing anemias. Anemias that may be treated prevented or diagnosed by the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention include iron deficiency anemia, hypochromic anemia, microcytic anemia, chlorosis, hereditary sideroblastic anemia, idiopathic acquired sideroblastic anemia, red cell aplasia, megaloblastic anemia (e.g., pernicious anemia, (vitamin B12 deficiency) and folic acid deficiency anemia), aplastic anemia, hemolytic anemias (e.g., autoimmune hemolytic anemia, microangiopathic hemolytic anemia, and paroxysmal nocturnal hemoglobinuria). The polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in treating, preventing, and/or diagnosing anemias associated with diseases including but not limited to, anemias associated with systemic lupus erythematosus, cancers, lymphomas, chronic renal disease, and enlarged spleens. The polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in treating, preventing, and/or diagnosing anemias arising from drug treatments such as anemias associated with methyl dopa, dapsone, and/or sulfadugs. Additionally, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in treating, preventing, and/or diagnosing anemias associated with abnormal red blood cell architecture including but not limited to, hereditary spherocytosis, hereditary elliptocytosis, glucose-6-phosphate dehydrogenase deficiency, and sickle cell anemia.

[0894] The polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in treating, preventing, and/or diagnosing hemoglobin

abnormalities, (e.g., those associated with sickle cell anemia, hemoglobin C disease, hemoglobin S-C disease, and hemoglobin E disease). Additionally, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in diagnosing, prognosing, preventing, and/or treating thalassemias, including, but not limited to major and minor forms of alpha-thalassemia and beta-thalassemia.

[0895] In another embodiment, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in diagnosing, prognosing, preventing, and/or treating bleeding disorders including, but not limited to, thrombocytopenia (e.g., idiopathic thrombocytopenic purpura, and thrombotic thrombocytopenic purpura), Von Willebrand's disease, hereditary platelet disorders (e.g., storage pool disease such as Chediak-Higashi and Hermansky-Pudlak syndromes, thromboxane A₂ dysfunction, thromboasthenia, and Bernard-Soulier syndrome), hemolytic-uremic syndrome, hemophelias such as hemophilia A or Factor VII deficiency and Christmas disease or Factor IX deficiency, Hereditary Hemorrhagic Telangiectasia, also known as Rendu-Osler-Weber syndrome, allergic purpura (Henoch Schonlein purpura) and disseminated intravascular coagulation.

[0896] The effect of the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention on the clotting time of blood may be monitored using any of the clotting tests known in the art including, but not limited to, whole blood partial thromboplastin time (PTT), the activated partial thromboplastin time (aPTT), the activated clotting time (ACT), the recalcified activated clotting time, or the Lee-White Clotting time.

[0897] Several diseases and a variety of drugs can cause platelet dysfunction. Thus, in a specific embodiment, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in diagnosing, prognosing, preventing, and/or treating acquired platelet dysfunction such as platelet dysfunction accompanying kidney failure, leukemia, multiple myeloma, cirrhosis of the liver, and systemic lupus erythematosus as well as platelet dysfunction associated with drug treatments, including treatment with aspirin, ticlopidine, nonsteroidal anti-inflammatory drugs (used for arthritis, pain, and sprains), and penicillin in high doses.

[0898] In another embodiment, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in diagnosing, prognosing,

preventing, and/or treating diseases and disorders characterized by or associated with increased or decreased numbers of white blood cells. Leukopenia occurs when the number of white blood cells decreases below normal. Leukopenias include, but are not limited to, neutropenia and lymphocytopenia. An increase in the number of white blood cells compared to normal is known as leukocytosis. The body generates increased numbers of white blood cells during infection. Thus, leukocytosis may simply be a normal physiological parameter that reflects infection. Alternatively, leukocytosis may be an indicator of injury or other disease such as cancer. Leukocytoses, include but are not limited to, eosinophilia, and accumulations of macrophages. In specific embodiments, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in diagnosing, prognosing, preventing, and/or treating leukopenia. In other specific embodiments, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in diagnosing, prognosing, preventing, and/or treating leukocytosis.

[0899] Leukopenia may be a generalized decreased in all types of white blood cells, or may be a specific depletion of particular types of white blood cells. Thus, in specific embodiments, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in diagnosing, prognosing, preventing, and/or treating decreases in neutrophil numbers, known as neutropenia. Neutropenias that may be diagnosed, prognosed, prevented, and/or treated by the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention include, but are not limited to, infantile genetic agranulocytosis, familial neutropenia, cyclic neutropenia, neutropenias resulting from or associated with dietary deficiencies (e.g., vitamin B 12 deficiency or folic acid deficiency), neutropenias resulting from or associated with drug treatments (e.g., antibiotic regimens such as penicillin treatment, sulfonamide treatment, anticoagulant treatment, anticonvulsant drugs, anti-thyroid drugs, and cancer chemotherapy), and neutropenias resulting from increased neutrophil destruction that may occur in association with some bacterial or viral infections, allergic disorders, autoimmune diseases, conditions in which an individual has an enlarged spleen (e.g., Felty syndrome, malaria and sarcoidosis), and some drug treatment regimens.

[0900] The polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in diagnosing, prognosing, preventing, and/or treating

lymphocytopenias (decreased numbers of B and/or T lymphocytes), including, but not limited lymphocytopenias resulting from or associated with stress, drug treatments (e.g., drug treatment with corticosteroids, cancer chemotherapies, and/or radiation therapies), AIDS infection and/or other diseases such as, for example, cancer, rheumatoid arthritis, systemic lupus erythematosus, chronic infections, some viral infections and/or hereditary disorders (e.g., DiGeorge syndrome, Wiskott-Aldrich Syndrome, severe combined immunodeficiency, ataxia telangiectasia).

[0901] The polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in diagnosing, prognosing, preventing, and/or treating diseases and disorders associated with macrophage numbers and/or macrophage function including, but not limited to, Gaucher's disease, Niemann-Pick disease, Letterer-Siwe disease and Hand-Schuller-Christian disease.

[0902] In another embodiment, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in diagnosing, prognosing, preventing, and/or treating diseases and disorders associated with eosinophil numbers and/or eosinophil function including, but not limited to, idiopathic hypereosinophilic syndrome, eosinophilia-myalgia syndrome, and Hand-Schuller-Christian disease.

[0903] In yet another embodiment, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in diagnosing, prognosing, preventing, and/or treating leukemias and lymphomas including, but not limited to, acute lymphocytic (lymphoblastic) leukemia (ALL), acute myeloid (myelocytic, myelogenous, myeloblastic, or myelomonocytic) leukemia, chronic lymphocytic leukemia (e.g., B cell leukemias, T cell leukemias, Sezary syndrome, and Hairy cell leukemia), chronic myelocytic (myeloid, myelogenous, or granulocytic) leukemia, Hodgkin's lymphoma, non-hodgkin's lymphoma, Burkitt's lymphoma, and mycosis fungoides.

[0904] In other embodiments, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in diagnosing, prognosing, preventing, and/or treating diseases and disorders of plasma cells including, but not limited to, plasma cell dyscrasias, monoclonal gammaopathies, monoclonal gammopathies of undetermined significance, multiple myeloma, macroglobulinemia, Waldenstrom's macroglobulinemia, cryoglobulinemia, and Raynaud's phenomenon.

[0905] In other embodiments, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in treating, preventing, and/or diagnosing myeloproliferative disorders, including but not limited to, polycythemia vera, relative polycythemia, secondary polycythemia, myelofibrosis, acute myelofibrosis, agnogenic myeloid metaplasia, thrombocythemia, (including both primary and secondary thrombocythemia) and chronic myelocytic leukemia.

[0906] In other embodiments, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful as a treatment prior to surgery, to increase blood cell production.

[0907] In other embodiments, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful as an agent to enhance the migration, phagocytosis, superoxide production, antibody dependent cellular cytotoxicity of neutrophils, eosinophils and macrophages.

[0908] In other embodiments, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful as an agent to increase the number of stem cells in circulation prior to stem cells pheresis. In another specific embodiment, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful as an agent to increase the number of stem cells in circulation prior to platelet pheresis.

[0909] In other embodiments, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful as an agent to increase cytokine production.

[0910] In other embodiments, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in preventing, diagnosing, and/or treating primary hematopoietic disorders.

Hyperproliferative Disorders

[0911] In certain embodiments, polynucleotides or polypeptides, or agonists or antagonists of the present invention can be used to treat or detect hyperproliferative disorders, including neoplasms. Polynucleotides or polypeptides, or agonists or antagonists of the present invention may inhibit the proliferation of the disorder through

direct or indirect interactions. Alternatively, Polynucleotides or polypeptides, or agonists or antagonists of the present invention may proliferate other cells which can inhibit the hyperproliferative disorder.

[0912] For example, by increasing an immune response, particularly increasing antigenic qualities of the hyperproliferative disorder or by proliferating, differentiating, or mobilizing T-cells, hyperproliferative disorders can be treated. This immune response may be increased by either enhancing an existing immune response, or by initiating a new immune response. Alternatively, decreasing an immune response may also be a method of treating hyperproliferative disorders, such as a chemotherapeutic agent.

[0913] Examples of hyperproliferative disorders that can be treated or detected by polynucleotides or polypeptides, or agonists or antagonists of the present invention include, but are not limited to neoplasms located in the: colon, abdomen, bone, breast, digestive system, liver, pancreas, peritoneum, endocrine glands (adrenal, parathyroid, pituitary, testicles, ovary, thymus, thyroid), eye, head and neck, nervous (central and peripheral), lymphatic system, pelvis, skin, soft tissue, spleen, thorax, and urogenital tract.

[0914] Similarly, other hyperproliferative disorders can also be treated or detected by polynucleotides or polypeptides, or agonists or antagonists of the present invention. Examples of such hyperproliferative disorders include, but are not limited to: Acute Childhood Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, Acute Lymphocytic Leukemia, Acute Myeloid Leukemia, Adrenocortical Carcinoma, Adult (Primary) Hepatocellular Cancer, Adult (Primary) Liver Cancer, Adult Acute Lymphocytic Leukemia, Adult Acute Myeloid Leukemia, Adult Hodgkin's Disease, Adult Hodgkin's Lymphoma, Adult Lymphocytic Leukemia, Adult Non-Hodgkin's Lymphoma, Adult Primary Liver Cancer, Adult Soft Tissue Sarcoma, AIDS-Related Lymphoma, AIDS-Related Malignancies, Anal Cancer, Astrocytoma, Bile Duct Cancer, Bladder Cancer, Bone Cancer, Brain Stem Glioma, Brain Tumors, Breast Cancer, Cancer of the Renal Pelvis and Ureter, Central Nervous System (Primary) Lymphoma, Central Nervous System Lymphoma, Cerebellar Astrocytoma, Cerebral Astrocytoma, Cervical Cancer, Childhood (Primary) Hepatocellular Cancer, Childhood (Primary) Liver Cancer, Childhood Acute Lymphoblastic Leukemia, Childhood Acute Myeloid Leukemia, Childhood Brain Stem Glioma, Childhood Cerebellar Astrocytoma, Childhood Cerebral Astrocytoma, Childhood Extracranial Germ Cell Tumors, Childhood Hodgkin's Disease,

Childhood Hodgkin's Lymphoma, Childhood Hypothalamic and Visual Pathway Glioma, Childhood Lymphoblastic Leukemia, Childhood Medulloblastoma, Childhood Non-Hodgkin's Lymphoma, Childhood Pineal and Supratentorial Primitive Neuroectodermal Tumors, Childhood Primary Liver Cancer, Childhood Rhabdomyosarcoma, Childhood Soft Tissue Sarcoma, Childhood Visual Pathway and Hypothalamic Glioma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Colon Cancer, Cutaneous T-Cell Lymphoma, Endocrine Pancreas Islet Cell Carcinoma, Endometrial Cancer, Ependymoma, Epithelial Cancer, Esophageal Cancer, Ewing's Sarcoma and Related Tumors, Exocrine Pancreatic Cancer, Extracranial Germ Cell Tumor, Extragonadal Germ Cell Tumor, Extrahepatic Bile Duct Cancer, Eye Cancer, Female Breast Cancer, Gaucher's Disease, Gallbladder Cancer, Gastric Cancer, Gastrointestinal Carcinoid Tumor, Gastrointestinal Tumors, Germ Cell Tumors, Gestational Trophoblastic Tumor, Hairy Cell Leukemia, Head and Neck Cancer, Hepatocellular Cancer, Hodgkin's Disease, Hodgkin's Lymphoma, Hypergammaglobulinemia, Hypopharyngeal Cancer, Intestinal Cancers, Intraocular Melanoma, Islet Cell Carcinoma, Islet Cell Pancreatic Cancer, Kaposi's Sarcoma, Kidney Cancer, Laryngeal Cancer, Lip and Oral Cavity Cancer, Liver Cancer, Lung Cancer, Lymphoproliferative Disorders, Macroglobulinemia, Male Breast Cancer, Malignant Mesothelioma, Malignant Thymoma, Medulloblastoma, Melanoma, Mesothelioma, Metastatic Occult Primary Squamous Neck Cancer, Metastatic Primary Squamous Neck Cancer, Metastatic Squamous Neck Cancer, Multiple Myeloma, Multiple Myeloma/Plasma Cell Neoplasm, Myelodysplastic Syndrome, Myelogenous Leukemia, Myeloid Leukemia, Myeloproliferative Disorders, Nasal Cavity and Paranasal Sinus Cancer, Nasopharyngeal Cancer, Neuroblastoma, Non-Hodgkin's Lymphoma During Pregnancy, Nonmelanoma Skin Cancer, Non-Small Cell Lung Cancer, Occult Primary Metastatic Squamous Neck Cancer, Oropharyngeal Cancer, Osteo-/Malignant Fibrous Sarcoma, Osteosarcoma/Malignant Fibrous Histiocytoma, Osteosarcoma/Malignant Fibrous Histiocytoma of Bone, Ovarian Epithelial Cancer, Ovarian Germ Cell Tumor, Ovarian Low Malignant Potential Tumor, Pancreatic Cancer, Paraproteinemias, Purpura, Parathyroid Cancer, Penile Cancer, Pheochromocytoma, Pituitary Tumor, Plasma Cell Neoplasm/Multiple Myeloma, Primary Central Nervous System Lymphoma, Primary Liver Cancer, Prostate Cancer, Rectal Cancer, Renal Cell Cancer, Renal Pelvis and Ureter Cancer, Retinoblastoma, Rhabdomyosarcoma, Salivary Gland Cancer, Sarcoidosis

Sarcomas, Sezary Syndrome, Skin Cancer, Small Cell Lung Cancer, Small Intestine Cancer, Soft Tissue Sarcoma, Squamous Neck Cancer, Stomach Cancer, Supratentorial Primitive Neuroectodermal and Pineal Tumors, T-Cell Lymphoma, Testicular Cancer, Thymoma, Thyroid Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Transitional Renal Pelvis and Ureter Cancer, Trophoblastic Tumors, Ureter and Renal Pelvis Cell Cancer, Urethral Cancer, Uterine Cancer, Uterine Sarcoma, Vaginal Cancer, Visual Pathway and Hypothalamic Glioma, Vulvar Cancer, Waldenstrom's Macroglobulinemia, Wilms' Tumor, and any other hyperproliferative disease, besides neoplasia, located in an organ system listed above.

[0915] In another preferred embodiment, polynucleotides or polypeptides, or agonists or antagonists of the present invention are used to diagnose, prognose, prevent, and/or treat premalignant conditions and to prevent progression to a neoplastic or malignant state, including but not limited to those disorders described above. Such uses are indicated in conditions known or suspected of preceding progression to neoplasia or cancer, in particular, where non-neoplastic cell growth consisting of hyperplasia, metaplasia, or most particularly, dysplasia has occurred (for review of such abnormal growth conditions, see Robbins and Angell, 1976, Basic Pathology, 2d Ed., W. B. Saunders Co., Philadelphia, pp. 68-79.)

[0916] Hyperplasia is a form of controlled cell proliferation, involving an increase in cell number in a tissue or organ, without significant alteration in structure or function. Hyperplastic disorders which can be diagnosed, prognosed, prevented, and/or treated with compositions of the invention (including polynucleotides, polypeptides, agonists or antagonists) include, but are not limited to, angiofollicular mediastinal lymph node hyperplasia, angiolymphoid hyperplasia with eosinophilia, atypical melanocytic hyperplasia, basal cell hyperplasia, benign giant lymph node hyperplasia, cementum hyperplasia, congenital adrenal hyperplasia, congenital sebaceous hyperplasia, cystic hyperplasia, cystic hyperplasia of the breast, denture hyperplasia, ductal hyperplasia, endometrial hyperplasia, fibromuscular hyperplasia, focal epithelial hyperplasia, gingival hyperplasia, inflammatory fibrous hyperplasia, inflammatory papillary hyperplasia, intravascular papillary endothelial hyperplasia, nodular hyperplasia of prostate, nodular regenerative hyperplasia, pseudoepitheliomatous hyperplasia, senile sebaceous hyperplasia, and verrucous hyperplasia.

[0917] Metaplasia is a form of controlled cell growth in which one type of adult or fully differentiated cell substitutes for another type of adult cell. Metaplastic disorders which can be diagnosed, prognosed, prevented, and/or treated with compositions of the invention (including polynucleotides, polypeptides, agonists or antagonists) include, but are not limited to, agnogenic myeloid metaplasia, apocrine metaplasia, atypical metaplasia, autoparenchymatous metaplasia, connective tissue metaplasia, epithelial metaplasia, intestinal metaplasia, metaplastic anemia, metaplastic ossification, metaplastic polyps, myeloid metaplasia, primary myeloid metaplasia, secondary myeloid metaplasia, squamous metaplasia, squamous metaplasia of amnion, and symptomatic myeloid metaplasia.

[0918] Dysplasia is frequently a forerunner of cancer, and is found mainly in the epithelia; it is the most disorderly form of non-neoplastic cell growth, involving a loss in individual cell uniformity and in the architectural orientation of cells. Dysplastic cells often have abnormally large, deeply stained nuclei, and exhibit pleomorphism. Dysplasia characteristically occurs where there exists chronic irritation or inflammation. Dysplastic disorders which can be diagnosed, prognosed, prevented, and/or treated with compositions of the invention (including polynucleotides, polypeptides, agonists or antagonists) include, but are not limited to, anhidrotic ectodermal dysplasia, anterofacial dysplasia, asphyxiating thoracic dysplasia, atriadigital dysplasia, bronchopulmonary dysplasia, cerebral dysplasia, cervical dysplasia, chondroectodermal dysplasia, cleidocranial dysplasia, congenital ectodermal dysplasia, craniodiaphysial dysplasia, craniocarpotarsal dysplasia, craniometaphysial dysplasia, dentin dysplasia, diaphysial dysplasia, ectodermal dysplasia, enamel dysplasia, encephalo-ophthalmic dysplasia, dysplasia epiphysialis hemimelia, dysplasia epiphysialis multiplex, dysplasia epiphysialis punctata, epithelial dysplasia, facioidigitogenital dysplasia, familial fibrous dysplasia of jaws, familial white folded dysplasia, fibromuscular dysplasia, fibrous dysplasia of bone, florid osseous dysplasia, hereditary renal-retinal dysplasia, hidrotic ectodermal dysplasia, hypohidrotic ectodermal dysplasia, lymphopenic thymic dysplasia, mammary dysplasia, mandibulofacial dysplasia, metaphysial dysplasia, Mondini dysplasia, monostotic fibrous dysplasia, mucoepithelial dysplasia, multiple epiphysial dysplasia, oculoauriculovertebral dysplasia, oculodentodigital dysplasia, oculovertbral dysplasia, odontogenic dysplasia, ophthalmomandibulomelic dysplasia, periapical cemental dysplasia, polyostotic fibrous

dysplasia, pseudoachondroplastic spondyloepiphyseal dysplasia, retinal dysplasia, septo-optic dysplasia, spondyloepiphyseal dysplasia, and ventriculoradial dysplasia.

[0919] Additional pre-neoplastic disorders which can be diagnosed, prognosed, prevented, and/or treated with compositions of the invention (including polynucleotides, polypeptides, agonists or antagonists) include, but are not limited to, benign dysproliferative disorders (e.g., benign tumors, fibrocystic conditions, tissue hypertrophy, intestinal polyps, colon polyps, and esophageal dysplasia), leukoplakia, keratoses, Bowen's disease, Farmer's Skin, solar cheilitis, and solar keratosis.

[0920] In another embodiment, a polypeptide of the invention, or polynucleotides, antibodies, agonists, or antagonists corresponding to that polypeptide, may be used to diagnose and/or prognose disorders associated with the tissue(s) in which the polypeptide of the invention is expressed, including one, two, three, four, five, or more tissues disclosed in Table 3, column 2 (Library Code).

[0921] In another embodiment, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention conjugated to a toxin or a radioactive isotope, as described herein, may be used to treat cancers and neoplasms, including, but not limited to those described herein. In a further preferred embodiment, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention conjugated to a toxin or a radioactive isotope, as described herein, may be used to treat acute myelogenous leukemia.

[0922] Additionally, polynucleotides, polypeptides, and/or agonists or antagonists of the invention may affect apoptosis, and therefore, would be useful in treating a number of diseases associated with increased cell survival or the inhibition of apoptosis. For example, diseases associated with increased cell survival or the inhibition of apoptosis that could be diagnosed, prognosed, prevented, and/or treated by polynucleotides, polypeptides, and/or agonists or antagonists of the invention, include cancers (such as follicular lymphomas, carcinomas with p53 mutations, and hormone-dependent tumors, including, but not limited to colon cancer, cardiac tumors, pancreatic cancer, melanoma, retinoblastoma, glioblastoma, lung cancer, intestinal cancer, testicular cancer, stomach cancer, neuroblastoma, myxoma, myoma, lymphoma, endothelioma, osteoblastoma, osteoclastoma, osteosarcoma, chondrosarcoma, adenoma, breast cancer, prostate cancer, Kaposi's sarcoma and ovarian cancer); autoimmune disorders such as, multiple sclerosis,

Sjogren's syndrome, Hashimoto's thyroiditis, biliary cirrhosis, Behcet's disease, Crohn's disease, polymyositis, systemic lupus erythematosus and immune-related glomerulonephritis and rheumatoid arthritis) and viral infections (such as herpes viruses, pox viruses and adenoviruses), inflammation, graft v. host disease, acute graft rejection, and chronic graft rejection.

[0923] In preferred embodiments, polynucleotides, polypeptides, and/or agonists or antagonists of the invention are used to inhibit growth, progression, and/or metastasis of cancers, in particular those listed above.

[0924] Additional diseases or conditions associated with increased cell survival that could be diagnosed, prognosed, prevented, and/or treated by polynucleotides, polypeptides, and/or agonists or antagonists of the invention, include, but are not limited to, progression, and/or metastases of malignancies and related disorders such as leukemia (including acute leukemias (e.g., acute lymphocytic leukemia, acute myelocytic leukemia (including myeloblastic, promyelocytic, myelomonocytic, monocytic, and erythroleukemia)) and chronic leukemias (e.g., chronic myelocytic (granulocytic) leukemia and chronic lymphocytic leukemia)), polycythemia vera, lymphomas (e.g., Hodgkin's disease and non-Hodgkin's disease), multiple myeloma, Waldenstrom's macroglobulinemia, heavy chain disease, and solid tumors including, but not limited to, sarcomas and carcinomas such as fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilm's tumor, cervical cancer, testicular tumor, lung carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, emangioblastoma, acoustic neuroma, oligodendroglioma, menangioma, melanoma, neuroblastoma, and retinoblastoma.

[0925] Diseases associated with increased apoptosis that could be diagnosed, prognosed, prevented, and/or treated by polynucleotides, polypeptides, and/or agonists or antagonists of the invention, include AIDS; neurodegenerative disorders (such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, retinitis pigmentosa, cerebellar degeneration and brain tumor or prior associated disease); autoimmune disorders (such as, multiple sclerosis, Sjogren's syndrome, Hashimoto's thyroiditis, biliary cirrhosis, Behcet's disease, Crohn's disease, polymyositis, systemic lupus erythematosus and immune-related glomerulonephritis and rheumatoid arthritis) myelodysplastic syndromes (such as aplastic anemia), graft v. host disease, ischemic injury (such as that caused by myocardial infarction, stroke and reperfusion injury), liver injury (e.g., hepatitis related liver injury, ischemia/reperfusion injury, cholestosis (bile duct injury) and liver cancer); toxin-induced liver disease (such as that caused by alcohol), septic shock, cachexia and anorexia.

[0926] Hyperproliferative diseases and/or disorders that could be diagnosed, prognosed, prevented, and/or treated by polynucleotides, polypeptides, and/or agonists or antagonists of the invention, include, but are not limited to, neoplasms located in the liver, abdomen, bone, breast, digestive system, pancreas, peritoneum, endocrine glands (adrenal, parathyroid, pituitary, testicles, ovary, thymus, thyroid), eye, head and neck, nervous system (central and peripheral), lymphatic system, pelvis, skin, soft tissue, spleen, thorax, and urogenital tract.

[0927] Similarly, other hyperproliferative disorders can also be diagnosed, prognosed, prevented, and/or treated by polynucleotides, polypeptides, and/or agonists or antagonists of the invention. Examples of such hyperproliferative disorders include, but are not limited to: hypergammaglobulinemia, lymphoproliferative disorders, paraproteinemias, purpura, sarcoidosis, Sezary Syndrome, Waldenström's macroglobulinemia, Gaucher's Disease, histiocytosis, and any other hyperproliferative disease, besides neoplasia, located in an organ system listed above.

[0928] Another preferred embodiment utilizes polynucleotides of the present invention to inhibit aberrant cellular division, by gene therapy using the present invention, and/or protein fusions or fragments thereof.

[0929] Thus, the present invention provides a method for treating cell proliferative disorders by inserting into an abnormally proliferating cell a polynucleotide of the present invention, wherein said polynucleotide represses said expression.

[0930] Another embodiment of the present invention provides a method of treating cell-proliferative disorders in individuals comprising administration of one or more active gene copies of the present invention to an abnormally proliferating cell or cells. In a preferred embodiment, polynucleotides of the present invention is a DNA construct comprising a recombinant expression vector effective in expressing a DNA sequence encoding said polynucleotides. In another preferred embodiment of the present invention, the DNA construct encoding the polynucleotides of the present invention is inserted into cells to be treated utilizing a retrovirus, or more preferably an adenoviral vector (See G J. Nabel, et. al., PNAS 1999 96: 324-326, which is hereby incorporated by reference). In a most preferred embodiment, the viral vector is defective and will not transform non-proliferating cells, only proliferating cells. Moreover, in a preferred embodiment, the polynucleotides of the present invention inserted into proliferating cells either alone, or in combination with or fused to other polynucleotides, can then be modulated via an external stimulus (i.e. magnetic, specific small molecule, chemical, or drug administration, etc.), which acts upon the promoter upstream of said polynucleotides to induce expression of the encoded protein product. As such the beneficial therapeutic affect of the present invention may be expressly modulated (i.e. to increase, decrease, or inhibit expression of the present invention) based upon said external stimulus.

[0931] Polynucleotides of the present invention may be useful in repressing expression of oncogenic genes or antigens. By "repressing expression of the oncogenic genes " is intended the suppression of the transcription of the gene, the degradation of the gene transcript (pre-message RNA), the inhibition of splicing, the destruction of the messenger RNA, the prevention of the post-translational modifications of the protein, the destruction of the protein, or the inhibition of the normal function of the protein.

[0932] For local administration to abnormally proliferating cells, polynucleotides of the present invention may be administered by any method known to those of skill in the art including, but not limited to transfection, electroporation, microinjection of cells, or in vehicles such as liposomes, lipofectin, or as naked polynucleotides, or any other method described throughout the specification. The polynucleotide of the present invention may

be delivered by known gene delivery systems such as, but not limited to, retroviral vectors (Gilboa, J. Virology 44:845 (1982); Hocke, Nature 320:275 (1986); Wilson, et al., Proc. Natl. Acad. Sci. U.S.A. 85:3014), vaccinia virus system (Chakrabarty et al., Mol. Cell Biol. 5:3403 (1985) or other efficient DNA delivery systems (Yates et al., Nature 313:812 (1985)) known to those skilled in the art. These references are exemplary only and are hereby incorporated by reference. In order to specifically deliver or transfect cells which are abnormally proliferating and spare non-dividing cells, it is preferable to utilize a retrovirus, or adenoviral (as described in the art and elsewhere herein) delivery system known to those of skill in the art. Since host DNA replication is required for retroviral DNA to integrate and the retrovirus will be unable to self replicate due to the lack of the retrovirus genes needed for its life cycle. Utilizing such a retroviral delivery system for polynucleotides of the present invention will target said gene and constructs to abnormally proliferating cells and will spare the non-dividing normal cells.

[0933] The polynucleotides of the present invention may be delivered directly to cell proliferative disorder/disease sites in internal organs, body cavities and the like by use of imaging devices used to guide an injecting needle directly to the disease site. The polynucleotides of the present invention may also be administered to disease sites at the time of surgical intervention.

[0934] By "cell proliferative disease" is meant any human or animal disease or disorder, affecting any one or any combination of organs, cavities, or body parts, which is characterized by single or multiple local abnormal proliferations of cells, groups of cells, or tissues, whether benign or malignant.

[0935] Any amount of the polynucleotides of the present invention may be administered as long as it has a biologically inhibiting effect on the proliferation of the treated cells. Moreover, it is possible to administer more than one of the polynucleotide of the present invention simultaneously to the same site. By "biologically inhibiting" is meant partial or total growth inhibition as well as decreases in the rate of proliferation or growth of the cells. The biologically inhibitory dose may be determined by assessing the effects of the polynucleotides of the present invention on target malignant or abnormally proliferating cell growth in tissue culture, tumor growth in animals and cell cultures, or any other method known to one of ordinary skill in the art.

[0936] The present invention is further directed to antibody-based therapies which involve administering of anti-polypeptides and anti-polynucleotide antibodies to a mammalian, preferably human, patient for treating one or more of the described disorders. Methods for producing anti-polypeptides and anti-polynucleotide antibodies polyclonal and monoclonal antibodies are described in detail elsewhere herein. Such antibodies may be provided in pharmaceutically acceptable compositions as known in the art or as described herein.

[0937] A summary of the ways in which the antibodies of the present invention may be used therapeutically includes binding polynucleotides or polypeptides of the present invention locally or systemically in the body or by direct cytotoxicity of the antibody, e.g. as mediated by complement (CDC) or by effector cells (ADCC). Some of these approaches are described in more detail below. Armed with the teachings provided herein, one of ordinary skill in the art will know how to use the antibodies of the present invention for diagnostic, monitoring or therapeutic purposes without undue experimentation.

[0938] In particular, the antibodies, fragments and derivatives of the present invention are useful for treating a subject having or developing cell proliferative and/or differentiation disorders as described herein. Such treatment comprises administering a single or multiple doses of the antibody, or a fragment, derivative, or a conjugate thereof.

[0939] The antibodies of this invention may be advantageously utilized in combination with other monoclonal or chimeric antibodies, or with lymphokines or hematopoietic growth factors, for example., which serve to increase the number or activity of effector cells which interact with the antibodies.

[0940] It is preferred to use high affinity and/or potent *in vivo* inhibiting and/or neutralizing antibodies against polypeptides or polynucleotides of the present invention, fragments or regions thereof, for both immunoassays directed to and therapy of disorders related to polynucleotides or polypeptides, including fragments thereof, of the present invention. Such antibodies, fragments, or regions, will preferably have an affinity for polynucleotides or polypeptides, including fragments thereof. Preferred binding affinities include those with a dissociation constant or K_d less than $5 \times 10^{-6}M$, $10^{-6}M$, $5 \times 10^{-7}M$, $10^{-7}M$, $5 \times 10^{-8}M$, $10^{-8}M$, $5 \times 10^{-9}M$, $10^{-9}M$, $5 \times 10^{-10}M$, $10^{-10}M$, $5 \times 10^{-11}M$, $10^{-11}M$, $5 \times 10^{-12}M$, $10^{-12}M$, $5 \times 10^{-13}M$, $10^{-13}M$, $5 \times 10^{-14}M$, $10^{-14}M$, $5 \times 10^{-15}M$, and $10^{-15}M$.

[0941] Moreover, polypeptides of the present invention are useful in inhibiting the angiogenesis of proliferative cells or tissues, either alone, as a protein fusion, or in combination with other polypeptides directly or indirectly, as described elsewhere herein. In a most preferred embodiment, said anti-angiogenesis effect may be achieved indirectly, for example, through the inhibition of hematopoietic, tumor-specific cells, such as tumor-associated macrophages (See Joseph IB, et al. *J Natl Cancer Inst*, 90(21):1648-53 (1998), which is hereby incorporated by reference). Antibodies directed to polypeptides or polynucleotides of the present invention may also result in inhibition of angiogenesis directly, or indirectly (See Witte L, et al., *Cancer Metastasis Rev*. 17(2):155-61 (1998), which is hereby incorporated by reference)).

[0942] Polypeptides, including protein fusions, of the present invention, or fragments thereof may be useful in inhibiting proliferative cells or tissues through the induction of apoptosis. Said polypeptides may act either directly, or indirectly to induce apoptosis of proliferative cells and tissues, for example in the activation of a death-domain receptor, such as tumor necrosis factor (TNF) receptor-1, CD95 (Fas/APO-1), TNF-receptor-related apoptosis-mediated protein (TRAMP) and TNF-related apoptosis-inducing ligand (TRAIL) receptor-1 and -2 (See Schulze-Osthoff K, et al., *Eur J Biochem* 254(3):439-59 (1998), which is hereby incorporated by reference). Moreover, in another preferred embodiment of the present invention, said polypeptides may induce apoptosis through other mechanisms, such as in the activation of other proteins which will activate apoptosis, or through stimulating the expression of said proteins, either alone or in combination with small molecule drugs or adjuvants, such as apoptonin, galectins, thioredoxins, anti-inflammatory proteins (See for example, *Mutat Res* 400(1-2):447-55 (1998), *Med Hypotheses*.50(5):423-33 (1998), *Chem Biol Interact*. Apr 24;111-112:23-34 (1998), *J Mol Med*.76(6):402-12 (1998), *Int J Tissue React*;20(1):3-15 (1998), which are all hereby incorporated by reference).

[0943] Polypeptides, including protein fusions to, or fragments thereof, of the present invention are useful in inhibiting the metastasis of proliferative cells or tissues. Inhibition may occur as a direct result of administering polypeptides, or antibodies directed to said polypeptides as described elsewhere herein, or indirectly, such as activating the expression of proteins known to inhibit metastasis, for example alpha 4 integrins, (See, e.g., *Curr Top Microbiol Immunol* 1998;231:125-41, which is hereby incorporated by reference). Such

therapeutic affects of the present invention may be achieved either alone, or in combination with small molecule drugs or adjuvants.

[0944] In another embodiment, the invention provides a method of delivering compositions containing the polypeptides of the invention (e.g., compositions containing polypeptides or polypeptide antibodies associated with heterologous polypeptides, heterologous nucleic acids, toxins, or prodrugs) to targeted cells expressing the polypeptide of the present invention. Polypeptides or polypeptide antibodies of the invention may be associated with heterologous polypeptides, heterologous nucleic acids, toxins, or prodrugs via hydrophobic, hydrophilic, ionic and/or covalent interactions.

[0945] Polypeptides, protein fusions to, or fragments thereof, of the present invention are useful in enhancing the immunogenicity and/or antigenicity of proliferating cells or tissues, either directly, such as would occur if the polypeptides of the present invention 'vaccinated' the immune response to respond to proliferative antigens and immunogens, or indirectly, such as in activating the expression of proteins known to enhance the immune response (e.g. chemokines), to said antigens and immunogens.

Renal Disorders

[0946] Polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention, may be used to treat, prevent, diagnose, and/or prognose disorders of the renal system. Renal disorders which can be diagnosed, prognosed, prevented, and/or treated with compositions of the invention include, but are not limited to, kidney failure, nephritis, blood vessel disorders of kidney, metabolic and congenital kidney disorders, urinary disorders of the kidney, autoimmune disorders, sclerosis and necrosis, electrolyte imbalance, and kidney cancers.

[0947] Kidney diseases which can be diagnosed, prognosed, prevented, and/or treated with compositions of the invention include, but are not limited to, acute kidney failure, chronic kidney failure, atheroembolic renal failure, end-stage renal disease, inflammatory diseases of the kidney (e.g., acute glomerulonephritis, postinfectious glomerulonephritis, rapidly progressive glomerulonephritis, nephrotic syndrome, membranous glomerulonephritis, familial nephrotic syndrome, membranoproliferative glomerulonephritis I and II, mesangial proliferative glomerulonephritis, chronic

glomerulonephritis, acute tubulointerstitial nephritis, chronic tubulointerstitial nephritis, acute post-streptococcal glomerulonephritis (PSGN), pyelonephritis, lupus nephritis, chronic nephritis, interstitial nephritis, and post-streptococcal glomerulonephritis), blood vessel disorders of the kidneys (e.g., kidney infarction, atheroembolic kidney disease, cortical necrosis, malignant nephrosclerosis, renal vein thrombosis, renal underperfusion, renal retinopathy, renal ischemia-reperfusion, renal artery embolism, and renal artery stenosis), and kidney disorders resulting from urinary tract disease (e.g., pyelonephritis, hydronephrosis, urolithiasis (renal lithiasis, nephrolithiasis), reflux nephropathy, urinary tract infections, urinary retention, and acute or chronic unilateral obstructive uropathy.)

[0948] In addition, compositions of the invention can be used to diagnose, prognose, prevent, and/or treat metabolic and congenital disorders of the kidney (e.g., uremia, renal amyloidosis, renal osteodystrophy, renal tubular acidosis, renal glycosuria, nephrogenic diabetes insipidus, cystinuria, Fanconi's syndrome, renal fibrocystic osteosis (renal rickets), Hartnup disease, Bartter's syndrome, Liddle's syndrome, polycystic kidney disease, medullary cystic disease, medullary sponge kidney, Alport's syndrome, nail-patella syndrome, congenital nephrotic syndrome, CRUSH syndrome, horseshoe kidney, diabetic nephropathy, nephrogenic diabetes insipidus, analgesic nephropathy, kidney stones, and membranous nephropathy), and autoimmune disorders of the kidney (e.g., systemic lupus erythematosus (SLE), Goodpasture syndrome, IgA nephropathy, and IgM mesangial proliferative glomerulonephritis).

[0949] Compositions of the invention can also be used to diagnose, prognose, prevent, and/or treat sclerotic or necrotic disorders of the kidney (e.g., glomerulosclerosis, diabetic nephropathy, focal segmental glomerulosclerosis (FSGS), necrotizing glomerulonephritis, and renal papillary necrosis), cancers of the kidney (e.g., nephroma, hypernephroma, nephroblastoma, renal cell cancer, transitional cell cancer, renal adenocarcinoma, squamous cell cancer, and Wilm's tumor), and electrolyte imbalances (e.g., nephrocalcinosis, pyuria, edema, hydronephritis, proteinuria, hyponatremia, hypernatremia, hypokalemia, hyperkalemia, hypocalcemia, hypercalcemia, hypophosphatemia, and hyperphosphatemia).

[0950] Polypeptides may be administered using any method known in the art, including, but not limited to, direct needle injection at the delivery site, intravenous injection, topical administration, catheter infusion, biolistic injectors, particle accelerators,

gelfoam sponge depots, other commercially available depot materials, osmotic pumps, oral or suppository solid pharmaceutical formulations, decanting or topical applications during surgery, aerosol delivery. Such methods are known in the art. Polypeptides may be administered as part of a Therapeutic, described in more detail below. Methods of delivering polynucleotides are described in more detail herein.

Cardiovascular Disorders

[0951] Polynucleotides or polypeptides, or agonists or antagonists of the present invention, may be used to treat, prevent, diagnose, and/or prognose cardiovascular disorders, including, but not limited to, peripheral artery disease, such as limb ischemia.

[0952] Cardiovascular disorders include, but are not limited to, cardiovascular abnormalities, such as arterio-arterial fistula, arteriovenous fistula, cerebral arteriovenous malformations, congenital heart defects, pulmonary atresia, and Scimitar Syndrome. Congenital heart defects include, but are not limited to, aortic coarctation, cor triatriatum, coronary vessel anomalies, crisscross heart, dextrocardia, patent ductus arteriosus, Ebstein's anomaly, Eisenmenger complex, hypoplastic left heart syndrome, levocardia, tetralogy of fallot, transposition of great vessels, double outlet right ventricle, tricuspid atresia, persistent truncus arteriosus, and heart septal defects, such as aortopulmonary septal defect, endocardial cushion defects, Lutembacher's Syndrome, trilog of Fallot, ventricular heart septal defects.

[0953] Cardiovascular disorders also include, but are not limited to, heart disease, such as arrhythmias, carcinoid heart disease, high cardiac output, low cardiac output, cardiac tamponade, endocarditis (including bacterial), heart aneurysm, cardiac arrest, congestive heart failure, congestive cardiomyopathy, paroxysmal dyspnea, cardiac edema, heart hypertrophy, congestive cardiomyopathy, left ventricular hypertrophy, right ventricular hypertrophy, post-infarction heart rupture, ventricular septal rupture, heart valve diseases, myocardial diseases, myocardial ischemia, pericardial effusion, pericarditis (including constrictive and tuberculous), pneumopericardium, postpericardiotomy syndrome, pulmonary heart disease, rheumatic heart disease, ventricular dysfunction, hyperemia, cardiovascular pregnancy complications, Scimitar Syndrome, cardiovascular syphilis, and cardiovascular tuberculosis.

[0954] Arrhythmias include, but are not limited to, sinus arrhythmia, atrial fibrillation, atrial flutter, bradycardia, extrasystole, Adams-Stokes Syndrome, bundle-branch block, sinoatrial block, long QT syndrome, parasystole, Lown-Ganong-Levine Syndrome, Mahaim-type pre-excitation syndrome, Wolff-Parkinson-White syndrome, sick sinus syndrome, tachycardias, and ventricular fibrillation. Tachycardias include paroxysmal tachycardia, supraventricular tachycardia, accelerated idioventricular rhythm, atrioventricular nodal reentry tachycardia, ectopic atrial tachycardia, ectopic junctional tachycardia, sinoatrial nodal reentry tachycardia, sinus tachycardia, Torsades de Pointes, and ventricular tachycardia.

[0955] Heart valve diseases include, but are not limited to, aortic valve insufficiency, aortic valve stenosis, hear murmurs, aortic valve prolapse, mitral valve prolapse, tricuspid valve prolapse, mitral valve insufficiency, mitral valve stenosis, pulmonary atresia, pulmonary valve insufficiency, pulmonary valve stenosis, tricuspid atresia, tricuspid valve insufficiency, and tricuspid valve stenosis.

[0956] Myocardial diseases include, but are not limited to, alcoholic cardiomyopathy, congestive cardiomyopathy, hypertrophic cardiomyopathy, aortic subvalvular stenosis, pulmonary subvalvular stenosis, restrictive cardiomyopathy, Chagas cardiomyopathy, endocardial fibroelastosis, endomyocardial fibrosis, Kearns Syndrome, myocardial reperfusion injury, and myocarditis.

[0957] Myocardial ischemias include, but are not limited to, coronary disease, such as angina pectoris, coronary aneurysm, coronary arteriosclerosis, coronary thrombosis, coronary vasospasm, myocardial infarction and myocardial stunning.

[0958] Cardiovascular diseases also include vascular diseases such as aneurysms, angiodysplasia, angiomatosis, bacillary angiomatosis, Hippel-Lindau Disease, Klippel-Trenaunay-Weber Syndrome, Sturge-Weber Syndrome, angioneurotic edema, aortic diseases, Takayasu's Arteritis, aortitis, Leriche's Syndrome, arterial occlusive diseases, arteritis, enarteritis, polyarteritis nodosa, cerebrovascular disorders, diabetic angiopathies, diabetic retinopathy, embolisms, thrombosis, erythromelalgia, hemorrhoids, hepatic veno-occlusive disease, hypertension, hypotension, ischemia, peripheral vascular diseases, phlebitis, pulmonary veno-occlusive disease, Raynaud's disease, CREST syndrome, retinal vein occlusion, Scimitar syndrome, superior vena cava syndrome, telangiectasia, atacia

telangiectasia, hereditary hemorrhagic telangiectasia, varicocele, varicose veins, varicose ulcer, vasculitis, and venous insufficiency.

[0959] Aneurysms include, but are not limited to, dissecting aneurysms, false aneurysms, infected aneurysms, ruptured aneurysms, aortic aneurysms, cerebral aneurysms, coronary aneurysms, heart aneurysms, and iliac aneurysms.

[0960] Arterial occlusive diseases include, but are not limited to, arteriosclerosis, intermittent claudication, carotid stenosis, fibromuscular dysplasias, mesenteric vascular occlusion, Moyamoya disease, renal artery obstruction, retinal artery occlusion, and thromboangiitis obliterans.

[0961] Cerebrovascular disorders include, but are not limited to, carotid artery diseases, cerebral amyloid angiopathy, cerebral aneurysm, cerebral anoxia, cerebral arteriosclerosis, cerebral arteriovenous malformation, cerebral artery diseases, cerebral embolism and thrombosis, carotid artery thrombosis, sinus thrombosis, Wallenberg's syndrome, cerebral hemorrhage, epidural hematoma, subdural hematoma, subarachnoid hemorrhage, cerebral infarction, cerebral ischemia (including transient), subclavian steal syndrome, periventricular leukomalacia, vascular headache, cluster headache, migraine, and vertebrobasilar insufficiency.

[0962] Embolisms include, but are not limited to, air embolisms, amniotic fluid embolisms, cholesterol embolisms, blue toe syndrome, fat embolisms, pulmonary embolisms, and thromboembolisms. Thrombosis include, but are not limited to, coronary thrombosis, hepatic vein thrombosis, retinal vein occlusion, carotid artery thrombosis, sinus thrombosis, Wallenberg's syndrome, and thrombophlebitis.

[0963] Ischemic disorders include, but are not limited to, cerebral ischemia, ischemic colitis, compartment syndromes, anterior compartment syndrome, myocardial ischemia, reperfusion injuries, and peripheral limb ischemia. Vasculitis includes, but is not limited to, aortitis, arteritis, Behcet's Syndrome, Churg-Strauss Syndrome, mucocutaneous lymph node syndrome, thromboangiitis obliterans, hypersensitivity vasculitis, Schoenlein-Henoch purpura, allergic cutaneous vasculitis, and Wegener's granulomatosis.

[0964] Polypeptides may be administered using any method known in the art, including, but not limited to, direct needle injection at the delivery site, intravenous injection, topical administration, catheter infusion, biolistic injectors, particle accelerators, gelfoam sponge depots, other commercially available depot materials, osmotic pumps, oral

or suppository solid pharmaceutical formulations, decanting or topical applications during surgery, aerosol delivery. Such methods are known in the art. Polypeptides may be administered as part of a Therapeutic, described in more detail below. Methods of delivering polynucleotides are described in more detail herein.

Respiratory Disorders

[0965] Polynucleotides or polypeptides, or agonists or antagonists of the present invention may be used to treat, prevent, diagnose, and/or prognose diseases and/or disorders of the respiratory system.

[0966] Diseases and disorders of the respiratory system include, but are not limited to, nasal vestibulitis, nonallergic rhinitis (e.g., acute rhinitis, chronic rhinitis, atrophic rhinitis, vasomotor rhinitis), nasal polyps, and sinusitis, juvenile angiofibromas, cancer of the nose and juvenile papillomas, vocal cord polyps, nodules (singer's nodules), contact ulcers, vocal cord paralysis, laryngoceles, pharyngitis (e.g., viral and bacterial), tonsillitis, tonsillar cellulitis, parapharyngeal abscess, laryngitis, laryngoceles, and throat cancers (e.g., cancer of the nasopharynx, tonsil cancer, larynx cancer), lung cancer (e.g., squamous cell carcinoma, small cell (oat cell) carcinoma, large cell carcinoma, and adenocarcinoma), allergic disorders (eosinophilic pneumonia, hypersensitivity pneumonitis (e.g., extrinsic allergic alveolitis, allergic interstitial pneumonitis, organic dust pneumoconiosis, allergic bronchopulmonary aspergillosis, asthma, Wegener's granulomatosis (granulomatous vasculitis), Goodpasture's syndrome)), pneumonia (e.g., bacterial pneumonia (e.g., *Streptococcus pneumoniae* (pneumococcal pneumonia), *Staphylococcus aureus* (staphylococcal pneumonia), Gram-negative bacterial pneumonia (caused by, e.g., *Klebsiella* and *Pseudomas spp.*), *Mycoplasma pneumoniae* pneumonia, *Hemophilus influenzae* pneumonia, *Legionella pneumophila* (Legionnaires' disease), and *Chlamydia psittaci* (Psittacosis)), and viral pneumonia (e.g., influenza, chickenpox (varicella).

[0967] Additional diseases and disorders of the respiratory system include, but are not limited to bronchiolitis, polio (poliomyelitis), croup, respiratory syncytial viral infection, mumps, erythema infectiosum (fifth disease), roseola infantum, progressive rubella panencephalitis, german measles, and subacute sclerosing panencephalitis), fungal pneumonia (e.g., Histoplasmosis, Coccidioidomycosis, Blastomycosis, fungal infections in

people with severely suppressed immune systems (e.g., cryptococcosis, caused by *Cryptococcus neoformans*; aspergillosis, caused by *Aspergillus spp.*; candidiasis, caused by *Candida*; and mucormycosis)), *Pneumocystis carinii* (pneumocystis pneumonia), atypical pneumonias (e.g., *Mycoplasma* and *Chlamydia spp.*), opportunistic infection pneumonia, nosocomial pneumonia, chemical pneumonitis, and aspiration pneumonia, pleural disorders (e.g., pleurisy, pleural effusion, and pneumothorax (e.g., simple spontaneous pneumothorax, complicated spontaneous pneumothorax, tension pneumothorax)), obstructive airway diseases (e.g., asthma, chronic obstructive pulmonary disease (COPD), emphysema, chronic or acute bronchitis), occupational lung diseases (e.g., silicosis, black lung (coal workers' pneumoconiosis), asbestosis, berylliosis, occupational asthma, byssinosis, and benign pneumoconioses), Infiltrative Lung Disease (e.g., pulmonary fibrosis (e.g., fibrosing alveolitis, usual interstitial pneumonia), idiopathic pulmonary fibrosis, desquamative interstitial pneumonia, lymphoid interstitial pneumonia, histiocytosis X (e.g., Letterer-Siwe disease, Hand-Schüller-Christian disease, eosinophilic granuloma), idiopathic pulmonary hemosiderosis, sarcoidosis and pulmonary alveolar proteinosis), Acute respiratory distress syndrome (also called, e.g., adult respiratory distress syndrome), edema, pulmonary embolism, bronchitis (e.g., viral, bacterial), bronchiectasis, atelectasis, lung abscess (caused by, e.g., *Staphylococcus aureus* or *Legionella pneumophila*), and cystic fibrosis.

Anti-Angiogenesis Activity

[0968] The naturally occurring balance between endogenous stimulators and inhibitors of angiogenesis is one in which inhibitory influences predominate. Rastinejad *et al.*, *Cell* 56:345-355 (1989). In those rare instances in which neovascularization occurs under normal physiological conditions, such as wound healing, organ regeneration, embryonic development, and female reproductive processes, angiogenesis is stringently regulated and spatially and temporally delimited. Under conditions of pathological angiogenesis such as that characterizing solid tumor growth, these regulatory controls fail. Unregulated angiogenesis becomes pathologic and sustains progression of many neoplastic and non-neoplastic diseases. A number of serious diseases are dominated by abnormal neovascularization including solid tumor growth and metastases, arthritis, some types of

eye disorders, and psoriasis. See, e.g., reviews by Moses *et al.*, *Biotech.* 9:630-634 (1991); Folkman *et al.*, *N. Engl. J. Med.*, 333:1757-1763 (1995); Auerbach *et al.*, *J. Microvasc. Res.* 29:401-411 (1985); Folkman, *Advances in Cancer Research*, eds. Klein and Weinhouse, Academic Press, New York, pp. 175-203 (1985); Patz, *Am. J. Ophthalmol.* 94:715-743 (1982); and Folkman *et al.*, *Science* 221:719-725 (1983). In a number of pathological conditions, the process of angiogenesis contributes to the disease state. For example, significant data have accumulated which suggest that the growth of solid tumors is dependent on angiogenesis. Folkman and Klagsbrun, *Science* 235:442-447 (1987).

[0969] The present invention provides for treatment of diseases or disorders associated with neovascularization by administration of the polynucleotides and/or polypeptides of the invention, as well as agonists or antagonists of the present invention. Malignant and metastatic conditions which can be treated with the polynucleotides and polypeptides, or agonists or antagonists of the invention include, but are not limited to, malignancies, solid tumors, and cancers described herein and otherwise known in the art (for a review of such disorders, see Fishman *et al.*, *Medicine*, 2d Ed., J. B. Lippincott Co., Philadelphia (1985)). Thus, the present invention provides a method of treating an angiogenesis-related disease and/or disorder, comprising administering to an individual in need thereof a therapeutically effective amount of a polynucleotide, polypeptide, antagonist and/or agonist of the invention. For example, polynucleotides, polypeptides, antagonists and/or agonists may be utilized in a variety of additional methods in order to therapeutically treat a cancer or tumor. Cancers which may be treated with polynucleotides, polypeptides, antagonists and/or agonists include, but are not limited to solid tumors, including prostate, lung, breast, ovarian, stomach, pancreas, larynx, esophagus, testes, liver, parotid, biliary tract, colon, rectum, cervix, uterus, endometrium, kidney, bladder, thyroid cancer; primary tumors and metastases; melanomas; glioblastoma; Kaposi's sarcoma; leiomyosarcoma; non-small cell lung cancer; colorectal cancer; advanced malignancies; and blood born tumors such as leukemias. For example, polynucleotides, polypeptides, antagonists and/or agonists may be delivered topically, in order to treat cancers such as skin cancer, head and neck tumors, breast tumors, and Kaposi's sarcoma.

[0970] Within yet other aspects, polynucleotides, polypeptides, antagonists and/or agonists may be utilized to treat superficial forms of bladder cancer by, for example, intravesical administration. Polynucleotides, polypeptides, antagonists and/or agonists

may be delivered directly into the tumor, or near the tumor site, via injection or a catheter. Of course, as the artisan of ordinary skill will appreciate, the appropriate mode of administration will vary according to the cancer to be treated. Other modes of delivery are discussed herein.

[0971] Polynucleotides, polypeptides, antagonists and/or agonists may be useful in treating other disorders, besides cancers, which involve angiogenesis. These disorders include, but are not limited to: benign tumors, for example hemangiomas, acoustic neuromas, neurofibromas, trachomas, and pyogenic granulomas; arteriosclerotic plaques; ocular angiogenic diseases, for example, diabetic retinopathy, retinopathy of prematurity, macular degeneration, corneal graft rejection, neovascular glaucoma, retrolental fibroplasia, rubeosis, retinoblastoma, uveitis and Pterygia (abnormal blood vessel growth) of the eye; rheumatoid arthritis; psoriasis; delayed wound healing; endometriosis; vasculogenesis; granulations; hypertrophic scars (keloids); nonunion fractures; scleroderma; trachoma; vascular adhesions; myocardial angiogenesis; coronary collaterals; cerebral collaterals; arteriovenous malformations; ischemic limb angiogenesis; Osler-Webber Syndrome; plaque neovascularization; telangiectasia; hemophilic joints; angiofibroma; fibromuscular dysplasia; wound granulation; Crohn's disease; and atherosclerosis.

[0972] For example, within one aspect of the present invention methods are provided for treating hypertrophic scars and keloids, comprising the step of administering a polynucleotide, polypeptide, antagonist and/or agonist of the invention to a hypertrophic scar or keloid.

[0973] Within one embodiment of the present invention polynucleotides, polypeptides, antagonists and/or agonists of the invention are directly injected into a hypertrophic scar or keloid, in order to prevent the progression of these lesions. This therapy is of particular value in the prophylactic treatment of conditions which are known to result in the development of hypertrophic scars and keloids (e.g., burns), and is preferably initiated after the proliferative phase has had time to progress (approximately 14 days after the initial injury), but before hypertrophic scar or keloid development. As noted above, the present invention also provides methods for treating neovascular diseases of the eye, including for example, corneal neovascularization, neovascular glaucoma, proliferative diabetic retinopathy, retrolental fibroplasia and macular degeneration.

[0974] Moreover, Ocular disorders associated with neovascularization which can be treated with the polynucleotides and polypeptides of the present invention (including agonists and/or antagonists) include, but are not limited to: neovascular glaucoma, diabetic retinopathy, retinoblastoma, retrolental fibroplasia, uveitis, retinopathy of prematurity macular degeneration, corneal graft neovascularization, as well as other eye inflammatory diseases, ocular tumors and diseases associated with choroidal or iris neovascularization. See, e.g., reviews by Waltman *et al.*, *Am. J. Ophthalmol.* 85:704-710 (1978) and Gartner *et al.*, *Surv. Ophthalmol.* 22:291-312 (1978).

[0975] Thus, within one aspect of the present invention methods are provided for treating neovascular diseases of the eye such as corneal neovascularization (including corneal graft neovascularization), comprising the step of administering to a patient a therapeutically effective amount of a compound (as described above) to the cornea, such that the formation of blood vessels is inhibited. Briefly, the cornea is a tissue which normally lacks blood vessels. In certain pathological conditions however, capillaries may extend into the cornea from the pericorneal vascular plexus of the limbus. When the cornea becomes vascularized, it also becomes clouded, resulting in a decline in the patient's visual acuity. Visual loss may become complete if the cornea completely opacitates. A wide variety of disorders can result in corneal neovascularization, including for example, corneal infections (e.g., trachoma, herpes simplex keratitis, leishmaniasis and onchocerciasis), immunological processes (e.g., graft rejection and Stevens-Johnson's syndrome), alkali burns, trauma, inflammation (of any cause), toxic and nutritional deficiency states, and as a complication of wearing contact lenses.

[0976] Within particularly preferred embodiments of the invention, may be prepared for topical administration in saline (combined with any of the preservatives and antimicrobial agents commonly used in ocular preparations), and administered in eyedrop form. The solution or suspension may be prepared in its pure form and administered several times daily. Alternatively, anti-angiogenic compositions, prepared as described above, may also be administered directly to the cornea. Within preferred embodiments, the anti-angiogenic composition is prepared with a muco-adhesive polymer which binds to cornea. Within further embodiments, the anti-angiogenic factors or anti-angiogenic compositions may be utilized as an adjunct to conventional steroid therapy. Topical therapy may also be useful prophylactically in corneal lesions which are known to have a

high probability of inducing an angiogenic response (such as chemical burns). In these instances the treatment, likely in combination with steroids, may be instituted immediately to help prevent subsequent complications.

[0977] Within other embodiments, the compounds described above may be injected directly into the corneal stroma by an ophthalmologist under microscopic guidance. The preferred site of injection may vary with the morphology of the individual lesion, but the goal of the administration would be to place the composition at the advancing front of the vasculature (i.e., interspersed between the blood vessels and the normal cornea). In most cases this would involve perilimbic corneal injection to "protect" the cornea from the advancing blood vessels. This method may also be utilized shortly after a corneal insult in order to prophylactically prevent corneal neovascularization. In this situation the material could be injected in the perilimbic cornea interspersed between the corneal lesion and its undesired potential limbic blood supply. Such methods may also be utilized in a similar fashion to prevent capillary invasion of transplanted corneas. In a sustained-release form injections might only be required 2-3 times per year. A steroid could also be added to the injection solution to reduce inflammation resulting from the injection itself.

[0978] Within another aspect of the present invention, methods are provided for treating neovascular glaucoma, comprising the step of administering to a patient a therapeutically effective amount of a polynucleotide, polypeptide, antagonist and/or agonist to the eye, such that the formation of blood vessels is inhibited. In one embodiment, the compound may be administered topically to the eye in order to treat early forms of neovascular glaucoma. Within other embodiments, the compound may be implanted by injection into the region of the anterior chamber angle. Within other embodiments, the compound may also be placed in any location such that the compound is continuously released into the aqueous humor. Within another aspect of the present invention, methods are provided for treating proliferative diabetic retinopathy, comprising the step of administering to a patient a therapeutically effective amount of a polynucleotide, polypeptide, antagonist and/or agonist to the eyes, such that the formation of blood vessels is inhibited.

[0979] Within particularly preferred embodiments of the invention, proliferative diabetic retinopathy may be treated by injection into the aqueous humor or the vitreous, in order to increase the local concentration of the polynucleotide, polypeptide, antagonist

and/or agonist in the retina. Preferably, this treatment should be initiated prior to the acquisition of severe disease requiring photocoagulation.

[0980] Within another aspect of the present invention, methods are provided for treating retrolental fibroplasia, comprising the step of administering to a patient a therapeutically effective amount of a polynucleotide, polypeptide, antagonist and/or agonist to the eye, such that the formation of blood vessels is inhibited. The compound may be administered topically, via intravitreal injection and/or via intraocular implants.

[0981] Additionally, disorders which can be treated with the polynucleotides, polypeptides, agonists and/or antagonists include, but are not limited to, hemangioma, arthritis, psoriasis, angiofibroma, atherosclerotic plaques, delayed wound healing, granulations, hemophilic joints, hypertrophic scars, nonunion fractures, Osler-Weber syndrome, pyogenic granuloma, scleroderma, trachoma, and vascular adhesions.

[0982] Moreover, disorders and/or states, which can be treated, prevented, diagnosed, and/or prognosed with the polynucleotides, polypeptides, agonists and/or antagonists of the invention include, but are not limited to, solid tumors, blood born tumors such as leukemias, tumor metastasis, Kaposi's sarcoma, benign tumors, for example hemangiomas, acoustic neuromas, neurofibromas, trachomas, and pyogenic granulomas, rheumatoid arthritis, psoriasis, ocular angiogenic diseases, for example, diabetic retinopathy, retinopathy of prematurity, macular degeneration, corneal graft rejection, neovascular glaucoma, retrolental fibroplasia, rubeosis, retinoblastoma, and uveitis, delayed wound healing, endometriosis, vasculogenesis, granulations, hypertrophic scars (keloids), nonunion fractures, scleroderma, trachoma, vascular adhesions, myocardial angiogenesis, coronary collaterals, cerebral collaterals, arteriovenous malformations, ischemic limb angiogenesis, Osler-Weber Syndrome, plaque neovascularization, telangiectasia, hemophilic joints, angiofibroma fibromuscular dysplasia, wound granulation, Crohn's disease, atherosclerosis, birth control agent by preventing vascularization required for embryo implantation controlling menstruation, diseases that have angiogenesis as a pathologic consequence such as cat scratch disease (Rochelle minalia quintosa), ulcers (*Helicobacter pylori*), Bartonellosis and bacillary angiomatosis.

[0983] In one aspect of the birth control method, an amount of the compound sufficient to block embryo implantation is administered before or after intercourse and fertilization have occurred, thus providing an effective method of birth control, possibly a "morning

after" method. Polynucleotides, polypeptides, agonists and/or agonists may also be used in controlling menstruation or administered as either a peritoneal lavage fluid or for peritoneal implantation in the treatment of endometriosis.

[0984] Polynucleotides, polypeptides, agonists and/or agonists of the present invention may be incorporated into surgical sutures in order to prevent stitch granulomas.

[0985] Polynucleotides, polypeptides, agonists and/or agonists may be utilized in a wide variety of surgical procedures. For example, within one aspect of the present invention a compositions (in the form of, for example, a spray or film) may be utilized to coat or spray an area prior to removal of a tumor, in order to isolate normal surrounding tissues from malignant tissue, and/or to prevent the spread of disease to surrounding tissues. Within other aspects of the present invention, compositions (e.g., in the form of a spray) may be delivered via endoscopic procedures in order to coat tumors, or inhibit angiogenesis in a desired locale. Within yet other aspects of the present invention, surgical meshes which have been coated with anti-angiogenic compositions of the present invention may be utilized in any procedure wherein a surgical mesh might be utilized. For example, within one embodiment of the invention a surgical mesh laden with an anti-angiogenic composition may be utilized during abdominal cancer resection surgery (e.g., subsequent to colon resection) in order to provide support to the structure, and to release an amount of the anti-angiogenic factor.

[0986] Within further aspects of the present invention, methods are provided for treating tumor excision sites, comprising administering a polynucleotide, polypeptide, agonist and/or agonist to the resection margins of a tumor subsequent to excision, such that the local recurrence of cancer and the formation of new blood vessels at the site is inhibited. Within one embodiment of the invention, the anti-angiogenic compound is administered directly to the tumor excision site (e.g., applied by swabbing, brushing or otherwise coating the resection margins of the tumor with the anti-angiogenic compound). Alternatively, the anti-angiogenic compounds may be incorporated into known surgical pastes prior to administration. Within particularly preferred embodiments of the invention, the anti-angiogenic compounds are applied after hepatic resections for malignancy, and after neurosurgical operations.

[0987] Within one aspect of the present invention, polynucleotides, polypeptides, agonists and/or agonists may be administered to the resection margin of a wide variety of

tumors, including for example, breast, colon, brain and hepatic tumors. For example, within one embodiment of the invention, anti-angiogenic compounds may be administered to the site of a neurological tumor subsequent to excision, such that the formation of new blood vessels at the site are inhibited.

[0988] The polynucleotides, polypeptides, agonists and/or agonists of the present invention may also be administered along with other anti-angiogenic factors. Representative examples of other anti-angiogenic factors include: Anti-Invasive Factor, retinoic acid and derivatives thereof, paclitaxel, Suramin, Tissue Inhibitor of Metalloproteinase-1, Tissue Inhibitor of Metalloproteinase-2, Plasminogen Activator Inhibitor-1, Plasminogen Activator Inhibitor-2, and various forms of the lighter "d group" transition metals.

[0989] Lighter "d group" transition metals include, for example, vanadium, molybdenum, tungsten, titanium, niobium, and tantalum species. Such transition metal species may form transition metal complexes. Suitable complexes of the above-mentioned transition metal species include oxo transition metal complexes.

[0990] Representative examples of vanadium complexes include oxo vanadium complexes such as vanadate and vanadyl complexes. Suitable vanadate complexes include metavanadate and orthovanadate complexes such as, for example, ammonium metavanadate, sodium metavanadate, and sodium orthovanadate. Suitable vanadyl complexes include, for example, vanadyl acetylacetonate and vanadyl sulfate including vanadyl sulfate hydrates such as vanadyl sulfate mono- and trihydrates.

[0991] Representative examples of tungsten and molybdenum complexes also include oxo complexes. Suitable oxo tungsten complexes include tungstate and tungsten oxide complexes. Suitable tungstate complexes include ammonium tungstate, calcium tungstate, sodium tungstate dihydrate, and tungstic acid. Suitable tungsten oxides include tungsten (IV) oxide and tungsten (VI) oxide. Suitable oxo molybdenum complexes include molybdate, molybdenum oxide, and molybdenyl complexes. Suitable molybdate complexes include ammonium molybdate and its hydrates, sodium molybdate and its hydrates, and potassium molybdate and its hydrates. Suitable molybdenum oxides include molybdenum (VI) oxide, molybdenum (VI) oxide, and molybdic acid. Suitable molybdenyl complexes include, for example, molybdenyl acetylacetonate. Other suitable

tungsten and molybdenum complexes include hydroxo derivatives derived from, for example, glycerol, tartaric acid, and sugars.

[0992] A wide variety of other anti-angiogenic factors may also be utilized within the context of the present invention. Representative examples include platelet factor 4; protamine sulphate; sulphated chitin derivatives (prepared from queen crab shells), (Murata et al., Cancer Res. 51:22-26, 1991); Sulphated Polysaccharide Peptidoglycan Complex (SP- PG) (the function of this compound may be enhanced by the presence of steroids such as estrogen, and tamoxifen citrate); Staurosporine; modulators of matrix metabolism, including for example, proline analogs, cishydroxyproline, d,L-3,4-dehydropoline, Thiaproline, alpha,alpha-dipyridyl, aminopropionitrile fumarate; 4-propyl-5-(4-pyridinyl)-2(3H)-oxazalone; Methotrexate; Mitoxantrone; Heparin; Interferons; 2 Macroglobulin-serum; ChIMP-3 (Pavloff et al., J. Bio. Chem. 267:17321-17326, 1992); Chymostatin (Tomkinson et al., Biochem J. 286:475-480, 1992); Cyclodextrin Tetradecasulfate; Eponemycin; Camptothecin; Fumagillin (Ingber et al., Nature 348:555-557, 1990); Gold Sodium Thiomalate ("GST"; Matsubara and Ziff, J. Clin. Invest. 79:1440-1446, 1987); anticollagenase-serum; alpha2-antiplasmin (Holmes et al., J. Biol. Chem. 262(4):1659-1664, 1987); Bisantrone (National Cancer Institute); Lobenzarit disodium (N-(2)-carboxyphenyl-4- chloroanthronilic acid disodium or "CCA"; Takeuchi et al., Agents Actions 36:312-316, 1992); Thalidomide; Angostatic steroid; AGM-1470; carboxynaminolmidazole; and metalloproteinase inhibitors such as BB94.

Diseases at the Cellular Level

[0993] Diseases associated with increased cell survival or the inhibition of apoptosis that could be treated, prevented, diagnosed, and/or prognosed using polynucleotides or polypeptides, as well as antagonists or agonists of the present invention, include cancers (such as follicular lymphomas, carcinomas with p53 mutations, and hormone-dependent tumors, including, but not limited to colon cancer, cardiac tumors, pancreatic cancer, melanoma, retinoblastoma, glioblastoma, lung cancer, intestinal cancer, testicular cancer, stomach cancer, neuroblastoma, myxoma, myoma, lymphoma, endothelioma, osteoblastoma, osteoclastoma, osteosarcoma, chondrosarcoma, adenoma, breast cancer, prostate cancer, Kaposi's sarcoma and ovarian cancer); autoimmune disorders (such as, multiple sclerosis, Sjogren's syndrome, Hashimoto's thyroiditis, biliary cirrhosis, Behcet's

disease, Crohn's disease, polymyositis, systemic lupus erythematosus and immune-related glomerulonephritis and rheumatoid arthritis) and viral infections (such as herpes viruses, pox viruses and adenoviruses), inflammation, graft v. host disease, acute graft rejection, and chronic graft rejection.

[0994] In preferred embodiments, polynucleotides, polypeptides, and/or antagonists of the invention are used to inhibit growth, progression, and/or metasis of cancers, in particular those listed above.

[0995] Additional diseases or conditions associated with increased cell survival that could be treated or detected by polynucleotides or polypeptides, or agonists or antagonists of the present invention include, but are not limited to, progression, and/or metastases of malignancies and related disorders such as leukemia (including acute leukemias (e.g., acute lymphocytic leukemia, acute myelocytic leukemia (including myeloblastic, promyelocytic, myelomonocytic, monocytic, and erythroleukemia)) and chronic leukemias (e.g., chronic myelocytic (granulocytic) leukemia and chronic lymphocytic leukemia)), polycythemia vera, lymphomas (e.g., Hodgkin's disease and non-Hodgkin's disease), multiple myeloma, Waldenstrom's macroglobulinemia, heavy chain disease, and solid tumors including, but not limited to, sarcomas and carcinomas such as fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilm's tumor, cervical cancer, testicular tumor, lung carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, menangioma, melanoma, neuroblastoma, and retinoblastoma.

[0996] Diseases associated with increased apoptosis that could be treated, prevented, diagnosed, and/or progressed using polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, include, but are not limited to, AIDS;

neurodegenerative disorders (such as Alzheimer's disease, Parkinson's disease, Amyotrophic lateral sclerosis, Retinitis pigmentosa, Cerebellar degeneration and brain tumor or prior associated disease); autoimmune disorders (such as, multiple sclerosis, Sjogren's syndrome, Hashimoto's thyroiditis, biliary cirrhosis, Behcet's disease, Crohn's disease, polymyositis, systemic lupus erythematosus and immune-related glomerulonephritis and rheumatoid arthritis) myelodysplastic syndromes (such as aplastic anemia), graft v. host disease, ischemic injury (such as that caused by myocardial infarction, stroke and reperfusion injury), liver injury (e.g., hepatitis related liver injury, ischemia/reperfusion injury, cholestasis (bile duct injury) and liver cancer); toxin-induced liver disease (such as that caused by alcohol), septic shock, cachexia and anorexia.

Wound Healing and Epithelial Cell Proliferation

[0997] In accordance with yet a further aspect of the present invention, there is provided a process for utilizing polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, for therapeutic purposes, for example, to stimulate epithelial cell proliferation and basal keratinocytes for the purpose of wound healing, and to stimulate hair follicle production and healing of dermal wounds. Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, may be clinically useful in stimulating wound healing including surgical wounds, excisional wounds, deep wounds involving damage of the dermis and epidermis, eye tissue wounds, dental tissue wounds, oral cavity wounds, diabetic ulcers, dermal ulcers, cubitus ulcers, arterial ulcers, venous stasis ulcers, burns resulting from heat exposure or chemicals, and other abnormal wound healing conditions such as uremia, malnutrition, vitamin deficiencies and complications associated with systemic treatment with steroids, radiation therapy and antineoplastic drugs and antimetabolites. Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could be used to promote dermal reestablishment subsequent to dermal loss

[0998] Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could be used to increase the adherence of skin grafts to a wound bed and to stimulate re-epithelialization from the wound bed. The following are types of grafts that polynucleotides or polypeptides, agonists or antagonists of the present invention, could be used to increase adherence to a wound bed: autografts, artificial skin, allografts,

autodermic graft, autoepidermic grafts, avacular grafts, Blair-Brown grafts, bone graft, brephoplastic grafts, cutis graft, delayed graft, dermic graft, epidermic graft, fascia graft, full thickness graft, heterologous graft, xenograft, homologous graft, hyperplastic graft, lamellar graft, mesh graft, mucosal graft, Ollier-Thiersch graft, omentopial graft, patch graft, pedicle graft, penetrating graft, split skin graft, thick split graft. Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, can be used to promote skin strength and to improve the appearance of aged skin.

[0999] It is believed that polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, will also produce changes in hepatocyte proliferation, and epithelial cell proliferation in the lung, breast, pancreas, stomach, small intestine, and large intestine. Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could promote proliferation of epithelial cells such as sebocytes, hair follicles, hepatocytes, type II pneumocytes, mucin-producing goblet cells, and other epithelial cells and their progenitors contained within the skin, lung, liver, and gastrointestinal tract. Polynucleotides or polypeptides, agonists or antagonists of the present invention, may promote proliferation of endothelial cells, keratinocytes, and basal keratinocytes.

[1000] Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could also be used to reduce the side effects of gut toxicity that result from radiation, chemotherapy treatments or viral infections. Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, may have a cytoprotective effect on the small intestine mucosa. Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, may also stimulate healing of mucositis (mouth ulcers) that result from chemotherapy and viral infections.

[1001] Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could further be used in full regeneration of skin in full and partial thickness skin defects, including burns, (i.e., repopulation of hair follicles, sweat glands, and sebaceous glands), treatment of other skin defects such as psoriasis. Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could be used to treat epidermolysis bullosa, a defect in adherence of the epidermis to the underlying dermis which results in frequent, open and painful blisters by accelerating reepithelialization of these lesions. Polynucleotides or polypeptides, as well as agonists or

antagonists of the present invention, could also be used to treat gastric and duodenal ulcers and help heal by scar formation of the mucosal lining and regeneration of glandular mucosa and duodenal mucosal lining more rapidly. Inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis, are diseases which result in destruction of the mucosal surface of the small or large intestine, respectively. Thus, polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could be used to promote the resurfacing of the mucosal surface to aid more rapid healing and to prevent progression of inflammatory bowel disease. Treatment with polynucleotides or polypeptides, agonists or antagonists of the present invention, is expected to have a significant effect on the production of mucus throughout the gastrointestinal tract and could be used to protect the intestinal mucosa from injurious substances that are ingested or following surgery. Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could be used to treat diseases associated with the under expression.

[1002] Moreover, polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could be used to prevent and heal damage to the lungs due to various pathological states. Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, which could stimulate proliferation and differentiation and promote the repair of alveoli and bronchiolar epithelium to prevent or treat acute or chronic lung damage. For example, emphysema, which results in the progressive loss of alveoli, and inhalation injuries, i.e., resulting from smoke inhalation and burns, that cause necrosis of the bronchiolar epithelium and alveoli could be effectively treated using polynucleotides or polypeptides, agonists or antagonists of the present invention. Also, polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could be used to stimulate the proliferation of and differentiation of type II pneumocytes, which may help treat or prevent disease such as hyaline membrane diseases, such as infant respiratory distress syndrome and bronchopulmonary dysplasia, in premature infants.

[1003] Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could stimulate the proliferation and differentiation of hepatocytes and, thus, could be used to alleviate or treat liver diseases and pathologies such as fulminant liver failure caused by cirrhosis, liver damage caused by viral hepatitis and toxic

substances (i.e., acetaminophen, carbon tetrachloride and other hepatotoxins known in the art).

[1004] In addition, polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could be used to treat or prevent the onset of diabetes mellitus. In patients with newly diagnosed Types I and II diabetes, where some islet cell function remains, polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could be used to maintain the islet function so as to alleviate, delay or prevent permanent manifestation of the disease. Also, polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could be used as an auxiliary in islet cell transplantation to improve or promote islet cell function.

Neural Activity and Neurological Diseases

[1005] The polynucleotides, polypeptides and agonists or antagonists of the invention may be used for the diagnosis and/or treatment of diseases, disorders, damage or injury of the brain and/or nervous system. Nervous system disorders that can be treated with the compositions of the invention (e.g., polypeptides, polynucleotides, and/or agonists or antagonists), include, but are not limited to, nervous system injuries, and diseases or disorders which result in either a disconnection of axons, a diminution or degeneration of neurons, or demyelination. Nervous system lesions which may be treated in a patient (including human and non-human mammalian patients) according to the methods of the invention, include but are not limited to, the following lesions of either the central (including spinal cord, brain) or peripheral nervous systems: (1) ischemic lesions, in which a lack of oxygen in a portion of the nervous system results in neuronal injury or death, including cerebral infarction or ischemia, or spinal cord infarction or ischemia; (2) traumatic lesions, including lesions caused by physical injury or associated with surgery, for example, lesions which sever a portion of the nervous system, or compression injuries; (3) malignant lesions, in which a portion of the nervous system is destroyed or injured by malignant tissue which is either a nervous system associated malignancy or a malignancy derived from non-nervous system tissue; (4) infectious lesions, in which a portion of the nervous system is destroyed or injured as a result of infection, for example, by an abscess or associated with infection by human immunodeficiency virus, herpes zoster, or herpes simplex virus or with Lyme disease, tuberculosis, or syphilis; (5) degenerative lesions, in

which a portion of the nervous system is destroyed or injured as a result of a degenerative process including but not limited to, degeneration associated with Parkinson's disease, Alzheimer's disease, Huntington's chorea, or amyotrophic lateral sclerosis (ALS); (6) lesions associated with nutritional diseases or disorders, in which a portion of the nervous system is destroyed or injured by a nutritional disorder or disorder of metabolism including, but not limited to, vitamin B12 deficiency, folic acid deficiency, Wernicke disease, tobacco-alcohol amblyopia, Marchiafava-Bignami disease (primary degeneration of the corpus callosum), and alcoholic cerebellar degeneration; (7) neurological lesions associated with systemic diseases including, but not limited to, diabetes (diabetic neuropathy, Bell's palsy), systemic lupus erythematosus, carcinoma, or sarcoidosis; (8) lesions caused by toxic substances including alcohol, lead, or particular neurotoxins; and (9) demyelinated lesions in which a portion of the nervous system is destroyed or injured by a demyelinating disease including, but not limited to, multiple sclerosis, human immunodeficiency virus-associated myelopathy, transverse myelopathy or various etiologies, progressive multifocal leukoencephalopathy, and central pontine myelinolysis.

[1006] In one embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to protect neural cells from the damaging effects of hypoxia. In a further preferred embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to protect neural cells from the damaging effects of cerebral hypoxia. According to this embodiment, the compositions of the invention are used to treat or prevent neural cell injury associated with cerebral hypoxia. In one non-exclusive aspect of this embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention, are used to treat or prevent neural cell injury associated with cerebral ischemia. In another non-exclusive aspect of this embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to treat or prevent neural cell injury associated with cerebral infarction.

[1007] In another preferred embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to treat or prevent neural cell injury associated with a stroke. In a specific embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to treat or prevent cerebral neural cell injury associated with a stroke.

[1008] In another preferred embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to treat or prevent neural cell injury associated with a heart attack. In a specific embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to treat or prevent cerebral neural cell injury associated with a heart attack.

[1009] The compositions of the invention which are useful for treating or preventing a nervous system disorder may be selected by testing for biological activity in promoting the survival or differentiation of neurons. For example, and not by way of limitation, compositions of the invention which elicit any of the following effects may be useful according to the invention: (1) increased survival time of neurons in culture either in the presence or absence of hypoxia or hypoxic conditions; (2) increased sprouting of neurons in culture or *in vivo*; (3) increased production of a neuron-associated molecule in culture or *in vivo*, e.g., choline acetyltransferase or acetylcholinesterase with respect to motor neurons; or (4) decreased symptoms of neuron dysfunction *in vivo*. Such effects may be measured by any method known in the art. In preferred, non-limiting embodiments, increased survival of neurons may routinely be measured using a method set forth herein or otherwise known in the art, such as, for example, in Zhang *et al.*, *Proc Natl Acad Sci USA* 97:3637-42 (2000) or in Arakawa *et al.*, *J. Neurosci.*, 10:3507-15 (1990); increased sprouting of neurons may be detected by methods known in the art, such as, for example, the methods set forth in Pestronk *et al.*, *Exp. Neurol.*, 70:65-82 (1980), or Brown *et al.*, *Ann. Rev. Neurosci.*, 4:17-42 (1981); increased production of neuron-associated molecules may be measured by bioassay, enzymatic assay, antibody binding, Northern blot assay, etc., using techniques known in the art and depending on the molecule to be measured; and motor neuron dysfunction may be measured by assessing the physical manifestation of motor neuron disorder, e.g., weakness, motor neuron conduction velocity, or functional disability.

[1010] In specific embodiments, motor neuron disorders that may be treated according to the invention include, but are not limited to, disorders such as infarction, infection, exposure to toxin, trauma, surgical damage, degenerative disease or malignancy that may affect motor neurons as well as other components of the nervous system, as well as disorders that selectively affect neurons such as amyotrophic lateral sclerosis, and including, but not limited to, progressive spinal muscular atrophy, progressive bulbar

palsy, primary lateral sclerosis, infantile and juvenile muscular atrophy, progressive bulbar paralysis of childhood (Fazio-Londe syndrome), poliomyelitis and the post polio syndrome, and Hereditary Motorsensory Neuropathy (Charcot-Marie-Tooth Disease).

[1011] Further, polypeptides or polynucleotides of the invention may play a role in neuronal survival; synapse formation; conductance; neural differentiation, etc. Thus, compositions of the invention (including polynucleotides, polypeptides, and agonists or antagonists) may be used to diagnose and/or treat or prevent diseases or disorders associated with these roles, including, but not limited to, learning and/or cognition disorders. The compositions of the invention may also be useful in the treatment or prevention of neurodegenerative disease states and/or behavioural disorders. Such neurodegenerative disease states and/or behavioral disorders include, but are not limited to, Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, compositions of the invention may also play a role in the treatment, prevention and/or detection of developmental disorders associated with the developing embryo, or sexually-linked disorders.

[1012] Additionally, polypeptides, polynucleotides and/or agonists or antagonists of the invention, may be useful in protecting neural cells from diseases, damage, disorders, or injury, associated with cerebrovascular disorders including, but not limited to, carotid artery diseases (e.g., carotid artery thrombosis, carotid stenosis, or Moyamoya Disease), cerebral amyloid angiopathy, cerebral aneurysm, cerebral anoxia, cerebral arteriosclerosis, cerebral arteriovenous malformations, cerebral artery diseases, cerebral embolism and thrombosis (e.g., carotid artery thrombosis, sinus thrombosis, or Wallenberg's Syndrome), cerebral hemorrhage (e.g., epidural or subdural hematoma, or subarachnoid hemorrhage), cerebral infarction, cerebral ischemia (e.g., transient cerebral ischemia, Subclavian Steal Syndrome, or vertebrobasilar insufficiency), vascular dementia (e.g., multi-infarct), leukomalacia, periventricular, and vascular headache (e.g., cluster headache or migraines).

[1013] In accordance with yet a further aspect of the present invention, there is provided a process for utilizing polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, for therapeutic purposes, for example, to stimulate neurological cell proliferation and/or differentiation. Therefore, polynucleotides,

polypeptides, agonists and/or antagonists of the invention may be used to treat and/or detect neurologic diseases. Moreover, polynucleotides or polypeptides, or agonists or antagonists of the invention, can be used as a marker or detector of a particular nervous system disease or disorder.

[1014] Examples of neurologic diseases which can be treated or detected with polynucleotides, polypeptides, agonists, and/or antagonists of the present invention include brain diseases, such as metabolic brain diseases which includes phenylketonuria such as maternal phenylketonuria, pyruvate carboxylase deficiency, pyruvate dehydrogenase complex deficiency, Wernicke's Encephalopathy, brain edema, brain neoplasms such as cerebellar neoplasms which include infratentorial neoplasms, cerebral ventricle neoplasms such as choroid plexus neoplasms, hypothalamic neoplasms, supratentorial neoplasms, canavan disease, cerebellar diseases such as cerebellar ataxia which include spinocerebellar degeneration such as ataxia telangiectasia, cerebellar dyssynergia, Friederich's Ataxia, Machado-Joseph Disease, olivopontocerebellar atrophy, cerebellar neoplasms such as infratentorial neoplasms, diffuse cerebral sclerosis such as encephalitis periaxialis, globoid cell leukodystrophy, metachromatic leukodystrophy and subacute sclerosing panencephalitis.

[1015] Additional neurologic diseases which can be treated or detected with polynucleotides, polypeptides, agonists, and/or antagonists of the present invention include cerebrovascular disorders (such as carotid artery diseases which include carotid artery thrombosis, carotid stenosis and Moyamoya Disease), cerebral amyloid angiopathy, cerebral aneurysm, cerebral anoxia, cerebral arteriosclerosis, cerebral arteriovenous malformations, cerebral artery diseases, cerebral embolism and thrombosis such as carotid artery thrombosis, sinus thrombosis and Wallenberg's Syndrome, cerebral hemorrhage such as epidural hematoma, subdural hematoma and subarachnoid hemorrhage, cerebral infarction, cerebral ischemia such as transient cerebral ischemia, Subclavian Steal Syndrome and vertebrobasilar insufficiency, vascular dementia such as multi-infarct dementia, periventricular leukomalacia, vascular headache such as cluster headache and migraine.

[1016] Additional neurologic diseases which can be treated or detected with polynucleotides, polypeptides, agonists, and/or antagonists of the present invention include dementia such as AIDS Dementia Complex, presenile dementia such as

Alzheimer's Disease and Creutzfeldt-Jakob Syndrome, senile dementia such as Alzheimer's Disease and progressive supranuclear palsy, vascular dementia such as multi-infarct dementia, encephalitis which include encephalitis periaxialis, viral encephalitis such as epidemic encephalitis, Japanese Encephalitis, St. Louis Encephalitis, tick-borne encephalitis and West Nile Fever, acute disseminated encephalomyelitis, meningoencephalitis such as uveomeningoencephalitic syndrome, Postencephalitic Parkinson Disease and subacute sclerosing panencephalitis, encephalomalacia such as periventricular leukomalacia, epilepsy such as generalized epilepsy which includes infantile spasms, absence epilepsy, myoclonic epilepsy which includes MERRF Syndrome, tonic-clonic epilepsy, partial epilepsy such as complex partial epilepsy, frontal lobe epilepsy and temporal lobe epilepsy, post-traumatic epilepsy, status epilepticus such as Epilepsia Partialis Continua, and Hallervorden-Spatz Syndrome.

[1017] Additional neurologic diseases which can be treated or detected with polynucleotides, polypeptides, agonists, and/or antagonists of the present invention include hydrocephalus such as Dandy-Walker Syndrome and normal pressure hydrocephalus, hypothalamic diseases such as hypothalamic neoplasms, cerebral malaria, narcolepsy which includes cataplexy, bulbar poliomyelitis, cerebri pseudotumor, Rett Syndrome, Reye's Syndrome, thalamic diseases, cerebral toxoplasmosis, intracranial tuberculoma and Zellweger Syndrome, central nervous system infections such as AIDS Dementia Complex, Brain Abscess, subdural empyema, encephalomyelitis such as Equine Encephalomyelitis, Venezuelan Equine Encephalomyelitis, Necrotizing Hemorrhagic Encephalomyelitis, Visna, and cerebral malaria.

[1018] Additional neurologic diseases which can be treated or detected with polynucleotides, polypeptides, agonists, and/or antagonists of the present invention include meningitis such as arachnoiditis, aseptic meningitis such as viral meningitis which includes lymphocytic choriomeningitis, Bacterial meningitis which includes Haemophilus Meningitis, Listeria Meningitis, Meningococcal Meningitis such as Waterhouse-Friderichsen Syndrome, Pneumococcal Meningitis and meningeal tuberculosis, fungal meningitis such as Cryptococcal Meningitis, subdural effusion, meningoencephalitis such as uveomeningoencephalitic syndrome, myelitis such as transverse myelitis, neurosyphilis such as tabes dorsalis, poliomyelitis which includes bulbar poliomyelitis and postpoliomyelitis syndrome, prion diseases (such as Creutzfeldt-

Jakob Syndrome, Bovine Spongiform Encephalopathy, Gerstmann-Straussler Syndrome, Kuru, Scrapie), and cerebral toxoplasmosis.

[1019] Additional neurologic diseases which can be treated or detected with polynucleotides, polypeptides, agonists, and/or antagonists of the present invention include central nervous system neoplasms such as brain neoplasms that include cerebellar neoplasms such as infratentorial neoplasms, cerebral ventricle neoplasms such as choroid plexus neoplasms, hypothalamic neoplasms and supratentorial neoplasms, meningeal neoplasms, spinal cord neoplasms which include epidural neoplasms, demyelinating diseases such as Canavan Diseases, diffuse cerebral sclerolosis which includes adrenoleukodystrophy, encephalitis periaxialis, globoid cell leukodystrophy, diffuse cerebral sclerosis such as metachromatic leukodystrophy, allergic encephalomyelitis, necrotizing hemorrhagic encephalomyelitis, progressive multifocal leukoencephalopathy, multiple sclerosis, central pontine myelinolysis, transverse myelitis, neuromyelitis optica, Scrapie, Swayback, Chronic Fatigue Syndrome, Visna, High Pressure Nervous Syndrome, Meningism, spinal cord diseases such as amyotonia congenita, amyotrophic lateral sclerosis, spinal muscular atrophy such as Werdnig-Hoffmann Disease, spinal cord compression, spinal cord neoplasms such as epidural neoplasms, syringomyelia, Tabes Dorsalis, Stiff-Man Syndrome, mental retardation such as Angelman Syndrome, Cri-du-Chat Syndrome, De Lange's Syndrome, Down Syndrome, Gangliosidoses such as gangliosidoses G(M1), Sandhoff Disease, Tay-Sachs Disease, Hartnup Disease, homocystinuria, Laurence-Moon- Biedl Syndrome, Lesch-Nyhan Syndrome, Maple Syrup Urine Disease, mucopolipidosis such as fucosidosis, neuronal ceroid-lipofuscinosis, oculocerebrorenal syndrome, phenylketonuria such as maternal phenylketonuria, Prader-Willi Syndrome, Rett Syndrome, Rubinstein-Taybi Syndrome, Tuberous Sclerosis, WAGR Syndrome, nervous system abnormalities such as holoprosencephaly, neural tube defects such as anencephaly which includes hydrangencephaly, Arnold-Chairi Deformity, encephalocele, meningocele, meningomyelocele, spinal dysraphism such as spina bifida cystica and spina bifida occulta.

[1020] Additional neurologic diseases which can be treated or detected with polynucleotides, polypeptides, agonists, and/or antagonists of the present invention include hereditary motor and sensory neuropathies which include Charcot-Marie Disease, Hereditary optic atrophy, Refsum's Disease, hereditary spastic paraplegia, Werdnig-

Hoffmann Disease, Hereditary Sensory and Autonomic Neuropathies such as Congenital Analgesia and Familial Dysautonomia, Neurologic manifestations (such as agnosia that include Gerstmann's Syndrome, Amnesia such as retrograde amnesia, apraxia, neurogenic bladder, cataplexy, communicative disorders such as hearing disorders that includes deafness, partial hearing loss, loudness recruitment and tinnitus, language disorders such as aphasia which include agraphia, anomia, broca aphasia, and Wernicke Aphasia, Dyslexia such as Acquired Dyslexia, language development disorders, speech disorders such as aphasia which includes anomia, broca aphasia and Wernicke Aphasia, articulation disorders, communicative disorders such as speech disorders which include dysarthria, echolalia, mutism and stuttering, voice disorders such as aphonia and hoarseness, decerebrate state, delirium, fasciculation, hallucinations, meningism, movement disorders such as angelman syndrome, ataxia, athetosis, chorea, dystonia, hypokinesia, muscle hypotonia, myoclonus, tic, torticollis and tremor, muscle hypertonia such as muscle rigidity such as stiff-man syndrome, muscle spasticity, paralysis such as facial paralysis which includes Herpes Zoster Oticus, Gastroparesis, Hemiplegia, ophthalmoplegia such as diplopia, Duane's Syndrome, Horner's Syndrome, Chronic progressive external ophthalmoplegia such as Kearns Syndrome, Bulbar Paralysis, Tropical Spastic Paraparesis, Paraplegia such as Brown-Sequard Syndrome, quadriplegia, respiratory paralysis and vocal cord paralysis, paresis, phantom limb, taste disorders such as ageusia and dysgeusia, vision disorders such as amblyopia, blindness, color vision defects, diplopia, hemianopsia, scotoma and subnormal vision, sleep disorders such as hypersomnia which includes Kleine-Levin Syndrome, insomnia, and somnambulism, spasm such as trismus, unconsciousness such as coma, persistent vegetative state and syncope and vertigo, neuromuscular diseases such as amyotonia congenita, amyotrophic lateral sclerosis, Lambert-Eaton Myasthenic Syndrome, motor neuron disease, muscular atrophy such as spinal muscular atrophy, Charcot-Marie Disease and Werdnig-Hoffmann Disease, Postpoliomyelitis Syndrome, Muscular Dystrophy, Myasthenia Gravis, Myotonia Atrophica, Myotonia Confenita, Nemaline Myopathy, Familial Periodic Paralysis, Multiplex Paramyoclonus, Tropical Spastic Paraparesis and Stiff-Man Syndrome, peripheral nervous system diseases such as acrodynia, amyloid neuropathies, autonomic nervous system diseases such as Adie's Syndrome, Barre-Lieou Syndrome, Familial Dysautonomia, Horner's Syndrome, Reflex Sympathetic Dystrophy and Shy-Drager

Syndrome, Cranial Nerve Diseases such as Acoustic Nerve Diseases such as Acoustic Neuroma which includes Neurofibromatosis 2, Facial Nerve Diseases such as Facial Neuralgia, Melkersson-Rosenthal Syndrome, ocular motility disorders which includes amblyopia, nystagmus, oculomotor nerve paralysis, ophthalmoplegia such as Duane's Syndrome, Horner's Syndrome, Chronic Progressive External Ophthalmoplegia which includes Kearns Syndrome, Strabismus such as Esotropia and Exotropia, Oculomotor Nerve Paralysis, Optic Nerve Diseases such as Optic Atrophy which includes Hereditary Optic Atrophy, Optic Disk Drusen, Optic Neuritis such as Neuromyelitis Optica, Papilledema, Trigeminal Neuralgia, Vocal Cord Paralysis, Demyelinating Diseases such as Neuromyelitis Optica and Swayback, and Diabetic neuropathies such as diabetic foot.

[1021] Additional neurologic diseases which can be treated or detected with polynucleotides, polypeptides, agonists, and/or antagonists of the present invention include nerve compression syndromes such as carpal tunnel syndrome, tarsal tunnel syndrome, thoracic outlet syndrome such as cervical rib syndrome, ulnar nerve compression syndrome, neuralgia such as causalgia, cervico-brachial neuralgia, facial neuralgia and trigeminal neuralgia, neuritis such as experimental allergic neuritis, optic neuritis, polyneuritis, polyradiculoneuritis and radiculitis such as polyradiculitis, hereditary motor and sensory neuropathies such as Charcot-Marie Disease, Hereditary Optic Atrophy, Refsum's Disease, Hereditary Spastic Paraplegia and Werdnig-Hoffmann Disease, Hereditary Sensory and Autonomic Neuropathies which include Congenital Analgesia and Familial Dysautonomia, POEMS Syndrome, Sciatica, Gustatory Sweating and Tetany).

Endocrine Disorders

[1022] Polynucleotides or polypeptides, or agonists or antagonists of the present invention, may be used to treat, prevent, diagnose, and/or prognose disorders and/or diseases related to hormone imbalance, and/or disorders or diseases of the endocrine system.

[1023] Hormones secreted by the glands of the endocrine system control physical growth, sexual function, metabolism, and other functions. Disorders may be classified in two ways: disturbances in the production of hormones, and the inability of tissues to

respond to hormones. The etiology of these hormone imbalance or endocrine system diseases, disorders or conditions may be genetic, somatic, such as cancer and some autoimmune diseases, acquired (e.g., by chemotherapy, injury or toxins), or infectious. Moreover, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention can be used as a marker or detector of a particular disease or disorder related to the endocrine system and/or hormone imbalance.

[1000] Endocrine system and/or hormone imbalance and/or diseases encompass disorders of uterine motility including, but not limited to: complications with pregnancy and labor (e.g., pre-term labor, post-term pregnancy, spontaneous abortion, and slow or stopped labor); and disorders and/or diseases of the menstrual cycle (e.g., dysmenorrhea and endometriosis).

[1001] Endocrine system and/or hormone imbalance disorders and/or diseases include disorders and/or diseases of the pancreas, such as, for example, diabetes mellitus, diabetes insipidus, congenital pancreatic agenesis, pheochromocytoma--islet cell tumor syndrome; disorders and/or diseases of the adrenal glands such as, for example, Addison's Disease, corticosteroid deficiency, virilizing disease, hirsutism, Cushing's Syndrome, hyperaldosteronism, pheochromocytoma; disorders and/or diseases of the pituitary gland, such as, for example, hyperpituitarism, hypopituitarism, pituitary dwarfism, pituitary adenoma, panhypopituitarism, acromegaly, gigantism; disorders and/or diseases of the thyroid, including but not limited to, hyperthyroidism, hypothyroidism, Plummer's disease, Graves' disease (toxic diffuse goiter), toxic nodular goiter, thyroiditis (Hashimoto's thyroiditis, subacute granulomatous thyroiditis, and silent lymphocytic thyroiditis), Pendred's syndrome, myxedema, cretinism, thyrotoxicosis, thyroid hormone coupling defect, thymic aplasia, Hurthle cell tumours of the thyroid, thyroid cancer, thyroid carcinoma, Medullary thyroid carcinoma; disorders and/or diseases of the parathyroid, such as, for example, hyperparathyroidism, hypoparathyroidism; disorders and/or diseases of the hypothalamus.

[1002] In specific embodiments, the polynucleotides and/or polypeptides corresponding to this gene and/or agonists or antagonists of those polypeptides (including antibodies) as well as fragments and variants of those polynucleotides, polypeptides, agonists and antagonists, may be used to diagnose, prognose, treat, prevent, or ameliorate

diseases and disorders associated with aberrant glucose metabolism or glucose uptake into cells.

[1003] In a specific embodiment, the polynucleotides and/or polypeptides corresponding to this gene and/or agonists and/or antagonists thereof may be used to diagnose, prognose, treat, prevent, and/or ameliorate type I diabetes mellitus (insulin dependent diabetes mellitus, IDDM).

[1004] In another embodiment, the polynucleotides and/or polypeptides corresponding to this gene and/or agonists and/or antagonists thereof may be used to diagnose, prognose, treat, prevent, and/or ameliorate type II diabetes mellitus (insulin resistant diabetes mellitus).

[1005] Additionally, in other embodiments, the polynucleotides and/or polypeptides corresponding to this gene and/or antagonists thereof (especially neutralizing or antagonistic antibodies) may be used to diagnose, prognose, treat, prevent, or ameliorate conditions associated with (type I or type II) diabetes mellitus, including, but not limited to, diabetic ketoacidosis, diabetic coma, nonketotic hyperglycemic-hyperosmolar coma, seizures, mental confusion, drowsiness, cardiovascular disease (e.g., heart disease, atherosclerosis, microvascular disease, hypertension, stroke, and other diseases and disorders as described in the "Cardiovascular Disorders" section), dyslipidemia, kidney disease (e.g., renal failure, nephropathy other diseases and disorders as described in the "Renal Disorders" section), nerve damage, neuropathy, vision impairment (e.g., diabetic retinopathy and blindness), ulcers and impaired wound healing, infections (e.g., infectious diseases and disorders as described in the "Infectious Diseases" section, especially of the urinary tract and skin), carpal tunnel syndrome and Dupuytren's contracture.

[1006] In other embodiments, the polynucleotides and/or polypeptides corresponding to this gene and/or agonists or antagonists thereof are administered to an animal, preferably a mammal, and most preferably a human, in order to regulate the animal's weight. In specific embodiments the polynucleotides and/or polypeptides corresponding to this gene and/or agonists or antagonists thereof are administered to an animal, preferably a mammal, and most preferably a human, in order to control the animal's weight by modulating a biochemical pathway involving insulin. In still other embodiments the polynucleotides and/or polypeptides corresponding to this gene and/or agonists or antagonists thereof are administered to an animal, preferably a mammal, and most

preferably a human, in order to control the animal's weight by modulating a biochemical pathway involving insulin-like growth factor.

[1007] In addition, endocrine system and/or hormone imbalance disorders and/or diseases may also include disorders and/or diseases of the testes or ovaries, including cancer. Other disorders and/or diseases of the testes or ovaries further include, for example, ovarian cancer, polycystic ovary syndrome, Klinefelter's syndrome, vanishing testes syndrome (bilateral anorchia), congenital absence of Leydig's cells, cryptorchidism, Noonan's syndrome, myotonic dystrophy, capillary haemangioma of the testis (benign), neoplasias of the testis and neo-testis.

[1008] Moreover, endocrine system and/or hormone imbalance disorders and/or diseases may also include disorders and/or diseases such as, for example, polyglandular deficiency syndromes, pheochromocytoma, neuroblastoma, multiple Endocrine neoplasia, and disorders and/or cancers of endocrine tissues.

[1009] In another embodiment, a polypeptide of the invention, or polynucleotides, antibodies, agonists, or antagonists corresponding to that polypeptide, may be used to diagnose, prognose, prevent, and/or treat endocrine diseases and/or disorders associated with the tissue(s) in which the polypeptide of the invention is expressed, including one, two, three, four, five, or more tissues disclosed in Table 3, column 2 (Library Code).

Reproductive System Disorders

[1010] The polynucleotides or polypeptides, or agonists or antagonists of the invention may be used for the diagnosis, treatment, or prevention of diseases and/or disorders of the reproductive system. Reproductive system disorders that can be treated by the compositions of the invention, include, but are not limited to, reproductive system injuries, infections, neoplastic disorders, congenital defects, and diseases or disorders which result in infertility, complications with pregnancy, labor, or parturition, and postpartum difficulties.

[1011] Reproductive system disorders and/or diseases include diseases and/or disorders of the testes, including testicular atrophy, testicular feminization, cryptorchism (unilateral and bilateral), anorchia, ectopic testis, epididymitis and orchitis (typically resulting from infections such as, for example, gonorrhea, mumps, tuberculosis, and syphilis), testicular

torsion, vasitis nodosa, germ cell tumors (e.g., seminomas, embryonal cell carcinomas, teratocarcinomas, choriocarcinomas, yolk sac tumors, and teratomas), stromal tumors (e.g., Leydig cell tumors), hydrocele, hematocele, varicocele, spermatocele, inguinal hernia, and disorders of sperm production (e.g., immotile cilia syndrome, aspermia, asthenozoospermia, azoospermia, oligospermia, and teratozoospermia).

[1012] Reproductive system disorders also include disorders of the prostate gland, such as acute non-bacterial prostatitis, chronic non-bacterial prostatitis, acute bacterial prostatitis, chronic bacterial prostatitis, prostatodystonia, prostatosis, granulomatous prostatitis, malacoplakia, benign prostatic hypertrophy or hyperplasia, and prostate neoplastic disorders, including adenocarcinomas, transitional cell carcinomas, ductal carcinomas, and squamous cell carcinomas.

[1013] Additionally, the compositions of the invention may be useful in the diagnosis, treatment, and/or prevention of disorders or diseases of the penis and urethra, including inflammatory disorders, such as balanoposthitis, balanitis xerotica obliterans, phimosis, paraphimosis, syphilis, herpes simplex virus, gonorrhea, non-gonococcal urethritis, chlamydia, mycoplasma, trichomonas, HIV, AIDS, Reiter's syndrome, condyloma acuminatum, condyloma latum, and pearly penile papules; urethral abnormalities, such as hypospadias, epispadias, and phimosis; premalignant lesions, including Erythroplasia of Queyrat, Bowen's disease, Bowenoid paplosis, giant condyloma of Buscke-Lowenstein, and verrucous carcinoma; penile cancers, including squamous cell carcinomas, carcinoma in situ, verrucous carcinoma, and disseminated penile carcinoma; urethral neoplastic disorders, including penile urethral carcinoma, bulbomembranous urethral carcinoma, and prostatic urethral carcinoma; and erectile disorders, such as priapism, Peyronie's disease, erectile dysfunction, and impotence.

[1014] Moreover, diseases and/or disorders of the vas deferens include vasculitis and CBAVD (congenital bilateral absence of the vas deferens); additionally, the polynucleotides, polypeptides, and agonists or antagonists of the present invention may be used in the diagnosis, treatment, and/or prevention of diseases and/or disorders of the seminal vesicles, including hydatid disease, congenital chloride diarrhea, and polycystic kidney disease.

[1015] Other disorders and/or diseases of the male reproductive system include, for example, Klinefelter's syndrome, Young's syndrome, premature ejaculation, diabetes

mellitus, cystic fibrosis, Kartagener's syndrome, high fever, multiple sclerosis, and gynecomastia.

[1016] Further, the polynucleotides, polypeptides, and agonists or antagonists of the present invention may be used in the diagnosis, treatment, and/or prevention of diseases and/or disorders of the vagina and vulva, including bacterial vaginosis, candida vaginitis, herpes simplex virus, chancroid, granuloma inguinale, lymphogranuloma venereum, scabies, human papillomavirus, vaginal trauma, vulvar trauma, adenositis, chlamydia vaginitis, gonorrhea, trichomonas vaginitis, condyloma acuminatum, syphilis, molluscum contagiosum, atrophic vaginitis, Paget's disease, lichen sclerosus, lichen planus, vulvodynia, toxic shock syndrome, vaginismus, vulvovaginitis, vulvar vestibulitis, and neoplastic disorders, such as squamous cell hyperplasia, clear cell carcinoma, basal cell carcinoma, melanomas, cancer of Bartholin's gland, and vulvar intraepithelial neoplasia.

[1017] Disorders and/or diseases of the uterus include dysmenorrhea, retroverted uterus, endometriosis, fibroids, adenomyosis, anovulatory bleeding, amenorrhea, Cushing's syndrome, hydatidiform moles, Asherman's syndrome, premature menopause, precocious puberty, uterine polyps, dysfunctional uterine bleeding (e.g., due to aberrant hormonal signals), and neoplastic disorders, such as adenocarcinomas, leiomyosarcomas, and sarcomas. Additionally, the polypeptides, polynucleotides, or agonists or antagonists of the invention may be useful as a marker or detector of, as well as in the diagnosis, treatment, and/or prevention of congenital uterine abnormalities, such as bicornuate uterus, septate uterus, simple unicornuate uterus, unicornuate uterus with a noncavitary rudimentary horn, unicornuate uterus with a non-communicating cavitary rudimentary horn, unicornuate uterus with a communicating cavitary horn, arcuate uterus, uterine didelphys, and T-shaped uterus.

[1018] Ovarian diseases and/or disorders include anovulation, polycystic ovary syndrome (Stein-Leventhal syndrome), ovarian cysts, ovarian hypofunction, ovarian insensitivity to gonadotropins, ovarian overproduction of androgens, right ovarian vein syndrome, amenorrhea, hirsutism, and ovarian cancer (including, but not limited to, primary and secondary cancerous growth, Sertoli-Leydig tumors, endometrioid carcinoma of the ovary, ovarian papillary serous adenocarcinoma, ovarian mucinous adenocarcinoma, and Ovarian Krukenberg tumors).

[1019] Cervical diseases and/or disorders include cervicitis, chronic cervicitis, mucopurulent cervicitis, cervical dysplasia, cervical polyps, Nabothian cysts, cervical erosion, cervical incompetence, and cervical neoplasms (including, for example, cervical carcinoma, squamous metaplasia, squamous cell carcinoma, adenosquamous cell neoplasia, and columnar cell neoplasia).

[1020] Additionally, diseases and/or disorders of the reproductive system include disorders and/or diseases of pregnancy, including miscarriage and stillbirth, such as early abortion, late abortion, spontaneous abortion, induced abortion, therapeutic abortion, threatened abortion, missed abortion, incomplete abortion, complete abortion, habitual abortion, missed abortion, and septic abortion; ectopic pregnancy, anemia, Rh incompatibility, vaginal bleeding during pregnancy, gestational diabetes, intrauterine growth retardation, polyhydramnios, HELLP syndrome, abruptio placentae, placenta previa, hyperemesis, preeclampsia, eclampsia, herpes gestationis, and urticaria of pregnancy. Additionally, the polynucleotides, polypeptides, and agonists or antagonists of the present invention may be used in the diagnosis, treatment, and/or prevention of diseases that can complicate pregnancy, including heart disease, heart failure, rheumatic heart disease, congenital heart disease, mitral valve prolapse, high blood pressure, anemia, kidney disease, infectious disease (e.g., rubella, cytomegalovirus, toxoplasmosis, infectious hepatitis, chlamydia, HIV, AIDS, and genital herpes), diabetes mellitus, Graves' disease, thyroiditis, hypothyroidism, Hashimoto's thyroiditis, chronic active hepatitis, cirrhosis of the liver, primary biliary cirrhosis, asthma, systemic lupus erythematosus, rheumatoid arthritis, myasthenia gravis, idiopathic thrombocytopenic purpura, appendicitis, ovarian cysts, gallbladder disorders, and obstruction of the intestine.

[1021] Complications associated with labor and parturition include premature rupture of the membranes, pre-term labor, post-term pregnancy, postmaturity, labor that progresses too slowly, fetal distress (e.g., abnormal heart rate (fetal or maternal), breathing problems, and abnormal fetal position), shoulder dystocia, prolapsed umbilical cord, amniotic fluid embolism, and aberrant uterine bleeding.

[1022] Further, diseases and/or disorders of the postdelivery period, including endometritis, myometritis, parametritis, peritonitis, pelvic thrombophlebitis, pulmonary embolism, endotoxemia, pyelonephritis, saphenous thrombophlebitis, mastitis, cystitis, postpartum hemorrhage, and inverted uterus.

[1023] Other disorders and/or diseases of the female reproductive system that may be diagnosed, treated, and/or prevented by the polynucleotides, polypeptides, and agonists or antagonists of the present invention include, for example, Turner's syndrome, pseudohermaphroditism, premenstrual syndrome, pelvic inflammatory disease, pelvic congestion (vascular engorgement), frigidity, anorgasmia, dyspareunia, ruptured fallopian tube, and Mittelschmerz.

Infectious Disease

[1024] Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention can be used to treat or detect infectious agents. For example, by increasing the immune response, particularly increasing the proliferation and differentiation of B and/or T cells, infectious diseases may be treated. The immune response may be increased by either enhancing an existing immune response, or by initiating a new immune response. Alternatively, polynucleotides or polypeptides, as well as agonists or antagonists of the present invention may also directly inhibit the infectious agent, without necessarily eliciting an immune response.

[1025] Viruses are one example of an infectious agent that can cause disease or symptoms that can be treated or detected by a polynucleotide or polypeptide and/or agonist or antagonist of the present invention. Examples of viruses, include, but are not limited to Examples of viruses, include, but are not limited to the following DNA and RNA viruses and viral families: Arbovirus, Adenoviridae, Arenaviridae, Arterivirus, Bimaviridae, Bunyaviridae, Caliciviridae, Circoviridae, Coronaviridae, Dengue, EBV, HIV, Flaviviridae, Hepadnaviridae (Hepatitis), Herpesviridae (such as, Cytomegalovirus, Herpes Simplex, Herpes Zoster), Mononegavirus (e.g., Paramyxoviridae, Morbillivirus, Rhabdoviridae), Orthomyxoviridae (e.g., Influenza A, Influenza B, and parainfluenza), Papiloma virus, Papovaviridae, Parvoviridae, Picomaviridae, Poxviridae (such as Smallpox or Vaccinia), Reoviridae (e.g., Rotavirus), Retroviridae (HTLV-I, HTLV-II, Lentivirus), and Togaviridae (e.g., Rubivirus). Viruses falling within these families can cause a variety of diseases or symptoms, including, but not limited to: arthritis, bronchiolitis, respiratory syncytial virus, encephalitis, eye infections (e.g., conjunctivitis, keratitis), chronic fatigue syndrome, hepatitis (A, B, C, E, Chronic Active, Delta),

Japanese B encephalitis, Junin, Chikungunya, Rift Valley fever, yellow fever, meningitis, opportunistic infections (e.g., AIDS), pneumonia, Burkitt's Lymphoma, chickenpox, hemorrhagic fever, Measles, Mumps, Parainfluenza, Rabies, the common cold, Polio, leukemia, Rubella, sexually transmitted diseases, skin diseases (e.g., Kaposi's, warts), and viremia. polynucleotides or polypeptides, or agonists or antagonists of the invention, can be used to treat or detect any of these symptoms or diseases. In specific embodiments, polynucleotides, polypeptides, or agonists or antagonists of the invention are used to treat: meningitis, Dengue, EBV, and/or hepatitis (e.g., hepatitis B). In an additional specific embodiment polynucleotides, polypeptides, or agonists or antagonists of the invention are used to treat patients nonresponsive to one or more other commercially available hepatitis vaccines. In a further specific embodiment polynucleotides, polypeptides, or agonists or antagonists of the invention are used to treat AIDS.

[1026] Similarly, bacterial and fungal agents that can cause disease or symptoms and that can be treated or detected by a polynucleotide or polypeptide and/or agonist or antagonist of the present invention include, but not limited to, the following Gram-Negative and Gram-positive bacteria, bacterial families, and fungi: Actinomyces (e.g., Norcardia), Acinetobacter, *Cryptococcus neoformans*, Aspergillus, Bacillaceae (e.g., *Bacillus anthracis*), Bacteroides (e.g., *Bacteroides fragilis*), Blastomycosis, Bordetella, Borrelia (e.g., *Borrelia burgdorferi*), Brucella, Candidia, Campylobacter, Chlamydia, Clostridium (e.g., *Clostridium botulinum*, *Clostridium difficile*, *Clostridium perfringens*, *Clostridium tetani*), Coccidioides, Corynebacterium (e.g., *Corynebacterium diphtheriae*), Cryptococcus, Dermatocycoses, *E. coli* (e.g., Enterotoxigenic *E. coli* and Enterohemorrhagic *E. coli*), Enterobacter (e.g. *Enterobacter aerogenes*), Enterobacteriaceae (Klebsiella, Salmonella (e.g., *Salmonella typhi*, *Salmonella enteritidis*, *Salmonella typhi*), Serratia, Yersinia, Shigella), Erysipelothrix, Haemophilus (e.g., *Haemophilus influenza* type B), Helicobacter, Legionella (e.g., *Legionella pneumophila*), Leptospira, Listeria (e.g., *Listeria monocytogenes*), Mycoplasma, Mycobacterium (e.g., *Mycobacterium leprae* and *Mycobacterium tuberculosis*), Vibrio (e.g., *Vibrio cholerae*), Neisseriaceae (e.g., *Neisseria gonorrhea*, *Neisseria meningitidis*), Pasteurellaceae, Proteus, Pseudomonas (e.g., *Pseudomonas aeruginosa*), Rickettsiaceae, Spirochetes (e.g., Treponema spp., Leptospira spp., Borrelia spp.), Shigella spp., Staphylococcus (e.g., *Staphylococcus aureus*), Meningioccocus, Pneumococcus and Streptococcus (e.g.,

Streptococcus pneumoniae and Groups A, B, and C Streptococci), and Ureaplasmas. These bacterial, parasitic, and fungal families can cause diseases or symptoms, including, but not limited to: antibiotic-resistant infections, bacteremia, endocarditis, septicemia, eye infections (e.g., conjunctivitis), uveitis, tuberculosis, gingivitis, bacterial diarrhea, opportunistic infections (e.g., AIDS related infections), paronychia, prosthesis-related infections, dental caries, Reiter's Disease, respiratory tract infections, such as Whooping Cough or Empyema, sepsis, Lyme Disease, Cat-Scratch Disease, dysentery, paratyphoid fever, food poisoning, Legionella disease, chronic and acute inflammation, erythema, yeast infections, typhoid, pneumonia, gonorrhea, meningitis (e.g., meningitis types A and B), chlamydia, syphilis, diphtheria, leprosy, brucellosis, peptic ulcers, anthrax, spontaneous abortions, birth defects, pneumonia, lung infections, ear infections, deafness, blindness, lethargy, malaise, vomiting, chronic diarrhea, Crohn's disease, colitis, vaginosis, sterility, pelvic inflammatory diseases, candidiasis, paratuberculosis, tuberculosis, lupus, botulism, gangrene, tetanus, impetigo, Rheumatic Fever, Scarlet Fever, sexually transmitted diseases, skin diseases (e.g., cellulitis, dermatocycoses), toxemia, urinary tract infections, wound infections, noscomial infections. Polynucleotides or polypeptides, agonists or antagonists of the invention, can be used to treat or detect any of these symptoms or diseases. In specific embodiments, polynucleotides, polypeptides, agonists or antagonists of the invention are used to treat: tetanus, diphtheria, botulism, and/or meningitis type B.

[1027] Moreover, parasitic agents causing disease or symptoms that can be treated, prevented, and/or diagnosed by a polynucleotide or polypeptide and/or agonist or antagonist of the present invention include, but not limited to, the following families or class: Amebiasis, Babesiosis, Coccidiosis, Cryptosporidiosis, Dientamoebiasis, Dourine, Ectoparasitic, Giardiasis, Helminthiasis, Leishmaniasis, Schistosoma, Theileriasis, Toxoplasmosis, Trypanosomiasis, and Trichomonas and Sporozoans (e.g., *Plasmodium virax*, *Plasmodium falciparum*, *Plasmodium malariae* and *Plasmodium ovale*). These parasites can cause a variety of diseases or symptoms, including, but not limited to: Scabies, Trombiculiasis, eye infections, intestinal disease (e.g., dysentery, giardiasis), liver disease, lung disease, opportunistic infections (e.g., AIDS related), malaria, pregnancy complications, and toxoplasmosis. polynucleotides or polypeptides, or agonists or antagonists of the invention, can be used to treat, prevent, and/or diagnose any of these

symptoms or diseases. In specific embodiments, polynucleotides, polypeptides, or agonists or antagonists of the invention are used to treat, prevent, and/or diagnose malaria.

[1028] Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention could either be by administering an effective amount of a polypeptide to the patient, or by removing cells from the patient, supplying the cells with a polynucleotide of the present invention, and returning the engineered cells to the patient (ex vivo therapy). Moreover, the polypeptide or polynucleotide of the present invention can be used as an antigen in a vaccine to raise an immune response against infectious disease.

Regeneration

[1029] Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention can be used to differentiate, proliferate, and attract cells, leading to the regeneration of tissues. (See, Science 276:59-87 (1997)). The regeneration of tissues could be used to repair, replace, or protect tissue damaged by congenital defects, trauma (wounds, burns, incisions, or ulcers), age, disease (e.g. osteoporosis, osteoarthritis, periodontal disease, liver failure), surgery, including cosmetic plastic surgery, fibrosis, reperfusion injury, or systemic cytokine damage.

[1030] Tissues that could be regenerated using the present invention include organs (e.g., pancreas, liver, intestine, kidney, skin, endothelium), muscle (smooth, skeletal or cardiac), vasculature (including vascular and lymphatics), nervous, hematopoietic, and skeletal (bone, cartilage, tendon, and ligament) tissue. Preferably, regeneration occurs without or decreased scarring. Regeneration also may include angiogenesis.

[1031] Moreover, polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, may increase regeneration of tissues difficult to heal. For example, increased tendon/ligament regeneration would quicken recovery time after damage. Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention could also be used prophylactically in an effort to avoid damage. Specific diseases that could be treated include of tendinitis, carpal tunnel syndrome, and other tendon or ligament defects. A further example of tissue regeneration of non-healing wounds includes pressure ulcers, ulcers associated with vascular insufficiency, surgical, and traumatic wounds.

[1032] Similarly, nerve and brain tissue could also be regenerated by using polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, to proliferate and differentiate nerve cells. Diseases that could be treated using this method include central and peripheral nervous system diseases, neuropathies, or mechanical and traumatic disorders (e.g., spinal cord disorders, head trauma, cerebrovascular disease, and stroke). Specifically, diseases associated with peripheral nerve injuries, peripheral neuropathy (e.g., resulting from chemotherapy or other medical therapies), localized neuropathies, and central nervous system diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and Shy-Drager syndrome), could all be treated using the polynucleotides or polypeptides, as well as agonists or antagonists of the present invention.

Gastrointestinal Disorders

[1033] Polynucleotides or polypeptides, or agonists or antagonists of the present invention, may be used to treat, prevent, diagnose, and/or prognose gastrointestinal disorders, including inflammatory diseases and/or conditions, infections, cancers (e.g., intestinal neoplasms (carcinoid tumor of the small intestine, non-Hodgkin's lymphoma of the small intestine, small bowel lymphoma)), and ulcers, such as peptic ulcers.

[1034] Gastrointestinal disorders include dysphagia, odynophagia, inflammation of the esophagus, peptic esophagitis, gastric reflux, submucosal fibrosis and stricturing, Mallory-Weiss lesions, leiomyomas, lipomas, epidermal cancers, adeoncarcinomas, gastric retention disorders, gastroenteritis, gastric atrophy, gastric/stomach cancers, polyps of the stomach, autoimmune disorders such as pernicious anemia, pyloric stenosis, gastritis (bacterial, viral, eosinophilic, stress-induced, chronic erosive, atrophic, plasma cell, and Ménétrier's), and peritoneal diseases (e.g., chyloperitoneum, hemoperitoneum, mesenteric cyst, mesenteric lymphadenitis, mesenteric vascular occlusion, panniculitis, neoplasms, peritonitis, pneumoperitoneum, bubphrenic abscess,).

[1035] Gastrointestinal disorders also include disorders associated with the small intestine, such as malabsorption syndromes, distension, irritable bowel syndrome, sugar intolerance, celiac disease, duodenal ulcers, duodenitis, tropical sprue, Whipple's disease, intestinal lymphangiectasia, Crohn's disease, appendicitis, obstructions of the ileum,

Meckel's diverticulum, multiple diverticula, failure of complete rotation of the small and large intestine, lymphoma, and bacterial and parasitic diseases (such as Traveler's diarrhea, typhoid and paratyphoid, cholera, infection by Roundworms (*Ascaris lumbricoides*), Hookworms (*Ancylostoma duodenale*), Threadworms (*Enterobius vermicularis*), Tapeworms (*Taenia saginata*, *Echinococcus granulosus*, *Diphyllobothrium spp.*, and *T. solium*).

[1036] Liver diseases and/or disorders include intrahepatic cholestasis (alagille syndrome, biliary liver cirrhosis), fatty liver (alcoholic fatty liver, reye syndrome), hepatic vein thrombosis, hepatolenticular degeneration, hepatomegaly, hepatopulmonary syndrome, hepatorenal syndrome, portal hypertension (esophageal and gastric varices), liver abscess (amebic liver abscess), liver cirrhosis (alcoholic, biliary and experimental), alcoholic liver diseases (fatty liver, hepatitis, cirrhosis), parasitic (hepatic echinococcosis, fascioliasis, amebic liver abscess), jaundice (hemolytic, hepatocellular, and cholestatic), cholestasis, portal hypertension, liver enlargement, ascites, hepatitis (alcoholic hepatitis, animal hepatitis, chronic hepatitis (autoimmune, hepatitis B, hepatitis C, hepatitis D, drug induced), toxic hepatitis, viral human hepatitis (hepatitis A, hepatitis B, hepatitis C, hepatitis D, hepatitis E), Wilson's disease, granulomatous hepatitis, secondary biliary cirrhosis, hepatic encephalopathy, portal hypertension, varices, hepatic encephalopathy, primary biliary cirrhosis, primary sclerosing cholangitis, hepatocellular adenoma, hemangiomas, bile stones, liver failure (hepatic encephalopathy, acute liver failure), and liver neoplasms (angiomyolipoma, calcified liver metastases, cystic liver metastases, epithelial tumors, fibrolamellar hepatocarcinoma, focal nodular hyperplasia, hepatic adenoma, hepatobiliary cystadenoma, hepatoblastoma, hepatocellular carcinoma, hepatoma, liver cancer, liver hemangioendothelioma, mesenchymal hamartoma, mesenchymal tumors of liver, nodular regenerative hyperplasia, benign liver tumors (Hepatic cysts [Simple cysts, Polycystic liver disease, Hepatobiliary cystadenoma, Choledochal cyst], Mesenchymal tumors [Mesenchymal hamartoma, Infantile hemangioendothelioma, Hemangioma, Peliosis hepatis, Lipomas, Inflammatory pseudotumor, Miscellaneous], Epithelial tumors [Bile duct epithelium (Bile duct hamartoma, Bile duct adenoma), Hepatocyte (Adenoma, Focal nodular hyperplasia, Nodular regenerative hyperplasia)], malignant liver tumors [hepatocellular, hepatoblastoma, hepatocellular carcinoma, cholangiocellular, cholangiocarcinoma,

cystadenocarcinoma, tumors of blood vessels, angiosarcoma, Kaposi's sarcoma, hemangioendothelioma, other tumors, embryonal sarcoma, fibrosarcoma, leiomyosarcoma, rhabdomyosarcoma, carcinosarcoma, teratoma, carcinoid, squamous carcinoma, primary lymphoma), peliosis hepatis, erythrohepatic porphyria, hepatic porphyria (acute intermittent porphyria, porphyria cutanea tarda), Zellweger syndrome).

[1037] Pancreatic diseases and/or disorders include acute pancreatitis, chronic pancreatitis (acute necrotizing pancreatitis, alcoholic pancreatitis), neoplasms (adenocarcinoma of the pancreas, cystadenocarcinoma, insulinoma, gastrinoma, and glucagonoma, cystic neoplasms, islet-cell tumors, pancreoblastoma), and other pancreatic diseases (e.g., cystic fibrosis, cyst (pancreatic pseudocyst, pancreatic fistula, insufficiency)).

[1038] Gallbladder diseases include gallstones (cholelithiasis and choledocholithiasis), postcholecystectomy syndrome, diverticulosis of the gallbladder, acute cholecystitis, chronic cholecystitis, bile duct tumors, and mucocele.

[1039] Diseases and/or disorders of the large intestine include antibiotic-associated colitis, diverticulitis, ulcerative colitis, acquired megacolon, abscesses, fungal and bacterial infections, anorectal disorders (e.g., fissures, hemorrhoids), colonic diseases (colitis, colonic neoplasms [colon cancer, adenomatous colon polyps (e.g., villous adenoma), colon carcinoma, colorectal cancer], colonic diverticulitis, colonic diverticulosis, megacolon [Hirschsprung disease, toxic megacolon]; sigmoid diseases [proctocolitis, sigmoid neoplasms]), constipation, Crohn's disease, diarrhea (infantile diarrhea, dysentery), duodenal diseases (duodenal neoplasms, duodenal obstruction, duodenal ulcer, duodenitis), enteritis (enterocolitis), HIV enteropathy, ileal diseases (ileal neoplasms, ileitis), immunoproliferative small intestinal disease, inflammatory bowel disease (ulcerative colitis, Crohn's disease), intestinal atresia, parasitic diseases (anisakiasis, balantidiasis, blastocystis infections, cryptosporidiosis, dientamoebiasis, amebic dysentery, giardiasis), intestinal fistula (rectal fistula), intestinal neoplasms (cecal neoplasms, colonic neoplasms, duodenal neoplasms, ileal neoplasms, intestinal polyps, jejunal neoplasms, rectal neoplasms), intestinal obstruction (afferent loop syndrome, duodenal obstruction, impacted feces, intestinal pseudo-obstruction [cecal volvulus], intussusception), intestinal perforation, intestinal polyps (colonic polyps, gardner syndrome, peutz-jeghers syndrome), jejunal diseases (jejunal neoplasms), malabsorption

syndromes (blind loop syndrome, celiac disease, lactose intolerance, short bowel syndrome, tropical sprue, whipple's disease), mesenteric vascular occlusion, pneumatosis cystoides intestinalis, protein-losing enteropathies (intestinal lymphangiectasis), rectal diseases (anus diseases, fecal incontinence, hemorrhoids, proctitis, rectal fistula, rectal prolapse, rectocele), peptic ulcer (duodenal ulcer, peptic esophagitis, hemorrhage, perforation, stomach ulcer, Zollinger-Ellison syndrome), postgastrectomy syndromes (dumping syndrome), stomach diseases (e.g., achlorhydria, duodenogastric reflux (bile reflux), gastric antral vascular ectasia, gastric fistula, gastric outlet obstruction, gastritis (atrophic or hypertrophic), gastroparesis, stomach dilatation, stomach diverticulum, stomach neoplasms (gastric cancer, gastric polyps, gastric adenocarcinoma, hyperplastic gastric polyp), stomach rupture, stomach ulcer, stomach volvulus), tuberculosis, visceroperitonitis, vomiting (e.g., hematemesis, hyperemesis gravidarum, postoperative nausea and vomiting) and hemorrhagic colitis.

[1040] Further diseases and/or disorders of the gastrointestinal system include biliary tract diseases, such as, gastroschisis, fistula (e.g., biliary fistula, esophageal fistula, gastric fistula, intestinal fistula, pancreatic fistula), neoplasms (e.g., biliary tract neoplasms, esophageal neoplasms, such as adenocarcinoma of the esophagus, esophageal squamous cell carcinoma, gastrointestinal neoplasms, pancreatic neoplasms, such as adenocarcinoma of the pancreas, mucinous cystic neoplasm of the pancreas, pancreatic cystic neoplasms, pancreatoblastoma, and peritoneal neoplasms), esophageal disease (e.g., bullous diseases, candidiasis, glycogenic acanthosis, ulceration, Barrett esophagus varices, atresia, cyst, diverticulum (e.g., Zenker's diverticulum), fistula (e.g., tracheoesophageal fistula), motility disorders (e.g., CREST syndrome, deglutition disorders, achalasia, spasm, gastroesophageal reflux), neoplasms, perforation (e.g., Boerhaave syndrome, Mallory-Weiss syndrome), stenosis, esophagitis, diaphragmatic hernia (e.g., hiatal hernia); gastrointestinal diseases, such as, gastroenteritis (e.g., cholera morbus, norwalk virus infection), hemorrhage (e.g., hematemesis, melena, peptic ulcer hemorrhage), stomach neoplasms (gastric cancer, gastric polyps, gastric adenocarcinoma, stomach cancer)), hernia (e.g., congenital diaphragmatic hernia, femoral hernia, inguinal hernia, obturator hernia, umbilical hernia, ventral hernia), and intestinal diseases (e.g., cecal diseases (appendicitis, cecal neoplasms)).

Chemotaxis

[1041] Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention may have chemotaxis activity. A chemotactic molecule attracts or mobilizes cells (e.g., monocytes, fibroblasts, neutrophils, T-cells, mast cells, eosinophils, epithelial and/or endothelial cells) to a particular site in the body, such as inflammation, infection, or site of hyperproliferation. The mobilized cells can then fight off and/or heal the particular trauma or abnormality.

[1042] Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention may increase chemotactic activity of particular cells. These chemotactic molecules can then be used to treat inflammation, infection, hyperproliferative disorders, or any immune system disorder by increasing the number of cells targeted to a particular location in the body. For example, chemotactic molecules can be used to treat wounds and other trauma to tissues by attracting immune cells to the injured location. Chemotactic molecules of the present invention can also attract fibroblasts, which can be used to treat wounds.

[1043] It is also contemplated that polynucleotides or polypeptides, as well as agonists or antagonists of the present invention may inhibit chemotactic activity. These molecules could also be used to treat disorders. Thus, polynucleotides or polypeptides, as well as agonists or antagonists of the present invention could be used as an inhibitor of chemotaxis.

Binding Activity

[1044] A polypeptide of the present invention may be used to screen for molecules that bind to the polypeptide or for molecules to which the polypeptide binds. The binding of the polypeptide and the molecule may activate (agonist), increase, inhibit (antagonist), or decrease activity of the polypeptide or the molecule bound. Examples of such molecules include antibodies, oligonucleotides, proteins (e.g., receptors), or small molecules.

[1045] Preferably, the molecule is closely related to the natural ligand of the polypeptide, e.g., a fragment of the ligand, or a natural substrate, a ligand, a structural or functional mimetic. (See, Coligan et al., Current Protocols in Immunology 1(2):Chapter 5 (1991)). Similarly, the molecule can be closely related to the natural receptor to which the

polypeptide binds, or at least, a fragment of the receptor capable of being bound by the polypeptide (e.g., active site). In either case, the molecule can be rationally designed using known techniques.

[1046] Preferably, the screening for these molecules involves producing appropriate cells which express the polypeptide. Preferred cells include cells from mammals, yeast, *Drosophila*, or *E. coli*. Cells expressing the polypeptide (or cell membrane containing the expressed polypeptide) are then preferably contacted with a test compound potentially containing the molecule to observe binding, stimulation, or inhibition of activity of either the polypeptide or the molecule.

[1047] The assay may simply test binding of a candidate compound to the polypeptide, wherein binding is detected by a label, or in an assay involving competition with a labeled competitor. Further, the assay may test whether the candidate compound results in a signal generated by binding to the polypeptide.

[1048] Alternatively, the assay can be carried out using cell-free preparations, polypeptide/molecule affixed to a solid support, chemical libraries, or natural product mixtures. The assay may also simply comprise the steps of mixing a candidate compound with a solution containing a polypeptide, measuring polypeptide/molecule activity or binding, and comparing the polypeptide/molecule activity or binding to a standard.

[1049] Preferably, an ELISA assay can measure polypeptide level or activity in a sample (e.g., biological sample) using a monoclonal or polyclonal antibody. The antibody can measure polypeptide level or activity by either binding, directly or indirectly, to the polypeptide or by competing with the polypeptide for a substrate.

[1050] Additionally, the receptor to which the polypeptide of the present invention binds can be identified by numerous methods known to those of skill in the art, for example, ligand panning and FACS sorting (Coligan, et al., *Current Protocols in Immun.*, 1(2), Chapter 5, (1991)). For example, expression cloning is employed wherein polyadenylated RNA is prepared from a cell responsive to the polypeptides, for example, NIH3T3 cells which are known to contain multiple receptors for the FGF family proteins, and SC-3 cells, and a cDNA library created from this RNA is divided into pools and used to transfect COS cells or other cells that are not responsive to the polypeptides. Transfected cells which are grown on glass slides are exposed to the polypeptide of the present invention, after they have been labeled. The polypeptides can be labeled by a

variety of means including iodination or inclusion of a recognition site for a site-specific protein kinase.

[1051] Following fixation and incubation, the slides are subjected to auto-radiographic analysis. Positive pools are identified and sub-pools are prepared and re-transfected using an iterative sub-pooling and re-screening process, eventually yielding a single clones that encodes the putative receptor.

[1052] As an alternative approach for receptor identification, the labeled polypeptides can be photoaffinity linked with cell membrane or extract preparations that express the receptor molecule. Cross-linked material is resolved by PAGE analysis and exposed to X-ray film. The labeled complex containing the receptors of the polypeptides can be excised, resolved into peptide fragments, and subjected to protein microsequencing. The amino acid sequence obtained from microsequencing would be used to design a set of degenerate oligonucleotide probes to screen a cDNA library to identify the genes encoding the putative receptors.

[1053] Moreover, the techniques of gene-shuffling, motif-shuffling, exon-shuffling, and/or codon-shuffling (collectively referred to as "DNA shuffling") may be employed to modulate the activities of the polypeptide of the present invention thereby effectively generating agonists and antagonists of the polypeptide of the present invention. *See generally*, U.S. Patent Nos. 5,605,793, 5,811,238, 5,830,721, 5,834,252, and 5,837,458, and Patten, P. A., *et al.*, *Curr. Opinion Biotechnol.* 8:724-33 (1997); Harayama, S. *Trends Biotechnol.* 16(2):76-82 (1998); Hansson, L. O., *et al.*, *J. Mol. Biol.* 287:265-76 (1999); and Lorenzo, M. M. and Blasco, R. *Biotechniques* 24(2):308-13 (1998); each of these patents and publications are hereby incorporated by reference). In one embodiment, alteration of polynucleotides and corresponding polypeptides may be achieved by DNA shuffling. DNA shuffling involves the assembly of two or more DNA segments into a desired molecule by homologous, or site-specific, recombination. In another embodiment, polynucleotides and corresponding polypeptides may be altered by being subjected to random mutagenesis by error-prone PCR, random nucleotide insertion or other methods prior to recombination. In another embodiment, one or more components, motifs, sections, parts, domains, fragments, etc., of the polypeptide of the present invention may be recombined with one or more components, motifs, sections, parts, domains, fragments, etc. of one or more heterologous molecules. In preferred embodiments, the heterologous

molecules are family members. In further preferred embodiments, the heterologous molecule is a growth factor such as, for example, platelet-derived growth factor (PDGF), insulin-like growth factor (IGF-I), transforming growth factor (TGF)-alpha, epidermal growth factor (EGF), fibroblast growth factor (FGF), TGF-beta, bone morphogenetic protein (BMP)-2, BMP-4, BMP-5, BMP-6, BMP-7, activins A and B, decapentaplegic(dpp), 60A, OP-2, dorsalin, growth differentiation factors (GDFs), nodal, MIS, inhibin-alpha, TGF-beta1, TGF-beta2, TGF-beta3, TGF-beta5, and glial-derived neurotrophic factor (GDNF).

[1054] Other preferred fragments are biologically active fragments of the polypeptide of the present invention. Biologically active fragments are those exhibiting activity similar, but not necessarily identical, to an activity of the polypeptide of the present invention. The biological activity of the fragments may include an improved desired activity, or a decreased undesirable activity.

[1055] Additionally, this invention provides a method of screening compounds to identify those which modulate the action of the polypeptide of the present invention. An example of such an assay comprises combining a mammalian fibroblast cell, a the polypeptide of the present invention, the compound to be screened and ^3H thymidine under cell culture conditions where the fibroblast cell would normally proliferate. A control assay may be performed in the absence of the compound to be screened and compared to the amount of fibroblast proliferation in the presence of the compound to determine if the compound stimulates proliferation by determining the uptake of ^3H thymidine in each case. The amount of fibroblast cell proliferation is measured by liquid scintillation chromatography which measures the incorporation of ^3H thymidine. Both agonist and antagonist compounds may be identified by this procedure.

[1056] In another method, a mammalian cell or membrane preparation expressing a receptor for a polypeptide of the present invention is incubated with a labeled polypeptide of the present invention in the presence of the compound. The ability of the compound to enhance or block this interaction could then be measured. Alternatively, the response of a known second messenger system following interaction of a compound to be screened and the receptor is measured and the ability of the compound to bind to the receptor and elicit a second messenger response is measured to determine if the compound is a potential

agonist or antagonist. Such second messenger systems include but are not limited to, cAMP guanylate cyclase, ion channels or phosphoinositide hydrolysis.

[1057] All of these above assays can be used as diagnostic or prognostic markers. The molecules discovered using these assays can be used to treat disease or to bring about a particular result in a patient (e.g., blood vessel growth) by activating or inhibiting the polypeptide/molecule. Moreover, the assays can discover agents which may inhibit or enhance the production of the polypeptides of the invention from suitably manipulated cells or tissues.

[1058] Therefore, the invention includes a method of identifying compounds which bind to a polypeptide of the invention comprising the steps of: (a) incubating a candidate binding compound with a polypeptide of the present invention; and (b) determining if binding has occurred. Moreover, the invention includes a method of identifying agonists/antagonists comprising the steps of: (a) incubating a candidate compound with a polypeptide of the present invention, (b) assaying a biological activity, and (b) determining if a biological activity of the polypeptide has been altered.

Targeted Delivery

[1059] In another embodiment, the invention provides a method of delivering compositions to targeted cells expressing a receptor for a polypeptide of the invention, or cells expressing a cell bound form of a polypeptide of the invention.

[1060] As discussed herein, polypeptides or antibodies of the invention may be associated with heterologous polypeptides, heterologous nucleic acids, toxins, or prodrugs via hydrophobic, hydrophilic, ionic and/or covalent interactions. In one embodiment, the invention provides a method for the specific delivery of compositions of the invention to cells by administering polypeptides of the invention (including antibodies) that are associated with heterologous polypeptides or nucleic acids. In one example, the invention provides a method for delivering a therapeutic protein into the targeted cell. In another example, the invention provides a method for delivering a single stranded nucleic acid (e.g., antisense or ribozymes) or double stranded nucleic acid (e.g., DNA that can integrate into the cell's genome or replicate episomally and that can be transcribed) into the targeted cell.

[1061] In another embodiment, the invention provides a method for the specific destruction of cells (e.g., the destruction of tumor cells) by administering polypeptides of the invention (e.g., polypeptides of the invention or antibodies of the invention) in association with toxins or cytotoxic prodrugs.

[1062] By "toxin" is meant compounds that bind and activate endogenous cytotoxic effector systems, radioisotopes, holotoxins, modified toxins, catalytic subunits of toxins, or any molecules or enzymes not normally present in or on the surface of a cell that under defined conditions cause the cell's death. Toxins that may be used according to the methods of the invention include, but are not limited to, radioisotopes known in the art, compounds such as, for example, antibodies (or complement fixing containing portions thereof) that bind an inherent or induced endogenous cytotoxic effector system, thymidine kinase, endonuclease, RNase, alpha toxin, ricin, abrin, *Pseudomonas* exotoxin A, diphtheria toxin, saporin, momordin, gelonin, pokeweed antiviral protein, alpha-sarcin and cholera toxin. By "cytotoxic prodrug" is meant a non-toxic compound that is converted by an enzyme, normally present in the cell, into a cytotoxic compound. Cytotoxic prodrugs that may be used according to the methods of the invention include, but are not limited to, glutamyl derivatives of benzoic acid mustard alkylating agent, phosphate derivatives of etoposide or mitomycin C, cytosine arabinoside, daunorubisin, and phenoxycetamide derivatives of doxorubicin.

Drug Screening

[1063] Further contemplated is the use of the polypeptides of the present invention, or the polynucleotides encoding these polypeptides, to screen for molecules which modify the activities of the polypeptides of the present invention. Such a method would include contacting the polypeptide of the present invention with a selected compound(s) suspected of having antagonist or agonist activity, and assaying the activity of these polypeptides following binding.

[1064] This invention is particularly useful for screening therapeutic compounds by using the polypeptides of the present invention, or binding fragments thereof, in any of a variety of drug screening techniques. The polypeptide or fragment employed in such a test may be affixed to a solid support, expressed on a cell surface, free in solution, or located

intracellularly. One method of drug screening utilizes eukaryotic or prokaryotic host cells which are stably transformed with recombinant nucleic acids expressing the polypeptide or fragment. Drugs are screened against such transformed cells in competitive binding assays. One may measure, for example, the formulation of complexes between the agent being tested and a polypeptide of the present invention.

[1065] Thus, the present invention provides methods of screening for drugs or any other agents which affect activities mediated by the polypeptides of the present invention. These methods comprise contacting such an agent with a polypeptide of the present invention or a fragment thereof and assaying for the presence of a complex between the agent and the polypeptide or a fragment thereof, by methods well known in the art. In such a competitive binding assay, the agents to screen are typically labeled. Following incubation, free agent is separated from that present in bound form, and the amount of free or uncomplexed label is a measure of the ability of a particular agent to bind to the polypeptides of the present invention.

[1066] Another technique for drug screening provides high throughput screening for compounds having suitable binding affinity to the polypeptides of the present invention, and is described in great detail in European Patent Application 84/03564, published on September 13, 1984, which is incorporated herein by reference herein. Briefly stated, large numbers of different small peptide test compounds are synthesized on a solid substrate, such as plastic pins or some other surface. The peptide test compounds are reacted with polypeptides of the present invention and washed. Bound polypeptides are then detected by methods well known in the art. Purified polypeptides are coated directly onto plates for use in the aforementioned drug screening techniques. In addition, non-neutralizing antibodies may be used to capture the peptide and immobilize it on the solid support.

[1067] This invention also contemplates the use of competitive drug screening assays in which neutralizing antibodies capable of binding polypeptides of the present invention specifically compete with a test compound for binding to the polypeptides or fragments thereof. In this manner, the antibodies are used to detect the presence of any peptide which shares one or more antigenic epitopes with a polypeptide of the invention.

Antisense And Ribozyme (Antagonists)

[1068] In specific embodiments, antagonists according to the present invention are nucleic acids corresponding to the sequences contained in SEQ ID NO:X, or the complementary strand thereof, and/or to cDNA sequences contained in cDNA plasmid:Z identified for example, in Table 1. In one embodiment, antisense sequence is generated internally, by the organism, in another embodiment, the antisense sequence is separately administered (see, for example, O'Connor, J., *Neurochem.* 56:560 (1991). *Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression*, CRC Press, Boca Raton, FL (1988). Antisense technology can be used to control gene expression through antisense DNA or RNA, or through triple-helix formation. Antisense techniques are discussed for example, in Okano, J., *Neurochem.* 56:560 (1991); *Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression*, CRC Press, Boca Raton, FL (1988). Triple helix formation is discussed in, for instance, Lee et al., *Nucleic Acids Research* 6:3073 (1979); Cooney et al., *Science* 241:456 (1988); and Dervan et al., *Science* 251:1300 (1991). The methods are based on binding of a polynucleotide to a complementary DNA or RNA.

[1069] For example, the use of c-myc and c-myb antisense RNA constructs to inhibit the growth of the non-lymphocytic leukemia cell line HL-60 and other cell lines was previously described. (Wickstrom et al. (1988); Anfossi et al. (1989)). These experiments were performed *in vitro* by incubating cells with the oligoribonucleotide. A similar procedure for *in vivo* use is described in WO 91/15580. Briefly, a pair of oligonucleotides for a given antisense RNA is produced as follows: A sequence complimentary to the first 15 bases of the open reading frame is flanked by an EcoRI site on the 5' end and a HindIII site on the 3' end. Next, the pair of oligonucleotides is heated at 90°C for one minute and then annealed in 2X ligation buffer (20mM TRIS HCl pH 7.5, 10mM MgCl₂, 10mM dithiothreitol (DTT) and 0.2 mM ATP) and then ligated to the EcoRI/Hind III site of the retroviral vector PMV7 (WO 91/15580).

[1070] For example, the 5' coding portion of a polynucleotide that encodes the polypeptide of the present invention may be used to design an antisense RNA oligonucleotide of from about 10 to 40 base pairs in length. A DNA oligonucleotide is designed to be complementary to a region of the gene involved in transcription thereby preventing transcription and the production of the receptor. The antisense RNA

oligonucleotide hybridizes to the mRNA *in vivo* and blocks translation of the mRNA molecule into receptor polypeptide.

[1071] In one embodiment, the antisense nucleic acid of the invention is produced intracellularly by transcription from an exogenous sequence. For example, a vector or a portion thereof, is transcribed, producing an antisense nucleic acid (RNA) of the invention. Such a vector would contain a sequence encoding the antisense nucleic acid. Such a vector can remain episomal or become chromosomally integrated, as long as it can be transcribed to produce the desired antisense RNA. Such vectors can be constructed by recombinant DNA technology methods standard in the art. Vectors can be plasmid, viral, or others known in the art, used for replication and expression in vertebrate cells. Expression of the sequence encoding the polypeptide of the present invention or fragments thereof, can be by any promoter known in the art to act in vertebrate, preferably human cells. Such promoters can be inducible or constitutive. Such promoters include, but are not limited to, the SV40 early promoter region (Bernoist and Chambon, Nature 29:304-310 (1981), the promoter contained in the 3' long terminal repeat of Rous sarcoma virus (Yamamoto et al., Cell 22:787-797 (1980), the herpes thymidine promoter (Wagner et al., Proc. Natl. Acad. Sci. U.S.A. 78:1441-1445 (1981), the regulatory sequences of the metallothionein gene (Brinster, et al., Nature 296:39-42 (1982)), etc.

[1072] The antisense nucleic acids of the invention comprise a sequence complementary to at least a portion of an RNA transcript of a gene of the present invention. However, absolute complementarity, although preferred, is not required. A sequence "complementary to at least a portion of an RNA," referred to herein, means a sequence having sufficient complementarity to be able to hybridize with the RNA, forming a stable duplex; in the case of double stranded antisense nucleic acids, a single strand of the duplex DNA may thus be tested, or triplex formation may be assayed. The ability to hybridize will depend on both the degree of complementarity and the length of the antisense nucleic acid. Generally, the larger the hybridizing nucleic acid, the more base mismatches with a RNA it may contain and still form a stable duplex (or triplex as the case may be). One skilled in the art can ascertain a tolerable degree of mismatch by use of standard procedures to determine the melting point of the hybridized complex.

[1073] Oligonucleotides that are complementary to the 5' end of the message, e.g., the 5' untranslated sequence up to and including the AUG initiation codon, should work most

efficiently at inhibiting translation. However, sequences complementary to the 3' untranslated sequences of mRNAs have been shown to be effective at inhibiting translation of mRNAs as well. See generally, Wagner, R., 1994, Nature 372:333-335. Thus, oligonucleotides complementary to either the 5'- or 3'- non-translated, non-coding regions of polynucleotide sequences described herein could be used in an antisense approach to inhibit translation of endogenous mRNA. Oligonucleotides complementary to the 5' untranslated region of the mRNA should include the complement of the AUG start codon. Antisense oligonucleotides complementary to mRNA coding regions are less efficient inhibitors of translation but could be used in accordance with the invention. Whether designed to hybridize to the 5'-, 3'- or coding region of mRNA of the present invention, antisense nucleic acids should be at least six nucleotides in length, and are preferably oligonucleotides ranging from 6 to about 50 nucleotides in length. In specific aspects the oligonucleotide is at least 10 nucleotides, at least 17 nucleotides, at least 25 nucleotides or at least 50 nucleotides.

[1074] The polynucleotides of the invention can be DNA or RNA or chimeric mixtures or derivatives or modified versions thereof, single-stranded or double-stranded. The oligonucleotide can be modified at the base moiety, sugar moiety, or phosphate backbone, for example, to improve stability of the molecule, hybridization, etc. The oligonucleotide may include other appended groups such as peptides (e.g., for targeting host cell receptors *in vivo*), or agents facilitating transport across the cell membrane (see, e.g., Letsinger et al., 1989, Proc. Natl. Acad. Sci. U.S.A. 86:6553-6556; Lemaitre et al., 1987, Proc. Natl. Acad. Sci. 84:648-652; PCT Publication No. WO88/09810, published December 15, 1988) or the blood-brain barrier (see, e.g., PCT Publication No. WO89/10134, published April 25, 1988), hybridization-triggered cleavage agents. (See, e.g., Krol et al., 1988, BioTechniques 6:958-976) or intercalating agents. (See, e.g., Zon, 1988, Pharm. Res. 5:539-549). To this end, the oligonucleotide may be conjugated to another molecule, e.g., a peptide, hybridization triggered cross-linking agent, transport agent, hybridization-triggered cleavage agent, etc.

[1075] The antisense oligonucleotide may comprise at least one modified base moiety which is selected from the group including, but not limited to, 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xantine, 4-acetylcytosine, 5-(carboxyhydroxymethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine,

5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine.

[1076] The antisense oligonucleotide may also comprise at least one modified sugar moiety selected from the group including, but not limited to, arabinose, 2-fluoroarabinose, xylulose, and hexose.

[1077] In yet another embodiment, the antisense oligonucleotide comprises at least one modified phosphate backbone selected from the group including, but not limited to, a phosphorothioate, a phosphorodithioate, a phosphoramidothioate, a phosphoramidate, a phosphordiamidate, a methylphosphonate, an alkyl phosphotriester, and a formacetal or analog thereof.

[1078] In yet another embodiment, the antisense oligonucleotide is an a-anomeric oligonucleotide. An a-anomeric oligonucleotide forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual b-units, the strands run parallel to each other (Gautier et al., 1987, Nucl. Acids Res. 15:6625-6641). The oligonucleotide is a 2'-O-methylribonucleotide (Inoue et al., 1987, Nucl. Acids Res. 15:6131-6148), or a chimeric RNA-DNA analogue (Inoue et al., 1987, FEBS Lett. 215:327-330).

[1079] Polynucleotides of the invention may be synthesized by standard methods known in the art, e.g. by use of an automated DNA synthesizer (such as are commercially available from Biosearch, Applied Biosystems, etc.). As examples, phosphorothioate oligonucleotides may be synthesized by the method of Stein et al. (1988, Nucl. Acids Res. 16:3209), methylphosphonate oligonucleotides can be prepared by use of controlled pore glass polymer supports (Sarin et al., 1988, Proc. Natl. Acad. Sci. U.S.A. 85:7448-7451), etc.

[1080] While antisense nucleotides complementary to the coding region sequence could be used, those complementary to the transcribed untranslated region are most preferred.

[1081] Potential antagonists according to the invention also include catalytic RNA, or a ribozyme (See, e.g., PCT International Publication WO 90/11364, published October 4, 1990; Sarver et al, Science 247:1222-1225 (1990). While ribozymes that cleave mRNA at site specific recognition sequences can be used to destroy mRNAs, the use of hammerhead ribozymes is preferred. Hammerhead ribozymes cleave mRNAs at locations dictated by flanking regions that form complementary base pairs with the target mRNA. The sole requirement is that the target mRNA have the following sequence of two bases: 5'-UG-3'. The construction and production of hammerhead ribozymes is well known in the art and is described more fully in Haseloff and Gerlach, Nature 334:585-591 (1988). There are numerous potential hammerhead ribozyme cleavage sites within the nucleotide sequence of SEQ ID NO:X. Preferably, the ribozyme is engineered so that the cleavage recognition site is located near the 5' end of the mRNA; i.e., to increase efficiency and minimize the intracellular accumulation of non-functional mRNA transcripts.

[1082] As in the antisense approach, the ribozymes of the invention can be composed of modified oligonucleotides (e.g., for improved stability, targeting, etc.) and should be delivered to cells which express *in vivo*. DNA constructs encoding the ribozyme may be introduced into the cell in the same manner as described above for the introduction of antisense encoding DNA. A preferred method of delivery involves using a DNA construct "encoding" the ribozyme under the control of a strong constitutive promoter, such as, for example, pol III or pol II promoter, so that transfected cells will produce sufficient quantities of the ribozyme to destroy endogenous messages and inhibit translation. Since ribozymes unlike antisense molecules, are catalytic, a lower intracellular concentration is required for efficiency.

[1083] Antagonist/agonist compounds may be employed to inhibit the cell growth and proliferation effects of the polypeptides of the present invention on neoplastic cells and tissues, i.e. stimulation of angiogenesis of tumors, and, therefore, retard or prevent abnormal cellular growth and proliferation, for example, in tumor formation or growth.

[1084] The antagonist/agonist may also be employed to prevent hyper-vascular diseases, and prevent the proliferation of epithelial lens cells after extracapsular cataract

surgery. Prevention of the mitogenic activity of the polypeptides of the present invention may also be desirous in cases such as restenosis after balloon angioplasty.

[1085] The antagonist/agonist may also be employed to prevent the growth of scar tissue during wound healing.

[1086] The antagonist/agonist may also be employed to treat the diseases described herein.

[1087] Thus, the invention provides a method of treating disorders or diseases, including but not limited to the disorders or diseases listed throughout this application, associated with overexpression of a polynucleotide of the present invention by administering to a patient (a) an antisense molecule directed to the polynucleotide of the present invention, and/or (b) a ribozyme directed to the polynucleotide of the present invention.

Binding Peptides and Other Molecules

[1088] The invention also encompasses screening methods for identifying polypeptides and nonpolypeptides that bind polypeptides of the invention, and the binding molecules identified thereby. These binding molecules are useful, for example, as agonists and antagonists of the polypeptides of the invention. Such agonists and antagonists can be used, in accordance with the invention, in the therapeutic embodiments described in detail, below.

[1089] This method comprises the steps of:

1. contacting polypeptides of the invention with a plurality of molecules;
and
2. identifying a molecule that binds the polypeptides of the invention.

[1090] The step of contacting the polypeptides of the invention with the plurality of molecules may be effected in a number of ways. For example, one may contemplate immobilizing the polypeptides on a solid support and bringing a solution of the plurality of molecules in contact with the immobilized polypeptides. Such a procedure would be akin to an affinity chromatographic process, with the affinity matrix being comprised of the immobilized polypeptides of the invention. The molecules having a selective affinity for the polypeptides can then be purified by affinity selection. The nature of the solid support, process for attachment of the polypeptides to the solid support, solvent, and conditions of

the affinity isolation or selection are largely conventional and well known to those of ordinary skill in the art.

[1091] Alternatively, one may also separate a plurality of polypeptides into substantially separate fractions comprising a subset of or individual polypeptides. For instance, one can separate the plurality of polypeptides by gel electrophoresis, column chromatography, or like method known to those of ordinary skill for the separation of polypeptides. The individual polypeptides can also be produced by a transformed host cell in such a way as to be expressed on or about its outer surface (e.g., a recombinant phage). Individual isolates can then be "probed" by the polypeptides of the invention, optionally in the presence of an inducer should one be required for expression, to determine if any selective affinity interaction takes place between the polypeptides and the individual clone. Prior to contacting the polypeptides with each fraction comprising individual polypeptides, the polypeptides could first be transferred to a solid support for additional convenience. Such a solid support may simply be a piece of filter membrane, such as one made of nitrocellulose or nylon. In this manner, positive clones could be identified from a collection of transformed host cells of an expression library, which harbor a DNA construct encoding a polypeptide having a selective affinity for polypeptides of the invention. Furthermore, the amino acid sequence of the polypeptide having a selective affinity for the polypeptides of the invention can be determined directly by conventional means or the coding sequence of the DNA encoding the polypeptide can frequently be determined more conveniently. The primary sequence can then be deduced from the corresponding DNA sequence. If the amino acid sequence is to be determined from the polypeptide itself, one may use microsequencing techniques. The sequencing technique may include mass spectroscopy.

[1092] In certain situations, it may be desirable to wash away any unbound polypeptides from a mixture of the polypeptides of the invention and the plurality of polypeptides prior to attempting to determine or to detect the presence of a selective affinity interaction. Such a wash step may be particularly desirable when the polypeptides of the invention or the plurality of polypeptides are bound to a solid support.

[1093] The plurality of molecules provided according to this method may be provided by way of diversity libraries, such as random or combinatorial peptide or nonpeptide libraries which can be screened for molecules that specifically bind polypeptides of the

invention. Many libraries are known in the art that can be used, e.g., chemically synthesized libraries, recombinant (e.g., phage display libraries), and in vitro translation-based libraries. Examples of chemically synthesized libraries are described in Fodor et al., 1991, *Science* 251:767-773; Houghten et al., 1991, *Nature* 354:84-86; Lam et al., 1991, *Nature* 354:82-84; Medynski, 1994, *Bio/Technology* 12:709-710; Gallop et al., 1994, *J. Medicinal Chemistry* 37(9):1233-1251; Ohlmeyer et al., 1993, *Proc. Natl. Acad. Sci. USA* 90:10922-10926; Erb et al., 1994, *Proc. Natl. Acad. Sci. USA* 91:11422-11426; Houghten et al., 1992, *Biotechniques* 13:412; Jayawickreme et al., 1994, *Proc. Natl. Acad. Sci. USA* 91:1614-1618; Salmon et al., 1993, *Proc. Natl. Acad. Sci. USA* 90:11708-11712; PCT Publication No. WO 93/20242; and Brenner and Lerner, 1992, *Proc. Natl. Acad. Sci. USA* 89:5381-5383.

[1094] Examples of phage display libraries are described in Scott and Smith, 1990, *Science* 249:386-390; Devlin et al., 1990, *Science*, 249:404-406; Christian, R. B., et al., 1992, *J. Mol. Biol.* 227:711-718; Lenstra, 1992, *J. Immunol. Meth.* 152:149-157; Kay et al., 1993, *Gene* 128:59-65; and PCT Publication No. WO 94/18318 dated Aug. 18, 1994.

[1095] In vitro translation-based libraries include but are not limited to those described in PCT Publication No. WO 91/05058 dated Apr. 18, 1991; and Mattheakis et al., 1994, *Proc. Natl. Acad. Sci. USA* 91:9022-9026.

[1096] By way of examples of nonpeptide libraries, a benzodiazepine library (see e.g., Bunin et al., 1994, *Proc. Natl. Acad. Sci. USA* 91:4708-4712) can be adapted for use. Peptoid libraries (Simon et al., 1992, *Proc. Natl. Acad. Sci. USA* 89:9367-9371) can also be used. Another example of a library that can be used, in which the amide functionalities in peptides have been permethylated to generate a chemically transformed combinatorial library, is described by Ostresh et al. (1994, *Proc. Natl. Acad. Sci. USA* 91:11138-11142).

[1097] The variety of non-peptide libraries that are useful in the present invention is great. For example, Ecker and Crooke, 1995, *Bio/Technology* 13:351-360 list benzodiazepines, hydantoin, piperazinediones, biphenyls, sugar analogs, beta-mercaptoketones, arylacetic acids, acylpiperidines, benzopyrans, cubanes, xanthines, aminimides, and oxazolones as among the chemical species that form the basis of various libraries.

[1098] Non-peptide libraries can be classified broadly into two types: decorated monomers and oligomers. Decorated monomer libraries employ a relatively simple

scaffold structure upon which a variety functional groups is added. Often the scaffold will be a molecule with a known useful pharmacological activity. For example, the scaffold might be the benzodiazepine structure.

[1099] Non-peptide oligomer libraries utilize a large number of monomers that are assembled together in ways that create new shapes that depend on the order of the monomers. Among the monomer units that have been used are carbamates, pyrrolinones, and morpholinos. Peptoids, peptide-like oligomers in which the side chain is attached to the alpha amino group rather than the alpha carbon, form the basis of another version of non-peptide oligomer libraries. The first non-peptide oligomer libraries utilized a single type of monomer and thus contained a repeating backbone. Recent libraries have utilized more than one monomer, giving the libraries added flexibility.

[1100] Screening the libraries can be accomplished by any of a variety of commonly known methods. See, e.g., the following references, which disclose screening of peptide libraries: Parmley and Smith, 1989, *Adv. Exp. Med. Biol.* 251:215-218; Scott and Smith, 1990, *Science* 249:386-390; Fowlkes et al., 1992; *BioTechniques* 13:422-427; Oldenburg et al., 1992, *Proc. Natl. Acad. Sci. USA* 89:5393-5397; Yu et al., 1994, *Cell* 76:933-945; Staudt et al., 1988, *Science* 241:577-580; Bock et al., 1992, *Nature* 355:564-566; Tuerk et al., 1992, *Proc. Natl. Acad. Sci. USA* 89:6988-6992; Ellington et al., 1992, *Nature* 355:850-852; U.S. Pat. No. 5,096,815, U.S. Pat. No. 5,223,409, and U.S. Pat. No. 5,198,346, all to Ladner et al.; Rebar and Pabo, 1993, *Science* 263:671-673; and CT Publication No. WO 94/18318.

[1101] In a specific embodiment, screening to identify a molecule that binds polypeptides of the invention can be carried out by contacting the library members with polypeptides of the invention immobilized on a solid phase and harvesting those library members that bind to the polypeptides of the invention. Examples of such screening methods, termed "panning" techniques are described by way of example in Parmley and Smith, 1988, *Gene* 73:305-318; Fowlkes et al., 1992, *BioTechniques* 13:422-427; PCT Publication No. WO 94/18318; and in references cited herein.

[1102] In another embodiment, the two-hybrid system for selecting interacting proteins in yeast (Fields and Song, 1989, *Nature* 340:245-246; Chien et al., 1991, *Proc. Natl. Acad. Sci. USA* 88:9578-9582) can be used to identify molecules that specifically bind to polypeptides of the invention.

[1103] Where the binding molecule is a polypeptide, the polypeptide can be conveniently selected from any peptide library, including random peptide libraries, combinatorial peptide libraries, or biased peptide libraries. The term "biased" is used herein to mean that the method of generating the library is manipulated so as to restrict one or more parameters that govern the diversity of the resulting collection of molecules, in this case peptides.

[1104] Thus, a truly random peptide library would generate a collection of peptides in which the probability of finding a particular amino acid at a given position of the peptide is the same for all 20 amino acids. A bias can be introduced into the library, however, by specifying, for example, that a lysine occur every fifth amino acid or that positions 4, 8, and 9 of a decapeptide library be fixed to include only arginine. Clearly, many types of biases can be contemplated, and the present invention is not restricted to any particular bias. Furthermore, the present invention contemplates specific types of peptide libraries, such as phage displayed peptide libraries and those that utilize a DNA construct comprising a lambda phage vector with a DNA insert.

[1105] As mentioned above, in the case of a binding molecule that is a polypeptide, the polypeptide may have about 6 to less than about 60 amino acid residues, preferably about 6 to about 10 amino acid residues, and most preferably, about 6 to about 22 amino acids. In another embodiment, a binding polypeptide has in the range of 15-100 amino acids, or 20-50 amino acids.

[1106] The selected binding polypeptide can be obtained by chemical synthesis or recombinant expression.

Other Activities

[1107] A polypeptide, polynucleotide, agonist, or antagonist of the present invention, as a result of the ability to stimulate vascular endothelial cell growth, may be employed in treatment for stimulating re-vascularization of ischemic tissues due to various disease conditions such as thrombosis, arteriosclerosis, and other cardiovascular conditions. The polypeptide, polynucleotide, agonist, or antagonist of the present invention may also be employed to stimulate angiogenesis and limb regeneration, as discussed above.

[1108] A polypeptide, polynucleotide, agonist, or antagonist of the present invention may also be employed for treating wounds due to injuries, burns, post-operative tissue

repair, and ulcers since they are mitogenic to various cells of different origins, such as fibroblast cells and skeletal muscle cells, and therefore, facilitate the repair or replacement of damaged or diseased tissue.

[1109] A polypeptide, polynucleotide, agonist, or antagonist of the present invention may also be employed stimulate neuronal growth and to treat and prevent neuronal damage which occurs in certain neuronal disorders or neuro-degenerative conditions such as Alzheimer's disease, Parkinson's disease, and AIDS-related complex. A polypeptide, polynucleotide, agonist, or antagonist of the present invention may have the ability to stimulate chondrocyte growth, therefore, they may be employed to enhance bone and periodontal regeneration and aid in tissue transplants or bone grafts.

[1110] A polypeptide, polynucleotide, agonist, or antagonist of the present invention may be also be employed to prevent skin aging due to sunburn by stimulating keratinocyte growth.

[1111] A polypeptide, polynucleotide, agonist, or antagonist of the present invention may also be employed for preventing hair loss, since FGF family members activate hair-forming cells and promotes melanocyte growth. Along the same lines, a polypeptide, polynucleotide, agonist, or antagonist of the present invention may be employed to stimulate growth and differentiation of hematopoietic cells and bone marrow cells when used in combination with other cytokines.

[1112] A polypeptide, polynucleotide, agonist, or antagonist of the present invention may also be employed to maintain organs before transplantation or for supporting cell culture of primary tissues. A polypeptide, polynucleotide, agonist, or antagonist of the present invention may also be employed for inducing tissue of mesodermal origin to differentiate in early embryos.

[1113] A polypeptide, polynucleotide, agonist, or antagonist of the present invention may also increase or decrease the differentiation or proliferation of embryonic stem cells, besides, as discussed above, hematopoietic lineage.

[1114] A polypeptide, polynucleotide, agonist, or antagonist of the present invention may also be used to modulate mammalian characteristics, such as body height, weight, hair color, eye color, skin, percentage of adipose tissue, pigmentation, size, and shape (e.g., cosmetic surgery). Similarly, a polypeptide, polynucleotide, agonist, or antagonist of

the present invention may be used to modulate mammalian metabolism affecting catabolism, anabolism, processing, utilization, and storage of energy.

[1115] A polypeptide, polynucleotide, agonist, or antagonist of the present invention may be used to treat weight disorders, including but not limited to, obesity, cachexia, wasting disease, anorexia, and bulimia.

[1116] A polypeptide, polynucleotide, agonist, or antagonist of the present invention may be used to change a mammal's mental state or physical state by influencing biorhythms, cardiac rhythms, depression (including depressive disorders), tendency for violence, tolerance for pain, reproductive capabilities (preferably by Activin or Inhibin-like activity), hormonal or endocrine levels, appetite, libido, memory, stress, or other cognitive qualities.

[1117] A polypeptide, polynucleotide, agonist, or antagonist of the present invention may also be used as a food additive or preservative, such as to increase or decrease storage capabilities, fat content, lipid, protein, carbohydrate, vitamins, minerals, cofactors or other nutritional components.

[1118] The above-recited applications have uses in a wide variety of hosts. Such hosts include, but are not limited to, human, murine, rabbit, goat, guinea pig, camel, horse, mouse, rat, hamster, pig, micro-pig, chicken, goat, cow, sheep, dog, cat, non-human primate, and human. In specific embodiments, the host is a mouse, rabbit, goat, guinea pig, chicken, rat, hamster, pig, sheep, dog or cat. In preferred embodiments, the host is a mammal. In most preferred embodiments, the host is a human.

Other Preferred Embodiments

[1119] Other preferred embodiments of the claimed invention include an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least about 50 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X or the complementary strand thereto, and/or cDNA plasmid:V.

[1120] Also preferred is a nucleic acid molecule wherein said sequence of contiguous nucleotides is included in the nucleotide sequence of SEQ ID NO:X in the range of positions identified for SEQ ID NO:X in Table I.

[1121] Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least about 150 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X or the complementary strand thereto, and/or cDNA plasmid:V.

[1122] Further preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least about 500 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X or the complementary strand thereto, and/or cDNA plasmid:V.

[1123] A further preferred embodiment is a nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the nucleotide sequence of SEQ ID NO:X in the range of positions identified for SEQ ID NO:X in Table 1.

[1124] A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the complete nucleotide sequence of SEQ ID NO:X or the complementary strand thereto, and/or cDNA plasmid:V.

[1125] Also preferred is an isolated nucleic acid molecule which hybridizes under stringent hybridization conditions to a nucleic acid molecule comprising a nucleotide sequence of SEQ ID NO:X or the complementary strand thereto and/or cDNA plasmid:V, wherein said nucleic acid molecule which hybridizes does not hybridize under stringent hybridization conditions to a nucleic acid molecule having a nucleotide sequence consisting of only A residues or of only T residues.

[1126] Also preferred is a composition of matter comprising a DNA molecule which comprises cDNA plasmid:V.

[1127] Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least 50 contiguous nucleotides in the nucleotide sequence of cDNA plasmid:V.

[1128] Also preferred is an isolated nucleic acid molecule, wherein said sequence of at least 50 contiguous nucleotides is included in the nucleotide sequence of an open reading frame sequence encoded by cDNA plasmid:V.

[1129] Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to sequence of at least 150 contiguous nucleotides in the nucleotide sequence encoded by cDNA plasmid:V.

[1130] A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to sequence of at least 500 contiguous nucleotides in the nucleotide sequence encoded by cDNA plasmid:V.

[1131] A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the complete nucleotide sequence encoded by cDNA plasmid:V.

[1132] A further preferred embodiment is a method for detecting in a biological sample a nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X or the complementary strand thereto and a nucleotide sequence encoded by cDNA plasmid:V; which method comprises a step of comparing a nucleotide sequence of at least one nucleic acid molecule in said sample with a sequence selected from said group and determining whether the sequence of said nucleic acid molecule in said sample is at least 95% identical to said selected sequence.

[1133] Also preferred is the above method wherein said step of comparing sequences comprises determining the extent of nucleic acid hybridization between nucleic acid molecules in said sample and a nucleic acid molecule comprising said sequence selected from said group. Similarly, also preferred is the above method wherein said step of comparing sequences is performed by comparing the nucleotide sequence determined from a nucleic acid molecule in said sample with said sequence selected from said group. The nucleic acid molecules can comprise DNA molecules or RNA molecules.

[1134] A further preferred embodiment is a method for identifying the species, tissue or cell type of a biological sample which method comprises a step of detecting nucleic acid molecules in said sample, if any, comprising a nucleotide sequence that is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X or the complementary strand thereto and a nucleotide sequence encoded by cDNA plasmid:V.

[1135] The method for identifying the species, tissue or cell type of a biological sample can comprise a step of detecting nucleic acid molecules comprising a nucleotide sequence in a panel of at least two nucleotide sequences, wherein at least one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from said group.

[1136] Also preferred is a method for diagnosing in a subject a pathological condition associated with abnormal structure or expression of a nucleotide sequence of SEQ ID NO:X or the complementary strand thereto or cDNA plasmid:V which encodes a protein, wherein the method comprises a step of detecting in a biological sample obtained from said subject nucleic acid molecules, if any, comprising a nucleotide sequence that is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X or the complementary strand thereto and a nucleotide sequence of cDNA plasmid:V.

[1137] The method for diagnosing a pathological condition can comprise a step of detecting nucleic acid molecules comprising a nucleotide sequence in a panel of at least two nucleotide sequences, wherein at least one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from said group.

[1138] Also preferred is a composition of matter comprising isolated nucleic acid molecules wherein the nucleotide sequences of said nucleic acid molecules comprise a panel of at least two nucleotide sequences, wherein at least one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X or the complementary strand thereto and a nucleotide sequence encoded by cDNA plasmid:V. The nucleic acid molecules can comprise DNA molecules or RNA molecules.

[1139] Also preferred is an isolated polypeptide comprising an amino acid sequence at least 90% identical to a sequence of at least about 10 contiguous amino acids in the polypeptide sequence of SEQ ID NO:Y; a polypeptide encoded by SEQ ID NO:X or the complementary strand thereto and/or a polypeptide encoded by cDNA plasmid:V.

[1140] Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 30 contiguous amino acids in the amino acid sequence of SEQ ID NO:Y; a polypeptide encoded by SEQ ID NO:X or the complementary strand thereto and/or a polypeptide encoded by cDNA plasmid:V.

[1141] Further preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 100 contiguous amino acids in the amino acid sequence of SEQ ID NO:Y; a polypeptide encoded by SEQ ID NO:X or the complementary strand thereto and/or a polypeptide encoded by cDNA plasmid:V.

[1142] Further preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to the complete amino acid sequence of SEQ ID NO:Y; a polypeptide encoded by SEQ ID NO:X or the complementary strand thereto and/or a polypeptide encoded by cDNA plasmid:V.

[1143] Further preferred is an isolated polypeptide comprising an amino acid sequence at least 90% identical to a sequence of at least about 10 contiguous amino acids in the complete amino acid sequence of a polypeptide encoded by cDNA plasmid:V.

[1144] Also preferred is a polypeptide wherein said sequence of contiguous amino acids is included in the amino acid sequence of a portion of said polypeptide encoded by cDNA plasmid:V; a polypeptide encoded by SEQ ID NO:X or the complementary strand thereto and/or the polypeptide sequence of SEQ ID NO:Y.

[1145] Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 30 contiguous amino acids in the amino acid sequence of a polypeptide encoded by cDNA plasmid:V.

[1146] Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 100 contiguous amino acids in the amino acid sequence of a polypeptide encoded by cDNA plasmid:V.

[1147] Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to the amino acid sequence of a polypeptide encoded by cDNA plasmid:V.

[1148] Further preferred is an isolated antibody which binds specifically to a polypeptide comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: a polypeptide sequence of SEQ ID NO:Y; a polypeptide encoded by SEQ ID NO:X or the complementary strand thereto and a polypeptide encoded by cDNA plasmid:V.

[1149] Further preferred is a method for detecting in a biological sample a polypeptide comprising an amino acid sequence which is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: a polypeptide sequence of SEQ ID NO:Y; a polypeptide encoded by SEQ ID NO:X or the complementary strand thereto and a polypeptide encoded by cDNA plasmid:V; which method comprises a step of comparing an amino acid sequence of at least one polypeptide molecule in said sample with a sequence selected from said group and determining

whether the sequence of said polypeptide molecule in said sample is at least 90% identical to said sequence of at least 10 contiguous amino acids.

[1150] Also preferred is the above method wherein said step of comparing an amino acid sequence of at least one polypeptide molecule in said sample with a sequence selected from said group comprises determining the extent of specific binding of polypeptides in said sample to an antibody which binds specifically to a polypeptide comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: a polypeptide sequence of SEQ ID NO:Y; a polypeptide encoded by SEQ ID NO:X or the complementary strand thereto and a polypeptide encoded by cDNA plasmid:V.

[1151] Also preferred is the above method wherein said step of comparing sequences is performed by comparing the amino acid sequence determined from a polypeptide molecule in said sample with said sequence selected from said group.

[1152] Also preferred is a method for identifying the species, tissue or cell type of a biological sample which method comprises a step of detecting polypeptide molecules in said sample, if any, comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: polypeptide sequence of SEQ ID NO:Y; a polypeptide encoded by SEQ ID NO:X or the complementary strand thereto and a polypeptide encoded by cDNA plasmid:V.

[1153] Also preferred is the above method for identifying the species, tissue or cell type of a biological sample, which method comprises a step of detecting polypeptide molecules comprising an amino acid sequence in a panel of at least two amino acid sequences, wherein at least one sequence in said panel is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the above group.

[1154] Also preferred is a method for diagnosing in a subject a pathological condition associated with abnormal structure or expression of a nucleic acid sequence identified in Table 1 encoding a polypeptide, which method comprises a step of detecting in a biological sample obtained from said subject polypeptide molecules comprising an amino acid sequence in a panel of at least two amino acid sequences, wherein at least one sequence in said panel is at least 90% identical to a sequence of at least 10 contiguous

amino acids in a sequence selected from the group consisting of: polypeptide sequence of SEQ ID NO:Y; a polypeptide encoded by SEQ ID NO:X or the complementary strand thereto and a polypeptide encoded by cDNA plasmid:V.

[1155] In any of these methods, the step of detecting said polypeptide molecules includes using an antibody.

[1156] Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a nucleotide sequence encoding a polypeptide wherein said polypeptide comprises an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: polypeptide sequence of SEQ ID NO:Y; a polypeptide encoded by SEQ ID NO:X or the complementary strand thereto and a polypeptide encoded by cDNA plasmid:V.

[1157] Also preferred is an isolated nucleic acid molecule, wherein said nucleotide sequence encoding a polypeptide has been optimized for expression of said polypeptide in a prokaryotic host.

[1158] Also preferred is an isolated nucleic acid molecule, wherein said polypeptide comprises an amino acid sequence selected from the group consisting of: polypeptide sequence of SEQ ID NO:Y; a polypeptide encoded by SEQ ID NO:X or the complementary strand thereto and a polypeptide encoded by cDNA plasmid:V.

[1159] Further preferred is a method of making a recombinant vector comprising inserting any of the above isolated nucleic acid molecule into a vector. Also preferred is the recombinant vector produced by this method. Also preferred is a method of making a recombinant host cell comprising introducing the vector into a host cell, as well as the recombinant host cell produced by this method.

[1160] Also preferred is a method of making an isolated polypeptide comprising culturing this recombinant host cell under conditions such that said polypeptide is expressed and recovering said polypeptide. Also preferred is this method of making an isolated polypeptide, wherein said recombinant host cell is a eukaryotic cell and said polypeptide is a human protein comprising an amino acid sequence selected from the group consisting of: polypeptide sequence of SEQ ID NO:Y; a polypeptide encoded by SEQ ID NO:X or the complementary strand thereto and a polypeptide encoded by cDNA plasmid:V. The isolated polypeptide produced by this method is also preferred.

[1161] Also preferred is a method of treatment of an individual in need of an increased level of a protein activity, which method comprises administering to such an individual a Therapeutic comprising an amount of an isolated polypeptide, polynucleotide, immunogenic fragment or analogue thereof, binding agent, antibody, or antigen binding fragment of the claimed invention effective to increase the level of said protein activity in said individual.

[1162] Also preferred is a method of treatment of an individual in need of a decreased level of a protein activity, which method comprised administering to such an individual a Therapeutic comprising an amount of an isolated polypeptide, polynucleotide, immunogenic fragment or analogue thereof, binding agent, antibody, or antigen binding fragment of the claimed invention effective to decrease the level of said protein activity in said individual.

[1163] In specific embodiments of the invention, for each "Contig ID" listed in the fourth column of Table 2, preferably excluded are one or more polynucleotides comprising, or alternatively consisting of, a nucleotide sequence referenced in the fifth column of Table 2 and described by the general formula of a-b, whereas a and b are uniquely determined for the corresponding SEQ ID NO:X referred to in column 3 of Table 2. Further specific embodiments are directed to polynucleotide sequences excluding one, two, three, four, or more of the specific polynucleotide sequences referred to in the fifth column of Table 2.

[1164] Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of c - d, where both c and d correspond to the positions of nucleotide residues shown in SEQ ID NO:X, and where d is greater than or equal to c + 14.

[1165] In no way is this listing meant to encompass all of the sequences which may be excluded by the general formula, it is just a representative example. All references available through these accessions are hereby incorporated by reference in their entirety.

TABLE 2

Gene No.	cDNA Plasmid: V	NT SEQ ID NO: X	Contig ID	Public Accession Numbers
1	HCE1P80	2	973903	BG033745, AA476827, AV704156, AL137944, AI971680, AW297211, BF760130, AI520706, BF833782, BE907421, BE242671, AW936474, AW936371, AW190143, AW519008, AI432598, AI393538, AW295856, AA393801, BF687731, AI765546, BF898133, AA146856, BF217337, BE146273, AL532972, AI204615, BF437991, AA146855, AL021453.1, AK026002.1, AL355838.3, AL009047.1, AL354696.11, AL356806.4, AC010460.6, AC010977.4, AC013242.7, AP000426.3, AL512268.10, AC009245.10, AP001001.4, AC022415.5, AC018517.6, AC005521.1, AC008163.2, AL138878.10, AC007881.4, AL136531.16, AL138976.5, AL050350.14, AL160254.10, AC004584.1, AL356379.10, AL158815.14, AL109751.19, AC005384.2, AC008736.6, AC022542.4, AL136160.18, AL591807.1, AL031681.16.
1	HCE1P80	22	I315876	
1	HCE1P80	23	I055553	
2	HUFGH53	3	I143339	AI672862, AI972278, AI090242, AI365229, AA524422, AI916766, AW242863, AW014261, AA044337, AI863149, AI658700, AI491865, AI344186, BF001214, AI658683, AW972265, AI680049, AI638089, AA044219, AA775576, AA034372, AI023942, AI276995, W25392, AA603067, AA034373, AI197784, W35182, AA339233, H55506, AW084219, AW168373, AA807088, AW151785, AI866798, AI673256, BF817402, AI473598, AI347701, AI799199, AI569309, AI866002, BF885085, BF815196, BG251264, AI474107, AI635367, AI682075, AI828731, AW089179, AW151714, AI633419, BE964767, AI696819, AW189424, AV682807, AW983822, AI491783, AI250848, AI933785, AI365256, AW085786, AI874151, AI932949, AW149869, AW023590, AI873644, AI697324, AI274013, AI539771, BG260144, AV682802, AI308032, AI251830, AI344785, BG058039, AI648502, AW954031, AW088899, AW168485, AI280670, AI590999, AI699011, AW088903, BG027280, BE613727, AI922901, AI922561, AI799195, AW004886, AI620868, AI859464, AI818578, BF921092, AW130863, AI687009, AW152550, AI538342, BF968910, BE963918, AI432736, AI249962, AI446373, AI636619, AW191892, AW129230, AW167238, BF914091, AI860045, AI433976, AW079159, AI619716, AW082060, AI890806, AW087938, AI687065,

			<p> AI539153, AI612759, BE963035, AW151729, BF816785, BF816455, AI867042, BF526861, AI566630, AI280661, BE061389, AI866608, BF814541, AI537617, BE963286, AI919345, AI922577, BF915537, AW834355, AI888621, AI476109, BF915208, BE072233, AI366549, AI636719, AI570966, AI610645, AI434242, BF904180, AI620093, AI811168, AI611743, AW083804, AA830821, AI696626, AI589993, BE964497, BE538466, AW265004, BE393551, AI598061, AI587606, AI677797, AI431909, BE965169, AI811684, AW118518, AI613449, AI254727, AI783861, AW192288, AW002174, N74355, AI520702, AI433021, AI859402, AW149227, AI800138, AI890182, AI628833, BF344652, BF795712, AW168031, AW264029, AW169275, AW167448, AW264727, AW083189, AW193203, AI680498, AI805688, AI953880, AI554427, BE907440, AW172723, BG249582, AI475394, AW169001, AI915576, AI868831, AW847410, AW163823, BF811780, BE928768, AI471548, AI559599, AV755332, AI689571, AI355849, AI860783, AI174394, AW189415, AI680457, AI805769, BF814449, BF920893, AI567351, BF339322, AI863321, AI569328, AI521386, AI371228, AI567243, AI952064, AI554218, AW081255, AI888944, AW198075, AW088134, AW079739, AI812015, AI498579, AI702406, AI470284, AI590686, AI468872, AI382670, AI921734, AI036638, AI802240, AW167918, AI560052, AI110306, AI584140, AI862144, AW085667, BG150947, AI628217, AI520810, AI866786, AI648567, AI400725, BE543089, Y07848.1, AI031186.8, Z95116.1, AI050138.1, BC008983.1, AI137461.1, Y14314.1, AI133645.1, BC006201.1, AI137463.1, AK024538.1, AK026408.1, AK026597.1, AI1389939.1, AI133075.1, AI1389978.1, AI137705.1, AB060929.1, AK026533.1, AK025349.1, AF218031.1, BC005151.1, AF358829.1, AI137556.1, BC003105.1, BC005678.1, AF091084.1, AK026591.1, AI1359618.1, AI162062.1, AK025312.1, U39656.1, X69819.1, AI137300.1, AI080137.1, AB056768.1, AK026504.1, BC005858.1, AK000647.1, AF217987.1, AB048974.1, AF090903.1, AI1389982.1, AI136749.1, AI080086.1, AF321617.1, BC003650.1, AK000450.1, AF026816.2, AK026947.1, BC001349.1, AJ242859.1, AF000145.1, BC008365.1, AF081197.1, AF081195.1, AI080060.1, AI137273.1, AI512761.1, AB052200.1, AF125949.1, AB049758.1, AK025383.1, BC006412.1, AI050393.1, BC006133.1, BC009033.1, BC003683.1, BC007355.1, AI133014.1, U80742.1, AI137294.1, AK026532.1, </p>
--	--	--	--

			BC009341.1, AK000652.1, AL162083.1, AF159141.1, BC002839.1, AB048919.1, BC002343.1, BC006494.1, AB063084.1, AB049848.1, AB019565.1, AL122098.1, AL133104.1, AL133565.1, AL512754.1, BC004370.1, AB056427.1, AB060905.1, AB060211.1, BC007641.1, AL157479.1, BC000316.1, BC003682.1, AK025708.1, AL080074.1, AB055361.1, AL390167.1, AL117649.1, AF162270.1, BC006508.1, BC006164.1, AB063008.1, BC008485.1, AB063079.1, AL080158.1, BC000556.1, BC003687.1, AL442072.1, AF242525.1, S61953.1, AC002467.1, BC008780.1, AL136928.1, AB060912.1, AL122049.1, AK026086.1, AB048964.1, AK026528.1, AF217966.1, AL122050.1, AF218014.1, AL162003.1, AL137271.1, AF177336.1, AL359583.1, AL136844.1, AL133665.1, AL133098.1, AK027182.1, AL512746.1, AK024601.1, AB047801.1, AL133557.1, AB060852.1, AL110221.1, BC006807.1, AK026608.1, AL157431.1, AL133568.1, AL136845.1, AL133113.1, BC008893.1, AL136784.1, AB047887.1, AF225424.1, AB055366.1, AK025491.1, AL136843.1, AL110280.1, AL080127.1, AL050149.1, AF217991.1, AL122093.1, AF003737.1, BC009026.1, AK026057.1, BC005890.1, AL049382.1, BC008417.1, AB063088.1, AK027193.1, AF113222.1, AL137538.1, AB055368.1, AK025524.1, BC009253.1, BC007198.1, AL136799.1, AK026865.1, AF078844.1, AL512718.1, AF219137.1, AK000445.1, AK026642.1, AL049465.1, AK026164.1, AF104032.1, AL133081.1, BC004951.1, AL122111.1, AB060863.1, AK025209.1, AL137648.1, AL162006.1, AK026592.1, AL117585.1, AK025573.1, AL136789.1, BC002342.1, AL353940.1, AF207829.1, AK027116.1, AL117432.1, AL512719.1, AL136790.1, AL050277.1, AL080124.1, AF271350.1, BC008387.1, AL359941.1, AL136622.1, AL133077.1, AK026526.1, AB047615.1, AK025906.1, AK026045.1, AB050534.1, AL353957.1, AK026885.1, L30117.1, AF183393.1, AK027164.1, AB060903.1, AL117440.1, AK026551.1, AL117435.1, AL110222.1, AK000718.1, AK026534.1, AF111112.1, AL162002.1, AK026855.1, AL137429.1, AK027113.1, AL137526.1, L19437.2, BC008070.1, AB055315.1.
2	HUFGH53	24	894857 AI672862, AI972278, AI090242, AI365229, AA524422, AI916766, AW242863, AW014261, AA044337, AI863149, AI658700, AI491865, AI344186, BF001214, AI658683, AW972265,

				AI680049, AI638089, AA044219, AA775576, AA034372, AI023942, AI276995, W25392, AA603067, AA034373, AI197784, W35182, H55506, AA339233, AL031186.8, Y07848.1, Z95116.1.
2	HUFGH53	25	1407421	
2	HUFGH53	26	1407330	
2	HUFGH53	27	1407326	
2	HUFGH53	28	1324108	
2	HUFGH53	29	1143314	
2	HUFGH53	30	1124368	
3	HWMMS09	4	1426876	AI634846, BF589994, AI660577, AW873053, BE906672, AI241049, AW008561, BF750885, BE963035, AI280661, BF816455, AW088899, AI446003, AI566630, BF694790, BG120816, AI702073, AI537617, BE061389, AI919345, AI633419, AI610645, BF038804, AI554218, AI866002, BF817402, AI867042, AI539028, BE963918, AI859464, AW083804, AI921386, BF968504, AI674912, AI469811, AI627880, AI636719, AI608676, BF904180, BF726504, AI250663, AI433976, BF815196, AI619716, AI561299, AI612759, AW151729, AI699011, BF811780, BF909758, BE621256, AI364788, AI611743, BF914091, BE613727, AW168485, BF814335, BE968711, BF913616, AW103371, AI697324, AI933785, AI805688, BF915537, BG026746, AI365256, AW079159, AI251830, BE964767, BG058039, AI689175, BE928768, AI635464, BE875407, AW087938, AI366549, AI539153, BF816785, BF726237, AW131954, AW090494, AW834355, BF344652, BE393551, BE964089, BG031664, AI494201, AI610756, AA830821, AI963040, AI679916, AL079794, AW102785, BF814409, BE887861, AI921176, AW084219, AW103886, AI499652, AW082594, AI633306, BE967016, BE897632, BF814541, AI345746, N80094, AW858254, AI251205, BF915208, AV682496, AI868831, AI888953, AI886124, AI655932, AW151785, AV683272, AI431909, BF885085, AV690007, AI828731, BF795712, AI432736, AI687065, AW089179, AI696819, AI783861, BE785868, AI680498, AW192375, AI520809, AI922577, AI799234, AI498579, BE875786, AI696626, AW198075, BE904051, BE072233, AI589993, BE544111, BG179099, AI566507, AI264741, AI952360, BF726603, AI866741, AI680457, AI468872, AI866608, BE963286, AI698401, BE884910, AW079572, AI572418, AW172723, AI400725, AI568870, AI241819, BE964497, BE538466, BF854113, AW029263, AI952920, AW020095, AW103893, AI805638, AI805769, AI963062, AW195957, AI624668, BF342070, BE966388, AW071417, AI628292, AW021588, AW085667, AI801605, AI888429, BG181012, AI885974,

			AI493559, AL041772, AI613017, AI432040, BE964981, AW089258, AI628217, AI866887, AI812015, AW235035, BF910810, AW192226, AW168031, AI474076, AI886022, AI891157, AI249962, AI872914, AW104146, BG171779, BF037484, AW088903, AW151714, AW129230, BE246734, AI471361, AI678443, AI587288, AI696378, AW088134, BE965060, AI598113, AW051107, BF752252, BE964198, AI648502, BF924882, AI590645, AI539771, AA425380, AW082040, AW103195, AW084131, AI677797, BF921092, BF792469, AW117907, AI569616, BE965481, BF910849, BF812933, BF204484, AL110306, AI745713, BF725863, AL119791, AI888621, AL041150, AI888944, BE964512, AW858243, BG030364, BE966947, AI922365, AI274769, AI540850, N74355, AI133489, AI929108, AI648663, BC001349.1, BC003683.1, AK025414.1, AB056427.1, AK025209.1, AK025906.1, AL133104.1, AK000652.1, AL512718.1, AB063100.1, AL389978.1, AK000753.1, AK025383.1, AK026865.1, AK024538.1, AK025958.1, AB063008.1, BC008417.1, AF225424.1, BC003548.1, AB060826.1, AL080124.1, AL137556.1, AB063046.1, AB019565.1, AL122098.1, BC007198.1, BC008893.1, AL080060.1, AK026642.1, BC005678.1, AF104032.1, AL050024.1, AL512719.1, AB050534.1, AK025491.1, AL136928.1, AL512761.1, AK024601.1, AK027116.1, AB049758.1, AL389939.1, AF271350.1, AL050138.1, AL136843.1, U80742.1, AB060214.1, AL137526.1, BC006164.1, U39656.1, X69819.1, AB060929.1, AB056768.1, AL390167.1, AK027868.1, AL512754.1, BC003687.1, AB060863.1, AB063079.1, AK026608.1, AB060839.1, AL117432.1, AF111112.1, BC009033.1, AK026592.1, AF177336.1, BC008485.1, AB047801.1, AF207829.1, AK025772.1, BC008899.1, AL080137.1, BC006807.1, AL133077.1, AK026532.1, AK000618.1, AK027113.1, AK026959.1, AB052191.1, AL133093.1, AB047887.1, Z82022.1, AK026947.1, AK027193.1, AF162270.1, AB063084.1, BC009341.1, AL137476.1, AK026533.1, AK027114.1, AB051158.1, AF146568.1, AB050510.1, AK026045.1, BC008280.1, BC003682.1, AL080127.1, AL133075.1, Y14314.1, AL117440.1, AL136845.1, AK026551.1, AK000718.1, AL122110.1, AL122049.1, AK026480.1, AL133080.1, AL049382.1, AL133640.1, AB048919.1, AL117583.1, AL133098.1, AK026784.1, AL117585.1, AL162062.1, AL136864.1, AL133113.1, AL133072.1, AL122123.1, X72889.1,
--	--	--	---

				AF348209.1, AL353625.5, AK026597.1, AB055374.1, AK027200.1, AB049848.1, AB060912.1, AK026086.1, AK000647.1, BC004951.1, AL359583.1, AL359618.1, AL162006.1, AL137538.1, AK026630.1, AK026452.1, AF125949.1, AF260566.1, AL353940.1, AL050277.1, BC004370.1, AF090901.1, AL137527.1, BC008387.1, AL133565.1, AL122121.1, AL136799.1, AK026408.1, AF078844.1, AK026464.1, X82434.1, AK026504.1, BC005890.1, AB063070.1, AF217966.1, AK000137.1, AF217987.1, BC004958.1, AK027164.1, AK025312.1, AK025524.1, AL442072.1, BC006412.1, BC008365.1, AL110280.1, AL136749.1, AL162002.1, BC008382.1, AL049466.1, BC008070.1, BC002839.1, AL512684.1, AK000445.1, AL080159.1, AK000432.1, AK026583.1, AB047615.1, L30117.1, AB056420.1, AB055366.1, AK025092.1, BC009212.1, S78214.1, AK025632.1, AL136768.1, AL050116.1, AL133016.1, AK025254.1, BC007021.1, AK000323.1, AK000391.1, AL136586.1, AK026534.1, AL137463.1, S61953.1, BC008780.1, AL162083.1, AB048964.1, AK025391.1, AB048953.1, AL122050.1, AF218014.1, AL136844.1, AL137459.1, AF113222.1, AL512746.1, AL117460.1, AB062938.1, AL133557.1, AB055303.1, AL135960.1, AB060887.1, AL117457.1, AL096744.1, AL359615.1, AL157431.1, AL133568.1, AL133014.1, AL359620.1, U91329.1, AF106862.1, AL110196.1, AK026542.1, AF219137.1, AF090896.1, AL359941.1, AL133067.1, Y16645.1, AL136786.1, AL080074.1, AK027204.1, AK025573.1, AK000486.1, AL110221.1, AK025484.1, AK026855.1, AJ012755.1, AK024524.1, AF003737.1, AF090934.1, AL137283.1, BC005151.1, AK026528.1, AK026629.1, AL359596.1, AB060916.1, AF183393.1, AK027160.1, AK025798.1, AB060852.1.
3	HWMMO59	31	1356977	
4	HSSJJ51	5	900561	BF526701, BF873331, BF929164, BF221973, AV688712, BF743216, A1682301, BF929165, AA368885, BE295879, A1078870, BE270667, A1611295, BF963547, AA323287, BF763407, BF002002, BF002176.
5	HCEWD38	6	1284936	AA746177, A1510718, R37382, A1247745, R52665, AA323018, H49570, N55573, BG236027, AW966998, AA323159, AL039810, R13472, AL039789, BF332816, AW955388, BF879416, AA304816, AW964665, AA323409, R52713.
5	HCEWD38	32	616396	AA323018, AA323159, AW966998, R13472, AW955388, AA304816, AW964665, AA323409.

				R52713, AI.132800. 4.
5	HCEWD38	33	411082	R37382, AA746177, AI510718, R52665, AI247745, AA323018, N55573, BG236027, H49570, AW966998, AA323159, R13472, AW955388, AI039810, AA304816, BF879416, AW964665, AA323409, AI039789, BF332816, R52713.
6	HUCMC56	7	1310874	R20045, AW965432, AA332557, R36770, R60458, AA340432, AW163243, AX018985, AX018987, M58583, S76975, AI.117383.
6	HUCMC56	34	967258	R60458, AW163243.
7	HWLZU06	8	1310875	BF055285, BF882978, AW070344, AI805087, BF906443, AI083823, W92687, AI085548, AI083824, W92830, BE138819, AW192716, AW150070, BF588518, AA775561, BF764330, AW172659, M91217, AI393090, AW137263, F33371, W05570, R70460, AA339837, AI564511, AA359338, AW380993, AW960500, AW192211, AI924106, AA377546, AI346326, AI825277, BF724241, AI432310, AI144286, AA301724, AI619600, AI783751, AI470161, AI457948, AW190639, AI338249, AW025095, AI110261, AF086482.
7	HWLZU06	35	933581	BF055285, BF882978, AI346326, AI432310, AI144286, AI805087, AW070344, AI338249, BF906443, AI457948, AI083823, AI470161, AI085548, W92687, AI083824, W92830, BE138819, AW192716, AW150070, BF588518, AA775561, BF764330, AW172659, AI393090, M91217, F33371, W05570, AW137263, R70460, AA339837, AI928593, AI564511, AA359338, AW380993, AW960500, AI924106, AA377546, AW192211, AI825277, AA301724, AI619600, AI783751, BF724241, AA704632, AW190639, N76120, AW025095.
8	HDPBA69	9	905708	BF343049, BF525949, AI300176, BF342466, AI193100, AW953836, N32601, AA894528, BF526118, AI749282, AA917673, AI200645, AA577400, AW001112, AI342526, AI561024, AA922077, BF339231, BG060138, AI274361, AW629891, AI811138, AI682589, AI598054, BF821354, AA703086, BF821349, AW000838, AI687717, BF879161, AI346224, AI283829, AW966426, BF878968, AI718510, N38801, AA609464, AA443822, AI285277, AI141075, C17007, AA827271, AI274203, AI278912, AW953891, AA485613, AI291153, AI184968, AI815092, BF879241, AA922163, AA954441, W92736, AI523358, AI582743, AI272748, T95291, AI304507, AW858976, BF823040, R47871, H90673, R71353, AV689909, W92820, AW515183, AA640081, R47872, AI749077, AA508675, AA025765, AI352318, H66699, R66274, T27046, H78056, AI873364, H66689, AW029317, AI336608, H64116, AI872250, H42114, T95371, AA383872, R24350, AI749260, BF087543, T72087, AA025953, BF820542.

				BF737942, AA371827, N90491, BG012708, AI459266, D31533, H64951, BE769806, AA368991, N69227, H01130, BF821339, I189819, R72785, BE769826, H01871, R62666, BF349116, N45434, R72786, AW374237, AW953834, H78057, T16823, AA295668, BE140683, AW277068, AW135690, AI088641, BF881707, AW374232, AW610099, H73228, R24669, H26462, T72232, T23681, H27838, H64952, BE769808, H70128, N47826, R43349, I183150, BF991147, AI476021, AI202813, AL514919, AL513597, AW605902, AL514627, AL513907, AL514791, AL513643, AL514691, AL513553, AI560012, AW105588, AL513693, AL514087, AL513911, AL514015, AI500553, AL513631, AL514473, BE966388, AI697137, AW195957, AI873731, AI567351, AI687728, AL514793, AI699857, AI630928, AW268253, BE785905, AI285735, AI436456, BG105445, AI613017, AV757455, AI499393, AI934036, BG260037, AL515041, AI679724, AI20968, AI862142, BF037097, BE964741, AI349645, AI625079, AI619502, AI281762, AI349772, AI047042, AI857296, AL514359, AL121270, AL513977, BF883916, AV706777, AL036396, BE047863, BF882343, BG058208, AI671679, AI271786, AW148320, AL514929, BF055737, AW827249, AL513763, AI874109, AV711509, AL515375, AL119049, AL514867, AI597750, AI597918, AL514261, BE048071, AW827203, AI538716, AV655645, AV682476, AV729890, AI281745, AL045500, AI064830, BG036846, AI475134, AI673256, AL036802, AI580984, BG179993, AI863014, AV755207, BF724691, AL046849, AI868831, BE964812, BE965111, BF795712, BG257535, AL513999, BF971016, BG178488, BF726322, BG180996, AL513803, AV755581, AW071349, AV681857, AL515413, AI445025, AL121365, BF343172.
8	HDPBA69	36	906482	BF343049, BF525949, AI300176, BF342466, AW953836, AI749282, AA894528, N32601, BF526118, AI193100, AA577400, AI200645, AA917673, AW001112, AA703086, AI687717, AI342526, AI561024, BF339231, AI141075, AA922077, AW629891, AI274361, AI184968, AA922163, AI815092, BF821349, W92736, BF821354, AI682589, AW000838, BF879161, BF878968, AI346224, AI718510, AI283829, N38801, AW966426, AA443822, AA609464, C17007, AI285277, BG060138, AA827271, AW953891, AI274203, AA485613, AI811138, AI278912, BF879241, AI291153, AI598054, AA954441, AW515183, AI272748, AI304507, T95291, AA508675, AW858976, AI582743, BF823040, R47871, R71353, AV689909, W92820, AA640081, R47872, AI749077, AI523358, AA025765, AI459266, H64116, T27046,

			<p> A1352318, H66689, R66274, H78056, A1873364, H90673, H42114, A1336608, T95371, AA383872, R24350, A1749260, AW029317, BF087543, T72087, AA025953, AW135690, BF820542, H64951, BF737942, AA371827, H01130, H66699, N90491, BG012708, D31533, H01871, A1872250, BE769806, AA368991, N69227, H89819, BF821339, R72785, BE769826, R62666, BF349116, N45434, R72786, AW374237, AW953834, T16823, AA295668, BE140683, AW277068, A1088641, H78057, H73228, BF881707, AW374232, AW610099, H26462, R24669, A1202813, T23681, T72232, H27838, H64952, BE769808, H70128, N47826, R43349, H83150, A1281745, BF991147, A1476021, AL513597, AL513907, AL514791, AL514627, A1500553, AL514919, AL514691, AW605902, AL514473, AL513911, AL513553, AL514087, BE785905, AV757455, AL513693, AL514359, AL515041, AL515375, BE966388, AL513803, AL047042, AV706777, A1349772, A1285735, AL513631, BG058208, BF054789, A1873731, AV682476, AL514793, BE048071, AW827203, A1567351, A1064830, AL119049, AL513643, BF724691, A1687728, AV729890, BF795712, BF726322, AL121270, AV681857, AV755581, BE964994, A1679724, AW071349, AL046849, A1868831, AV758806, A1349645, A1863014, BG179993, A1815383, A1560012, AV757639, A1906328, AV655645, AL513817, BF970162, BG108147, AL515373, BE047863, A1673256, AL515047, AV682249, A1499393, AV758110, AV682772, BG257535, AL514935, BG036846, AV682441, AV681716, BG168696, BF883916, AV682330, BE964812, BG260037, AW162071, AW827211, AV681668, BF971016, A1934036, A1697137, AV733397, A1436456, AV682351, AV710479, AW195957, AV756477, AV681951, BE048135, AV682466, BF793644, A1671679, AV757327, AV681630, AL514543, AV682252, BF343172, AV711924, AL514803, AW268253, AV711509, AL515413, AV733326, AL514015, BE965891, A1521012, R17629, AA835433. </p>
8	HDPBA69	37	906481 <p> A1346224, A1291153, AA922163, A1352318, A1342526, W92736, AA577400, AW000838, AA508675, A1598054, A1815092, A1749077, A1523358, AA703086, N38801, A1718510, AW001112, AA025765, A1561024, H66689, AW515183, H66699, R47872, A1873364, A1184968, AA894528, N32601, A1274361, A1274203, A1459266, A1200645, A1687717, A1682589, A1285277, AA917673, BG060138, A1193100, AA922077, A1283829, A1749260, A1272748, AA827271, A1141075, AA443822, A1300176, A1749282, AA609464, A1278912, A1088641, T95291, A1582743, H90673, AA954441, H78057, A1304507, A1811138, </p>

				AI336608, AW277068, AI202813, AW135690, H64952, H73228, T23681, N69227, R43349, T16823, AW966426, R72785, R72786, AA383872, AI281745, BF087543, R71353, BF820542, BF823040, AW610099, AW605902, BF879161, BF821354, D31533, BF879241, BF878968, AI281707, BE011964, AW858976, R24350, AA835433, AW105588.
8	HDPBA69	38	906480	BF343049, BF525949, BF339231, AW629891, R47871, T27046, H42114, H64116, BF342466, H64951, N90491, H01871, H01130, H89819, N45434, H26462, H27838, BF526118, T72232, H83150, BF991147, AA640081, N47826, BE769806, AV689909, BF737942, R17629.
9	HLWAE11	10	783071	AI344312, AI276017, AI476822, AI139478, AI160906, AI240398, AW001088, AA425919, AA011278, AA428788, AI354692, AI089176, AA622689, BF431807, AI968918, N68826, AI467807, BF436247, AW673768, AW135943, R24434, R16812, R31419, R31434, R24435, H83155, AI865939, R31418, AW673133, W67349, R31433, AA027080, R28030, BE542160, T81223, AI631986, AA677315, BF760063, AI872675, BF331923, BE926682, BE926741, AF329842.1, Z82188.2.
10	HSZAF47	11	1283068	AW298370, AI433823, AI239867, D62170, D61860.
10	HSZAF47	39	456551	AW298370, AI433823, AI239867, D62170, D61860, AF329839.1, AC007016.5.
11	HWTAY65	12	908762	AI916779, AW304481, AA732948, AI288625, AW965223, AA443244, AA194106, W79527, BF511014, AI038644, AA443206, W93527, AA346195, W79559, BE296248, BE269743, AF329836.1.
11	HWTAY65	40	905611	AI916779, AW304481, AA732948, AI288625, AW965223, AA443244, AA194106, W79527, BF511014, AI038644, AA443206, W93527, AA346195, W79559, BE296248, AW975618, AW960414, AV724520, D51799, C14389, C14331, AW960553, AW966531, AW964468, AV718692, AW956397, AV720791, AV718489, AW973541, AW965175, AW949645, AW978634, AW966013, AW973307, AV720533, AW973474, D81030, AW949642, AW966059, AV720211, C14429, AW959202, AW966053, D80212, AW964756, AW960465, AW959136, D80166, AV718707, AV719822, AV719557, AW959799, AV720731, D59859, AW964477, AW966022, AW966029, AV718938, D80188, AV718633, AW975613, D51423, D59619, AW965177, AW949630, AW978661, D80210, AW966075, AW973488, D80240, D80253, AW966065, AV719324, AW949629, AW975605, AW973334, AV718931, AV720878, AW966032, AW966534, AV699447, D58283, AW958993, AV722801, AV723927, AW949656, AW966041, AW949631, AW949643, AW949618, AW949657, D59275, AW973482.

				AV721386, D80022, AV700889, D80195, AA305578, D80219, AW975621, AW978648, D80043, AW959597, D59467, AW960473, AW959570, AW949654, AW965163, D80391, D80164, AW966030, AW966054, AV720203, AV720150, AW966050, AV719188, D59787, AW958992, D80227, AW966062, AV718440, AV719783, AV720028, D59502, AV699550, AW959628, AW962082, BE269743, AV719468, AV718800, AW965185, AW965197, AW965196, AW973485, AW965184, AW960454, D57483, AV718844, AV720464, AV718770, AW959062, AW956434, AW964488, AW949641, D59610, AV699927, AA305409, D80366, D80024, D59889, D80196, AW973330, C15076, AW973447, AW949632, AW959582, D59927, AW949653, AW949655, D80269, D80038, D50979, AW959469, D51022, D80193, AW177440, D50995, AW964532, AW962245, AW964737, AW965158, AW949646, AW949633, AW949658, D80241, AW960532, D80378, AW966043, AV720812, D80045, AV720220, D51060, AW753053, AW966023, AV723097, AV699866, AW179328, D80248, AW960564, AW973490, D81026, AW752082, AW960504, AW965176, AW966389, AW975623, AV744690, AV699652, AW966330, AW178893, AV699746, AV718530, AV720616, D80522, AV701004, C14014, AV700229, AW973445, AW973465, T03269, C75259, AW960570, AV699479, AW962395, AV701335, AV718681, AV701043, AV701332, AV701017, AV701248, AV719000, AV701431, AV699682, AA514188, AA514186, AV719628, AV720654, D80268, D80251, AV742001, AV742667, AW753067, AV701125, AV701166, AV742430, AV701149, AW378532, AV742048, D80133, AV699669, AW966331, AW360811, AW377671, AV738340, AW177501, AW973473, AW177511, AW966332, AV720151.
12	HHGDP51	13	1310873	AI652297, BF967925, AW769372, BE857943, AA446941, BF115527, AI209086, AA443365, BF059139, D59611, AW204677, AI446405, AI918554, BE538466, BE965527, AW079768, BF816041, BF816031, AW082600, AW893295, BF885675, BF915537, AI537837, AA464646, AI582912, BF987113, AA835966, AI865116, AI620093, AI573026, AW058233, AV735118, AI889147, AI371228, AI349957, AA848053, AI345005, AI627880, AW084132, AW020592, BE613727, BG057418, AI345014, AW022494, N22406, AW020288, AI560679, BF913615, AW059713, AI636719, BE966928, BF817746, BF925348, BF915316, AI349814, BE875407, AW858254, AI583578, AW083804, AA830821, BG105895, AW075084, AI310925, BE904051, AI312399, AI349937, AI623736, AI334884, AI307543, AW411043, AI345251, BE245461,

			<p> AW071412, AI307708, AI312325, AW071395, AV738918, BE964937, AI242736, AI340659, AW071377, AI311159, AI340644, BE138684, BF885000, AV736474, AI334930, AI309443, AI471909, AI307520, AI345026, AI307545, AI752007, AI340664, AI310592, AI307542, AI569632, AW151138, AI345817, BE621040, AI345739, AI345674, AI312143, BE965355, AI349637, AI334920, AW071276, AI310927, AI307578, AI336488, F32537, AI364788, AW082623, BE155168, AI636619, BG179295, AI349955, AW075093, AL046463, AI312432, AW084097, AI918408, BE172412, AI312357, BE907440, AI475151, AI680226, AI312237, W33163, AI250627, AW500379, AI950664, BE897632, AI873638, AI537643, AI866608, BE964700, AW073898, AW268261, BE271279, AA468418, AA514684, BF038804, AI805688, AI349213, AI611743, BE965169, AW263804, AI249877, BE965503, AI804505, AW900453, AI951222, AI888621, BF868927, AI696626, AI357599, AW149876, AI589993, AI365256, AW079334, BF909758, BE964497, BE910005, AI553669, AW085786, AI345677, AI636788, BF814449, AW265004, AW999906, BE393551, AI886055, AV738628, AI472536, AI677797, AI452857, AW196105, W81248, AW191844, BG113493, AI366959, AW074301, AI249946, AI244380, AI784233, AA493923, AI344935, AV648263, BG113236, BG178735, AW130430, AI828574, AW059828, AI738867, AI589428, AI805769, AI434242, AI345397, AW025533, BF572734, BE172499, BF924897, BE313517, BE964078, AW193467, BF872670, AI280670, AI802372, AI921420, AI446124, AI688848, AI499986, AI540606, AW089572, AI345737, AV738730, BG058217, AI345114, N99092, BE138712, AI915295, AI254226, BF814072, AI307210, AI590423, AI866786, AI336513, AI500659, AI336662, BG001293, AI336634, AI345261, AI868204, AI702301, AI307569, BF680133, AW079432, AI348895, AI345736, AW068845, AI313320, AI050666, AW081383, AI336495, N74355, AF120268, I41145, AI8777, AK024545, AF085809, AF107847, AL049460, AR068466, L13297, AJ301634, AF219137, S77771, AL137521, I89947, I48978, A08913, AF155148, AL389935, I89931, A08912, A08910, A08911, AR087170, A08909, AR038854, A08907, AL133104, A08908, AL122111, AF119856, AF125949, AF090896, X62773, S76508, I89934, AB019565, X62580, U42031, AF113676, E02253, E01812, AF254119, U91329, AF207829, AL035458, AF271350, AF094850, AK024601, AB025103, AF176651, AL080158, AB048995, E08631, AL137300, AK000652, AL133093, X87582, AK026590, AB051158, AF305835, </p>
--	--	--	--

				<p>AF217991, AB049848, X99257, AK026651, AB049629, AF114818, AL133098, AJ242859, AL117585, AL080127, U00686, AF040751, AL137705, A12297, A93016, I00734, AK026395, AL162083, AF119894, AK024594, AK000445, L40363, AB047897, AL133081, AK000212, AK025669, AK025573, AF188698, AB049758, E00617, E00717, E00778, AX027129, AF261883, A18788, AJ006417, U75370, U57352, AK025889, E02914, AL137283, AL133645, X70685, U57715, AK026541, I17767, AB046642, AB044390, AK000291, AL110225, AL389951, S53987, AL117394, AF119358, AF057300, AF057299, AF242525, I89944, AK026592, AK027105, AF117959, I09360, AK026571, AR038969, E15582, AK026924, AF111847, AL137547, X59414, AL110222, AK024538, AK026608, D55641, Z22828, AK026591, AF078844, AL080060, Y16258, Y16257, E02756, Y16256, AF065135, AF130054, Z72491, AF203473, AL353957, AF119909, AK025208, AL137648, U66274, AR079011, AR079012, A90832, AL137555, AL137659, AL117629, U77594, AK025383, AF030165, AF012536, AF003737, AK026533, AF116676, AB047248, AL389978, AF159141, AK027104, AF067420, U90884, AL359600, AF116644, AF031147, I26207, AL157479, AF017790, AK025541, AL117578, AK026452, X54971, AX011676, AL080137, AF000145, U72620, AB047904, AC004227, AK026600, A08916, AK026629, S75997, AF113694, AR068751, AF110329, AL133067, AL049464, S63521, AF022813, AL137557, AL133558, AX046603, AK026353, AF051325, AB047966, AX005848, AX005804, AX014095, AK025084, I46765, AL137459, AB026675, AK025491, AK025349, AF311287, AB038698, U68233, I92592, E07108, AR059883, AF130068, AF036268, AF260566, AK000391, AF016271, AF178432, AL389939, AF040723, AB029065, AF114168, AC010128, AC005902, AL137276, AL110171, AF314091, Y10655, AF116691, X76228, AL133054, AF090943, AF218031, AK025391, AK027129, AF218004, AB047615, AK025906, AF069506, AK026164, AL359596, M30514, AL050280, I52013.</p>
12	HHGDP51	41	857703	<p>A1652297, BF967925, AW769372, BE857943, BF115527, AA446941, AI209086, AA443365, D59611, BF059139, AW204677.</p>
13	HBCBS41, HDMB147	14	1310706	<p>BF525534, BF525878, AI188462, AV706177, AA835791, AI573089, AV706657, AA828067, BF338495, AI1141312, AI961924, AA563724, AI829025, AV733099, AA464950, AA845819, AA618072, AI343736, AA576567, AI370917, AA622849, AI591077, AA039329, AW084144, AI719443, AA978073, BE819803, AI968544, AA910242, AI344535, AI554230, BF994888,</p>

			AI299970, AA948689, AA828804, BE219403, AI298788, AA775331, AV702739, AA937438, N49449, T70926, AI299637, AA516376, H27042, AI565682, AA933874, AV706862, AA953314, AW951361, AA838059, AA865068, AA663921, AA338264, R68898, AV707811, AV703148, AI097249, AI879461, AA394279, AA582298, BE138913, AA879122, AW238763, H26166, AA039414, AW383740, BF951235, AW951363, AI125081, AA577157, AA582289, BF591527, AA603650, AA465026, AA837695, N54606, T95006, AI299684, AA828747, AW137828, BF945969, AI720693, AA834499, H26167, T91949, N33604, AW087254, AA295894, AA293797, R68796, BG236868, AA988656, AI817977, T49380, AA628820, AA379748, AW628890, AI589170, AI582116, T49379, AW516492, BF842441, AW815770, AA984912, AI581583, AI000183, T84931, T53963, AI079151, R36633, T71284, T53830, AA369370, BG059309, AA369514, AI869893, T94953, BE465572, T86178, AI950559, T70988, T86179, AI749183, AA369395, AI344355, BG153207, AI582011, AI826458, AW797707, AA486985, T72982, AA913653, AA362998, R28940, T72203, AI749099, BF951201, N76686, AW798220, AA369611, T71421, AA603651, AI676040, T28386, AL080021, BF379002, AA369396, BG012359, R39712, AI734970, AL047857, AA913190, AA318607, AW816674, AI719214, D45294, R10854, BF870900, X03084, K03430, M36278, BG272985, BG677431.
13	HBCBS41, HDMBJ47	42	1225229 BF525534, BF525878, AI188462, AV706177, AI573089, AA835791, AV706657, AA828067, BF338495, AI141312, AI961924, AA563724, AI829025, AV733099, AA576567, AA464950, AA845819, AA618072, AI343736, AI370917, AA622849, AW084144, AA039329, AI591077, AI719443, AA978073, BE819803, AI968544, AA910242, AI344535, AI554230, BF994888, AI299970, AI298788, AA948689, AA828804, BE219403, AV702739, AA775331, AA937438, N49449, AI299637, AA516376, T70926, H27042, AI565682, AA933874, AV706862, AA953314, AW951361, AA838059, AA865068, AI097249, AA663921, AA338264, R68898, AV707811, AV703148, AI879461, AA394279, AA582298, BE138913, AA879122, AW238763, H26166, AA039414, AW383740, BF951235, AW951363, AI125081, AA577157, AA582289, BF591527, AI299684, AA603650, AA465026, AA837695, AW137828, N54606, T95006, AA828747, BF945969, AI720693, AA834499, H26167, T91949, N33604, BG236868, AW087254, AA295894, AA293797, R68796, AA988656, AI817977, T49380, AA628820, AA379748, AW628890, AI589170, AW516492, AI079151,

				AI582116, T49379, BF842441, AW815770, AA984912, AI581583, AI000183, T84931, T53963, R36633, T71284, T53830, AA369370, AI950559, BG059309, AA369514, AI869893, T94953, BE465572, T86178, T70988, T86179, AI749183, AA369395, AI344355, AI826458, BG153207, AI582011, AW797707, AA486985, T72982, AA913653, AA362998, R28940, T72203, AI749099, BF951201, N76686, AW798220, AA369611, AI676040, T71421, AA603651, T28386, AL080021, BF379002, AA369396, BG012359, R39712, AI734970, AL047857, AA913190, AA318607, AW816674, AI719214, D45294, R10854, BF870900.
13	HBCBS41, HDMBJ47	43	933547	AI188462, AA835791, AV706657, BF338495, AI141312, AA563724, AA828067, AI573089, AI829025, AI961924, AA576567, AV733099, AA464950, AA622849, AW084144, AI370917, AA845819, AA618072, AI343736, AA039329, AI591077, AA910242, AI719443, AA978073, AI968544, AI344535, AI298788, AI554230, AV702739, AI299970, AA948689, BF994888, T70926, AI299637, AA516376, BF525534, BE219403, AA775331, AA937438, N49449, H27042, AI565682, AI097249, AA838059, AA933874, AA865068, AV706862, AA953314, AA663921, BF945969, BE819803, AV706177, R68898, AA879122, BF525878, AA582298, AV707811, AI879461, AV703148, AA603650, AA394279, AA039414, BE138913, AW383740, H26166, AW238763, AA582289, BF951235, AA577157, BF591527, AI299684, AW951361, AI125081, N54606, T95006, N33604, AI720693, AW137828, AA834499, H26167, BG236868, AA465026, T91949, AA828804, AA295894, AW087254, R68796, AA293797, AW951363, AI817977, T49380, AA988656, AA628820, AW628890, AW516492, BF842441, AI079151, AW815770, AI582116, AI589170, AA984912, R36633, AI000183, AI581583, AA837695, T71284, T53830, AI950559, AA369370, BG059309, T94953, AI869893, BE465572, AI826458, T86179, T86178, AI749183, T53963, AA369395, AI344355, BG153207, AA486985, R28940, AA913653, AW797707, AI582011, AI749099, AW798220, AA369514, BF951201, AA603651, AA379748, AI676040, T71421, T28386, N76686, R39712, AI734970, AA362998, AL047857, AA913190, AA369611, BF379002, AA318607, T70988, AW816674, AA369396, T72203, AI719214, BF870900.
13	HBCBS41, HDMBJ47	44	967511	BF525534, BF525878, AV706657, AI188462, AV706177, AW084144, AA618072, AI573089, AA835791, BF338495, AA828067, AI141312, AI961924, AA563724, AI829025, AV733099, AA576567, AA464950, AA845819, AI343736, AI370917, AA838059, AA622849, AA039329,

			AI591077, BE138913, AI719443, AA978073, BE819803, AI968544, AA910242, AI344535, AI554230, BF994888, AI299970, AA948689, AA828804, BE219403, AI298788, AI565682, AA775331, N54606, AV702739, AA937438, N49449, N33604, AI299637, AA516376, T70926, AI079151, H27042, AI817977, R68796, AV706862, T95006, AA933874, AW951361, AA953314, AA865068, AA988656, AA663921, AA338264, AI097249, R68898, AA984912, AV707811, AV703148, AI879461, AA582298, AA394279, AA879122, AW238763, H26166, AA039414, AW383740, BF951235, R36633, AW951363, AA582289, AI125081, BF591527, T86179, AA603650, AA465026, AA577157, AA837695, AI299684, AA569124, BF945969, AA828747, AW137828, AI582011, AI720693, AA834499, H26167, AA913653, T91949, AA486985, AW087254, AA295894, AA293797, BG236868, T71421, T49380, AA628820, AA379748, AI589170, AW628890, AW516492, AI582116, T49379, BF842441, AW815770, AI000183, T84931, AI581583, T53963, T71284, T53830, AA913190, AI734970, AA369370, AI869893, BE465572, AA369514, T94953, AI950559, T86178, BG059309, T70988, AI749183, AA369395, AI344355, BG153207, AI826458, AW797707, T72982, AA362998, T82940, AI749099, T72203, BF951201, N76686, AW798220, AA369611, AI473594, AA603651, AI676040, AL080021, T28386, BF379002, AA369396, BG012359, R39712, AL047857, BF437726, AA318607, AW816674, BF870900, AI719214, D45294, BF870899, R10854.
14	HDPZR206	15	1384228 BE622709, BE622543, AW195694, AA449506, BE349118, AW836407, BE218589, BE018663, AI671569, AI990535, AI338971, AI656295, BF352595, BF352547, BF353066, AA449077, BF902513, BF756315, AA991669, AA971051, AA009692, AA837005, AA009411, AA639511, AA365182, AA365181, AW236877, AI766763, BF214429, AW983562, AV704180, BF195732, AV703542, BF352031, AA045125, AV706910, BF368967, T03588, BE142783, AV704660, AV706223, AV727314, AV701643, AV660516, AV727978, AV726502, AV703591, AV731070, AV703266, AV660258, AV705550, AV727238, AV728436, AV706851, AV652001, AV705518, AV725577, AV727954, AV729424, AV727139, AV702322, AV725618, AV705992, AV726337, AV653353, AV704626, AW959346, AV727822, AV728743, AV702149, AV652528, AV728404, AV651897, AV725441, AV725031, AV707024, AV708786, AV725582, AV709580, AV708872, AV726194, AV704144, AV726392, AV727618, AV727583, AW955629, AV725991, AV729255, AV703168, AV726590, AV725255, AV703632,

				AV725596, AV701516, AV708858, AV651955, AV705481, AV728309, AV704590, AV729473, AV742050, AV707151, AW952013, AV687342, AV701874, AV706147, AV726830, AV729366, AV708520, AV704376, AV707882, AV728464, AV661286, AV703366, AV726480, AV704605, AW956292, AV706677, AV705453, AV704916, AV703086, AV706076, AV706718, AV707311, AV728546, AV702498, AV726542, AV706290, AV725321, AV706871, AV706734, AV702958, AV727018, AV709356, AV703417, AV727347, AV707770, AV701876, AV703761, AV703367, AV707556, AV701873, AV656240, AV702463, AV702781, AV652156, AV661744, AV709222, AV707009, AV726156, AV705234, AV702721, AV660096, AV708347, AV707329, AV706025, AV654287, AV725617, AV725393, AV703214, AV701879, AV706683, AV709939, AV704712, AV705655, AV727576, AV702417, AV701754, AV701184, AV703505, AV702164, AV709596, AV701704, AV728874, AV709776, AV729408, AV725927, AV703213, AV702280, AV729532, AV703388, AV707322, AV704879, AV647692, AV707268, AV726755, AV707088, AV703232, AV704442, AV727469, AV702783, AV706874, AV703927, AV702600, AV707401, AV702409, AV706035, AV705239, AV707420, AV706991, AV706104, AV709326, AV703137, AV704217, AV701783, AV706012, AV651075, AV709880, AV706330, AV704865, AV702102, AV651704, AV702673, AV705267, AV702637, AV646347, AV707640, AV729219, AV654035, AV703783, AV688061, AV706410, AV726628, AV701669, AV709886, AV701499, AV697350, AV702800, AV708320, AV702671, AV707589, AV707264, AV709256, AV703320, AV729220, AV729129, AV703844, AV702851, AV702625, AV727932, AV706882, AV648619, AV702817, AV727047, AV702354, AV655067, AV704954, AV702725, AV704245, AV647654, AF270513.1, AL117592.1, AJ244005.1, AJ244004.1, D78345.1, AJ244003.1, U94592.1, AJ244007.1, D50010.1, D13316.1, AB025273.1, AF144029.1, AJ276256.1, AJ276254.1, Z30183.1, AF058696.1, AB028859.1, Y14219.1, AB002449.1, X67155.2, AF271371.1, AF144028.1, AJ244006.1, D34614.1, D88547.1, AB005666.1, AB038216.1, X82834.1, AJ276255.1, AA887644.
14	HDPRZ06	45	1303540	BE622709, BE622543, AW195694, BE349118, AA449506, BE218589, AI671569, AI990535, AI656295, AA449077, BF902513, BE018663, AA971051, AA991669, AA009411, AA009692, AA837005, AA639511, AA365182, AA365181, AW236877, AI766763, BF214429, BE142783, AW971745, AA887644, AL134524, AW968355, AW877209, AW972092, AL119324, AW968356,

				AI432644, AW861944, AI623302, AW972093, AW968729, AW971740, AW858525, AI432653, AW858522, AW081103, AW972091, AI432654, AI431351, AI431323, AI432650, AI119457, AW972090, AW969229, AI119399, BE672759, AI431307, AI431316, AI432677, AI042544, AI431230, AI431328, AI431238, AI045327, AW804686, AI128900, AI431353, AI431312, AI432666, AI432655, AI431310, AW858455, AI431354, AI043152, AI431347, AI492519, BF448552, AW604723, AI043168, AI431321, AI431315, AI432675, AW858526, BE672748, AI432661, Z99396, AI431337, AI431246, AI042508, BE672745, AI791349, BE672719, BE672732, AI431243, AX041928, AI117592, AX041927, AR080280, AX030435, Y17793, AX030436, AR066494, AX046357, AJ251859, AF019249, AB026436, AR071207, AI133076, AF064854, AI133053, AI133049, AI133074, AR060234, AI122101, AR054110, AX040974, AX041002, A81671, AJ279014, AI133068, AX040958, AI096720, AR069079, AI049423, AI133655, U30290, AC012104, E13998.
14	HDPRZ06	46	1223606	
15	HKBI69	16	1286614	AI417523, BG120479, AI749321, AW057748, AW043700, AW057920, AW305168, AA608713, AW474850, AA404349, BF594226, BF541540, AW022120, AA579971, AA629969, AI127940, AU151624, AW005378, AA705289, AW377397, AI610162, AA625142, AI689091, AA887126, AA835810, AA181946, AI084438, AW450806, BE378048, BF149104, AI133172, AI269303, AI378772, AA470804, R56253, AA707300, AA725191, R99908, W42777, AI540847, AA766559, AA496910, T78435, AA256605, AA683171, AI536732, AW021074, BF589574, BF062307, AI359641, AA694404, AA903168, AA258076, AI537144, AI264091, AW191603, R42797, BF727469, N95366, AA354837, AA083067, AI134604, AW301165, Z41690, R48102, H48756, N66512, R40560, AI270253, C01933, AW473992, AA497072, R44523, R47988, T97892, AA362636, R49171, T23045, F04485, R55714, AW889340, BE155973, AA775162, AW902313, BE243585, T75572, AI967943, AI119457, AI042544, AI119399, AI119511, AW877209, AI119324, T97891, AA258647, AI042382, AI043152, AI079794, BG032704, AW970048, AI043168, AI037081, T61538, AI042866, BG113493, AW971745, BG164558, AI037104, AI554245, AI538028, BG168640, AI134524, BF525578, AI133559, BE536058, BG260144, BG029053, BE968711, BF970449, AW827289, AW827276, AV756359, BE047852, BF338723, BE785868, AI784219, BE876033, AI364788, BF038131, BG256592, BE880182, BF806065, BG034459, BF822127, BE874133.

			<p> AW673679, BG028528, BF885082, AV682462, BF726894, BE542893, BE782605, BF970362, BE893142, BG106619, AW088903, AI926669, AL079741, AV682052, BE877372, AA715307, AV755840, BG034373, BG033357, BE548542, BG163297, BE896632, BE881131, BG256705, BG110797, BG250841, AW020693, BF726237, BE874997, BF752999, BF814447, AI540759, BE011880, AW772685, BF032768, BF339322, BF032910, BE047952, AL045500, BE622183, BF107493, AI468872, BG027766, AW148716, AL045349, AV756030, BG254352, BG032208, BE910373, AW129230, BF916181, BF816037, AA938092, BE887488, BE904178, AI539771, AI916419, BE877769, BG032994, AI830259, AW162194, BF726207, BG168646, AW172723, AA641818, BF811793, AV729119, AI866082, BG109711, BG249582, AI269862, AI680498, AI494201, BE047737, BF753056, AW191003, BF911528, BE620444, BF968910, AI619723, AI224027, BF885080, BE895765, AI564448, BG110704, AV682467, BG251840, BG026482, BF814420, BE875243, AI699011, BE048071, AI436429, BF794756, BE963286, BF338002, AW151714, AV648430, AI610557, AI648684, BG034609, BG029667, AW834325, BF339594, AL042628, AL036214, AI433157, AI538885, AI554821, AW858243, BG252929, AW151136, BE897632, AC010198, AK026222, AK024247, U77594, AX030435, AJ251859, Y11587, AK024524, AK025431, I00734, E00617, E00717, E00778, AL162062, L10353, AL122049, U96683, A08916, A08910, A08909, AR080280, AL162002, AL390167, AK026647, I48978, S68736, AL389935, AF008439, AF130087, S61953, AF314091, AF067728, AX042059, AL389939, AJ238278, AL122098, AF177401, AF119337, AF162270, I89947, AK026959, A08913, L30117, I89931, AK024538, AB026436, AK025798, AL080127, X93495, AR087170, AB047904, AK025015, AL133072, AF183393, AL080159, AF155221, AF116644, AB048964, AF119909, AL117440, AL080137, AL137476, AX040958, AF119896, AR000496, U39656, X52128, AF090901, X81464, AK026408, I33392, AR059958, AK025524, AK027188, AB049758, AL137548, AL122110, AF113019, AL049283, AK026480, AL133080, AL049466, AK000432, AL162003, AK026885, I17767, AK026927, AL133077, AK026551, AL050393, AL389982, AL122121, AF116639, AK026464, AK025857, E05822, AL049382, Z82022, AF153205, AK027160, AL359601, Y14314, AR038854, AL133031, AL137463, AK027182, AF113689, AK025391, AF017152, AK000310, AF116649, A08912, AL359620, AL050138, AF113013, AJ012755, AF116631, AF271350, AF119883, </p>
--	--	--	--

				E03348, AL137526, L19437, AF097996, AF028823, AF218031, A65341, AB041801, AK026045, AB050534, AF130100, AF177336, AK025209, AX040974, AF130092, AL110221, E15569, S78214, AR020905, X76228, A07588, AF119878, E02349, AF110640, AF218034, AF090900, AL133014, AK026532, AF111112, AF003737, AK026533, AF017437, AK026086, AK027121, AF106827, AL110296, AL049452, AK026624, E07108, AF158248, AL359618, AF061573, E07361, AL080124, AL080060, AK000652, AL137556, I48979, AL389978, AF130055, AK026597, AL049430, AK026642, AF132676, AF225424, AB047941, AR070212, AF061836, AF111851, AB048974, AX020124, AK025312, AF125948, AF113676, AK000718, AK026534, AK027116, AK026865, AF078844, AL050277, AL357195, AL050024, AX019230, AF217966, AB047887, AK000137, AX014095, Z72491, AK027164, Y09972, AL137550, AK026452, AF205861, AK000690, AK000486, AF104032, AF175983, AF207829, AF026816, AL080086, AL359941, A18777, AF130066, AK024588, AK027096, AL162008, AF119875, AK026583, AL133640, AB048919, AF119871, AF210052, AB052191, AK025084, AF217987, AF017790, AK025092, AL162006, AB048975, AK025632, A93350, AF116646, AK000647, AL117457, AL133016, AK025254, A45787, AK000323, AX010492, AF146568, AL122093, AK025208, AL133565, AL133606, AK027136, AJ006417, AL137479, X98834, AK026462, BE552256.
16	HOHBO69	17	1282370	BG114252, BF344333, AW029321, BE619018, BF591735, AI084509, BE877796, AW068693, BF002157, AW068694, AA872420, N23787, AW613589, AI752218, AW630180, AI752219, AI752163, AI750192, AI753307, AI752164, N24399, AA789067, BF197886, W19235, AI424724, AA233788, AW392772, AW068274, AA627580, AA853772, AA853676, H99150, H89055, AA853685, BF448509, BF741968, BF132395, AA577443, AW392783, H99383, D79968, D62487, AA853675, AA290849, AA283763, W25429, AA853686, X57527, J05042, X66977, AF044969, AF054891, S63458, X66976, AF055330, AC007275, AF170702, AL022143.
16	HOHBO69	47	1280342	None
17	HCEES60	18	1305240	BG251391, AL138070, AA639738, AL138071, R38469, AA317570, W30872, AA043621, AA853712, AI806793, AA702490, AA780815, AI751694, AL138787, M60832, M60833.
18	HDALV07	19	1316192	AR034253, D45371, AB012165, AJ131461, AR034252, U49915, AJ131460, AB012164.
19	HEQAHA7	20	877634	AL519977, BE383449, AL043766, BF061686, BF221776, BF310701, BF060773, BF434074, BF062728, AI659849, BE313561, BF314046.

				BF316323, AI659290, AI824840, BF061701, BF312471, AI751263, AI685765, AI591068, AI587181, AI920932, AI400351, AI148305, AI955664, AI652541, AI675888, AI653379, AI424943, AI128448, BE313794, BF437698, AI275016, BF590996, AI561014, AI660936, AI491938, AI968617, BE047763, AI127265, AA643524, BF313828, AI866540, AI751264, AI828892, AI824814, AA970985, BE855979, AI589275, AI768084, AA477627, AW371357, AI926713, AI969893, AI335684, AA057195, AA478085, AW193325, AW002099, AI672890, AI991492, AI225080, AW191017, AI804237, AI918988, AI215462, AI660046, AW263221, AW166456, AW361968, AI923034, BF939318, AI672957, AW008276, AI421034, BF941981, AA101823, AI474549, BF514389, AA968480, AW591386, AI972480, AI758252, AI277535, AI611291, AI4446797, AA627406, AW082500, AI673160, AA127893, AW085658, AA101824, AI491939, AI445814, AW513225, AI656563, W21432, AW590943, AA128143, AW196052, AW452957, AI419247, AI356191, BF593921, AI339204, AA973738, BF196865, AA973140, BF941530, AA423796, AA962026, AI572714, BF593478, AA057129, AA834119, AI333104, AI401697, AI539260, AI628325, AI345415, AW163834, AI590043, AI698391, AI440238, AL047763, AW130362, AI523973, AW150622, AW008166, BF531023, AA565269, AL042567, AI361701, AI619820, AI434731, AI653402, AI880111, AI500061, AI345688, AI862067, AI800648, BE393784, AL037602, AI872423, AI524179, AI289791, AI927233, AI565172, AL037582, AI866469, AI370623, AL079963, AI678446, BG250475, AW189716, BF909758, AW196720, AW129659, AW081383, AI784214, BE964705, AV659072, AI244343, AI445611, AI680467, AI250646, BG260772, BE877401, BE907624, BG034598, AI699823, BF724420, BE904851, BF750886, AI869125, AI869377, AI582932, BE957870, AI638644, AA659688, AL036241, AI972112, AI345612, BE867194, BF035213, BE905161, BE873695, BE877904, AI345416, BE967004, AI627714, AW188525, AI251221, AL036673, BG169738, BF525838, AI290677, BG256090, AI470717, AI499570, BE963809, AW051088, AW983832, AW117882, AI471282, AI621341, AI440239, AW130104, AI866127, W45039, AI536574, AI583558, AI583578, BG118199, AI889189, AW075382, AI348847, AW083572, AW161202, AI366959, AI633125, AI800341, AI310575, AI869765, AI860027, AI538564, AI335476, AI866040, AI915291, AW152182, AI538817, AW130534, AI274655, AW025279, AI284060, BE965159, AI866770, BF811804, AI581362, AI270295,
--	--	--	--	--

				BE891834, BF669151, AV681858, AW073824, AI589428, AL050138.1, AF088916.1, BC007530.1, AF162780.1, Y09340.1, AL137480.1, BC000090.1, AK026542.1, AL080146.1, BC007522.1, BC001675.1, BC002491.1, AL162002.1, AB060889.1, BC006091.1, AJ012582.1, AL137558.1, AL389935.1, BC001199.1, AK026462.1, AL161802.15, AL117587.1, BC001166.1, AF183393.1, BC007571.1, BC003104.1, BC002631.1, AB055303.1, AB060887.1, BC007767.1, AL136765.1, BC006345.1, AK000618.1, BC008708.1, BC006119.1, Y14040.1, BC008364.1, BC001785.1, BC004925.1, AF249267.3, AL080154.1, AK027161.1, AL080110.1, AL117438.1, BC003410.1, BC003569.1, BC008382.1, AK024974.1, AK027160.1, AL136864.1, BC003101.1, AK000655.1, AL049382.1, AB047627.1, AL137292.1, BC008591.1, AL137530.1, AK027102.1, AK025435.1, AF044323.1, BC001964.1, U73682.1, AB060876.1, BC002911.1, BC003587.1, BC002370.1, AL442083.1, AF132730.1, BC000570.1, AL136752.1, AL136893.1, AL137495.1, AK026633.1, AL359583.1, BC002535.1, AL117416.1, BC006410.1, AL512718.1, AL137574.1, BC003590.1, AL133088.1, X66417.1, AL137461.1, U70981.1, AK024533.1, BC003573.1, AB050410.1, BC003591.1, AK025099.1, Z82022.1, AF271781.1, BC002471.1, AB050431.1, BC005854.1, AK025113.1, AL137256.1, AF369701.1, AL080148.1, AL133049.1, X53587.1, AF026816.2, AL359941.1, BC004945.1, BC004292.1, AK000418.1, AL136850.1, AL080159.1, AB060897.1, AF339775.1, BC004908.1, BC009333.1, AL137533.1, AF195092.1, BC007381.1, BC008649.1, AK027095.1, S76508.1, BC005002.1, X83544.1, BC004119.1, Y14314.1, BC000235.1, AL389982.1, BC006181.1, AL136784.1, BC001082.1, BC000751.1, AK024588.1, AK025860.1, AK025084.1, AB063074.1, S77771.1, U37359.1, BC002473.1, AL136774.1, BC005070.1, BC000860.1, AL133559.1, S61953.1, AK000476.1, BC000199.1, AB060864.1, AF245044.1, AL137478.1, BC008686.1, BC006103.1, BC005816.1, BC007460.1, AK025798.1, BC002466.1, AF124728.1, AF104032.1, AL137550.1, AF106862.1, X82434.1, L19437.2, AL137557.1, AL162003.1, BC004899.1, AK026164.1, AL137271.1, AB060837.1, AF141289.1, AB060916.1, BC004395.1, AK025350.1, AL137554.1, BC002356.1, AL353956.1, BC001844.1, AL080126.1,
--	--	--	--	--

				AI050092.1, BC008078.1, BC008417.1, AF271350.1, AL512751.1, BC007453.1, BC009026.1, AF131773.1, AL136615.1, BC000253.1, AK026647.1, AK026744.1, AL136844.1, AB056420.1, BC008717.1, BC008723.1, AL133062.1, BC006161.1, AF081571.1, AL050155.1, AF230496.1, AC026464.6, AF242525.1, BC002516.1, AF239683.1, BC004349.1, AL512684.1, AL133081.1, AF131821.1, AB047953.1, BC001763.1, AB048974.1, AJ299431.1, AL050149.1, BC005843.1, AF184965.1, AL136586.1, AL137488.1, AK024747.1, AL136768.1, AL122121.1, AL110280.1, AC006288.1, AK026506.1, BC004960.1, AL136884.1.
19	HEQAH47	48	1254417	
20	HATNA88	21	1282006	BG032839, AI217963, AW665995, BG178505, AI032401, AI016792, AW973741, AA889643, BE041602, AW983637, AW983608, AW983601, AW983610, AW983628, AW983645, AW983688, AW983603, AW983607, AW983625, AW983640, AW983612, AW983642, AW983617, AW983624, AW983634, AW983687, AW983602, AW983630, AW983635, AW983636, AW983689, AW983616, AW983639, AW983609, AW983644, AW983618, AW983604, AW983611, AW983615, AW983619, AW983686, AW983622, AW983633, AW983605, AW983626, AW983631, AW983643, AW983627, AW983620, AW983638, AW983632, AW983613, AW983685, AW983621, AW983592, AA559283, AW983641, AW983623, AW983589, AW983593, BF349085, AW983594, AW983614, AA583866, AA883836, AA557662, AA593227, BF512098, AI275909, AA578056, AL445985, AX047347, AFI78931.
20	HATNA88	49	1285117	

TABLE 3

cDNA Plasmid: V	Library Code(s)
HCE1P80	H0052 H0179 H0253 H0266 H0375 H0543 H0551 H0575 H0618 H0790 L1290 S0027
HUFGH53	H0009 H0012 H0024 H0059 H0087 H0208 H0483 H0506 H0529 H0540 H0617 H0622 H0624 H0625 H0660 H0672 H0687 L1290 S0038 S0354 S0374 S0418 S0444 S0626
HWMMO59	H0024 H0392 H0617 L1290 S0358 S0444
HSSJJ51	H0030 H0052 H0087 H0100 H0251 H0253 H0286 H0318 H0445 H0486 H0550 H0594 H0599 H0618 H0619 H0693 H0713 H0757 H0762 L1290 S0037 S0196 S0280 S0378 S0436 S0476
HCEWD38	H0052 H0194 H0261 H0581 L1290
HUCMC56	H0013 H0144 H0178 H0244 H0563 H0570 H0624 L1290 S0051 S0442
HWLZU06	H0549 S0222 S0406 S0436
HDPBA69	H0009 H0014 H0031 H0039 H0062 H0063 H0090 H0108 H0122 H0123 H0163 H0189 H0213 H0252 H0264 H0309 H0333 H0343 H0345 H0352 H0375 H0376 H0427 H0444 H0445 H0486 H0506 H0509 H0510 H0521 H0522 H0553 H0555 H0570 H0575 H0581 H0583 H0595 H0597 H0619 H0620 H0622 H0638 H0644 H0652 H0658 H0661 H0662 H0663 H0666 H0668 H0672 H0682 H0710 H0713 H0726 H0753 H0754 H0757 H0762 H0773 H0774 H0777 L1290 S0106 S0190 S0212 S0280 S0282 S0330 S0354 S0358 S0360 S0362 S0374 S0376 S0378 S0384 S0406 S0408 S0434 S0436 S0438 S0440 S0442
HLWAE11	H0050 H0056 H0266 H0521 H0553 L1290
HSZAF47	H0013 H0321 L1290
HWTAY65	H0012 H0013 H0019 H0123 H0351 H0352 H0550 H0553 H0570 L1290 S0007
HHGDP51	H0424 H0455 H0617 L1290
HBCBS41	H0004 H0009 H0014 H0031 H0042 H0068 H0086 H0087 H0090 H0124 H0144 H0190 H0255 H0263 H0309 H0327 H0329 H0351 H0370 H0375 H0376 H0393 H0415 H0421 H0427 H0441 H0445 H0486 H0489 H0521 H0522 H0538 H0549 H0550 H0553 H0555 H0575 H0581 H0583 H0587 H0591 H0592 H0606 H0617 H0638 H0641 H0644 H0646 H0649 H0653 H0658 H0659 H0662 H0672 H0673 H0689 H0690 H0710 H0716 H0722 H0726 H0753 H0754 H0755 H0762 H0768 H0777 H0778 H0789 L1290 S0010 S0031 S0036 S0044 S0260 S0280 S0328 S0354 S0356 S0358 S0360 S0374 S0376 S0406 S0408 S0434 S0436 S0440 S0442 S0444 T0068
HDPRZ06	H0124 H0188 H0250 H0271 H0328 H0486 H0521 H0522 H0539 H0540 H0580 H0638 H0641 H0645 L1290 S0044 S0116 S0344 S0426 S0434 T0006
HKB1F69	H0013 H0384 H0412 H0616 H0659 H0688 L1290 S0007 S0026

	S0222 S0402 S0444
HOHBO69	H0024 H0050 H0100 H0266 H0486 H0519 H0538 H0544 H0545 H0550 H0551 H0575 H0593 H0615 H0619 H0622 H0623 H0653 H0665 H0667 H0770 H0771 L1290 S0015 S0022 S0028 S0032 S0040 S0126 S0134 S0180 S0196 S0208 S0212 S0250 S0276 S0298 S0360 S0390 S0418 S0420 S0434 S3014
HCEES60	H0052 H0123 H0135 H0144 H0251 H0594 H0615 H0622 H0628 H0645 L1290 S0040 S0126 S0142 S0344 S0420 S0430 T0082
HDALV07	H0081 H0427 H0706 H0713 H0716 H0717 H0725 L1290 S0212 S0260 S0280 S6022
HEQAH47	H0544
HATNA88	H0599 H0616 H0708 H0713 L1290 S0216

TABLE 4

SEQ ID NO: X	Cytologic Band or Chromosome:	OMIM Reference(s):
2	22q13.2	188826 602049
4	17q25.2	603967 606800
5	14q11.2	162080 182600 186880 190195 600243 602279 603593 605463 606439 606675
7	11q23.3	176000 236680 261640 600644 602574 603113 604763 605201 607086
9	22q13.1	103050 124030 138981 182380 188826 190040 218040 602049 603590
12	11q11	606860
13	1p36.3-p34.1	115665 116600 120550 120570 120575 121800 130500 138140 142461 153390 153454 155600 164780 167410 171760 172411 172430 178300 185470 211420 256700 600423 600975 601990 602023 603324 603490 603688 603776 604630 604933 605225 605425 605747 605909 605995 606210 606324 606693 606811 606928 606953 606996 607093 607215
17	7p15-p12	107776 138079 139191 142958 142959 153880 165240 180104 203740 261670 600994 601472 601583 603023 603284 606224 606246
18	3q27	109565 120520 142640 210200 228960 600044 602322 603273 603285 603945 603959 605229 605441 605552 607037

TABLE 5

Library Code	Library Description	Disease
H0004	Human Adult Spleen	
H0009	Human Fetal Brain	
H0012	Human Fetal Kidney	
H0013	Human 8 Week Whole Embryo	
H0014	Human Gall Bladder	
H0019	Human Fetal Heart	
H0024	Human Fetal Lung III	
H0030	Human Placenta	
H0031	Human Placenta	
H0039	Human Pancreas Tumor	disease
H0042	Human Adult Pulmonary	
H0050	Human Fetal Heart	
H0052	Human Cerebellum	
H0056	Human Umbilical Vein, Endo. remake	
H0059	Human Uterine Cancer	disease
H0062	Human Thymus	
H0063	Human Thymus	
H0068	Human Skin Tumor	disease
H0081	Human Fetal Epithelium (Skin)	
H0086	Human epithelioid sarcoma	disease
H0087	Human Thymus	
H0090	Human T-Cell Lymphoma	disease
H0100	Human Whole Six Week Old Embryo	
H0108	Human Adult Lymph Node, subtracted	
H0122	Human Adult Skeletal Muscle	
H0123	Human Fetal Dura Mater	
H0124	Human Rhabdomyosarcoma	disease
H0135	Human Synovial Sarcoma	
H0144	Nine Week Old Early Stage Human	
H0163	Human Synovium	
H0178	Human Fetal Brain	
H0179	Human Neutrophil	
H0188	Human Normal Breast	
H0189	Human Resting Macrophage	
H0190	Human Activated Macrophage (LPS)	
H0194	Human Cerebellum, subtracted	
H0208	Early Stage Human Lung, subtracted	
H0213	Human Pituitary, subtracted	
H0244	Human 8 Week Whole Embryo, subtracted	
H0250	Human Activated Monocytes	
H0251	Human Chondrosarcoma	disease
H0252	Human Osteosarcoma	disease

H0253	Human adult testis, large inserts	
H0255	breast lymph node CDNA library	
H0261	H. cerebellum, Enzyme subtracted	
H0263	human colon cancer	disease
H0264	human tonsils	
H0266	Human Microvascular Endothelial Cells, fract. A	
H0271	Human Neutrophil, Activated	
H0286	Human OB MG63 treated (10 nM E2) fraction I	
H0309	Human Chronic Synovitis	disease
H0318	HUMAN B CELL LYMPHOMA	disease
H0321	HUMAN SCHWANOMA	disease
H0327	human corpus colosum	
H0328	human ovarian cancer	disease
H0329	Dermatofibrosarcoma Protuberance	disease
H0333	Hemangiopericytoma	disease
H0343	stomach cancer (human)	disease
H0345	SKIN	
H0351	Glioblastoma	disease
H0352	wilm's tumor	disease
H0370	H. Lymph node breast Cancer	disease
H0375	Human Lung	
H0376	Human Spleen	
H0384	Brain, Kozak	
H0392	H. Meningioma, M1	
H0393	Fetal Liver, subtraction II	
H0412	Human umbilical vein endothelial cells, IL-4 induced	
H0415	H. Ovarian Tumor, II, OV5232	disease
H0421	Human Bone Marrow, re-excision	
H0424	Human Pituitary, subt IX	
H0427	Human Adipose	
H0441	H. Kidney Cortex, subtracted	
H0444	Spleen metastatic melanoma	disease
H0445	Spleen, Chronic lymphocytic leukemia	disease
H0455	H. Striatum Depression, subt	
H0483	Breast Cancer cell line, MDA 36	
H0486	Hodgkin's Lymphoma II	disease
H0489	Crohn's Disease	disease
H0506	Ulcerative Colitis	
H0509	Liver, Hepatoma	disease
H0510	Human Liver, normal	
H0519	NTERA2, control	
H0521	Primary Dendritic Cells, lib 1	
H0522	Primary Dendritic cells, frac 2	
H0529	Myeloid Progenitor Cell Line	
H0538	Merkel Cells	

H0539	Pancreas Islet Cell Tumor	disease
H0540	Skin, burned	
H0543	T cell helper II	
H0544	Human endometrial stromal cells	
H0545	Human endometrial stromal cells-treated with progesterone	
H0549	H. Epididymus, caput & corpus	
H0550	H. Epididymus, cauda	
H0551	Human Thymus Stromal Cells	
H0553	Human Placenta	
H0555	Rejected Kidney, lib 4	disease
H0563	Human Fetal Brain, normalized 50021F	
H0570	Human Fetal Brain, normalized C500H	
H0575	Human Adult Pulmonary, re-excision	
H0580	Dendritic cells, pooled	
H0581	Human Bone Marrow, treated	
H0583	B Cell lymphoma	disease
H0587	Healing groin wound, 7.5 hours post incision	disease
H0591	Human T-cell lymphoma, re-excision	disease
H0592	Healing groin wound - zero hr post-incision (control)	disease
H0593	Olfactory epithelium, nasal cavity	
H0594	Human Lung Cancer, re-excision	disease
H0595	Stomach cancer (human), re-excision	disease
H0597	Human Colon, re-excision	
H0599	Human Adult Heart, re-excision	
H0606	Human Primary Breast Cancer, re-excision	disease
H0615	Human Ovarian Cancer Reexcision	disease
H0616	Human Testes, Reexcision	
H0617	Human Primary Breast Cancer Reexcision	disease
H0618	Human Adult Testes, Large Inserts, Reexcision	
H0619	Fetal Heart, reexcision	
H0620	Human Fetal Kidney, Reexcision	
H0622	Human Pancreas Tumor, Reexcision	disease
H0623	Human Umbilical Vein, Reexcision	
H0624	12 Week Early Stage Human II, Reexcision	
H0625	Ku 812F Basophils Line	
H0628	Human Pre-Differentiated Adipocytes	
H0638	CD40 activated monocyte dendritic cells	
H0641	LPS activated derived dendritic cells	
H0644	Human Placenta (re-excision)	
H0645	Fetal Heart, re-excision	
H0646	Lung, Cancer (4005313 A3): Invasive Poorly Differentiated Lung Adenocarcinoma,	
H0649	Lung, Normal: (4005313 B1)	
H0652	Lung, Normal: (4005313 B1)	

H0653	Stromal Cells	
H0658	Ovary, Cancer (9809C332): Poorly differentiated adenocarcinoma	disease
H0659	Ovary, Cancer (15395A1F): Grade II Papillary Carcinoma	disease
H0660	Ovary, Cancer: (15799A1F) Poorly differentiated carcinoma	disease
H0661	Breast, Cancer: (4004943 A5)	disease
H0662	Breast, Normal: (4005522B2)	
H0663	Breast, Cancer: (4005522 A2)	disease
H0665	Stromal cells 3.88	
H0666	Ovary, Cancer: (4004332 A2)	disease
H0667	Stromal cells(HBM3.18)	
H0668	stromal cell clone 2.5	
H0672	Ovary, Cancer: (4004576 A8)	
H0673	Human Prostate Cancer, Stage B2, re-excision	
H0682	Ovarian cancer, Serous Papillary Adenocarcinoma	
H0687	Human normal ovary(#9610G215)	
H0688	Human Ovarian Cancer(#9807G017)	
H0689	Ovarian Cancer	
H0690	Ovarian Cancer, # 9702G001	
H0693	Normal Prostate #ODQ3958EN	
H0706	Human Adult Skeletal Muscle	
H0708	Human Skeletal Muscle	
H0710	Acute Myeloid Leukemia /SGAH (Patient #6)	
H0713	Adipose tissue (diabetic type I, obese) #41706	
H0716	Adipose tissue (diabetic type II)#41689	
H0717	Adipose tissue (diabetic type II) #41661	
H0722	Diabetic Liver 99-09-A281a	
H0725	Normal Adipose Tissue #41838-08	
H0726	Normal skeletal muscle #96-08-A171	
H0753	pancreatic cancer sample # 4004959A1	
H0754	Pancreatic cancer #14677A1L	
H0755	Pancreatic cancer sample#4004959 A1	
H0757	normal pancreas #400556A8	
H0762	Normal Pancreas 42206	
H0768	Lung cancer	
H0770	Esophageal Cancer #2109A5A ductal carcinoma	
H0771	esophageal cancer #0011C075Ra	
H0773	Malignant Esophagus #9706C049	
H0774	Prostate infiltrated by adenocarcinoma #4007645B1	
H0777	esophageal cancer #9902C094	
H0778	Esophageal Cancer #9804C013Rb	
H0789	renal cell carcinoma of kidney	
H0790	HMC-1 untreated	

L1290	Soares_testis_NHT	
S0007	Early Stage Human Brain	
S0010	Human Amygdala	
S0015	Kidney medulla	
S0022	Human Osteoclastoma Stromal Cells - unamplified	
S0026	Stromal cell TF274	
S0027	Smooth muscle, serum treated	
S0028	Smooth muscle, control	
S0031	Spinal cord	
S0032	Smooth muscle-ILb induced	
S0036	Human Substantia Nigra	
S0037	Smooth muscle, IL1b induced	
S0038	Human Whole Brain #2 - Oligo dT > 1.5Kb	
S0040	Adipocytes	
S0044	Prostate BPH	disease
S0051	Human Hypothalamus, Schizophrenia	disease
S0106	STRIATUM DEPRESSION	disease
S0116	Bone marrow	
S0126	Osteoblasts	
S0134	Apoptotic T-cell	
S0142	Macrophage-oxLDL	
S0180	Bone Marrow Stroma, TNF&LPS ind	disease
S0190	Prostate BPH, Lib 2, subtracted	
S0196	Synovial IL-1/TNF stimulated	
S0208	Mesangial cell, frac 1	
S0212	Bone Marrow Stromal Cell, untreated	
S0216	Neutrophils IL-1 and LPS induced	
S0222	H. Frontal cortex, epileptic, re-excision	disease
S0250	Human Osteoblasts II	disease
S0260	Spinal Cord, re-excision	
S0276	Synovial hypoxia-RSF subtracted	
S0280	Human Adipose Tissue, re-excision	
S0282	Brain Frontal Cortex, re-excision	
S0298	Bone marrow stroma, treated	
S0328	Palate carcinoma	disease
S0330	Palate normal	
S0344	Macrophage-oxLDL, re-excision	
S0354	Colon Normal II	
S0356	Colon Carcinoma	disease
S0358	Colon Normal III	
S0360	Colon Tumor II	disease
S0362	Human Gastrocnemius	
S0374	Normal colon	
S0376	Colon Tumor	disease
S0378	Pancreas normal PCA4 No	

S0384	Tongue carcinoma	disease
S0390	Smooth muscle, control, re-excision	
S0402	Adrenal Gland,normal	
S0406	Rectum tumour	
S0408	Colon, normal	
S0418	CHME Cell Line,treated 5 hrs	
S0420	CHME Cell Line,untreated	
S0426	Monocyte activated, re-excision	
S0430	Aryepiglottis Normal	
S0434	Stomach Normal	disease
S0436	Stomach Tumour	disease
S0438	Liver Normal Met5No	
S0440	Liver Tumour Met 5 Tu	
S0442	Colon Normal	
S0444	Colon Tumor	disease
S0476	Epithelial-TNF α and INF induced	
S3014	Smooth muscle, serum induced,re-exc	
S6022	H. Adipose Tissue	
S6026	Frontal Lobe, Dementia	
T0006	Human Pineal Gland	
T0068	Normal Ovary, Premenopausal	
T0082	Human Adult Retina	

TABLE 6

OMIM Reference	Description
103050	Adenylosuccinase deficiency Autism, succinylpurinemic
107776	Colton blood group, I10450 [Aquaporin-1 deficiency]
109565	Lymphoma, B-cell
115665	Cataract, congenital, Volkmann type
116600	Cataract, posterior polar
120520	Membranous glomerulonephritis, antenatal [Neutral endopeptidase deficiency]
120550	Clq deficiency, type A
120570	Clq deficiency, type B
120575	Clq deficiency, type C
121300	Coproporphyrria Harderoporphyria
121800	Corneal dystrophy, crystalline, Schnyder
124030	Debrisoquine sensitivity Parkinsonism, susceptibility to

126453	Dystonia, primary cervical Blepharospasm, primary benign, 606798
130500	Elliptocytosis-1
138079	Diabetes mellitus, neonatal-onset, 606176 Hyperinsulinism, familial, 602485 MODY, type II, 125851
138140	Glucose transport defect, blood-brain barrier, 606777
138981	Pulmonary alveolar proteinosis, 265120
139191	Growth hormone deficient dwarfism
142461	Dyssegmental dysplasia, Silverman-Handmaker type, 224410 Schwartz-Jampel syndrome, type 1, 255800
142640	Thrombophilia due to HRG deficiency Thrombophilia due to elevated HRG
142958	Radioulnar synostosis with amegakaryocytic thrombocytopenia, 605432
142959	Guttmacher syndrome, 176305 Hand-foot-uterus syndrome, 140000
146200	Hypoparathyroidism, familial
153390	SCID due to LCK deficiency
153454	Ehlers-Danlos syndrome, type VI, 225400
153880	Macular dystrophy, dominant cystoid
155600	Malignant melanoma, cutaneous
162080	Retinitis pigmentosa, autosomal dominant
164780	1p36 deletion syndrome
165240	Greig cephalopolysyndactyly syndrome, 175700 Pallister-Hall syndrome, 146510 Polydactyly, postaxial, types A1 and B, 174200 Polydactyly, preaxial, type IV, 174700
167410	Rhabdomyosarcoma, alveolar, 268220
171760	Hypophosphatasia, adult, 146300 Hypophosphatasia, childhood, 241510 Hypophosphatasia, infantile, 241500
172411	Colorectal cancer, resistance to
172430	Enolase deficiency
176000	Porphyria, acute intermittent Porphyria, acute intermittent, nonerythroid variant
178300	Ptois, hereditary congenital, 1
180104	Retinitis pigmentosa-9
182380	Glucose/galactose malabsorption, 606824
182600	Spastic paraplegia-3A
185470	Pheochromocytoma, extraadrenal, and cervical paraganglioma, 115310
186880	Leukemia/lymphoma, T-cell
188826	Sorsby fundus dystrophy, 136900
190040	Dermatofibrosarcoma protuberans Giant-cell fibroblastoma

	Meningioma, SIS-related
190195	Ichthyosiform erythroderma, congenital, 242100 Ichthyosis, lamellar, autosomal recessive, 242300
190300	Tremor, familial essential, 1
203740	Alpha-ketoglutarate dehydrogenase deficiency
210200	3-Methylcrotonylglycinuria I
211420	Breast cancer, ductal
218040	Costello syndrome
228960	[Kininogen deficiency]
236680	Hydrolethalus syndrome
256700	Neuroblastoma
258900	Oroticaciduria
261630	Phenylketonuria due to dihydropteridine reductase deficiency
261640	Phenylketonuria due to PTS deficiency
261670	Myopathy due to phosphoglycerate mutase deficiency
600044	Thrombocythemia, essential, 187950
600243	Temperature-sensitive apoptosis
600423	Hirschsprung disease, cardiac defects, and autonomic dysfunction
600467	Malignant hyperthermia susceptibility 4
600532	Parkinson disease, susceptibility to, 168600
600593	Craniosynostosis, Adelaide type
600644	Cleft lip/palate ectodermal dysplasia syndrome, 225000 Ectodermal dysplasia, Margarita Island type, 225060 Zlotogora-Ogur syndrome, 225000
600882	Charcot-Marie-Tooth disease, type 2B
600975	Glaucoma 3, primary infantile, B
600994	Deafness, autosomal dominant 5
601472	Charcot-Marie-Tooth neuropathy, type 2D
601583	Wilms tumor susceptibility-5
601990	Neuroblastoma
602023	Bartter syndrome, 241200 Bartter syndrome, antenatal, 601678
602049	Neutrophil immunodeficiency syndrome
602279	Oculopharyngeal muscular dystrophy, 164300 Oculopharyngeal muscular dystrophy, autosomal recessive, 257950
602322	Dyskeratosis congenita, 127550
602574	Deafness, autosomal dominant 12, 601842 Deafness, autosomal dominant 8, 601543 Deafness, autosomal recessive 21, 603629
602630	Holoprosencephaly-4, 142946
602773	Renal cell carcinoma 4
603023	Leukemia, acute lymphoblastic
603113	Lung cancer, 211980
603273	ADULT syndrome, 103285 Ectrodactyly, ectodermal dysplasia, and cleft lip/palate syndrome 3,

	604292 Hay-Wells syndrome, 106260 Limb-mammary syndrome, 603543 Split-hand/foot malformation, type 4, 605289
603284	Cerebral cavernous malformations-2
603285	Cerebral cavernous malformations-3
603324	Deafness, autosomal dominant 2, 600101 Deafness, autosomal dominant, with peripheral neuropathy Deafness, autosomal recessive Erythrokeratoderma variabilis, 133200
603490	XY female
603590	Meningioma
603593	Lysinuric protein intolerance, 222700
603688	Prostate cancer-brain cancer susceptibility
603776	Hypercholesterolemia, familial, 3
603945	Leukoencephalopathy with vanishing white matter, 603896
603959	Hypomagnesemia, primary, 248250
603967	Cramps, familial, potassium-aggravated Hyperkalemic periodic paralysis, 170500 Hypokalemic periodic paralysis, 170400 Myotonia congenita, atypical, acetazolamide-responsive, 170500 Paramyotonia congenita, 168300
604365	Retinal degeneration, autosomal recessive, prominin-related
604484	Neuropathy, hereditary motor and sensory, Okinawa type
604630	Obesity, mild, early-onset, 601665
604763	Leukemia, acute myeloid
604802	Huntington disease-like 3
604831	Ellis-van Creveld syndrome, 225500 Weyers acrodermal dysostosis, 193530
604933	Adenomatous polyposis of the colon, susceptibility to, 175100
605201	Hypoalphalipoproteinemia, primary
605225	Inflammatory bowel disease-7, 266600
605229	Spastic paraplegia 14, autosomal recessive
605389	Hypotrichosis simplex
605425	Erythrokeratoderma variabilis with erythema gyratum repens, 133200
605441	Adiponectin deficiency
605463	Radiation sensitivity/chromosome instability syndrome, autosomal dominant
605480	Systemic lupus erythematosus, susceptibility to, 3, 152700
605543	Parkinson disease 4, autosomal dominant, Lewy body
605552	Abdominal obesity-metabolic syndrome
605747	Hypercholesterolemia, familial, autosomal recessive, 603813
605841	Narcolepsy, 161400
605909	Parkinson disease, 168600
605995	Charcot-Marie-Tooth neuropathy, type 2A, 118210

606210	Muscular dystrophy, rigid spine, 1, 602771
606224	Anemia, hemolytic, due to UMPH1 deficiency, 266120
606246	Endometrial stromal tumors
606324	Parkinson disease, 168600
606439	Spastic paraplegia-3A, 182600
606675	Inflammatory bowel disease-4, 266600
606693	Kufo-Rakeb syndrome
606800	Glycogen storage disease II, 232300
606811	Hyperprolinemia, type II, 239510
606860	Angioedema, hereditary, 106100
606928	[Bone mineral density variability 3], 601884
606953	Galactose epimerase deficiency, 230350
606996	Senior-Loken syndrome 4
607037	Peroxisomal bifunctional enzyme deficiency, 261515
607086	Aortic aneurysm, familial thoracic 1
607093	Homocystinuria due to MTHFR deficiency, 236250
607107	Nasopharyngeal carcinoma 1, 161550
607215	Nephronophthisis 4, 606966

[1166] Having generally described the invention, the same will be more readily understood by reference to the following examples, which are provided by way of illustration and are not intended as limiting.

EXAMPLES

Example 1: Isolation of a Selected cDNA Clone From the Deposited Sample

[1167] Each cDNA clone in a cited ATCC deposit is contained in a plasmid vector. Table 1 identifies the vectors used to construct the cDNA library from which each clone was isolated. In many cases, the vector used to construct the library is a phage vector from which a plasmid has been excised. The table immediately below correlates the related plasmid for each phage vector used in constructing the cDNA library. For example, where a particular clone is identified in Table 1 as being isolated in the vector "Lambda Zap," the corresponding deposited clone is in "pBluescript."

<u>Vector Used to Construct Library</u>	<u>Corresponding Deposited Plasmid</u>
Lambda Zap	pBluescript (pBS)
Uni-Zap XR	pBluescript (pBS)
Zap Express	pBK
lalfmid BA	plafmid BA
pSport1	pSport1
pCMVSPORT 2.0	pCMVSPORT 2.0
pCMVSPORT 3.0	pCMVSPORT 3.0
pCR [®] 2.1	pCR [®] 2.1

[1168] Vectors Lambda Zap (U.S. Patent Nos. 5,128,256 and 5,286,636), Uni-Zap XR (U.S. Patent Nos. 5,128, 256 and 5,286,636), Zap Express (U.S. Patent Nos. 5,128,256 and 5,286,636), pBluescript (pBS) (Short et al., *Nucleic Acids Res.*, 16:7583-7600 (1988); Altting-Mees et al., *Nucleic Acids Res.*, 17:9494 (1989)) and pBK (Altting-Mees et al., *Strategies*, 5:58-61 (1992)) are commercially available from Stratagene Cloning Systems, Inc., 11011 N. Torrey Pines Road, La Jolla, CA, 92037. pBS contains an ampicillin resistance gene and pBK contains a neomycin resistance gene. Both can be transformed into E. coli strain XL-1 Blue, also available from Stratagene. pBS comes in 4 forms SK+, SK-, KS+ and KS-. The S and K refers to the orientation of the polylinker to the T7 and T3 primer sequences which flank the polylinker region ("S" is for SacI and "K" is for KpnI which are the first sites on each respective end of the linker). "+" or "-" refer to the orientation of the f1 origin of replication ("ori"), such that in one orientation, single

stranded rescue initiated from the f1 ori generates sense strand DNA and in the other, antisense.

[1169] Vectors pSport1, pCMVSPORT 2.0 and pCMVSPORT 3.0, were obtained from Life Technologies, Inc., P. O. Box 6009, Gaithersburg, MD 20897. All Sport vectors contain an ampicillin resistance gene and may be transformed into *E. coli* strain DH10B, also available from Life Technologies. (See, for instance, Gruber, C. E., et al., *Focus* 15:59 (1993)). Vector lafmid BA (Bento Soares, Columbia University, NY) contains an ampicillin resistance gene and can be transformed into *E. coli* strain XL-1 Blue. Vector pCR[®]2.1, which is available from Invitrogen, 1600 Faraday Avenue, Carlsbad, CA 92008, contains an ampicillin resistance gene and may be transformed into *E. coli* strain DH10B, available from Life Technologies. (See, for instance, Clark, *Nuc. Acids Res.*, 16:9677-9686 (1988) and Mead et al., *BioTechnology*, 9 (1991)). Preferably, a polynucleotide of the present invention does not comprise the phage vector sequences identified for the particular clone in Table 1, as well as the corresponding plasmid vector sequences designated above.

[1170] The deposited material in the sample assigned the ATCC Deposit Number cited in Table 1 for any given cDNA clone also may contain one or more additional plasmids, each comprising a cDNA clone different from that given clone. Thus, deposits sharing the same ATCC Deposit Number contain at least a plasmid for each cDNA Plasmid:V identified in Table 1. Typically, each ATCC deposit sample cited in Table 1 comprises a mixture of approximately equal amounts (by weight) of about 50 plasmid DNAs, each containing a different cDNA clone; but such a deposit sample may include plasmids for more or less than 50 cDNA clones, up to about 500 cDNA clones.

[1171] Two approaches can be used to isolate a particular clone from the deposited sample of plasmid DNAs cited for that clone in Table 1. First, a plasmid is directly isolated by screening the clones using a polynucleotide probe corresponding to SEQ ID NO:X.

[1172] Particularly, a specific polynucleotide with 30-40 nucleotides is synthesized using an Applied Biosystems DNA synthesizer according to the sequence reported. The oligonucleotide is labeled, for instance, with ³²P-γ-ATP using T4 polynucleotide kinase and purified according to routine methods. (E.g., Maniatis et al., *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Press, Cold Spring, NY (1982)). The plasmid

mixture is transformed into a suitable host, as indicated above (such as XL-1 Blue (Stratagene)) using techniques known to those of skill in the art, such as those provided by the vector supplier or in related publications or patents cited above. The transformants are plated on 1.5% agar plates (containing the appropriate selection agent, e.g., ampicillin) to a density of about 150 transformants (colonies) per plate. These plates are screened using Nylon membranes according to routine methods for bacterial colony screening (e.g., Sambrook et al., *Molecular Cloning: A Laboratory Manual*, 2nd Edit., (1989), Cold Spring Harbor Laboratory Press, pages 1.93 to 1.104), or other techniques known to those of skill in the art.

[1173] Alternatively, two primers of 17-20 nucleotides derived from both ends of the SEQ ID NO:X (i.e., within the region of SEQ ID NO:X bounded by the 5' NT and the 3' NT of the clone defined in Table 1) are synthesized and used to amplify the desired cDNA using the deposited cDNA plasmid as a template. The polymerase chain reaction is carried out under routine conditions, for instance, in 25 μ l of reaction mixture with 0.5 μ g of the above cDNA template. A convenient reaction mixture is 1.5-5 mM $MgCl_2$, 0.01% (w/v) gelatin, 20 μ M each of dATP, dCTP, dGTP, dTTP, 25 pmol of each primer and 0.25 Unit of Taq polymerase. Thirty five cycles of PCR (denaturation at 94°C for 1 min; annealing at 55°C for 1 min; elongation at 72°C for 1 min) are performed with a Perkin-Elmer Cetus automated thermal cycler. The amplified product is analyzed by agarose gel electrophoresis and the DNA band with expected molecular weight is excised and purified. The PCR product is verified to be the selected sequence by subcloning and sequencing the DNA product.

[1174] Several methods are available for the identification of the 5' or 3' non-coding portions of a gene which may not be present in the deposited clone. These methods include but are not limited to, filter probing, clone enrichment using specific probes, and protocols similar or identical to 5' and 3' "RACE" protocols which are well known in the art. For instance, a method similar to 5' RACE is available for generating the missing 5' end of a desired full-length transcript. (Fromont-Racine et al., *Nucleic Acids Res.*, 21(7):1683-1684 (1993)).

[1175] Briefly, a specific RNA oligonucleotide is ligated to the 5' ends of a population of RNA presumably containing full-length gene RNA transcripts. A primer set containing a primer specific to the ligated RNA oligonucleotide and a primer specific to a known

sequence of the gene of interest is used to PCR amplify the 5' portion of the desired full-length gene. This amplified product may then be sequenced and used to generate the full length gene.

[1176] This above method starts with total RNA isolated from the desired source, although poly-A+ RNA can be used. The RNA preparation can then be treated with phosphatase if necessary to eliminate 5' phosphate groups on degraded or damaged RNA which may interfere with the later RNA ligase step. The phosphatase should then be inactivated and the RNA treated with tobacco acid pyrophosphatase in order to remove the cap structure present at the 5' ends of messenger RNAs. This reaction leaves a 5' phosphate group at the 5' end of the cap cleaved RNA which can then be ligated to an RNA oligonucleotide using T4 RNA ligase.

[1177] This modified RNA preparation is used as a template for first strand cDNA synthesis using a gene specific oligonucleotide. The first strand synthesis reaction is used as a template for PCR amplification of the desired 5' end using a primer specific to the ligated RNA oligonucleotide and a primer specific to the known sequence of the gene of interest. The resultant product is then sequenced and analyzed to confirm that the 5' end sequence belongs to the desired gene.

Example 2: Isolation of Genomic Clones Corresponding to a Polynucleotide

[1178] A human genomic Pl library (Genomic Systems, Inc.) is screened by PCR using primers selected for the cDNA sequence corresponding to SEQ ID NO:X., according to the method described in Example 1. (See also, Sambrook.)

Example 3: Tissue Distribution of Polypeptide

[1179] Tissue distribution of mRNA expression of polynucleotides of the present invention is determined using protocols for Northern blot analysis, described by, among others, Sambrook et al. For example, a cDNA probe produced by the method described in Example 1 is labeled with P³² using the rediprime™ DNA labeling system (Amersham Life Science), according to manufacturer's instructions. After labeling, the probe is purified using CHROMA SPIN-100™ column (Clontech Laboratories, Inc.), according to manufacturer's protocol number PT1200-1. The purified labeled probe is then used to examine various human tissues for mRNA expression.

[1180] Multiple Tissue Northern (MTN) blots containing various human tissues (H) or human immune system tissues (IM) (Clontech) are examined with the labeled probe using ExpressHyb™ hybridization solution (Clontech) according to manufacturer's protocol number PT1190-1. Following hybridization and washing, the blots are mounted and exposed to film at -70°C overnight, and the films developed according to standard procedures.

Example 4: Chromosomal Mapping of the Polynucleotides

[1181] An oligonucleotide primer set is designed according to the sequence at the 5' end of SEQ ID NO:X. This primer preferably spans about 100 nucleotides. This primer set is then used in a polymerase chain reaction under the following set of conditions : 30 seconds, 95°C; 1 minute, 56°C; 1 minute, 70°C. This cycle is repeated 32 times followed by one 5 minute cycle at 70°C. Human, mouse, and hamster DNA is used as template in addition to a somatic cell hybrid panel containing individual chromosomes or chromosome fragments (Bios, Inc). The reactions is analyzed on either 8% polyacrylamide gels or 3.5 % agarose gels. Chromosome mapping is determined by the presence of an approximately 100 bp PCR fragment in the particular somatic cell hybrid.

Example 5: Bacterial Expression of a Polypeptide

[1182] A polynucleotide encoding a polypeptide of the present invention is amplified using PCR oligonucleotide primers corresponding to the 5' and 3' ends of the DNA sequence, as outlined in Example 1, to synthesize insertion fragments. The primers used to amplify the cDNA insert should preferably contain restriction sites, such as BamHI and XbaI and initiation/stop codons, if necessary, to clone the amplified product into the expression vector. For example, BamHI and XbaI correspond to the restriction enzyme sites on the bacterial expression vector pQE-9. (Qiagen, Inc., Chatsworth, CA). This plasmid vector encodes antibiotic resistance (Amp^r), a bacterial origin of replication (ori), an IPTG-regulatable promoter/operator (P/O), a ribosome binding site (RBS), a 6-histidine tag (6-His), and restriction enzyme cloning sites.

[1183] The pQE-9 vector is digested with BamHI and XbaI and the amplified fragment is ligated into the pQE-9 vector maintaining the reading frame initiated at the bacterial

RBS. The ligation mixture is then used to transform the *E. coli* strain M15/rep4 (Qiagen, Inc.) which contains multiple copies of the plasmid pREP4, which expresses the lacI repressor and also confers kanamycin resistance (Kan^r). Transformants are identified by their ability to grow on LB plates and ampicillin/kanamycin resistant colonies are selected. Plasmid DNA is isolated and confirmed by restriction analysis.

[1184] Clones containing the desired constructs are grown overnight (O/N) in liquid culture in LB media supplemented with both Amp (100 ug/ml) and Kan (25 ug/ml). The O/N culture is used to inoculate a large culture at a ratio of 1:100 to 1:250. The cells are grown to an optical density 600 (O.D.⁶⁰⁰) of between 0.4 and 0.6. IPTG (Isopropyl-B-D-thiogalacto pyranoside) is then added to a final concentration of 1 mM. IPTG induces by inactivating the lacI repressor, clearing the P/O leading to increased gene expression.

[1185] Cells are grown for an extra 3 to 4 hours. Cells are then harvested by centrifugation (20 mins at 6000Xg). The cell pellet is solubilized in the chaotropic agent 6 Molar Guanidine HCl by stirring for 3-4 hours at 4°C. The cell debris is removed by centrifugation, and the supernatant containing the polypeptide is loaded onto a nickel-nitrilo-tri-acetic acid ("Ni-NTA") affinity resin column (available from QIAGEN, Inc., *supra*). Proteins with a 6 x His tag bind to the Ni-NTA resin with high affinity and can be purified in a simple one-step procedure (for details see: The QIAexpressionist (1995) QIAGEN, Inc., *supra*).

[1186] Briefly, the supernatant is loaded onto the column in 6 M guanidine-HCl, pH 8, the column is first washed with 10 volumes of 6 M guanidine-HCl, pH 8, then washed with 10 volumes of 6 M guanidine-HCl pH 6, and finally the polypeptide is eluted with 6 M guanidine-HCl, pH 5.

[1187] The purified protein is then renatured by dialyzing it against phosphate-buffered saline (PBS) or 50 mM Na-acetate, pH 6 buffer plus 200 mM NaCl. Alternatively, the protein can be successfully refolded while immobilized on the Ni-NTA column. The recommended conditions are as follows: renature using a linear 6M-1M urea gradient in 500 mM NaCl, 20% glycerol, 20 mM Tris/HCl pH 7.4, containing protease inhibitors. The renaturation should be performed over a period of 1.5 hours or more. After renaturation the proteins are eluted by the addition of 250 mM imidazole. Imidazole is removed by a final dialyzing step against PBS or 50 mM sodium acetate pH 6 buffer plus 200 mM NaCl. The purified protein is stored at 4°C or frozen at -80°C.

[1188] In addition to the above expression vector, the present invention further includes an expression vector comprising phage operator and promoter elements operatively linked to a polynucleotide of the present invention, called pHE4a. (ATCC Accession Number 209645, deposited on February 25, 1998.) This vector contains: 1) a neomycinphosphotransferase gene as a selection marker, 2) an *E. coli* origin of replication, 3) a T5 phage promoter sequence, 4) two lac operator sequences, 5) a Shine-Delgarno sequence, and 6) the lactose operon repressor gene (*lacIq*). The origin of replication (*oriC*) is derived from pUC19 (LTI, Gaithersburg, MD). The promoter sequence and operator sequences are made synthetically.

[1189] DNA can be inserted into the pHEa by restricting the vector with *NdeI* and *XbaI*, *BamHI*, *XhoI*, or *Asp718*, running the restricted product on a gel, and isolating the larger fragment (the stuffer fragment should be about 310 base pairs). The DNA insert is generated according to the PCR protocol described in Example 1, using PCR primers having restriction sites for *NdeI* (5' primer) and *XbaI*, *BamHI*, *XhoI*, or *Asp718* (3' primer). The PCR insert is gel purified and restricted with compatible enzymes. The insert and vector are ligated according to standard protocols.

[1190] The engineered vector could easily be substituted in the above protocol to express protein in a bacterial system.

Example 6: Purification of a Polypeptide from an Inclusion Body

[1191] The following alternative method can be used to purify a polypeptide expressed in *E. coli* when it is present in the form of inclusion bodies. Unless otherwise specified, all of the following steps are conducted at 4-10°C.

[1192] Upon completion of the production phase of the *E. coli* fermentation, the cell culture is cooled to 4-10°C and the cells harvested by continuous centrifugation at 15,000 rpm (Heraeus Sepatech). On the basis of the expected yield of protein per unit weight of cell paste and the amount of purified protein required, an appropriate amount of cell paste, by weight, is suspended in a buffer solution containing 100 mM Tris, 50 mM EDTA, pH 7.4. The cells are dispersed to a homogeneous suspension using a high shear mixer.

[1193] The cells are then lysed by passing the solution through a microfluidizer (Microfluidics, Corp. or APV Gaulin, Inc.) twice at 4000-6000 psi. The homogenate is then mixed with NaCl solution to a final concentration of 0.5 M NaCl, followed by

centrifugation at 7000 xg for 15 min. The resultant pellet is washed again using 0.5M NaCl, 100 mM Tris, 50 mM EDTA, pH 7.4.

[1194] The resulting washed inclusion bodies are solubilized with 1.5 M guanidine hydrochloride (GuHCl) for 2-4 hours. After 7000 xg centrifugation for 15 min., the pellet is discarded and the polypeptide containing supernatant is incubated at 4°C overnight to allow further GuHCl extraction.

[1195] Following high speed centrifugation (30,000 xg) to remove insoluble particles, the GuHCl solubilized protein is refolded by quickly mixing the GuHCl extract with 20 volumes of buffer containing 50 mM sodium, pH 4.5, 150 mM NaCl, 2 mM EDTA by vigorous stirring. The refolded diluted protein solution is kept at 4°C without mixing for 12 hours prior to further purification steps.

[1196] To clarify the refolded polypeptide solution, a previously prepared tangential filtration unit equipped with 0.16 µm membrane filter with appropriate surface area (e.g., Filtron), equilibrated with 40 mM sodium acetate, pH 6.0 is employed. The filtered sample is loaded onto a cation exchange resin (e.g., Poros HS-50, Perseptive Biosystems). The column is washed with 40 mM sodium acetate, pH 6.0 and eluted with 250 mM, 500 mM, 1000 mM, and 1500 mM NaCl in the same buffer, in a stepwise manner. The absorbance at 280 nm of the effluent is continuously monitored. Fractions are collected and further analyzed by SDS-PAGE.

[1197] Fractions containing the polypeptide are then pooled and mixed with 4 volumes of water. The diluted sample is then loaded onto a previously prepared set of tandem columns of strong anion (Poros HQ-50, Perseptive Biosystems) and weak anion (Poros CM-20, Perseptive Biosystems) exchange resins. The columns are equilibrated with 40 mM sodium acetate, pH 6.0. Both columns are washed with 40 mM sodium acetate, pH 6.0, 200 mM NaCl. The CM-20 column is then eluted using a 10 column volume linear gradient ranging from 0.2 M NaCl, 50 mM sodium acetate, pH 6.0 to 1.0 M NaCl, 50 mM sodium acetate, pH 6.5. Fractions are collected under constant A_{280} monitoring of the effluent. Fractions containing the polypeptide (determined, for instance, by 16% SDS-PAGE) are then pooled.

[1198] The resultant polypeptide should exhibit greater than 95% purity after the above refolding and purification steps. No major contaminant bands should be observed from Commaissie blue stained 16% SDS-PAGE gel when 5 µg of purified protein is loaded.

The purified protein can also be tested for endotoxin/LPS contamination, and typically the LPS content is less than 0.1 ng/ml according to LAL assays.

Example 7: Cloning and Expression of a Polypeptide in a Baculovirus Expression System

[1199] In this example, the plasmid shuttle vector pA2 is used to insert a polynucleotide into a baculovirus to express a polypeptide. This expression vector contains the strong polyhedrin promoter of the *Autographa californica* nuclear polyhedrosis virus (AcMNPV) followed by convenient restriction sites such as BamHI, Xba I and Asp718. The polyadenylation site of the simian virus 40 ("SV40") is used for efficient polyadenylation. For easy selection of recombinant virus, the plasmid contains the beta-galactosidase gene from *E. coli* under control of a weak *Drosophila* promoter in the same orientation, followed by the polyadenylation signal of the polyhedrin gene. The inserted genes are flanked on both sides by viral sequences for cell-mediated homologous recombination with wild-type viral DNA to generate a viable virus that express the cloned polynucleotide.

[1200] Many other baculovirus vectors can be used in place of the vector above, such as pAc373, pVL941, and pAcIM1, as one skilled in the art would readily appreciate, as long as the construct provides appropriately located signals for transcription, translation, secretion and the like, including a signal peptide and an in-frame AUG as required. Such vectors are described, for instance, in Luckow et al., *Virology* 170:31-39 (1989).

[1201] Specifically, the cDNA sequence contained in the deposited clone is amplified using the PCR protocol described in Example 1 using primers with appropriate restriction sites and initiation/stop codons. If the naturally occurring signal sequence is used to produce the secreted protein, the pA2 vector does not need a second signal peptide. Alternatively, the vector can be modified (pA2 GP) to include a baculovirus leader sequence, using the standard methods described in Summers et al., "A Manual of Methods for Baculovirus Vectors and Insect Cell Culture Procedures," Texas Agricultural Experimental Station Bulletin NO: 1555 (1987).

[1202] The amplified fragment is isolated from a 1% agarose gel using a commercially available kit ("Geneclean," BIO 101 Inc., La Jolla, Ca.). The fragment then is digested with appropriate restriction enzymes and again purified on a 1% agarose gel.

[1203] The plasmid is digested with the corresponding restriction enzymes and optionally, can be dephosphorylated using calf intestinal phosphatase, using routine procedures known in the art. The DNA is then isolated from a 1% agarose gel using a commercially available kit ("Geneclean" BIO 101 Inc., La Jolla, Ca.).

[1204] The fragment and the dephosphorylated plasmid are ligated together with T4 DNA ligase. *E. coli* HB101 or other suitable *E. coli* hosts such as XL-1 Blue (Stratagene Cloning Systems, La Jolla, CA) cells are transformed with the ligation mixture and spread on culture plates. Bacteria containing the plasmid are identified by digesting DNA from individual colonies and analyzing the digestion product by gel electrophoresis. The sequence of the cloned fragment is confirmed by DNA sequencing.

[1205] Five μg of a plasmid containing the polynucleotide is co-transfected with 1.0 μg of a commercially available linearized baculovirus DNA ("BaculoGold™ baculovirus DNA", Pharmingen, San Diego, CA), using the lipofection method described by Felgner et al., Proc. Natl. Acad. Sci. USA 84:7413-7417 (1987). One μg of BaculoGold™ virus DNA and 5 μg of the plasmid are mixed in a sterile well of a microtiter plate containing 50 μl of serum-free Grace's medium (Life Technologies Inc., Gaithersburg, MD). Afterwards, 10 μl Lipofectin plus 90 μl Grace's medium are added, mixed and incubated for 15 minutes at room temperature. Then the transfection mixture is added drop-wise to Sf9 insect cells (ATCC CRL 1711) seeded in a 35 mm tissue culture plate with 1 ml Grace's medium without serum. The plate is then incubated for 5 hours at 27° C. The transfection solution is then removed from the plate and 1 ml of Grace's insect medium supplemented with 10% fetal calf serum is added. Cultivation is then continued at 27° C for four days.

[1206] After four days the supernatant is collected and a plaque assay is performed, as described by Summers and Smith, *supra*. An agarose gel with "Blue Gal" (Life Technologies Inc., Gaithersburg) is used to allow easy identification and isolation of gal-expressing clones, which produce blue-stained plaques. (A detailed description of a "plaque assay" of this type can also be found in the user's guide for insect cell culture and baculovirology distributed by Life Technologies Inc., Gaithersburg, page 9-10.) After appropriate incubation, blue stained plaques are picked with the tip of a micropipettor (e.g., Eppendorf). The agar containing the recombinant viruses is then resuspended in a microcentrifuge tube containing 200 μl of Grace's medium and the suspension containing

the recombinant baculovirus is used to infect Sf9 cells seeded in 35 mm dishes. Four days later the supernatants of these culture dishes are harvested and then they are stored at 4° C.

[1207] To verify the expression of the polypeptide, Sf9 cells are grown in Grace's medium supplemented with 10% heat-inactivated FBS. The cells are infected with the recombinant baculovirus containing the polynucleotide at a multiplicity of infection ("MOI") of about 2. If radiolabeled proteins are desired, 6 hours later the medium is removed and is replaced with SF900 II medium minus methionine and cysteine (available from Life Technologies Inc., Rockville, MD). After 42 hours, 5 μ Ci of 35 S-methionine and 5 μ Ci 35 S-cysteine (available from Amersham) are added. The cells are further incubated for 16 hours and then are harvested by centrifugation. The proteins in the supernatant as well as the intracellular proteins are analyzed by SDS-PAGE followed by autoradiography (if radiolabeled).

[1208] Microsequencing of the amino acid sequence of the amino terminus of purified protein may be used to determine the amino terminal sequence of the produced protein.

Example 8: Expression of a Polypeptide in Mammalian Cells

[1209] The polypeptide of the present invention can be expressed in a mammalian cell. A typical mammalian expression vector contains a promoter element, which mediates the initiation of transcription of mRNA, a protein coding sequence, and signals required for the termination of transcription and polyadenylation of the transcript. Additional elements include enhancers, Kozak sequences and intervening sequences flanked by donor and acceptor sites for RNA splicing. Highly efficient transcription is achieved with the early and late promoters from SV40, the long terminal repeats (LTRs) from Retroviruses, e.g., RSV, HTLV1, HIV1 and the early promoter of the cytomegalovirus (CMV). However, cellular elements can also be used (e.g., the human actin promoter).

[1210] Suitable expression vectors for use in practicing the present invention include, for example, vectors such as pSVL and pMSG (Pharmacia, Uppsala, Sweden), pRSVcat (ATCC 37152), pSV2dhfr (ATCC 37146), pBC12MI (ATCC 67109), pCMVSPORT 2.0, and pCMVSPORT 3.0. Mammalian host cells that could be used include, human Hela, 293, H9 and Jurkat cells, mouse NIH3T3 and C127 cells, Cos 1, Cos 7 and CV1, quail QC1-3 cells, mouse L cells and Chinese hamster ovary (CHO) cells.

[1211] Alternatively, the polypeptide can be expressed in stable cell lines containing the polynucleotide integrated into a chromosome. The co-transfection with a selectable

marker such as dhfr, gpt, neomycin, hygromycin allows the identification and isolation of the transfected cells.

[1212] The transfected gene can also be amplified to express large amounts of the encoded protein. The DHFR (dihydrofolate reductase) marker is useful in developing cell lines that carry several hundred or even several thousand copies of the gene of interest. (See, e.g., Alt et al., *J. Biol. Chem.*, 253:1357-1370 (1978); Hamlin et al., *Biochem. et Biophys. Acta*, 1097:107-143 (1990); Page et al., *Biotechnology*, 9:64-68 (1991)). Another useful selection marker is the enzyme glutamine synthase (GS) (Murphy et al., *Biochem J.*, 227:277-279 (1991); Bebbington et al., *Bio/Technology*, 10:169-175 (1992)). Using these markers, the mammalian cells are grown in selective medium and the cells with the highest resistance are selected. These cell lines contain the amplified gene(s) integrated into a chromosome. Chinese hamster ovary (CHO) and NSO cells are often used for the production of proteins.

[1213] Derivatives of the plasmid pSV2-dhfr (ATCC Accession No.: 37146), the expression vectors pC4 (ATCC Accession No.: 209646) and pC6 (ATCC Accession No.:209647) contain the strong promoter (LTR) of the Rous Sarcoma Virus (Cullen et al., *Molecular and Cellular Biology*, 438-447 (March, 1985)) plus a fragment of the CMV-enhancer (Boshart et al., *Cell*, 41:521-530 (1985)). Multiple cloning sites, e.g., with the restriction enzyme cleavage sites BamHI, XbaI and Asp718, facilitate the cloning of the gene of interest. The vectors also contain the 3' intron, the polyadenylation and termination signal of the rat preproinsulin gene, and the mouse DHFR gene under control of the SV40 early promoter.

[1214] Specifically, the plasmid pC6, for example, is digested with appropriate restriction enzymes and then dephosphorylated using calf intestinal phosphates by procedures known in the art. The vector is then isolated from a 1% agarose gel.

[1215] A polynucleotide of the present invention is amplified according to the protocol outlined in Example 1 using primers with appropriate restrictions sites and initiation/stop codons, if necessary. The vector can be modified to include a heterologous signal sequence if necessary for secretion. (See, e.g., WO 96/34891.)

[1216] The amplified fragment is isolated from a 1% agarose gel using a commercially available kit ("Geneclean," BIO 101 Inc., La Jolla, Ca.). The fragment then is digested with appropriate restriction enzymes and again purified on a 1% agarose gel.

[1217] The amplified fragment is then digested with the same restriction enzyme and purified on a 1% agarose gel. The isolated fragment and the dephosphorylated vector are then ligated with T4 DNA ligase. *E. coli* HB101 or XL-1 Blue cells are then transformed and bacteria are identified that contain the fragment inserted into plasmid pC6 using, for instance, restriction enzyme analysis.

[1218] Chinese hamster ovary cells lacking an active DHFR gene is used for transfection. Five μg of the expression plasmid pC6 is cotransfected with 0.5 μg of the plasmid pSVneo using lipofectin (Felgner et al., *supra*). The plasmid pSV2-neo contains a dominant selectable marker, the *neo* gene from Tn5 encoding an enzyme that confers resistance to a group of antibiotics including G418. The cells are seeded in alpha minus MEM supplemented with 1 mg/ml G418. After 2 days, the cells are trypsinized and seeded in hybridoma cloning plates (Greiner, Germany) in alpha minus MEM supplemented with 10, 25, or 50 ng/ml of methotrexate plus 1 mg/ml G418. After about 10-14 days single clones are trypsinized and then seeded in 6-well petri dishes or 10 ml flasks using different concentrations of methotrexate (50 nM, 100 nM, 200 nM, 400 nM, 800 nM). Clones growing at the highest concentrations of methotrexate are then transferred to new 6-well plates containing even higher concentrations of methotrexate (1 μM , 2 μM , 5 μM , 10 mM, 20 mM). The same procedure is repeated until clones are obtained which grow at a concentration of 100 - 200 μM . Expression of the desired gene product is analyzed, for instance, by SDS-PAGE and Western blot or by reversed phase HPLC analysis.

Example 9: Protein Fusions

[1219] The polypeptides of the present invention are preferably fused to other proteins. These fusion proteins can be used for a variety of applications. For example, fusion of the present polypeptides to His-tag, HA-tag, protein A, IgG domains, and maltose binding protein facilitates purification. (See Example 5; see also EP A 394,827; Traunecker, et al., *Nature*, 331:84-86 (1988)) The polypeptides can also be fused to heterologous polypeptide sequences to facilitate secretion and intracellular trafficking (e.g., KDEL). Moreover, fusion to IgG-1, IgG-3, and albumin increases the half-life time in vivo. Nuclear localization signals fused to the polypeptides of the present invention can target the protein to a specific subcellular localization, while covalent heterodimer or

homodimers can increase or decrease the activity of a fusion protein. Fusion proteins can also create chimeric molecules having more than one function. Finally, fusion proteins can increase solubility and/or stability of the fused protein compared to the non-fused protein. All of the types of fusion proteins described above can be made by modifying the following protocol, which outlines the fusion of a polypeptide to an IgG molecule, or the protocol described in Example 5.

[1220] Briefly, the human Fc portion of the IgG molecule can be PCR amplified, using primers that span the 5' and 3' ends of the sequence described below. These primers also should have convenient restriction enzyme sites that will facilitate cloning into an expression vector, preferably a mammalian expression vector, and initiation/stop codons, if necessary.

[1221] For example, if pC4 (Accession No.: 209646) is used, the human Fc portion can be ligated into the BamHI cloning site. Note that the 3' BamHI site should be destroyed. Next, the vector containing the human Fc portion is re-restricted with BamHI, linearizing the vector, and a polynucleotide of the present invention, isolated by the PCR protocol described in Example 1, is ligated into this BamHI site. Note that the polynucleotide is cloned without a stop codon, otherwise a fusion protein will not be produced.

[1222] If the naturally occurring signal sequence is used to produce the secreted protein, pC4 does not need a second signal peptide. Alternatively, if the naturally occurring signal sequence is not used, the vector can be modified to include a heterologous signal sequence. (See, e.g., WO 96/34891.)

Human IgG Fc region:

```
GGGATCCGGAGCCCAATCTTCTGACAAAACCTCACACATGCCACCGTGCCAGCACCTGAAT
TCGAGGGTGACACCGTCAGTCTTCCTCTTCCCCCAAAACCCAAGGACACCTCATGATCTCCCG
GACTCCTGAGGTACATGCGTGGTGGTGACGTAAGCCACGAAGACCTTGAGGTCAAGTTCAA
CTGGTACGTGGACGGCGTGAGGTGCATAATGCCAAGACAAAGCCGGGAGGAGCAGTACA
ACAGCACGTACCGTGTGGTCAGCGTCTCACCCTCTGCACCAGGACTGGCTGAATGGCAAGG
AGTACAAGTGCAAGGTCTCCAAACAAAGCCCTCCCAACCCCATCGAGAAAACCATCTCCAAAG
CCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCATCCCGGGATGAGCTGACCA
AGAACCAGGTACGCTGACCTGCCTGGTCAAAGGCTTCTATCCAAGCAGATCGCCGTGGAGT
GGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGAC
GGCTCTTCTTCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTG
```

TTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGT
CTCCGGGTAAATGAGTGCGACGGCCGCACTCTAGAGGAT (SEQ ID NO:1)

Example 10: Formulating a Polypeptide

[1223] The invention also provides methods of treatment and/or prevention of diseases or disorders (such as, for example, any one or more of the diseases or disorders disclosed herein) by administration to a subject of an effective amount of a Therapeutic. By Therapeutic is meant polynucleotides or polypeptides of the invention (including fragments and variants), agonists or antagonists thereof, and/or antibodies thereto, in combination with a pharmaceutically acceptable carrier type (e.g., a sterile carrier).

[1224] The polypeptide composition will be formulated and dosed in a fashion consistent with good medical practice, taking into account the clinical condition of the individual patient (especially the side effects of treatment with the secreted polypeptide alone), the site of delivery, the method of administration, the scheduling of administration, and other factors known to practitioners. The "effective amount" for purposes herein is thus determined by such considerations.

[1225] As a general proposition, the total pharmaceutically effective amount of polypeptide administered parenterally per dose will be in the range of about 1 $\mu\text{g/kg/day}$ to 10 mg/kg/day of patient body weight, although, as noted above, this will be subject to therapeutic discretion. More preferably, this dose is at least 0.01 mg/kg/day , and most preferably for humans between about 0.01 and 1 mg/kg/day for the hormone. If given continuously, the polypeptide is typically administered at a dose rate of about 1 $\mu\text{g/kg/hour}$ to about 50 $\mu\text{g/kg/hour}$, either by 1-4 injections per day or by continuous subcutaneous infusions, for example, using a mini-pump. An intravenous bag solution may also be employed. The length of treatment needed to observe changes and the interval following treatment for responses to occur appears to vary depending on the desired effect.

[1226] Pharmaceutical compositions containing the polypeptide of the invention are administered orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, gels, drops or transdermal patch), buccally, or as an oral or nasal spray. "Pharmaceutically acceptable carrier" refers to a non-toxic solid, semisolid or liquid filler, diluent, encapsulating material or formulation auxiliary of any

type. The term "parenteral" as used herein refers to modes of administration which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion.

[1227] The polypeptide is also suitably administered by sustained-release systems. Suitable examples of sustained-release compositions include semi-permeable polymer matrices in the form of shaped articles, e.g., films, or microcapsules. Sustained-release matrices include polylactides (U.S. Pat. NO: 3,773,919, EP 58,481), copolymers of L-glutamic acid and gamma-ethyl-L-glutamate (Sidman et al., *Biopolymers*, 22:547-556 (1983)), poly (2- hydroxyethyl methacrylate) (Langer et al., *J. Biomed. Mater. Res.* 15:167-277 (1981), and Langer, *Chem. Tech.*, 12:98-105 (1982)), ethylene vinyl acetate (R. Langer et al.) or poly-D- (-)-3-hydroxybutyric acid (EP 133,988).

[1228] In a preferred embodiment, compositions of the invention are formulated in a biodegradable, polymeric drug delivery system, for example as described in U.S. Patent Nos. 4,938,763; 5,278,201; 5,278,202; 5,324,519; 5,340,849; and 5,487,897 and in International Publication Numbers WO01/35929, WO00/24374, and WO00/06117 which are hereby incorporated by reference in their entirety. In specific preferred embodiments the compositions of the invention are formulated using the ATRIGEL® Biodegradable System of Atrix Laboratories, Inc. (Fort Collins, Colorado).

[1229] Examples of biodegradable polymers which can be used in the formulation of compositions of the invention include, but are not limited to, polylactides, polyglycolides, polycaprolactones, polyanhydrides, polyamides, polyurethanes, polyesteramides, polyorthoesters, polydioxanones, polyacetals, polyketals, polycarbonates, polyorthocarbonates, polyphosphazenes, polyhydroxybutyrates, polyhydroxyvalerates, polyalkylene oxalates, polyalkylene succinates, poly(malic acid), poly(amino acids), poly(methyl vinyl ether), poly(maleic anhydride), polyvinylpyrrolidone, polyethylene glycol, polyhydroxycellulose, chitin, chitosan, and copolymers, terpolymers, or combinations or mixtures of the above materials. The preferred polymers are those that have a lower degree of crystallization and are more hydrophobic. These polymers and copolymers are more soluble in the biocompatible solvents than the highly crystalline polymers such as polyglycolide and chitin which also have a high degree of hydrogen-bonding. Preferred materials with the desired solubility parameters are the polylactides, polycaprolactones, and copolymers of these with glycolide in which there are more

amorphous regions to enhance solubility. In specific preferred embodiments, the biodegradable polymers which can be used in the formulation of compositions of the invention are poly(lactide-co-glycolides). Polymer properties such as molecular weight, hydrophobicity, and lactide/glycolide ratio may be modified to obtain the desired drug release profile (See, e.g., Ravivarapu et al., *Journal of Pharmaceutical Sciences* 89:732-741 (2000), which is hereby incorporated by reference in its entirety).

[1230] It is also preferred that the solvent for the biodegradable polymer be non-toxic, water miscible, and otherwise biocompatible. Examples of such solvents include, but are not limited to, N-methyl-2-pyrrolidone, 2-pyrrolidone, C2 to C6 alkanols, C1 to C15 alcohols, diols, triols, and tetraols such as ethanol, glycerine propylene glycol, butanol; C3 to C15 alkyl ketones such as acetone, diethyl ketone and methyl ethyl ketone; C3 to C15 esters such as methyl acetate, ethyl acetate, ethyl lactate; alkyl ketones such as methyl ethyl ketone, C1 to C15 amides such as dimethylformamide, dimethylacetamide and caprolactam; C3 to C20 ethers such as tetrahydrofuran, or solketal; tweens, triacetin, propylene carbonate, decylmethylsulfoxide, dimethyl sulfoxide, oleic acid, 1-dodecylazacycloheptan-2-one, Other preferred solvents are benzyl alcohol, benzyl benzoate, dipropylene glycol, tributyrin, ethyl oleate, glycerin, glycofural, isopropyl myristate, isopropyl palmitate, oleic acid, polyethylene glycol, propylene carbonate, and triethyl citrate. The most preferred solvents are N-methyl-2-pyrrolidone, 2-pyrrolidone, dimethyl sulfoxide, triacetin, and propylene carbonate because of the solvating ability and their compatibility.

[1231] Additionally, formulations comprising compositions of the invention and a biodegradable polymer may also include release-rate modification agents and/or pore-forming agents. Examples of release-rate modification agents include, but are not limited to, fatty acids, triglycerides, other like hydrophobic compounds, organic solvents, plasticizing compounds and hydrophilic compounds. Suitable release rate modification agents include, for example, esters of mono-, di-, and tricarboxylic acids, such as 2-ethoxyethyl acetate, methyl acetate, ethyl acetate, diethyl phthalate, dimethyl phthalate, dibutyl phthalate, dimethyl adipate, dimethyl succinate, dimethyl oxalate, dimethyl citrate, triethyl citrate, acetyl tributyl citrate, acetyl triethyl citrate, glycerol triacetate, di(n-butyl) sebecate, and the like; polyhydroxy alcohols, such as propylene glycol, polyethylene glycol, glycerin, sorbitol, and the like; fatty acids; triesters of glycerol, such as

triglycerides, epoxidized soybean oil, and other epoxidized vegetable oils; sterols, such as cholesterol; alcohols, such as C.sub.6 -C.sub.12 alkanols, 2-ethoxyethanol, and the like. The release rate modification agent may be used singly or in combination with other such agents. Suitable combinations of release rate modification agents include, but are not limited to, glycerin/propylene glycol, sorbitol/glycerine, ethylene oxide/propylene oxide, butylene glycol/adipic acid, and the like. Preferred release rate modification agents include, but are not limited to, dimethyl citrate, triethyl citrate, ethyl heptanoate, glycerin, and hexanediol. Suitable pore-forming agents that may be used in the polymer composition include, but are not limited to, sugars such as sucrose and dextrose, salts such as sodium chloride and sodium carbonate, polymers such as hydroxylpropylcellulose, carboxymethylcellulose, polyethylene glycol, and polyvinylpyrrolidone. Solid crystals that will provide a defined pore size, such as salt or sugar, are preferred.

[1232] In specific preferred embodiments the compositions of the invention are formulated using the BEMA™ BioErodible Mucoadhesive System, MCA™ MucoCutaneous Absorption System, SMP™ Solvent MicroParticle System, or BCP™ BioCompatible Polymer System of Atrix Laboratories, Inc. (Fort Collins, Colorado).

[1233] Sustained-release compositions also include liposomally entrapped polypeptides. Liposomes containing the secreted polypeptide are prepared by methods known per se: DE 3,218,121; Epstein et al., *Proc. Natl. Acad. Sci. USA*, 82:3688-3692 (1985); Hwang et al., *Proc. Natl. Acad. Sci. USA*, 77:4030-4034 (1980); EP 52,322; EP 36,676; EP 88,046; EP 143,949; EP 142,641; Japanese Pat. Appl. 83-118008; U.S. Pat. Nos. 4,485,045 and 4,544,545; and EP 102,324. Ordinarily, the liposomes are of the small (about 200-800 Angstroms) unilamellar type in which the lipid content is greater than about 30 mol. percent cholesterol, the selected proportion being adjusted for the optimal secreted polypeptide therapy.

[1234] For parenteral administration, in one embodiment, the polypeptide is formulated generally by mixing it at the desired degree of purity, in a unit dosage injectable form (solution, suspension, or emulsion), with a pharmaceutically acceptable carrier, i.e., one that is non-toxic to recipients at the dosages and concentrations employed and is compatible with other ingredients of the formulation. For example, the formulation preferably does not include oxidizing agents and other compounds that are known to be deleterious to polypeptides.

[1235] Generally, the formulations are prepared by contacting the polypeptide uniformly and intimately with liquid carriers or finely divided solid carriers or both. Then, if necessary, the product is shaped into the desired formulation. Preferably the carrier is a parenteral carrier, more preferably a solution that is isotonic with the blood of the recipient. Examples of such carrier vehicles include water, saline, Ringer's solution, and dextrose solution. Non-aqueous vehicles such as fixed oils and ethyl oleate are also useful herein, as well as liposomes.

[1236] The carrier suitably contains minor amounts of additives such as substances that enhance isotonicity and chemical stability. Such materials are non-toxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, succinate, acetic acid, and other organic acids or their salts; antioxidants such as ascorbic acid; low molecular weight (less than about ten residues) polypeptides, e.g., polyarginine or tripeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids, such as glycine, glutamic acid, aspartic acid, or arginine; monosaccharides, disaccharides, and other carbohydrates including cellulose or its derivatives, glucose, manose, or dextrans; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; counterions such as sodium; and/or nonionic surfactants such as polysorbates, poloxamers, or PEG.

[1237] The polypeptide is typically formulated in such vehicles at a concentration of about 0.1 mg/ml to 100 mg/ml, preferably 1-10 mg/ml, at a pH of about 3 to 8. It will be understood that the use of certain of the foregoing excipients, carriers, or stabilizers will result in the formation of polypeptide salts.

[1238] Any polypeptide to be used for therapeutic administration can be sterile. Sterility is readily accomplished by filtration through sterile filtration membranes (e.g., 0.2 micron membranes). Therapeutic polypeptide compositions generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle.

[1239] Polypeptides ordinarily will be stored in unit or multi-dose containers, for example, sealed ampoules or vials, as an aqueous solution or as a lyophilized formulation for reconstitution. As an example of a lyophilized formulation, 10-ml vials are filled with 5 ml of sterile-filtered 1% (w/v) aqueous polypeptide solution, and the resulting mixture is

lyophilized. The infusion solution is prepared by reconstituting the lyophilized polypeptide using bacteriostatic Water-for-Injection.

[1240] The invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention. Associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration. In addition, the polypeptides of the present invention may be employed in conjunction with other therapeutic compounds.

[1241] The Therapeutics of the invention may be administered alone or in combination with adjuvants. Adjuvants that may be administered with the Therapeutics of the invention include, but are not limited to, alum, alum plus deoxycholate (ImmunoAg), MTP-PE (Biocine Corp.), QS21 (Genentech, Inc.), BCG (e.g., THERACYS®), MPL and nonviable preparations of *Corynebacterium parvum*. In a specific embodiment, Therapeutics of the invention are administered in combination with alum. In another specific embodiment, Therapeutics of the invention are administered in combination with QS-21. Further adjuvants that may be administered with the Therapeutics of the invention include, but are not limited to, Monophosphoryl lipid immunomodulator, AdjuVax 100a, QS-21, QS-18, CRL1005, Aluminum salts, MF-59, and Viroosomal adjuvant technology. Vaccines that may be administered with the Therapeutics of the invention include, but are not limited to, vaccines directed toward protection against MMR (measles, mumps, rubella), polio, varicella, tetanus/diphtheria, hepatitis A, hepatitis B, haemophilus influenzae B, whooping cough, pneumonia, influenza, Lyme's Disease, rotavirus, cholera, yellow fever, Japanese encephalitis, poliomyelitis, rabies, typhoid fever, and pertussis. Combinations may be administered either concomitantly, e.g., as an admixture, separately but simultaneously or concurrently; or sequentially. This includes presentations in which the combined agents are administered together as a therapeutic mixture, and also procedures in which the combined agents are administered separately but simultaneously, e.g., as through separate intravenous lines into the same individual. Administration "in combination" further includes the separate administration of one of the compounds or agents given first, followed by the second.

[1242] The Therapeutics of the invention may be administered alone or in combination with other therapeutic agents. In preferred embodiments, therapeutic agents that may be administered in combination with the Therapeutics of the invention, include but not limited to antidiabetic agents (e.g., a biguanide antidiabetic agent, a glitazone antidiabetic agent, and a sulfonylurea antidiabetic agent). In additional embodiments, therapeutic agents that may be administered in combination with the Therapeutics of the invention, include chemotherapeutic agents, antibiotics, steroidal and non-steroidal anti-inflammatories, conventional immunotherapeutic agents, and/or therapeutic treatments described below. Combinations may be administered either concomitantly, e.g., as an admixture, separately but simultaneously or concurrently; or sequentially. This includes presentations in which the combined agents are administered together as a therapeutic mixture, and also procedures in which the combined agents are administered separately but simultaneously, e.g., as through separate intravenous lines into the same individual. Administration "in combination" further includes the separate administration of one of the compounds or agents given first, followed by the second.

[1243] In one embodiment, the Therapeutics of the invention are administered in combination with an anticoagulant. Anticoagulants that may be administered with the compositions of the invention include, but are not limited to, heparin, low molecular weight heparin, warfarin sodium (e.g., COUMADIN®), dicumarol, 4-hydroxycoumarin, anisindione (e.g., MIRADON™), acenocoumarol (e.g., nicoumalone, SINTHROME™), indan-1,3-dione, phenprocoumon (e.g., MARCUMAR™), ethyl biscoumacetate (e.g., TROMEXAN™), and aspirin. In a specific embodiment, compositions of the invention are administered in combination with heparin and/or warfarin. In another specific embodiment, compositions of the invention are administered in combination with warfarin. In another specific embodiment, compositions of the invention are administered in combination with warfarin and aspirin. In another specific embodiment, compositions of the invention are administered in combination with heparin. In another specific embodiment, compositions of the invention are administered in combination with heparin and aspirin.

[1244] In another embodiment, the Therapeutics of the invention are administered in combination with thrombolytic drugs. Thrombolytic drugs that may be administered with the compositions of the invention include, but are not limited to, plasminogen, lys-

plasminogen, alpha2-antiplasmin, streptokinase (e.g., KABIKINASE™), antirespace (e.g., EMINASE™), tissue plasminogen activator (t-PA, altevase, ACTIVASE™), urokinase (e.g., ABBOKINASE™), sauruplase, (Prourokinase, single chain urokinase), and aminocaproic acid (e.g., AMICAR™). In a specific embodiment, compositions of the invention are administered in combination with tissue plasminogen activator and aspirin.

[1245] In another embodiment, the Therapeutics of the invention are administered in combination with antiplatelet drugs. Antiplatelet drugs that may be administered with the compositions of the invention include, but are not limited to, aspirin, dipyridamole (e.g., PERSANTINE™), and ticlopidine (e.g., TICLID™).

[1246] In specific embodiments, the use of anti-coagulants, thrombolytic and/or antiplatelet drugs in combination with Therapeutics of the invention is contemplated for the prevention, diagnosis, and/or treatment of thrombosis, arterial thrombosis, venous thrombosis, thromboembolism, pulmonary embolism, atherosclerosis, myocardial infarction, transient ischemic attack, unstable angina. In specific embodiments, the use of anticoagulants, thrombolytic drugs and/or antiplatelet drugs in combination with Therapeutics of the invention is contemplated for the prevention of occlusion of saphenous grafts, for reducing the risk of periprocedural thrombosis as might accompany angioplasty procedures, for reducing the risk of stroke in patients with atrial fibrillation including nonrheumatic atrial fibrillation, for reducing the risk of embolism associated with mechanical heart valves and or mitral valves disease. Other uses for the therapeutics of the invention, alone or in combination with antiplatelet, anticoagulant, and/or thrombolytic drugs, include, but are not limited to, the prevention of occlusions in extracorporeal devices (e.g., intravascular canulas, vascular access shunts in hemodialysis patients, hemodialysis machines, and cardiopulmonary bypass machines).

[1247] In certain embodiments, Therapeutics of the invention are administered in combination with antiretroviral agents, nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), and/or protease inhibitors (PIs). NRTIs that may be administered in combination with the Therapeutics of the invention, include, but are not limited to, RETROVIR™ (zidovudine/AZT), VIDEX™ (didanosine/ddI), HIVID™ (zalcitabine/ddC), ZERIT™ (stavudine/d4T), EPIVIR™ (lamivudine/3TC), and COMBIVIR™ (zidovudine/lamivudine). NNRTIs that may be administered in combination with the

Therapeutics of the invention, include, but are not limited to, VIRAMUNE™ (nevirapine), RESCRIPTOR™ (delavirdine), and SUSTIVA™ (efavirenz). Protease inhibitors that may be administered in combination with the Therapeutics of the invention, include, but are not limited to, CRIVAN™ (indinavir), NORVIR™ (ritonavir), INVIRASE™ (saquinavir), and VIRACEPT™ (nelfinavir). In a specific embodiment, antiretroviral agents, nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, and/or protease inhibitors may be used in any combination with Therapeutics of the invention to treat AIDS and/or to prevent or treat HIV infection.

[1248] Additional NRTIs include LODENOSINE™ (F-ddA; an acid-stable adenosine NRTI; Triangle/Abbott); COVIRACIL™ (emtricitabine/FTC; structurally related to lamivudine (3TC) but with 3- to 10-fold greater activity *in vitro*; Triangle/Abbott); dOTC (BCH-10652, also structurally related to lamivudine but retains activity against a substantial proportion of lamivudine-resistant isolates; Biochem Pharma); Adefovir (refused approval for anti-HIV therapy by FDA; Gilead Sciences); PREVEON® (Adefovir Dipivoxil, the active prodrug of adefovir; its active form is PMEAs-pp); TENOFOVIR™ (bis-POC PMPA, a PMPA prodrug; Gilead); DAPD/DXG (active metabolite of DAPD; Triangle/Abbott); D-D4FC (related to 3TC, with activity against AZT/3TC-resistant virus); GW420867X (Glaxo Wellcome); ZIAGEN™ (abacavir/159U89; Glaxo Wellcome Inc.); CS-87 (3'-azido-2',3'-dideoxyuridine; WO 99/66936); and S-acyl-2-thioethyl (SATE)-bearing prodrug forms of β -L-FD4C and β -L-FddC (WO 98/17281).

[1249] Additional NNRTIs include COACTINON™ (Emivirine/MKC-442, potent NNRTI of the HEPT class; Triangle/Abbott); CAPRAVIRINE™ (AG-1549/S-1153, a next generation NNRTI with activity against viruses containing the K103N mutation; Agouron); PNU-142721 (has 20- to 50-fold greater activity than its predecessor delavirdine and is active against K103N mutants; Pharmacia & Upjohn); DPC-961 and DPC-963 (second-generation derivatives of efavirenz, designed to be active against viruses with the K103N mutation; DuPont); GW-420867X (has 25-fold greater activity than HBY097 and is active against K103N mutants; Glaxo Wellcome); CALANOLIDE A (naturally occurring agent from the latex tree; active against viruses containing either or both the Y181C and K103N mutations); and Propolis (WO 99/49830).

[1250] Additional protease inhibitors include LOPINAVIR™ (ABT378/r; Abbott Laboratories); BMS-232632 (an azapeptide; Bristol-Myers Squibb); TIPRANAVIR™ (PNU-140690, a non-peptic dihydropyrrone; Pharmacia & Upjohn); PD-178390 (a nonpeptidic dihydropyrrone; Parke-Davis); BMS 232632 (an azapeptide; Bristol-Myers Squibb); L-756,423 (an indinavir analog; Merck); DMP-450 (a cyclic urea compound; Avid & DuPont); AG-1776 (a peptidomimetic with *in vitro* activity against protease inhibitor-resistant viruses; Agouron); VX-175/GW-433908 (phosphate prodrug of amprenavir; Vertex & Glaxo Wellcome); CGP61755 (Ciba); and AGENERASE™ (amprenavir; Glaxo Wellcome Inc.).

[1251] Additional antiretroviral agents include fusion inhibitors/gp41 binders. Fusion inhibitors/gp41 binders include T-20 (a peptide from residues 643-678 of the HIV gp41 transmembrane protein ectodomain which binds to gp41 in its resting state and prevents transformation to the fusogenic state; Trimeris) and T-1249 (a second-generation fusion inhibitor; Trimeris).

[1252] Additional antiretroviral agents include fusion inhibitors/chemokine receptor antagonists. Fusion inhibitors/chemokine receptor antagonists include CXCR4 antagonists such as AMD 3100 (a bicyclam), SDF-1 and its analogs, and ALX40-4C (a cationic peptide), T22 (an 18 amino acid peptide; Trimeris) and the T22 analogs T134 and T140; CCR5 antagonists such as RANTES (9-68), AOP-RANTES, NNY-RANTES, and TAK-779; and CCR5/CXCR4 antagonists such as NSC 651016 (a distamycin analog). Also included are CCR2B, CCR3, and CCR6 antagonists. Chemokine receptor agonists such as RANTES, SDF-1, MIP-1 α , MIP-1 β , etc., may also inhibit fusion.

[1253] Additional antiretroviral agents include integrase inhibitors. Integrase inhibitors include dicaffeoylquinic (DFQA) acids; L-chicoric acid (a dicaffeoyltartaric (DCTA) acid); quinalizarin (QLC) and related anthraquinones; ZINTEVIR™ (AR 177, an oligonucleotide that probably acts at cell surface rather than being a true integrase inhibitor; Arondex); and naphthols such as those disclosed in WO 98/50347.

[1254] Additional antiretroviral agents include hydroxyurea-like compounds such as BCX-34 (a purine nucleoside phosphorylase inhibitor; Biocryst); ribonucleotide reductase inhibitors such as DIDOX™ (Molecules for Health); inosine monophosphate

dehydrogenase (IMPDH) inhibitors such as VX-497 (Vertex); and mycopholic acids such as CellCept (mycophenolate mofetil; Roche).

[1255] Additional antiretroviral agents include inhibitors of viral integrase, inhibitors of viral genome nuclear translocation such as arylene bis(methylketone) compounds; inhibitors of HIV entry such as AOP-RANTES, NNY-RANTES, RANTES-IgG fusion protein, soluble complexes of RANTES and glycosaminoglycans (GAG), and AMD-3100; nucleocapsid zinc finger inhibitors such as dithiane compounds; targets of HIV Tat and Rev; and pharmacoenhancers such as ABT-378.

[1256] Other antiretroviral therapies and adjunct therapies include cytokines and lymphokines such as MIP-1 α , MIP-1 β , SDF-1 α , IL-2, PROLEUKIN™ (aldesleukin/L2-7001; Chiron), IL-4, IL-10, IL-12, and IL-13; interferons such as IFN- α 2a; antagonists of TNFs, NF κ B, GM-CSF, M-CSF, and IL-10; agents that modulate immune activation such as cyclosporin and prednisone; vaccines such as Remune™ (HIV Immunogen), APL 400-003 (Apollon), recombinant gp120 and fragments, bivalent (B/E) recombinant envelope glycoprotein, rgp120CM235, MN rgp120, SF-2 rgp120, gp120/soluble CD4 complex, Delta JR-FL protein, branched synthetic peptide derived from discontinuous gp120 C3/C4 domain, fusion-competent immunogens, and Gag, Pol, Nef, and Tat vaccines; gene-based therapies such as genetic suppressor elements (GSEs; WO 98/54366), and intrakines (genetically modified CC chemokines targetted to the ER to block surface expression of newly synthesized CCR5 (Yang *et al.*, *PNAS* 94:11567-72 (1997); Chen *et al.*, *Nat. Med.* 3:1110-16 (1997)); antibodies such as the anti-CXCR4 antibody 12G5, the anti-CCR5 antibodies 2D7, 5C7, PA8, PA9, PA10, PA11, PA12, and PA14, the anti-CD4 antibodies Q4120 and RPA-T4, the anti-CCR3 antibody 7B11, the anti-gp120 antibodies 17b, 48d, 447-52D, 257-D, 268-D and 50.1, anti-Tat antibodies, anti-TNF- α antibodies, and monoclonal antibody 33A; aryl hydrocarbon (AH) receptor agonists and antagonists such as TCDD, 3,3',4,4',5-pentachlorobiphenyl, 3,3',4,4'-tetrachlorobiphenyl, and α -naphthoflavone (WO 98/30213); and antioxidants such as γ -L-glutamyl-L-cysteine ethyl ester (γ -GCE; WO 99/56764).

[1257] In a further embodiment, the Therapeutics of the invention are administered in combination with an antiviral agent. Antiviral agents that may be administered with the

Therapeutics of the invention include, but are not limited to, acyclovir, ribavirin, amantadine, and remantidine.

[1258] In other embodiments, Therapeutics of the invention may be administered in combination with anti-opportunistic infection agents. Anti-opportunistic agents that may be administered in combination with the Therapeutics of the invention, include, but are not limited to, TRIMETHOPRIM-SULFAMETHOXAZOLE™, DAPSONE™, PENTAMIDINE™, ATOVAQUONE™, ISONIAZID™, RIFAMPIN™, PYRAZINAMIDE™, ETHAMBUTOL™, RIFABUTIN™, CLARITHROMYCIN™, AZITHROMYCIN™, GANCICLOVIR™, FOSCARNET™, CIDOFOVIR™, FLUCONAZOLE™, ITRACONAZOLE™, KETOCONAZOLE™, ACYCLOVIR™, FAMCICOLVIR™, PYRIMETHAMINE™, LEUCOVORIN™, NEUPOGEN™ (filgrastim/G-CSF), and LEUKINE™ (sargramostim/GM-CSF). In a specific embodiment, Therapeutics of the invention are used in any combination with TRIMETHOPRIM-SULFAMETHOXAZOLE™, DAPSONE™, PENTAMIDINE™, and/or ATOVAQUONE™ to prophylactically treat or prevent an opportunistic *Pneumocystis carinii* pneumonia infection. In another specific embodiment, Therapeutics of the invention are used in any combination with ISONIAZID™, RIFAMPIN™, PYRAZINAMIDE™, and/or ETHAMBUTOL™ to prophylactically treat or prevent an opportunistic *Mycobacterium avium* complex infection. In another specific embodiment, Therapeutics of the invention are used in any combination with RIFABUTIN™, CLARITHROMYCIN™, and/or AZITHROMYCIN™ to prophylactically treat or prevent an opportunistic *Mycobacterium tuberculosis* infection. In another specific embodiment, Therapeutics of the invention are used in any combination with GANCICLOVIR™, FOSCARNET™, and/or CIDOFOVIR™ to prophylactically treat or prevent an opportunistic cytomegalovirus infection. In another specific embodiment, Therapeutics of the invention are used in any combination with FLUCONAZOLE™, ITRACONAZOLE™, and/or KETOCONAZOLE™ to prophylactically treat or prevent an opportunistic fungal infection. In another specific embodiment, Therapeutics of the invention are used in any combination with ACYCLOVIR™ and/or FAMCICOLVIR™ to prophylactically treat or prevent an opportunistic herpes simplex virus type I and/or type II infection. In another specific embodiment, Therapeutics of the invention are used in any combination with

PYRIMETHAMINE™ and/or LEUCOVORIN™ to prophylactically treat or prevent an opportunistic *Toxoplasma gondii* infection. In another specific embodiment, Therapeutics of the invention are used in any combination with LEUCOVORIN™ and/or NEUPOGEN™ to prophylactically treat or prevent an opportunistic bacterial infection.

[1259] In a further embodiment, the Therapeutics of the invention are administered in combination with an antibiotic agent. Antibiotic agents that may be administered with the Therapeutics of the invention include, but are not limited to, amoxicillin, beta-lactamases, aminoglycosides, beta-lactam (glycopeptide), beta-lactamases, Clindamycin, chloramphenicol, cephalosporins, ciprofloxacin, erythromycin, fluoroquinolones, macrolides, metronidazole, penicillins, quinolones, rapamycin, rifampin, streptomycin, sulfonamide, tetracyclines, trimethoprim, trimethoprim-sulfamethoxazole, and vancomycin.

[1260] In other embodiments, the Therapeutics of the invention are administered in combination with immunostimulants. Immunostimulants that may be administered in combination with the Therapeutics of the invention include, but are not limited to, levamisole (e.g., ERGAMISOL™), isoprinosine (e.g. INOSIPLEX™), interferons (e.g. interferon alpha), and interleukins (e.g., IL-2).

[1261] In other embodiments, Therapeutics of the invention are administered in combination with immunosuppressive agents. Immunosuppressive agents that may be administered in combination with the Therapeutics of the invention include, but are not limited to, steroids, cyclosporine, cyclosporine analogs, cyclophosphamide methylprednisone, prednisone, azathioprine, FK-506, 15-deoxyspergualin, and other immunosuppressive agents that act by suppressing the function of responding T cells. Other immunosuppressive agents that may be administered in combination with the Therapeutics of the invention include, but are not limited to, prednisolone, methotrexate, thalidomide, methoxsalen, rapamycin, leflunomide, mizoribine (BREDININ™), brequinar, deoxyspergualin, and azaspirane (SKF 105685), ORTHOCLONE OKT® 3 (muromonab-CD3), SANDIMMUN™, NEORAL™, SANGDYA™ (cyclosporine), PROGRAF® (FK506, tacrolimus), CELLCEPT® (mycophenolate mofetil, of which the active metabolite is mycophenolic acid), IMURANT™ (azathioprine), glucocorticosteroids, adrenocortical steroids such as DELTASONE™ (prednisone) and HYDELTRASOL™ (prednisolone), FOLEX™ and MEXATE™ (methotrexate), OXSORALEN-ULTRA™

(methoxsalen) and RAPAMUNE™ (sirolimus). In a specific embodiment, immunosuppressants may be used to prevent rejection of organ or bone marrow transplantation.

[1262] In an additional embodiment, Therapeutics of the invention are administered alone or in combination with one or more intravenous immune globulin preparations. Intravenous immune globulin preparations that may be administered with the Therapeutics of the invention include, but not limited to, GAMMAR™, IVEEGAM™, SANDOGLOBULIN™, GAMMAGARD S/D™, ATGAM™ (antithymocyte globulin), and GAMIMUNE™. In a specific embodiment, Therapeutics of the invention are administered in combination with intravenous immune globulin preparations in transplantation therapy (e.g., bone marrow transplant).

[1263] In certain embodiments, the Therapeutics of the invention are administered alone or in combination with an anti-inflammatory agent. Anti-inflammatory agents that may be administered with the Therapeutics of the invention include, but are not limited to, corticosteroids (e.g. betamethasone, budesonide, cortisone, dexamethasone, hydrocortisone, methylprednisolone, prednisolone, prednisone, and triamcinolone), nonsteroidal anti-inflammatory drugs (e.g., diclofenac, diflunisal, etodolac, fenoprofen, floctafenine, flurbiprofen, ibuprofen, indomethacin, ketoprofen, meclofenamate, mefenamic acid, meloxicam, nabumetone, naproxen, oxaprozin, phenylbutazone, piroxicam, sulindac, tenoxicam, tiaprofenic acid, and tolmetin.), as well as antihistamines, aminoarylcarboxylic acid derivatives, arylacetic acid derivatives, arylbutyric acid derivatives, arylcarboxylic acids, arylpropionic acid derivatives, pyrazoles, pyrazolones, salicylic acid derivatives, thiazinecarboxamides, e-acetamidocaproic acid, S-adenosylmethionine, 3-amino-4-hydroxybutyric acid, amixetrine, bendazac, benzydamine, bucolome, difenpiramide, ditazol, emorfazone, guaiazulene, nabumetone, nimesulide, orgotein, oxaceprol, paranyline, perisoxal, pifoxime, proquazone, proxazole, and tenidap.

[1264] In an additional embodiment, the compositions of the invention are administered alone or in combination with an anti-angiogenic agent. Anti-angiogenic agents that may be administered with the compositions of the invention include, but are not limited to, Angiostatin (Entremed, Rockville, MD), Troponin-I (Boston Life Sciences, Boston, MA), anti-Invasive Factor, retinoic acid and derivatives thereof, paclitaxel (Taxol), Suramin, Tissue Inhibitor of Metalloproteinase-1, Tissue Inhibitor of

Metalloproteinase-2, VEGF, Plasminogen Activator Inhibitor-1, Plasminogen Activator Inhibitor-2, and various forms of the lighter "d group" transition metals.

[1265] Lighter "d group" transition metals include, for example, vanadium, molybdenum, tungsten, titanium, niobium, and tantalum species. Such transition metal species may form transition metal complexes. Suitable complexes of the above-mentioned transition metal species include oxo transition metal complexes.

[1266] Representative examples of vanadium complexes include oxo vanadium complexes such as vanadate and vanadyl complexes. Suitable vanadate complexes include metavanadate and orthovanadate complexes such as, for example, ammonium metavanadate, sodium metavanadate, and sodium orthovanadate. Suitable vanadyl complexes include, for example, vanadyl acetylacetonate and vanadyl sulfate including vanadyl sulfate hydrates such as vanadyl sulfate mono- and trihydrates.

[1267] Representative examples of tungsten and molybdenum complexes also include oxo complexes. Suitable oxo tungsten complexes include tungstate and tungsten oxide complexes. Suitable tungstate complexes include ammonium tungstate, calcium tungstate, sodium tungstate dihydrate, and tungstic acid. Suitable tungsten oxides include tungsten (IV) oxide and tungsten (VI) oxide. Suitable oxo molybdenum complexes include molybdate, molybdenum oxide, and molybdenyl complexes. Suitable molybdate complexes include ammonium molybdate and its hydrates, sodium molybdate and its hydrates, and potassium molybdate and its hydrates. Suitable molybdenum oxides include molybdenum (VI) oxide, molybdenum (VI) oxide, and molybdic acid. Suitable molybdenyl complexes include, for example, molybdenyl acetylacetonate. Other suitable tungsten and molybdenum complexes include hydroxo derivatives derived from, for example, glycerol, tartaric acid, and sugars.

[1268] A wide variety of other anti-angiogenic factors may also be utilized within the context of the present invention. Representative examples include, but are not limited to, platelet factor 4; protamine sulphate; sulphated chitin derivatives (prepared from queen crab shells), (Murata et al., Cancer Res. 51:22-26, (1991)); Sulphated Polysaccharide Peptidoglycan Complex (SP- PG) (the function of this compound may be enhanced by the presence of steroids such as estrogen, and tamoxifen citrate); Staurosporine; modulators of matrix metabolism, including for example, proline analogs, cishydroxyproline, d,L-3,4-dehydroproline, Thiaproline, alpha,alpha-dipyridyl, aminopropionitrile fumarate; 4-

propyl-5-(4-pyridinyl)-2(3H)-oxazolone; Methotrexate; Mitoxantrone; Heparin; Interferons; 2 Macroglobulin-serum; ChIMP-3 (Pavloff et al., *J. Bio. Chem.* 267:17321-17326, (1992)); Chymostatin (Tomkinson et al., *Biochem J.* 286:475-480, (1992)); Cyclodextrin Tetradecasulfate; Eponemycin; Camptothecin; Fumagillin (Ingber et al., *Nature* 348:555-557, (1990)); Gold Sodium Thiomalate ("GST"; Matsubara and Ziff, *J. Clin. Invest.* 79:1440-1446, (1987)); anticollagenase-serum; alpha2-antiplasmin (Holmes et al., *J. Biol. Chem.* 262(4):1659-1664, (1987)); Bisantrene (National Cancer Institute); Lobenzarit disodium (N-(2-carboxyphenyl)-4-chloroanthronilic acid disodium or "CCA"; (Takeuchi et al., *Agents Actions* 36:312-316, (1992)); and metalloproteinase inhibitors such as BB94.

[1269] Additional anti-angiogenic factors that may also be utilized within the context of the present invention include Thalidomide, (Celgene, Warren, NJ); Angiostatic steroid; AGM-1470 (H. Brem and J. Folkman *J. Pediatr. Surg.* 28:445-51 (1993)); an integrin alpha v beta 3 antagonist (C. Storgard et al., *J. Clin. Invest.* 103:47-54 (1999)); carboxynaminolmidazole; Carboxyamidotriazole (CAI) (National Cancer Institute, Bethesda, MD); Conbretastatin A-4 (CA4P) (OXiGENE, Boston, MA); Squalamine (Magainin Pharmaceuticals, Plymouth Meeting, PA); TNP-470, (Tap Pharmaceuticals, Deerfield, IL); ZD-0101 AstraZeneca (London, UK); APRA (CT2584); Benefin, Byrostatin-1 (SC339555); CGP-41251 (PKC 412); CM101; Dexrazoxane (ICRF187); DMXAA; Endostatin; Flavopridiol; Genestein; GTE; ImmTher; Iressa (ZD1839); Octreotide (Somatostatin); Panretin; Penacillamine; Photopoint; PI-88; Prinomastat (AG-3340) Purlitin; Suradista (FCE26644); Tamoxifen (Nolvadex); Tazarotene; Tetrathiomolybdate; Xeloda (Capecitabine); and 5-Fluorouracil.

[1270] Anti-angiogenic agents that may be administered in combination with the compounds of the invention may work through a variety of mechanisms including, but not limited to, inhibiting proteolysis of the extracellular matrix, blocking the function of endothelial cell-extracellular matrix adhesion molecules, by antagonizing the function of angiogenesis inducers such as growth factors, and inhibiting integrin receptors expressed on proliferating endothelial cells. Examples of anti-angiogenic inhibitors that interfere with extracellular matrix proteolysis and which may be administered in combination with the compositions of the invention include, but are not limited to, AG-3340 (Agouron, La Jolla, CA), BAY-12-9566 (Bayer, West Haven, CT), BMS-275291 (Bristol Myers Squibb,

Princeton, NJ), CGS-27032A (Novartis, East Hanover, NJ), Marimastat (British Biotech, Oxford, UK), and Metastat (Aeterna, St-Foy, Quebec). Examples of anti-angiogenic inhibitors that act by blocking the function of endothelial cell-extracellular matrix adhesion molecules and which may be administered in combination with the compositions of the invention include, but are not limited to, EMD-121974 (Merck KgaA Darmstadt, Germany) and Vitaxin (Ixsys, La Jolla, CA/Medimmune, Gaithersburg, MD). Examples of anti-angiogenic agents that act by directly antagonizing or inhibiting angiogenesis inducers and which may be administered in combination with the compositions of the invention include, but are not limited to, Angiozyme (Ribozyme, Boulder, CO), Anti-VEGF antibody (Genentech, S. San Francisco, CA), PTK-787/ZK-225846 (Novartis, Basel, Switzerland), SU-101 (Sugen, S. San Francisco, CA), SU-5416 (Sugen/ Pharmacia Upjohn, Bridgewater, NJ), and SU-6668 (Sugen). Other anti-angiogenic agents act to indirectly inhibit angiogenesis. Examples of indirect inhibitors of angiogenesis which may be administered in combination with the compositions of the invention include, but are not limited to, IM-862 (Cytran, Kirkland, WA), Interferon-alpha, IL-12 (Roche, Nutley, NJ), and Pentosan polysulfate (Georgetown University, Washington, DC).

[1271] In particular embodiments, the use of compositions of the invention in combination with anti-angiogenic agents is contemplated for the treatment, prevention, and/or amelioration of an autoimmune disease, such as for example, an autoimmune disease described herein.

[1272] In a particular embodiment, the use of compositions of the invention in combination with anti-angiogenic agents is contemplated for the treatment, prevention, and/or amelioration of arthritis. In a more particular embodiment, the use of compositions of the invention in combination with anti-angiogenic agents is contemplated for the treatment, prevention, and/or amelioration of rheumatoid arthritis.

[1273] In another embodiment, the polynucleotides encoding a polypeptide of the present invention are administered in combination with an angiogenic protein, or polynucleotides encoding an angiogenic protein. Examples of angiogenic proteins that may be administered with the compositions of the invention include, but are not limited to, acidic and basic fibroblast growth factors, VEGF-1, VEGF-2, VEGF-3, epidermal growth factor alpha and beta, platelet-derived endothelial cell growth factor, platelet-derived growth factor, tumor necrosis factor alpha, hepatocyte growth factor, insulin-like growth

factor, colony stimulating factor, macrophage colony stimulating factor, granulocyte/macrophage colony stimulating factor, and nitric oxide synthase.

[1274] In additional embodiments, compositions of the invention are administered in combination with a chemotherapeutic agent. Chemotherapeutic agents that may be administered with the Therapeutics of the invention include, but are not limited to alkylating agents such as nitrogen mustards (for example, Mechlorethamine, cyclophosphamide, Cyclophosphamide Ifosfamide, Melphalan (L-sarcolysin), and Chlorambucil), ethylenimines and methylmelamines (for example, Hexamethylmelamine and Thiotepea), alkyl sulfonates (for example, Busulfan), nitrosoureas (for example, Carmustine (BCNU), Lomustine (CCNU), Semustine (methyl-CCNU), and Streptozocin (streptozotocin)), triazenes (for example, Dacarbazine (DTIC; dimethyltriazenoimidazolecarboxamide)), folic acid analogs (for example, Methotrexate (amethopterin)), pyrimidine analogs (for example, Fluorouacil (5-fluorouracil; 5-FU), Floxuridine (fluorodeoxyuridine; FudR), and Cytarabine (cytosine arabinoside)), purine analogs and related inhibitors (for example, Mercaptopurine (6-mercaptopurine; 6-MP), Thioguanine (6-thioguanine; TG), and Pentostatin (2'-deoxycorformycin)), vinca alkaloids (for example, Vinblastine (VLB, vinblastine sulfate)) and Vincristine (vincristine sulfate)), epipodophyllotoxins (for example, Etoposide and Teniposide), antibiotics (for example, Dactinomycin (actinomycin D), Daunorubicin (daunomycin; rubidomycin), Doxorubicin, Bleomycin, Plicamycin (mithramycin), and Mitomycin (mitomycin C), enzymes (for example, L-Asparaginase), biological response modifiers (for example, Interferon-alpha and interferon-alpha-2b), platinum coordination compounds (for example, Cisplatin (cis-DDP) and Carboplatin), anthracenedione (Mitoxantrone), substituted ureas (for example, Hydroxyurea), methylhydrazine derivatives (for example, Procarbazine (N-methylhydrazine; MIH), adrenocorticosteroids (for example, Prednisone), progestins (for example, Hydroxyprogesterone caproate, Medroxyprogesterone, Medroxyprogesterone acetate, and Megestrol acetate), estrogens (for example, Diethylstilbestrol (DES), Diethylstilbestrol diphosphate, Estradiol, and Ethinyl estradiol), antiestrogens (for example, Tamoxifen), androgens (Testosterone propionate, and Fluoxymesterone), antiandrogens (for example, Flutamide), gonadotropin-releasing hormone analogs (for example, Leuprolide), other hormones and hormone analogs (for example,

methyltestosterone, estramustine, estramustine phosphate sodium, chlorotrianisene, and testolactone), and others (for example, dicarbazine, glutamic acid, and mitotane).

[1275] In one embodiment, the compositions of the invention are administered in combination with one or more of the following drugs: infliximab (also known as Remicade™ Centocor, Inc.), Trocade (Roche, RO-32-3555), Leflunomide (also known as Arava™ from Hoechst Marion Roussel), Kineret™ (an IL-1 Receptor antagonist also known as Anakinra from Amgen, Inc.)

[1276] In a specific embodiment, compositions of the invention are administered in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) or combination of one or more of the components of CHOP. In one embodiment, the compositions of the invention are administered in combination with anti-CD20 antibodies, human monoclonal anti-CD20 antibodies. In another embodiment, the compositions of the invention are administered in combination with anti-CD20 antibodies and CHOP, or anti-CD20 antibodies and any combination of one or more of the components of CHOP, particularly cyclophosphamide and/or prednisone. In a specific embodiment, compositions of the invention are administered in combination with Rituximab. In a further embodiment, compositions of the invention are administered with Rituximab and CHOP, or Rituximab and any combination of one or more of the components of CHOP, particularly cyclophosphamide and/or prednisone. In a specific embodiment, compositions of the invention are administered in combination with tositumomab. In a further embodiment, compositions of the invention are administered with tositumomab and CHOP, or tositumomab and any combination of one or more of the components of CHOP, particularly cyclophosphamide and/or prednisone. The anti-CD20 antibodies may optionally be associated with radioisotopes, toxins or cytotoxic prodrugs.

[1277] In another specific embodiment, the compositions of the invention are administered in combination Zevalin™. In a further embodiment, compositions of the invention are administered with Zevalin™ and CHOP, or Zevalin™ and any combination of one or more of the components of CHOP, particularly cyclophosphamide and/or prednisone. Zevalin™ may be associated with one or more radisotopes. Particularly preferred isotopes are ⁹⁰Y and ¹¹¹In.

[1278] In an additional embodiment, the Therapeutics of the invention are administered in combination with cytokines. Cytokines that may be administered with the Therapeutics

of the invention include, but are not limited to, IL2, IL3, IL4, IL5, IL6, IL7, IL10, IL12, IL13, IL15, anti-CD40, CD40L, IFN-gamma and TNF-alpha. In another embodiment, Therapeutics of the invention may be administered with any interleukin, including, but not limited to, IL-1alpha, IL-1beta, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18, IL-19, IL-20, and IL-21.

[1279] In one embodiment, the Therapeutics of the invention are administered in combination with members of the TNF family. TNF, TNF-related or TNF-like molecules that may be administered with the Therapeutics of the invention include, but are not limited to, soluble forms of TNF-alpha, lymphotoxin-alpha (LT-alpha, also known as TNF-beta), LT-beta (found in complex heterotrimer LT-alpha2-beta), OPGL, FasL, CD27L, CD30L, CD40L, 4-1BBL, DcR3, OX40L, TNF-gamma (International Publication No. WO 96/14328), AIM-I (International Publication No. WO 97/33899), endokine-alpha (International Publication No. WO 98/07880), OPG, and neutrokin-alpha (International Publication No. WO 98/18921, OX40, and nerve growth factor (NGF), and soluble forms of Fas, CD30, CD27, CD40 and 4-1BB, TR2 (International Publication No. WO 96/34095), DR3 (International Publication No. WO 97/33904), DR4 (International Publication No. WO 98/32856), TR5 (International Publication No. WO 98/30693), TRANK, TR9 (International Publication No. WO 98/56892), TR10 (International Publication No. WO 98/54202), 312C2 (International Publication No. WO 98/06842), and TR12, and soluble forms CD154, CD70, and CD153.

[1280] In an additional embodiment, the Therapeutics of the invention are administered in combination with angiogenic proteins. Angiogenic proteins that may be administered with the Therapeutics of the invention include, but are not limited to, Glioma Derived Growth Factor (GDGF), as disclosed in European Patent Number EP-399816; Platelet Derived Growth Factor-A (PDGF-A), as disclosed in European Patent Number EP-682110; Platelet Derived Growth Factor-B (PDGF-B), as disclosed in European Patent Number EP-282317; Placental Growth Factor (PIGF), as disclosed in International Publication Number WO 92/06194; Placental Growth Factor-2 (PIGF-2), as disclosed in Hauser et al., Growth Factors, 4:259-268 (1993); Vascular Endothelial Growth Factor (VEGF), as disclosed in International Publication Number WO 90/13649; Vascular Endothelial Growth Factor-A (VEGF-A), as disclosed in European Patent Number EP-506477; Vascular Endothelial Growth Factor-2 (VEGF-2), as disclosed in International

Publication Number WO 96/39515; Vascular Endothelial Growth Factor B (VEGF-3); Vascular Endothelial Growth Factor B-186 (VEGF-B186), as disclosed in International Publication Number WO 96/26736; Vascular Endothelial Growth Factor-D (VEGF-D), as disclosed in International Publication Number WO 98/02543; Vascular Endothelial Growth Factor-D (VEGF-D), as disclosed in International Publication Number WO 98/07832; and Vascular Endothelial Growth Factor-E (VEGF-E), as disclosed in German Patent Number DE19639601. The above mentioned references are herein incorporated by reference in their entireties.

[1281] In an additional embodiment, the Therapeutics of the invention are administered in combination with Fibroblast Growth Factors. Fibroblast Growth Factors that may be administered with the Therapeutics of the invention include, but are not limited to, FGF-1, FGF-2, FGF-3, FGF-4, FGF-5, FGF-6, FGF-7, FGF-8, FGF-9, FGF-10, FGF-11, FGF-12, FGF-13, FGF-14, and FGF-15.

[1282] In an additional embodiment, the Therapeutics of the invention are administered in combination with hematopoietic growth factors. Hematopoietic growth factors that may be administered with the Therapeutics of the invention include, but are not limited to, granulocyte macrophage colony stimulating factor (GM-CSF) (sargramostim, LEUKINE™, PROKINE™), granulocyte colony stimulating factor (G-CSF) (filgrastim, NEUPOGEN™), macrophage colony stimulating factor (M-CSF, CSF-1) erythropoietin (epoetin alfa, EPOGEN™, PROCRIT™), stem cell factor (SCF, c-kit ligand, steel factor), megakaryocyte colony stimulating factor, PIXY321 (a GMCSF/IL-3 fusion protein), interleukins, especially any one or more of IL-1 through IL-12, interferon-gamma, or thrombopoietin.

[1283] In certain embodiments, Therapeutics of the present invention are administered in combination with adrenergic blockers, such as, for example, acebutolol, atenolol, betaxolol, bisoprolol, carteolol, labetalol, metoprolol, nadolol, oxprenolol, penbutolol, pindolol, propranolol, sotalol, and timolol.

[1284] In another embodiment, the Therapeutics of the invention are administered in combination with an antiarrhythmic drug (e.g., adenosine, amiodarone, bretylium, digitalis, digoxin, digitoxin, diltiazem, disopyramide, esmolol, flecainide, lidocaine, mexiletine, moricizine, phenytoin, procainamide, N-acetyl procainamide, propafenone, propranolol, quinidine, sotalol, tocainide, and verapamil).

[1285] In another embodiment, the Therapeutics of the invention are administered in combination with diuretic agents, such as carbonic anhydrase-inhibiting agents (e.g., acetazolamide, dichlorphenamide, and methazolamide), osmotic diuretics (e.g., glycerin, isosorbide, mannitol, and urea), diuretics that inhibit $\text{Na}^+\text{-K}^+\text{-2Cl}^-$ symport (e.g., furosemide, bumetanide, azosemide, piretanide, triparamide, ethacrynic acid, muzolimine, and torsemide), thiazide and thiazide-like diuretics (e.g., bendroflumethiazide, benzthiazide, chlorothiazide, hydrochlorothiazide, hydroflumethiazide, methyclothiazide, polythiazide, trichormethiazide, chlorthalidone, indapamide, metolazone, and quinethazone), potassium sparing diuretics (e.g., amiloride and triamterene), and mineralcorticoid receptor antagonists (e.g., spironolactone, canrenone, and potassium canrenoate).

[1286] In one embodiment, the Therapeutics of the invention are administered in combination with treatments for endocrine and/or hormone imbalance disorders. Treatments for endocrine and/or hormone imbalance disorders include, but are not limited to, ^{127}I , radioactive isotopes of iodine such as ^{131}I and ^{123}I ; recombinant growth hormone, such as HUMATROPE™ (recombinant somatotropin); growth hormone analogs such as PROTROPIN™ (somatrem); dopamine agonists such as PARLODEL™ (bromocriptine); somatostatin analogs such as SANDOSTATIN™ (octreotide); gonadotropin preparations such as PREGNYL™, A.P.L.™ and PROFASI™ (chorionic gonadotropin (CG)), PERGONAL™ (menotropins), and METRODIN™ (urofollitropin (uFSH)); synthetic human gonadotropin releasing hormone preparations such as FACTREL™ and LUTREPULSE™ (gonadorelin hydrochloride); synthetic gonadotropin agonists such as LUPRON™ (leuprolide acetate), SUPPRELIN™ (histrelin acetate), SYNAREL™ (nafarelin acetate), and ZOLADEX™ (goserelin acetate); synthetic preparations of thyrotropin-releasing hormone such as RELEFACT TRH™ and THYPINONE™ (protirelin); recombinant human TSH such as THYROGEN™; synthetic preparations of the sodium salts of the natural isomers of thyroid hormones such as L-T₄™, SYNTHROID™ and LEVOTHROID™ (levothyroxine sodium), L-T₃™, CYTOMEL™ and TRIOSTAT™ (liothyroine sodium), and THYROLAR™ (liotrix); antithyroid compounds such as 6-*n*-propylthiouracil (propylthiouracil), 1-methyl-2-mercaptoimidazole and TAPAZOLE™ (methimazole), NEO-MERCAZOLE™

(carbimazole); beta-adrenergic receptor antagonists such as propranolol and esmolol; Ca^{2+} channel blockers; dexamethasone and iodinated radiological contrast agents such as TELEPAQUE™ (iopanoic acid) and ORAGRAFIN™ (sodium ipodate).

[1287] Additional treatments for endocrine and/or hormone imbalance disorders include, but are not limited to, estrogens or conjugated estrogens such as ESTRACE™ (estradiol), ESTINYL™ (ethinyl estradiol), PREMARIN™, ESTRATAB™, ORTHO-EST™, OGEN™ and estropipate (estrone), ESTROVIS™ (quinestrol), ESTRADERM™ (estradiol), DELESTROGEN™ and VALERGEN™ (estradiol valerate), DEPO-ESTRADIOL CYPIONATE™ and ESTROJECT LA™ (estradiol cypionate); antiestrogens such as NOLVADEX™ (tamoxifen), SEROPHENE™ and CLOMID™ (clomiphene); progestins such as DURALUTIN™ (hydroxyprogesterone caproate), MPA™ and DEPO-PROVERA™ (medroxyprogesterone acetate), PROVERA™ and CYCRIN™ (MPA), MEGACE™ (megestrol acetate), NORLUTIN™ (norethindrone), and NORLUTATE™ and AYGESTIN™ (norethindrone acetate); progesterone implants such as NORPLANT SYSTEM™ (subdermal implants of norgestrel); antiprogestins such as RU 486™ (mifepristone); hormonal contraceptives such as ENOVID™ (norethynodrel plus mestranol), PROGESTASERT™ (intrauterine device that releases progesterone), LOESTRIN™, BREVICON™, MODICON™, GENORA™, NELONA™, NORINYL™, OVACON-35™ and OVACON-50™ (ethinyl estradiol/norethindrone), LEVLEN™, NORDETTE™, TRI-LEVLEN™ and TRIPHASIL-21™ (ethinyl estradiol/levonorgestrel) LO/OVRAL™ and OVRAL™ (ethinyl estradiol/norgestrel), DEMULEN™ (ethinyl estradiol/ethynodiol diacetate), NORINYL™, ORTHO-NOVUM™, NORETHIN™, GENORA™, and NELOVA™ (norethindrone/mestranol), DESOGEN™ and ORTHO-CEPT™ (ethinyl estradiol/desogestrel), ORTHO-CYCLEN™ and ORTHO-TRICYCLEN™ (ethinyl estradiol/norgestimate), MICRONOR™ and NOR-QD™ (norethindrone), and OVRETTE™ (norgestrel).

[1288] Additional treatments for endocrine and/or hormone imbalance disorders include, but are not limited to, testosterone esters such as methenolone acetate and testosterone undecanoate; parenteral and oral androgens such as TESTOJECT-50™ (testosterone), TESTEX™ (testosterone propionate), DELATESTRYL™ (testosterone

enanthate), DEPO-TESTOSTERONE™ (testosterone cypionate), DANOCRINE™ (danazol), HALOTESTIN™ (fluoxymesterone), ORETON METHYL™, TESTRED™ and VIRILON™ (methyltestosterone), and OXANDRIN™ (oxandrolone); testosterone transdermal systems such as TESTODERM™; androgen receptor antagonist and 5-alpha-reductase inhibitors such as ANDROCUR™ (cyproterone acetate), EULEXIN™ (flutamide), and PROSCAR™ (finasteride); adrenocorticotrophic hormone preparations such as CORTOSYN™ (cosyntropin); adrenocortical steroids and their synthetic analogs such as ACLOVATE™ (alclometasone dipropionate), CYCLOCORT™ (amcinonide), BECLOVENT™ and VANCERIL™ (beclomethasone dipropionate), CELESTONE™ (betamethasone), BENISON™ and UTICORT™ (betamethasone benzoate), DIPROSON™ (betamethasone dipropionate), CELESTONE PHOSPHATE™ (betamethasone sodium phosphate), CELESTONE SOLUSPAN™ (betamethasone sodium phosphate and acetate), BETA-VAL™ and VALISON™ (betamethasone valerate), TEMOVATE™ (clobetasol propionate), CLODERM™ (clocortolone pivalate), CORTEF™ and HYDROCORTONE™ (cortisol (hydrocortisone)), HYDROCORTONE ACETATE™ (cortisol (hydrocortisone) acetate), LOCOID™ (cortisol (hydrocortisone) butyrate), HYDROCORTONE PHOSPHATE™ (cortisol (hydrocortisone) sodium phosphate), A-HYDROCORT™ and SOLU CORTEF™ (cortisol (hydrocortisone) sodium succinate), WESTCORT™ (cortisol (hydrocortisone) valerate), CORTISONE ACETATE™ (cortisone acetate), DESOWEN™ and TRIDESILON™ (desonide), TOPICORT™ (desoximetasone), DECADRON™ (dexamethasone), DECADRON LA™ (dexamethasone acetate), DECADRON PHOSPHATE™ and HEXADROL PHOSPHATE™ (dexamethasone sodium phosphate), FLORONE™ and MAXIFLOR™ (diflurasone diacetate), FLORINEF ACETATE™ (fludrocortisone acetate), AEROBID™ and NASALIDE™ (flunisolide), FLUONID™ and SYNALAR™ (fluocinolone acetonide), LIDEX™ (fluocinonide), FLUOR-OP™ and FML™ (fluorometholone), CORDRAN™ (flurandrenolide), HALOG™ (halcinonide), HMS LIZUIFILM™ (medrysone), MEDROL™ (methylprednisolone), DEPO-MEDROL™ and MEDROL ACETATE™ (methylprednisone acetate), A-METHAPRED™ and SOLUMEDROL™ (methylprednisolone sodium succinate), ELOCON™ (mometasone furoate),

HALDRONE™ (paramethasone acetate), DELTA-CORTEF™ (prednisolone), ECONOPRED™ (prednisolone acetate), HYDELTRASOL™ (prednisolone sodium phosphate), HYDELTRA-T.B.A™ (prednisolone tebutate), DELTASONE™ (prednisone), ARISTOCORT™ and KENACORT™ (triamcinolone), KENALOG™ (triamcinolone acetate), ARISTOCORT™ and KENACORT DIACETATE™ (triamcinolone diacetate), and ARISTOSPAN™ (triamcinolone hexacetate); inhibitors of biosynthesis and action of adrenocortical steroids such as CYTADREN™ (aminoglutethimide), NIZORAL™ (ketoconazole), MODRASTANE™ (trilostane), and METOPIRONE™ (metyrapone);

[1289] Additional treatments for endocrine and/or hormone imbalance disorders include, but are not limited to bovine, porcine or human insulin or mixtures thereof; insulin analogs; recombinant human insulin such as HUMULIN™ and NOVOLIN™; oral hypoglycemic agents such as ORAMIDE™ and ORINASE™ (tolbutamide), DIABINESE™ (chlorpropamide), TOLAMIDE™ and TOLINASE™ (tolazamide), DYMELOR™ (acetohexamide), glibenclamide, MICRONASE™, DIBETA™ and GLYNASE™ (glyburide), GLUCOTROL™ (glipizide), and DIAMICRON™ (gliclazide), GLUCOPHAGE™ (metformin), PRECOSE™ (acarbose), AMARYL™ (glimepiride), and ciglitazone; thiazolidinediones (TZDs) such as rosiglitazone, AVANDIA™ (rosiglitazone maleate) ACTOS™ (pioglitazone), and troglitazone; alpha-glucosidase inhibitors; bovine or porcine glucagon; somatostatins such as SANDOSTATIN™ (octreotide); and diazoxides such as PROGLYCEM™ (diazoxide). In still other embodiments, Therapeutics of the invention are administered in combination with one or more of the following: a biguanide antidiabetic agent, a glitazone antidiabetic agent, and a sulfonylurea antidiabetic agent.

[1290] In one embodiment, the Therapeutics of the invention are administered in combination with treatments for uterine motility disorders. Treatments for uterine motility disorders include, but are not limited to, estrogen drugs such as conjugated estrogens (e.g., PREMARIN® and ESTRATAB®), estradiols (e.g., CLIMARA® and ALORA®), estropipate, and chlorotrianisene; progestin drugs (e.g., AMEN® (medroxyprogesterone), MICRONOR® (norethidrone acetate), PROMETRIUM® progesterone, and megestrol acetate); and estrogen/progesterone combination therapies such as, for example,

conjugated estrogens/medroxyprogesterone (e.g., PREMPRO™ and PREMPHASE®) and norethindrone acetate/ethinyl estradiol (e.g., FEMHRT™).

[1291] In an additional embodiment, the Therapeutics of the invention are administered in combination with drugs effective in treating iron deficiency and hypochromic anemias, including but not limited to, ferrous sulfate (iron sulfate, FEOSOL™), ferrous fumarate (e.g., FEOSTAT™), ferrous gluconate (e.g., FERGON™), polysaccharide-iron complex (e.g., NIFEREX™), iron dextran injection (e.g., INFED™), cupric sulfate, pyroxidine, riboflavin, Vitamin B₁₂, cyanocobalamin injection (e.g., REDISOL™, RUBRAMIN PC™), hydroxocobalamin, folic acid (e.g., FOLVITE™), leucovorin (folic acid, 5-CHOH4PteGlu, citrovorum factor) or WELLCOVORIN (Calcium salt of leucovorin), transferrin or ferritin.

[1292] In certain embodiments, the Therapeutics of the invention are administered in combination with agents used to treat psychiatric disorders. Psychiatric drugs that may be administered with the Therapeutics of the invention include, but are not limited to, antipsychotic agents (e.g., chlorpromazine, chlorprothixene, clozapine, fluphenazine, haloperidol, loxapine, mesoridazine, molindone, olanzapine, perphenazine, pimozone, quetiapine, risperidone, thioridazine, thiothixene, trifluoperazine, and triflupromazine), antimanic agents (e.g., carbamazepine, divalproex sodium, lithium carbonate, and lithium citrate), antidepressants (e.g., amitriptyline, amoxapine, bupropion, citalopram, clomipramine, desipramine, doxepin, fluvoxamine, fluoxetine, imipramine, isocarboxazid, maprotiline, mirtazapine, nefazodone, nortriptyline, paroxetine, phenelzine, protriptyline, sertraline, tranylcypromine, trazodone, trimipramine, and venlafaxine), antianxiety agents (e.g., alprazolam, buspirone, chlordiazepoxide, clorazepate, diazepam, halazepam, lorazepam, oxazepam, and prazepam), and stimulants (e.g., d-amphetamine, methylphenidate, and pemoline).

[1293] In other embodiments, the Therapeutics of the invention are administered in combination with agents used to treat neurological disorders. Neurological agents that may be administered with the Therapeutics of the invention include, but are not limited to, antiepileptic agents (e.g., carbamazepine, clonazepam, ethosuximide, phenobarbital, phenytoin, primidone, valproic acid, divalproex sodium, felbamate, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, tiagabine, topiramate, zonisamide, diazepam, lorazepam, and clonazepam), antiparkinsonian agents (e.g., levodopa/carbidopa,

selegiline, amantidine, bromocriptine, pergolide, ropinirole, pramipexole, benzotropine; biperiden; ethopropazine; procyclidine; trihexyphenidyl, tolcapone), and ALS therapeutics (e.g. riluzole).

[1294] In another embodiment, Therapeutics of the invention are administered in combination with vasodilating agents and/or calcium channel blocking agents. Vasodilating agents that may be administered with the Therapeutics of the invention include, but are not limited to, Angiotensin Converting Enzyme (ACE) inhibitors (e.g., papaverine, isoxsuprine, benazepril, captopril, cilazapril, enalapril, enalaprilat, fosinopril, lisinopril, moexipril, perindopril, quinapril, ramipril, spirapril, trandolapril, and nylidrin), and nitrates (e.g., isosorbide dinitrate, isosorbide mononitrate, and nitroglycerin). Examples of calcium channel blocking agents that may be administered in combination with the Therapeutics of the invention include, but are not limited to amlodipine, bepridil, diltiazem, felodipine, flunarizine, isradipine, nicardipine, nifedipine, nimodipine, and verapamil.

[1295] In certain embodiments, the Therapeutics of the invention are administered in combination with treatments for gastrointestinal disorders. Treatments for gastrointestinal disorders that may be administered with the Therapeutic of the invention include, but are not limited to, H₂ histamine receptor antagonists (e.g., TAGAMETTM (cimetidine), ZANTACTM (ranitidine), PEPACIDTM (famotidine), and AXIDTM (nizatidine)); inhibitors of H⁺, K⁺ ATPase (e.g., PREVACIDTM (lansoprazole) and PRILOSECTM (omeprazole)); Bismuth compounds (e.g., PEPTO-BISMOLTM (bismuth subsalicylate) and DE-NOLTM (bismuth subcitrate)); various antacids; sucralfate; prostaglandin analogs (e.g. CYTOTECTM (misoprostol)); muscarinic cholinergic antagonists; laxatives (e.g., surfactant laxatives, stimulant laxatives, saline and osmotic laxatives); antiarrheal agents (e.g., LOMOTILTM (diphenoxylate), MOTOFENTM (diphenoxin), and LMODIUMTM (loperamide hydrochloride)), synthetic analogs of somatostatin such as SANDOSTATINTM (octreotide), antiemetic agents (e.g., ZOFRANTM (ondansetron), KYTRILTM (granisetron hydrochloride), tropisetron, dolasetron, metoclopramide, chlorpromazine, perphenazine, prochlorperazine, promethazine, thiethylperazine, trifluorpromazine, domperidone, haloperidol, droperidol, trimethobenzamide, dexamethasone, methylprednisolone, dronabinol, and nabilone); D₂ antagonists (e.g., metoclopramide, trimethobenzamide and chlorpromazine); bile salts; chenodeoxycholic

acid; ursodeoxycholic acid; and pancreatic enzyme preparations such as pancreatin and pancrelipase.

[1296] In additional embodiments, the Therapeutics of the invention are administered in combination with other therapeutic or prophylactic regimens, such as, for example, radiation therapy.

Example 11: Method of Treating Decreased Levels of the Polypeptide

[1297] It will be appreciated that conditions caused by a decrease in the standard or normal expression level of a polypeptide in an individual can be treated by administering the polypeptide of the present invention, preferably in the secreted and/or soluble form. Thus, the invention also provides a method of treatment of an individual in need of an increased level of the polypeptide comprising administering to such an individual a pharmaceutical composition comprising an amount of the polypeptide to increase the activity level of the polypeptide in such an individual.

[1298] For example, a patient with decreased levels of a polypeptide receives a daily dose 0.1-100 ug/kg of the polypeptide for six consecutive days. Preferably, the polypeptide is in the secreted form. The exact details of the dosing scheme, based on administration and formulation, are provided in Example 10.

Example 12: Method of Treating Increased Levels of the Polypeptide

[1299] Antisense technology is used to inhibit production of a polypeptide of the present invention. This technology is one example of a method of decreasing levels of a polypeptide, preferably a secreted form, due to a variety of etiologies, such as cancer.

[1300] For example, a patient diagnosed with abnormally increased levels of a polypeptide is administered intravenously antisense polynucleotides at 0.5, 1.0, 1.5, 2.0 and 3.0 mg/kg day for 21 days. This treatment is repeated after a 7-day rest period if the treatment was well tolerated. The antisense polynucleotides of the present invention can be formulated using techniques and formulations described herein (e.g., see Example 10) or otherwise known in the art.

Example 13: Method of Treatment Using Gene Therapy - Ex Vivo

[1301] One method of gene therapy transplants fibroblasts, which are capable of expressing a polypeptide, onto a patient. Generally, fibroblasts are obtained from a subject by skin biopsy. The resulting tissue is placed in tissue-culture medium and separated into small pieces. Small chunks of the tissue are placed on a wet surface of a tissue culture flask, approximately ten pieces are placed in each flask. The flask is turned upside down, closed tight and left at room temperature over night. After 24 hours at room temperature, the flask is inverted and the chunks of tissue remain fixed to the bottom of the flask and fresh media (e.g., Ham's F12 media, with 10% FBS, penicillin and streptomycin) is added. The flasks are then incubated at 37°C for approximately one week.

[1302] At this time, fresh media is added and subsequently changed every several days. After an additional two weeks in culture, a monolayer of fibroblasts emerge. The monolayer is trypsinized and scaled into larger flasks.

[1303] pMV-7 (Kirschmeier, P.T. et al., DNA, 7:219-25 (1988)), flanked by the long terminal repeats of the Moloney murine sarcoma virus, is digested with EcoRI and HindIII and subsequently treated with calf intestinal phosphatase. The linear vector is fractionated on agarose gel and purified, using glass beads.

[1304] The cDNA encoding a polypeptide of the present invention can be amplified using PCR primers which correspond to the 5' and 3' end sequences respectively as set forth in Example 1 using primers and having appropriate restriction sites and initiation/stop codons, if necessary. Preferably, the 5' primer contains an EcoRI site and the 3' primer includes a HindIII site. Equal quantities of the Moloney murine sarcoma virus linear backbone and the amplified EcoRI and HindIII fragment are added together, in the presence of T4 DNA ligase. The resulting mixture is maintained under conditions appropriate for ligation of the two fragments. The ligation mixture is then used to transform bacteria HB101, which are then plated onto agar containing kanamycin for the purpose of confirming that the vector has the gene of interest properly inserted.

[1305] The amphotropic pA317 or GP+am12 packaging cells are grown in tissue culture to confluent density in Dulbecco's Modified Eagles Medium (DMEM) with 10% calf serum (CS), penicillin and streptomycin. The MSV vector containing the gene is then

added to the media and the packaging cells transduced with the vector. The packaging cells now produce infectious viral particles containing the gene (the packaging cells are now referred to as producer cells).

[1306] Fresh media is added to the transduced producer cells, and subsequently, the media is harvested from a 10 cm plate of confluent producer cells. The spent media, containing the infectious viral particles, is filtered through a millipore filter to remove detached producer cells and this media is then used to infect fibroblast cells. Media is removed from a sub-confluent plate of fibroblasts and quickly replaced with the media from the producer cells. This media is removed and replaced with fresh media. If the titer of virus is high, then virtually all fibroblasts will be infected and no selection is required. If the titer is very low, then it is necessary to use a retroviral vector that has a selectable marker, such as neo or his. Once the fibroblasts have been efficiently infected, the fibroblasts are analyzed to determine whether protein is produced.

[1307] The engineered fibroblasts are then transplanted onto the host, either alone or after having been grown to confluence on cytodex 3 microcarrier beads.

Example 14: Gene Therapy Using Endogenous ACRP30-Like Genes

[1308] Another method of gene therapy according to the present invention involves operably associating the endogenous ACRP30-Like gene sequence with a promoter via homologous recombination as described, for example, in U.S. Patent NO: 5,641,670, issued June 24, 1997; International Publication NO: WO 96/29411, published September 26, 1996; International Publication NO: WO 94/12650, published August 4, 1994; Koller et al., *Proc. Natl. Acad. Sci. USA*, 86:8932-8935 (1989); and Zijlstra et al., *Nature*, 342:435-438 (1989). This method involves the activation of a gene which is present in the target cells, but which is not expressed in the cells, or is expressed at a lower level than desired.

[1309] Polynucleotide constructs are made which contain a promoter and targeting sequences, which are homologous to the 5' non-coding sequence of the endogenous ACRP30-Like gene, flanking the promoter. The targeting sequence will be sufficiently near the 5' end of the ACRP30-Like gene so the promoter will be operably linked to the endogenous sequence upon homologous recombination. The promoter and the targeting

sequences can be amplified using PCR. Preferably, the amplified promoter contains distinct restriction enzyme sites on the 5' and 3' ends. Preferably, the 3' end of the first targeting sequence contains the same restriction enzyme site as the 5' end of the amplified promoter and the 5' end of the second targeting sequence contains the same restriction site as the 3' end of the amplified promoter.

[1310] The amplified promoter and the amplified targeting sequences are digested with the appropriate restriction enzymes and subsequently treated with calf intestinal phosphatase. The digested promoter and digested targeting sequences are added together in the presence of T4 DNA ligase. The resulting mixture is maintained under conditions appropriate for ligation of the two fragments. The construct is size fractionated on an agarose gel then purified by phenol extraction and ethanol precipitation.

[1311] In this Example, the polynucleotide constructs are administered as naked polynucleotides via electroporation. However, the polynucleotide constructs may also be administered with transfection-facilitating agents, such as liposomes, viral sequences, viral particles, precipitating agents, etc. Such methods of delivery are known in the art.

[1312] Once the cells are transfected, homologous recombination will take place which results in the promoter being operably linked to the endogenous ACRP30-Like gene sequence. This results in the expression of ACRP30-Like polypeptides in the cell. Expression may be detected by immunological staining, or any other method known in the art.

[1313] Fibroblasts are obtained from a subject by skin biopsy. The resulting tissue is placed in DMEM + 10% fetal calf serum. Exponentially growing or early stationary phase fibroblasts are trypsinized and rinsed from the plastic surface with nutrient medium. An aliquot of the cell suspension is removed for counting, and the remaining cells are subjected to centrifugation. The supernatant is aspirated and the pellet is resuspended in 5 ml of electroporation buffer (20 mM HEPES pH 7.3, 137 mM NaCl, 5 mM KCl, 0.7 mM Na₂ HPO₄, 6 mM dextrose). The cells are recentrifuged, the supernatant aspirated, and the cells resuspended in electroporation buffer containing 1 mg/ml acetylated bovine serum albumin. The final cell suspension contains approximately 3×10^6 cells/ml. Electroporation should be performed immediately following resuspension.

[1314] Plasmid DNA is prepared according to standard techniques. For example, to construct a plasmid for targeting to the ACRP30-Like locus, plasmid pUC18 (MBI

Fermentas, Amherst, NY) is digested with HindIII. The CMV promoter is amplified by PCR with an XbaI site on the 5' end and a BamHI site on the 3'end. Two ACRP30-Like non-coding gene sequences are amplified via PCR: one ACRP30-Like non-coding sequence (ACRP30-Like fragment 1) is amplified with a HindIII site at the 5' end and an Xba site at the 3'end; the other ACRP30-Like non-coding sequence (ACRP30-Like fragment 2) is amplified with a BamHI site at the 5'end and a HindIII site at the 3'end. The CMV promoter and ACRP30-Like fragments are digested with the appropriate enzymes (CMV promoter - XbaI and BamHI; ACRP30-Like fragment 1 - XbaI; ACRP30-Like fragment 2 - BamHI) and ligated together. The resulting ligation product is digested with HindIII, and ligated with the HindIII-digested pUC18 plasmid.

[1315] Plasmid DNA is added to a sterile cuvette with a 0.4 cm electrode gap (Bio-Rad). The final DNA concentration is generally at least 120 $\mu\text{g/ml}$. 0.5 ml of the cell suspension (containing approximately 1.5×10^6 cells) is then added to the cuvette, and the cell suspension and DNA solutions are gently mixed. Electroporation is performed with a Gene-Pulser apparatus (Bio-Rad). Capacitance and voltage are set at 960 μF and 250-300 V, respectively. As voltage increases, cell survival decreases, but the percentage of surviving cells that stably incorporate the introduced DNA into their genome increases dramatically. Given these parameters, a pulse time of approximately 14-20 mSec should be observed.

[1316] Electroporated cells are maintained at room temperature for approximately 5 min, and the contents of the cuvette are then gently removed with a sterile transfer pipette. The cells are added directly to 10 ml of prewarmed nutrient media (DMEM with 15% calf serum) in a 10 cm dish and incubated at 37 degree C. The following day, the media is aspirated and replaced with 10 ml of fresh media and incubated for a further 16-24 hours.

[1317] The engineered fibroblasts are then injected into the host, either alone or after having been grown to confluence on cytodex 3 microcarrier beads. The fibroblasts now produce the protein product. The fibroblasts can then be introduced into a patient as described above.

Example 15: Method of Treatment Using Gene Therapy - In Vivo

[1318] Another aspect of the present invention is using *in vivo* gene therapy methods

to treat disorders, diseases and conditions. The gene therapy method relates to the introduction of naked nucleic acid (DNA, RNA, and antisense DNA or RNA) ACRP30-Like sequences into an animal to increase or decrease the expression of the ACRP30-Like polypeptide. The ACRP30-Like polynucleotide may be operatively linked to a promoter or any other genetic elements necessary for the expression of the ACRP30-Like polypeptide by the target tissue. Such gene therapy and delivery techniques and methods are known in the art, see, for example, WO90/11092, WO98/11779; U.S. Patent NO: 5693622, 5705151, 5580859; Tabata et al., *Cardiovasc. Res.* 35(3):470-479 (1997), Chao J et al., *Pharmacol. Res.*, 35(6):517-522 (1997), Wolff, *Neuromuscul. Disord.* 7(5):314-318 (1997), Schwartz et al., *Gene Ther.*, 3(5):405-411 (1996), Tsurumi Y. et al., *Circulation*, 94(12):3281-3290 (1996) (incorporated herein by reference).

[1319] The ACRP30-Like polynucleotide constructs may be delivered by any method that delivers injectable materials to the cells of an animal, such as, injection into the interstitial space of tissues (heart, muscle, skin, lung, liver, intestine and the like). The ACRP30-Like polynucleotide constructs can be delivered in a pharmaceutically acceptable liquid or aqueous carrier.

[1320] The term "naked" polynucleotide, DNA or RNA, refers to sequences that are free from any delivery vehicle that acts to assist, promote, or facilitate entry into the cell, including viral sequences, viral particles, liposome formulations, lipofectin or precipitating agents and the like. However, the ACRP30-Like polynucleotides may also be delivered in liposome formulations (such as those taught in Felgner et al., *Ann. NY Acad. Sci.*, 772:126-139 (1995) and Abdallah et al., *Biol. Cell*, 85(1):1-7 (1995)) which can be prepared by methods well known to those skilled in the art.

[1321] The ACRP30-Like polynucleotide vector constructs used in the gene therapy method are preferably constructs that will not integrate into the host genome nor will they contain sequences that allow for replication. Any strong promoter known to those skilled in the art can be used for driving the expression of DNA. Unlike other gene therapies techniques, one major advantage of introducing naked nucleic acid sequences into target cells is the transitory nature of the polynucleotide synthesis in the cells. Studies have shown that non-replicating DNA sequences can be introduced into cells to provide production of the desired polypeptide for periods of up to six months.

[1322] The polynucleotide constructs can be delivered to the interstitial space of tissues

within the an animal, including of muscle, skin, brain, lung, liver, spleen, bone marrow, thymus, heart, lymph, blood, bone, cartilage, pancreas, kidney, gall bladder, stomach, intestine, testis, ovary, uterus, rectum, nervous system, eye, gland, and connective tissue. Interstitial space of the tissues comprises the intercellular fluid, mucopolysaccharide matrix among the reticular fibers of organ tissues, elastic fibers in the walls of vessels or chambers, collagen fibers of fibrous tissues, or that same matrix within connective tissue ensheathing muscle cells or in the lacunae of bone. It is similarly the space occupied by the plasma of the circulation and the lymph fluid of the lymphatic channels. Delivery to the interstitial space of muscle tissue is preferred for the reasons discussed below. They may be conveniently delivered by injection into the tissues comprising these cells. They are preferably delivered to and expressed in persistent, non-dividing cells which are differentiated, although delivery and expression may be achieved in non-differentiated or less completely differentiated cells, such as, for example, stem cells of blood or skin fibroblasts. *In vivo* muscle cells are particularly competent in their ability to take up and express polynucleotides.

[1323] For the naked ACRP30-Like polynucleotide injection, an effective dosage amount of DNA or RNA will be in the range of from about 0.05 g/kg body weight to about 50 mg/kg body weight. Preferably the dosage will be from about 0.005 mg/kg to about 20 mg/kg and more preferably from about 0.05 mg/kg to about 5 mg/kg. Of course, as the artisan of ordinary skill will appreciate, this dosage will vary according to the tissue site of injection. The appropriate and effective dosage of nucleic acid sequence can readily be determined by those of ordinary skill in the art and may depend on the condition being treated and the route of administration. The preferred route of administration is by the parenteral route of injection into the interstitial space of tissues. However, other parenteral routes may also be used, such as, inhalation of an aerosol formulation particularly for delivery to lungs or bronchial tissues, throat or mucous membranes of the nose. In addition, naked ACRP30-Like polynucleotide constructs can be delivered to arteries during angioplasty by the catheter used in the procedure.

[1324] The dose response effects of injected ACRP30-Like polynucleotide in muscle *in vivo* is determined as follows. Suitable ACRP30-Like template DNA for production of mRNA coding for ACRP30-Like polypeptide is prepared in accordance with a standard recombinant DNA methodology. The template DNA, which may be either circular or

linear, is either used as naked DNA or complexed with liposomes. The quadriceps muscles of mice are then injected with various amounts of the template DNA.

[1325] Five to six week old female and male Balb/C mice are anesthetized by intraperitoneal injection with 0.3 ml of 2.5% Avertin. A 1.5 cm incision is made on the anterior thigh, and the quadriceps muscle is directly visualized. The ACRP30-Like template DNA is injected in 0.1 ml of carrier in a 1 cc syringe through a 27 gauge needle over one minute, approximately 0.5 cm from the distal insertion site of the muscle into the knee and about 0.2 cm deep. A suture is placed over the injection site for future localization, and the skin is closed with stainless steel clips.

[1326] After an appropriate incubation time (e.g., 7 days) muscle extracts are prepared by excising the entire quadriceps. Every fifth 15 um cross-section of the individual quadriceps muscles is histochemically stained for ACRP30-Like protein expression. A time course for ACRP30-Like protein expression may be done in a similar fashion except that quadriceps from different mice are harvested at different times. Persistence of ACRP30-Like DNA in muscle following injection may be determined by Southern blot analysis after preparing total cellular DNA and HIRT supernatants from injected and control mice. The results of the above experimentation in mice can be used to extrapolate proper dosages and other treatment parameters in humans and other animals using ACRP30-Like naked DNA.

Example 16: Production of an Antibody

a) Hybridoma Technology

[1327] The antibodies of the present invention can be prepared by a variety of methods. (See, Current Protocols, Chapter 2.) As one example of such methods, cells expressing ACRP30-Like polypeptide(s) are administered to an animal to induce the production of sera containing polyclonal antibodies. In a preferred method, a preparation of ACRP30-Like polypeptide(s) is prepared and purified to render it substantially free of natural contaminants. Such a preparation is then introduced into an animal in order to produce polyclonal antisera of greater specific activity.

[1328] Monoclonal antibodies specific for ACRP30-Like polypeptide(s) are prepared using hybridoma technology. (Kohler et al., Nature 256:495 (1975); Kohler et al., Eur. J.

Immunol. 6:511 (1976); Kohler et al., *Eur. J. Immunol.* 6:292 (1976); Hammerling et al., in: *Monoclonal Antibodies and T-Cell Hybridomas*, Elsevier, N.Y., pp. 563-681 (1981)). In general, an animal (preferably a mouse) is immunized with ACRP30-Like polypeptide(s) or, more preferably, with a secreted ACRP30-Like polypeptide-expressing cell. Such polypeptide-expressing cells are cultured in any suitable tissue culture medium, preferably in Earle's modified Eagle's medium supplemented with 10% fetal bovine serum (inactivated at about 56°C), and supplemented with about 10 g/l of nonessential amino acids, about 1,000 U/ml of penicillin, and about 100 µg/ml of streptomycin.

[1329] The splenocytes of such mice are extracted and fused with a suitable myeloma cell line. Any suitable myeloma cell line may be employed in accordance with the present invention; however, it is preferable to employ the parent myeloma cell line (SP2O), available from the ATCC. After fusion, the resulting hybridoma cells are selectively maintained in HAT medium, and then cloned by limiting dilution as described by Wands et al. (*Gastroenterology* 80:225-232 (1981)). The hybridoma cells obtained through such a selection are then assayed to identify clones which secrete antibodies capable of binding the ACRP30-Like polypeptide(s).

[1330] Alternatively, additional antibodies capable of binding to ACRP30-Like polypeptide(s) can be produced in a two-step procedure using anti-idiotypic antibodies. Such a method makes use of the fact that antibodies are themselves antigens, and therefore, it is possible to obtain an antibody which binds to a second antibody. In accordance with this method, protein specific antibodies are used to immunize an animal, preferably a mouse. The splenocytes of such an animal are then used to produce hybridoma cells, and the hybridoma cells are screened to identify clones which produce an antibody whose ability to bind to the ACRP30-Like protein-specific antibody can be blocked by ACRP30-Like polypeptide(s). Such antibodies comprise anti-idiotypic antibodies to the ACRP30-Like protein-specific antibody and are used to immunize an animal to induce formation of further ACRP30-Like protein-specific antibodies.

[1331] For in vivo use of antibodies in humans, an antibody is "humanized". Such antibodies can be produced using genetic constructs derived from hybridoma cells producing the monoclonal antibodies described above. Methods for producing chimeric and humanized antibodies are known in the art and are discussed herein. (See, for review, Morrison, *Science* 229:1202 (1985); Oi et al., *BioTechniques* 4:214 (1986); Cabilly et al.,

U.S. Patent No. 4,816,567; Taniguchi et al., EP 171496; Morrison et al., EP 173494; Neuberger et al., WO 8601533; Robinson et al., WO 8702671; Boulianne et al., Nature 312:643 (1984); Neuberger et al., Nature 314:268 (1985)).

b) Isolation Of Antibody Fragments Directed Against ACRP30-Like Polypeptide(s) From A Library Of scFvs

[1332] Naturally occurring V-genes isolated from human PBLs are constructed into a library of antibody fragments which contain reactivities against ACRP30-Like polypeptide(s) to which the donor may or may not have been exposed (see e.g., U.S. Patent 5,885,793 incorporated herein by reference in its entirety).

Rescue of the Library.

[1333] A library of scFvs is constructed from the RNA of human PBLs as described in PCT publication WO 92/01047. To rescue phage displaying antibody fragments, approximately 109 E. coli harboring the phagemid are used to inoculate 50 ml of 2xTY containing 1% glucose and 100 µg/ml of ampicillin (2xTY-AMP-GLU) and grown to an O.D. of 0.8 with shaking. Five ml of this culture is used to inoculate 50 ml of 2xTY-AMP-GLU, 2 x 10⁸ TU of delta gene 3 helper (M13 delta gene III, see PCT publication WO 92/01047) are added and the culture incubated at 37°C for 45 minutes without shaking and then at 37°C for 45 minutes with shaking. The culture is centrifuged at 4000 r.p.m. for 10 min. and the pellet resuspended in 2 liters of 2xTY containing 100 µg/ml ampicillin and 50 µg/ml kanamycin and grown overnight. Phage are prepared as described in PCT publication WO 92/01047.

[1334] M13 delta gene III is prepared as follows: M13 delta gene III helper phage does not encode gene III protein, hence the phage(mid) displaying antibody fragments have a greater avidity of binding to antigen. Infectious M13 delta gene III particles are made by growing the helper phage in cells harboring a pUC19 derivative supplying the wild type gene III protein during phage morphogenesis. The culture is incubated for 1 hour at 37° C without shaking and then for a further hour at 37°C with shaking. Cells are spun down (IEC-Centra 8,400 r.p.m. for 10 min), resuspended in 300 ml 2xTY broth containing 100 µg ampicillin/ml and 25 µg kanamycin/ml (2xTY-AMP-KAN) and grown overnight, shaking at 37°C. Phage particles are purified and concentrated from the culture medium

by two PEG-precipitations (Sambrook et al., 1990), resuspended in 2 ml PBS and passed through a 0.45 μ m filter (Minisart NML; Sartorius) to give a final concentration of approximately 1013 transducing units/ml (ampicillin-resistant clones).

Panning of the Library.

[1335] Immunotubes (Nunc) are coated overnight in PBS with 4 ml of either 100 μ g/ml or 10 μ g/ml of a polypeptide of the present invention. Tubes are blocked with 2% Marvel-PBS for 2 hours at 37°C and then washed 3 times in PBS. Approximately 1013 TU of phage is applied to the tube and incubated for 30 minutes at room temperature tumbling on an over and under turntable and then left to stand for another 1.5 hours. Tubes are washed 10 times with PBS 0.1% Tween-20 and 10 times with PBS. Phage are eluted by adding 1 ml of 100 mM triethylamine and rotating 15 minutes on an under and over turntable after which the solution is immediately neutralized with 0.5 ml of 1.0M Tris-HCl, pH 7.4. Phage are then used to infect 10 ml of mid-log E. coli TG1 by incubating eluted phage with bacteria for 30 minutes at 37°C. The E. coli are then plated on TYE plates containing 1% glucose and 100 μ g/ml ampicillin. The resulting bacterial library is then rescued with delta gene 3 helper phage as described above to prepare phage for a subsequent round of selection. This process is then repeated for a total of 4 rounds of affinity purification with tube-washing increased to 20 times with PBS, 0.1% Tween-20 and 20 times with PBS for rounds 3 and 4.

Characterization of Binders.

[1336] Eluted phage from the 3rd and 4th rounds of selection are used to infect E. coli HB 2151 and soluble scFv is produced (Marks, et al., 1991) from single colonies for assay. ELISAs are performed with microtitre plates coated with either 10 μ g/ml of the polypeptide of the present invention in 50 mM bicarbonate pH 9.6. Clones positive in ELISA are further characterized by PCR fingerprinting (see, e.g., PCT publication WO 92/01047) and then by sequencing. These ELISA positive clones may also be further characterized by techniques known in the art, such as, for example, epitope mapping, binding affinity, receptor signal transduction, ability to block or competitively inhibit antibody/antigen binding, and competitive agonistic or antagonistic activity.

Example 17: [³H]-2-Deoxyglucose Uptake Assay

[1337] Adipose, skeletal muscle, and liver are insulin-sensitive tissues. Insulin can stimulate glucose uptake/transport into these tissues. In the case of adipose and skeletal muscle, insulin initiates the signal transduction that eventually leads to the translocation of GLUT4, the glucose transporter 4 molecule, from a specialized intracellular compartment to the cell surface. Once on the cell surface, GLUT4 allows for glucose uptake/transport.

[1338] A number of adipose and muscle related cell-lines can be used to test for glucose uptake/transport activity in the presence of an ACRP-30 Like polypeptide of the invention. In particular, the 3T3-L1 murine fibroblast cells and the L6 murine skeletal muscle cells can be differentiated into 3T3-L1 adipocytes and into myotubes, respectively, to serve as appropriate *in vitro* models for the ³H-2-deoxyglucose uptake assay (Haspel et al., 1999, J Membr Biol, 169 (1): 45-53; Tsakiridis et al., 1995, Endocrinology, 136(10): 4315-22). Briefly, 2 x 10⁵ cells/100 uL of adipocytes or differentiated L6 cells are transferred to 96-well Tissue-Culture, "TC", treated, i.e. coated with 50 ug/mL of poly-L-lysine, plates for 4 hours at 37 °C. The cells are washed once with HEPES buffered saline. Insulin, or an ACRP-30 Like polypeptide, is added at various dilutions (e.g., 5 nM, 10 nM, 100 nM, and 500 nM for insulin) in HEPES buffered saline for 30 min at 37 °C. A final concentration of 10 uM cytochalasin B is added to measure the non-specific uptake. The cells are washed three times with HEPES buffered saline. Labeled, i.e. 10 uM of [³H]-2-deoxyglucose, and unlabeled, i.e. 2-deoxyglucose, are added for 10 minutes at room temperature. The cells are washed three times with cold Phosphate Buffered Saline, "PBS". The cells are lysed upon the addition of 150 uL/well of 0.05 N NaOH and subsequent incubation with shaking for 20 minutes at room temperature. Samples are then transferred to a scintillation vial to which is added 5 mL of scintillation fluid. The vials are counted in a Beta-Scintillation counter. Maximal responses of about 5-fold and 3-fold that of controls for adipocytes and myotubes, respectively, are to be expected.

[1339] It will be clear that the invention may be practiced otherwise than as particularly described in the foregoing description and examples. Numerous modifications and variations of the present invention are possible in light of the above teachings and, therefore, are within the scope of the appended claims.

[1340] The entire disclosure of each document cited (including patents, patent applications, journal articles, abstracts, laboratory manuals, books, or other disclosures) in the Background of the Invention, Detailed Description, and Examples is hereby incorporated herein by reference. Further, the hard copy of the sequence listing submitted herewith and the corresponding computer readable form are both incorporated herein by reference in their entireties.

[1341] Certain ACRP-30-Like polynucleotides and polypeptides of the present invention, including antibodies, were disclosed in U.S. provisional application number 60/328,419, filed October 12, 2001, the specification and sequence listing of which are herein incorporated by reference in their entireties.

**INDICATIONS RELATING TO A DEPOSITED MICROORGANISM
OR OTHER BIOLOGICAL MATERIAL**

(PCT Rule 13bis)

A. The indications made below relate to the deposited microorganism or other biological material referred to in the description on Page 180, Table I.

B. IDENTIFICATION OF DEPOSIT

Further deposits are identified on an additional sheet ☐

Name of depositary institution: American Type Culture Collection

Address of depositary institution (*including postal code and country*)

10801 University Boulevard
Manassas, Virginia 20110-2209
United States of America

Date of deposit

October 13, 1999

Accession Number

PTA-844

C. ADDITIONAL INDICATIONS (*leave blank if not applicable*)

This information is continued on an additional sheet ☐

D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (*if the indications are not for all designated States*)

Europe

In respect of those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC).

Continued on additional sheets

E. SEPARATE FURNISHING OF INDICATIONS (*leave blank if not applicable*)

The indications listed below will be submitted to the international Bureau later (*specify the general nature of the indications e.g., "Accession Number of Deposit"*)

For receiving Office use only

For International Bureau use only

☒ This sheet was received with the international application

11 OCT 2002

☐ This sheet was received by the International Bureau on:

Authorized officer

B. J. J. J.

Authorized officer

ATCC Deposit No. PTA-844**CANADA**

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

ATCC Deposit No.: PTA-844

UNITED KINGDOM

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by an applicant in the individual case.

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

**INDICATIONS RELATING TO A DEPOSITED MICROORGANISM
OR OTHER BIOLOGICAL MATERIAL**

(PCT Rule 13bis)

A. The indications made below relate to the deposited microorganism or other biological material referred to in the description on Page 180, Table 1.

B. IDENTIFICATION OF DEPOSIT

Further deposits are identified on an additional sheet ☐

Name of depositary institution: American Type Culture Collection

Address of depositary institution (*including postal code and country*)

10801 University Boulevard
Manassas, Virginia 20110-2209
United States of America

Date of deposit:

September 2, 1999

Accession Number

PTA-623

C. ADDITIONAL INDICATIONS (*leave blank if not applicable*)

This information is continued on an additional sheet ☐

D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (*if the indications are not for all designated States*)


Europe

In respect of those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC).

Continued on additional sheets

E. SEPARATE FURNISHING OF INDICATIONS (*leave blank if not applicable*)

The indications listed below will be submitted to the international Bureau later (*specify the general nature of the indications e.g., "Accession Number of Deposit"*)

	For receiving Office use only			For International Bureau use only	
<input checked="" type="checkbox"/> This sheet was received with the international application <div style="text-align: center; font-weight: bold;">11 OCT 2002</div>				<input type="checkbox"/> This sheet was received by the International Bureau on:	
Authorized officer				Authorized officer	

ATCC Deposit No. PTA-623**CANADA**

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

ATCC Deposit No.: PTA-623**UNITED KINGDOM**

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by an applicant in the individual case.

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

**INDICATIONS RELATING TO A DEPOSITED MICROORGANISM
OR OTHER BIOLOGICAL MATERIAL**

(PCT Rule 13bis)

A. The indications made below relate to the deposited microorganism or other biological material referred to in the description on Page 181, Table 1.

B. IDENTIFICATION OF DEPOSIT

Further deposits are identified on an additional sheet ☐

Name of depositary institution: American Type Culture Collection

Address of depositary institution (including postal code and country)

10801 University Boulevard
Manassas, Virginia 20110-2209
United States of America

Date of deposit

August 13, 1999

Accession Number

PTA-536

C. ADDITIONAL INDICATIONS (leave blank if not applicable)

This information is continued on an additional sheet ☐

D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)

Europe

In respect of those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC).

Continued on additional sheets

E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)

The indications listed below will be submitted to the international Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")

	For receiving Office use only				For International Bureau use only	
<input checked="" type="checkbox"/>	This sheet was received with the international application			<input type="checkbox"/>	This sheet was received by the International Bureau on:	
	11 OCT 2002					
Authorized officer				Authorized officer		

ATCC Deposit No. PTA-536**CANADA**

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

ATCC Deposit No.: PTA-536**UNITED KINGDOM**

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by an applicant in the individual case.

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

**INDICATIONS RELATING TO A DEPOSITED MICROORGANISM
OR OTHER BIOLOGICAL MATERIAL**

(PCT Rule 13bis)

A. The indications made below relate to the deposited microorganism or other biological material referred to in the description on Page 181, Table I.

B. IDENTIFICATION OF DEPOSIT

Further deposits are identified on an additional sheet ☐

Name of depositary institution: American Type Culture Collection

Address of depositary institution (including postal code and country)

10801 University Boulevard
Manassas, Virginia 20110-2209
United States of America

Date of deposit

September 10, 2001

Accession Number

PTA-3696

C. ADDITIONAL INDICATIONS (leave blank if not applicable)

This information is continued on an additional sheet ☐

D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)

Europe

In respect of those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC).

Continued on additional sheets

E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)

The indications listed below will be submitted to the international Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")

For receiving Office use only

For International Bureau use only

☒ This sheet was received with the international application

11 OCT 2002

☐ This sheet was received by the International Bureau on:

Authorized officer

B. Indli

Authorized officer

ATCC Deposit No. PTA-3696**CANADA**

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

ATCC Deposit No.: PTA-3696

UNITED KINGDOM

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by an applicant in the individual case.

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

**INDICATIONS RELATING TO A DEPOSITED MICROORGANISM
OR OTHER BIOLOGICAL MATERIAL**

(PCT Rule 13bis)

A. The indications made below relate to the deposited microorganism or other biological material referred to in the description on Page 181, Table 1.

B. IDENTIFICATION OF DEPOSIT

Further deposits are identified on an additional sheet ☐

Name of depositary institution: American Type Culture Collection

Address of depositary institution *(including postal code and country)*

10801 University Boulevard
Manassas, Virginia 20110-2209
United States of America

Date of deposit

October 5, 2000

Accession Number

PTA-2574

C. ADDITIONAL INDICATIONS *(leave blank if not applicable)*

This information is continued on an additional sheet ☐

D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE *(if the indications are not for all designated States)*

Europe

In respect of those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC).
Continued on additional sheets

E. SEPARATE FURNISHING OF INDICATIONS *(leave blank if not applicable)*

The indications listed below will be submitted to the International Bureau later *(specify the general nature of the indications e.g., "Accession Number of Deposit")*

	For receiving Office use only			For International Bureau use only	
<input checked="" type="checkbox"/>	This sheet was received with the international application			<input type="checkbox"/>	This sheet was received by the International Bureau on:
11 OCT 2002 Authorized officer <i>B. Miller</i>			Authorized officer		

Revised Form PCT/RO/134 (January 2001)

Pctrol34ep.solist

ATCC Deposit No. PTA-2574**CANADA**

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

ATCC Deposit No.: PTA-2574

UNITED KINGDOM

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by an applicant in the individual case.

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

**INDICATIONS RELATING TO A DEPOSITED MICROORGANISM
OR OTHER BIOLOGICAL MATERIAL**

(PCT Rule 13bis)

A. The indications made below relate to the deposited microorganism or other biological material referred to in the description on Page 181, Table I.

B. IDENTIFICATION OF DEPOSIT

Further deposits are identified on an additional sheet ☐

Name of depositary institution: American Type Culture Collection

Address of depositary institution (including postal code and country)

10801 University Boulevard
Manassas, Virginia 20110-2209
United States of America

Date of deposit

October 5, 2000

Accession Number

PTA-2575

C. ADDITIONAL INDICATIONS (leave blank if not applicable)

This information is continued on an additional sheet ☐

D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)


Europe

In respect of those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC).

Continued on additional sheets

E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)

The indications listed below will be submitted to the international Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")

	For receiving Office use only				For International Bureau use only	
<input checked="" type="checkbox"/> This sheet was received with the international application 11 OCT 2002			<input type="checkbox"/> This sheet was received by the International Bureau on:			
Authorized officer 			Authorized officer			

ATCC Deposit No. PTA-2575**CANADA**

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

ATCC Deposit No.: PTA-2575

UNITED KINGDOM

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by an applicant in the individual case.

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

**INDICATIONS RELATING TO A DEPOSITED MICROORGANISM
OR OTHER BIOLOGICAL MATERIAL**

(PCT Rule 13bis)

A. The indications made below relate to the deposited microorganism or other biological material referred to in the description on Page 182, Table 1.

B. IDENTIFICATION OF DEPOSIT

Further deposits are identified on an additional sheet ☐

Name of depositary institution: American Type Culture Collection

Address of depositary institution (including postal code and country)

10801 University Boulevard
Manassas, Virginia 20110-2209
United States of America

Date of deposit

July 27, 1998

Accession Number

203071

C. ADDITIONAL INDICATIONS (leave blank if not applicable)

This information is continued on an additional sheet ☐

D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)

Europe

In respect of those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC).

Continued on additional sheets

E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)

The indications listed below will be submitted to the international Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")

	For receiving Office use only			For International Bureau use only	
<input checked="" type="checkbox"/>	This sheet was received with the international application	<input type="checkbox"/>	This sheet was received by the International Bureau on:		
Authorized officer	11 OCT 2002 <i>D. J. J. J.</i>	Authorized officer			

ATCC Deposit No. 203071**CANADA**

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

ATCC Deposit No.: 203071

UNITED KINGDOM

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by an applicant in the individual case.

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

**INDICATIONS RELATING TO A DEPOSITED MICROORGANISM
OR OTHER BIOLOGICAL MATERIAL**

(PCT Rule 13bis)

A. The indications made below relate to the deposited microorganism or other biological material referred to in the description on Page 182, Table I.

B. IDENTIFICATION OF DEPOSIT

Further deposits are identified on an additional sheet ☐

Name of depositary institution: American Type Culture Collection

Address of depositary institution (*including postal code and country*)

10801 University Boulevard
Manassas, Virginia 20110-2209
United States of America

Date of deposit

June 19, 1997

Accession Number

209124

C. ADDITIONAL INDICATIONS (*leave blank if not applicable*)

This information is continued on an additional sheet ☐

D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (*if the indications are not for all designated States*)

Europe

In respect of those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC).

Continued on additional sheets

E. SEPARATE FURNISHING OF INDICATIONS (*leave blank if not applicable*)

The indications listed below will be submitted to the international Bureau later (*specify the general nature of the indications e.g., "Accession Number of Deposit"*)

For receiving Office use only

For International Bureau use only

☒ This sheet was received with the international application

☐ This sheet was received by the International Bureau on:

11 OCT 2002

Authorized officer

Authorized officer

ATCC Deposit No. 209124**CANADA**

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

ATCC Deposit No.: 209124

UNITED KINGDOM

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by an applicant in the individual case.

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

**INDICATIONS RELATING TO A DEPOSITED MICROORGANISM
OR OTHER BIOLOGICAL MATERIAL**

(PCT Rule 13bis)

A. The indications made below relate to the deposited microorganism or other biological material referred to in the description on Page 182, Table 1.

B. IDENTIFICATION OF DEPOSIT

Further deposits are identified on an additional sheet ☐

Name of depositary institution: American Type Culture Collection

Address of depositary institution (*including postal code and country*)

10801 University Boulevard
Manassas, Virginia 20110-2209
United States of America

Date of deposit

September 27, 1999

Accession Number

PTA-791

C. ADDITIONAL INDICATIONS (*leave blank if not applicable*)

This information is continued on an additional sheet ☐

D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (*if the indications are not for all designated States*)


Europe

In respect of those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC).

Continued on additional sheets

E. SEPARATE FURNISHING OF INDICATIONS (*leave blank if not applicable*)

The indications listed below will be submitted to the international Bureau later (*specify the general nature of the indications e.g., "Accession Number of Deposit"*)

For receiving Office use only		For International Bureau use only	
<input checked="" type="checkbox"/> This sheet was received with the international application <div style="text-align: center; font-weight: bold; font-size: 1.2em;">11 OCT 2002</div>		<input type="checkbox"/> This sheet was received by the International Bureau on:	
Authorized officer 		Authorized officer	

ATCC Deposit No. PTA-791**CANADA**

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

ATCC Deposit No.: PTA-791

UNITED KINGDOM

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by an applicant in the individual case.

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

**INDICATIONS RELATING TO A DEPOSITED MICROORGANISM
OR OTHER BIOLOGICAL MATERIAL**

(PCT Rule 13bis)

A. The indications made below relate to the deposited microorganism or other biological material referred to in the description on Page 182, Table 1.

B. IDENTIFICATION OF DEPOSIT

Further deposits are identified on an additional sheet ☐

Name of depositary institution: American Type Culture Collection

Address of depositary institution (*including postal code and country*)

10801 University Boulevard
Manassas, Virginia 20110-2209
United States of America

Date of deposit

June 11, 2001

Accession Number

PTA-3449

C. ADDITIONAL INDICATIONS (*leave blank if not applicable*)

This information is continued on an additional sheet ☐

D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (*if the indications are not for all designated States*)

Europe

In respect of those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC).

Continued on additional sheets

E. SEPARATE FURNISHING OF INDICATIONS (*leave blank if not applicable*)

The indications listed below will be submitted to the international Bureau later (*specify the general nature of the indications e.g., "Accession Number of Deposit"*)

For receiving Office use only

For International Bureau use only

☒ This sheet was received with the international application

11 OCT 2002

☐ This sheet was received by the International Bureau on:

Authorized officer

[Signature]

Authorized officer

ATCC Deposit No. PTA-3449**CANADA**

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

ATCC Deposit No.: PTA-3449

UNITED KINGDOM

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by an applicant in the individual case.

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

CLAIMS

We claim:

1. An isolated nucleic acid molecule comprising a polynucleotide selected from the group consisting of:
 - (a) the polynucleotide shown as SEQ ID NO:X or the polynucleotide encoded by a cDNA included in ATCC Deposit No:Z;
 - (b) a polynucleotide encoding a biologically active polypeptide fragment of SEQ ID NO:Y or a biologically active polypeptide fragment encoded by the cDNA sequence included in ATCC Deposit No:Z;
 - (c) a polynucleotide encoding a polypeptide epitope of SEQ ID NO:Y or a polypeptide epitope encoded by the cDNA sequence included in ATCC Deposit No:Z;
 - (d) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(c), wherein said polynucleotide does not hybridize under stringent conditions to a nucleic acid molecule having a nucleotide sequence of only A residues or of only T residues.
2. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide comprises a nucleotide sequence encoding a soluble polypeptide.
3. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide comprises a nucleotide sequence encoding the sequence identified as SEQ ID NO:Y or the polypeptide encoded by the cDNA sequence included in ATCC Deposit No:Z.
4. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide comprises the entire nucleotide sequence of SEQ ID NO:X or a cDNA included in ATCC Deposit No:Z.
5. The isolated nucleic acid molecule of claim 2, wherein the polynucleotide is DNA.

6. The isolated nucleic acid molecule of claim 3, wherein the polynucleotide is RNA.

7. A vector comprising the isolated nucleic acid molecule of claim 1.

8. A host cell comprising the vector of claim 7.

9. A recombinant host cell comprising the nucleic acid molecule of claim 1 operably limited to a heterologous regulating element which controls gene expression.

10. A method of producing a polypeptide comprising expressing the encoded polypeptide from the host cell of claim 9 and recovering said polypeptide.

11. An isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence selected from the group consisting of:

(a) the polypeptide shown as SEQ ID NO:Y or the polypeptide encoded by the cDNA;

(b) a polypeptide fragment of SEQ ID NO:Y or the polypeptide encoded by the cDNA;

(c) a polypeptide epitope of SEQ ID NO:Y or the polypeptide encoded by the cDNA; and

(d) a variant of SEQ ID NO:Y.

12. The isolated polypeptide of claim 11, comprising a polypeptide having SEQ ID NO:Y.

13. An isolated antibody that binds specifically to the isolated polypeptide of claim 11.

14. A recombinant host cell that expresses the isolated polypeptide of claim 11.

15. A method of making an isolated polypeptide comprising:
- (a) culturing the recombinant host cell of claim 14 under conditions such that said polypeptide is expressed; and
 - (b) recovering said polypeptide.
16. The polypeptide produced by claim 15.
17. A method for preventing, treating, or ameliorating a medical condition, comprising administering to a mammalian subject a therapeutically effective amount of the polynucleotide of claim 1.
18. A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising:
- (a) determining the presence or absence of a mutation in the polynucleotide of claim 1; and
 - (b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or absence of said mutation.
19. A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising:
- (a) determining the presence or amount of expression of the polypeptide of claim 11 in a biological sample; and
 - (b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or amount of expression of the polypeptide.
20. A method for identifying a binding partner to the polypeptide of claim 11 comprising:
- (a) contacting the polypeptide of claim 11 with a binding partner; and
 - (b) determining whether the binding partner effects an activity of the polypeptide.

21. A method of screening for molecules which modify activities of the polypeptide of claim 11 comprising:

- (a) contacting said polypeptide with a compound suspected of having agonist or antagonist activity; and
- (b) assaying for activity of said polypeptide.

22. A method for preventing, treating, or ameliorating a medical condition, comprising administering to a mammalian subject a therapeutically effective amount the polypeptide of claim 11.

<110> Human Genome Sciences, Inc. et al.

<120> ACRP-30-like Polynucleotides, Polypeptides, and Antibodies

<130> PT316PCT

<150> 60/328,419

<151> 2001-10-12

<160> 107

<170> PatentIn Ver. 2.0

<210> 1

<211> 733

<212> DNA

<213> Homo sapiens

<400> 1

gggatccggga	gcccaaatct	tctgacaaaa	ctcacacatg	cccaccgtgc	ccagcacctg	60
aattccgaggg	tgcaccgtca	gtttctctct	tccccccaaa	acccaaggac	accctcatga	120
tcttccggagc	tcttgaggtc	acatgcgtgg	tggtggagct	aagccacgaa	gaccttgagg	180
tcaagttctaa	ctggtacgtg	gacggcgtgg	aggtgcataa	tgccaagaca	aagcccgagg	240
aggagcagta	caacagcagc	taccgtgtgg	tcagcgtcct	caccgtcctg	caccaggact	300
gggtgaattgg	caaggagatc	aagtgcgaag	tctccaacaa	agccctccca	accccatcat	360
agaaaaccatc	ctccaaagcc	aaagggcagc	cccgagaacc	acaggtgtac	acccctcccc	420
catccccggga	tgagctgacc	aagaaccagg	tcagcctgac	ctgcctgggt	aaaggtctct	480
atccaaagcga	catcgccgtg	gagtgaggaga	gcaatgggca	gcggagagac	aactacaaga	540
ccacgcctccc	cgtgctggac	tcgcacgggt	ctctcttctc	ctacagcaag	ctccaccgtg	600
acaaagacag	gtggcagcag	gggaacgctc	tctcatgctc	cgtagtgcac	gaggtctctg	660
acaaccacta	cgacgagaag	agcctctccc	tgtctccggg	taaatgagtg	cgaagccggc	720
gaetctagag	gat					733

<210> 2

<211> 3522

<212> DNA

<213> Homo sapiens

<400> 2

ggcacgaggt	tggaccttcg	agcctagctg	ctcgcacagg	actcggccac	ctgcccttcc	60
tgccacagct	ggccagctca	agaggtttgg	atatggacct	tcttcaattc	ctggccttcc	120
tcttttgcct	gctttttgct	gggatgggag	ccacaggcac	cttgaggacc	tccctggacc	180
caagctcgca	gattctacag	aagatgtttg	aggtgaaagc	gcgggagcag	ctgtttggac	240
tgaaagacct	ggcacagctg	aacgacatcc	accagcagta	caagatcctt	gatgtcatgc	300
tcaaggggct	ctttaaggtg	ctggaggact	cccggacagt	gctcacccgt	gctgatgtgc	360
tcccagatgg	gccctgcccc	caggacgaga	agctgaaagga	tgctttctcc	caagtgggtg	420
agaacacggc	ctctttcgcc	gatgtggtgc	tgcgcttccc	gaggattgtg	cactattact	480
ttagccacaa	ctccaaactg	aaactctcca	tcgctggggg	tatcagtttc	tgcaaccaga	540
cgagcgtctt	caaccagggg	cccactcgc	ccatcctcag	cctgatggcc	caggagctgg	600
ggatcagtga	gaagagctcc	aacttccaga	accattttaa	aatcgaccgc	acagagtcca	660
tcccagcac	tgaccttttc	cagaaggccc	tgagagaaga	agagaaacgc	cgaaagaaag	720
aggagaagcg	gaaggagatc	cgaaaagccc	caaggaatct	cagatccccg	tctgagttat	780
agccctcggc	cagctcaggg	ctcagggggg	cacaaggagg	cagatcggga	ggaagaagag	840
gtggaggtgt	ggttgtggtg	gagagcacca	gctagccctc	tccagaaggg	gaggccacat	900
tgtcccgccc	ccctggagct	gggtctgagc	cccagctgaa	gggactgagc	ctcagatggc	960
tggattttct	ctcaggggcc	tcttctgtaa	ggggccttca	gaggatttta	tgctggaaat	1020
atgacctgct	gcagactgct	ggggggaggca	ggaggatgcc	tgctgggacc	ctgttggtgg	1080
ctgaagacct	ctggccagct	ggcttccgcc	cttggtgggg	aagcagcaga	actaggttct	1140
gagccacagg	tcaggggtgc	accttctgct	tgccccactc	gtgtcacaga	gctgctggc	1200
acaggttccc	gccccctcgc	agagacacaa	taaaagccag	cagacacctt	ggagccagca	1260
aggctgggtg	ggacactgtg	aggggaacag	ggccccctcg	ggatgtagaa	acagcttgga	1320
ggatgcctct	gccccaccag	gagggggccc	agggcctggc	agggcagaga	aggaaggggg	1380
tgggtcttgg	ctctctgggt	ctacgcctc	actcgcttgg	acaaatgatt	gtgtcttggg	1440
aaggacctgg	aagtgccttg	ggacctggga	aacatttagc	tcaagaagac	cttgagagcaa	1500

catgatccct	gtccctcagat	gtctggggac	agtcatttag	caagcacagg	gaagtcagct	1560
tgttctctct	ggcagcgtcg	gaagacagct	aacctgtggg	tggggggctg	cagggggaga	1620
ggcccgagct	ctgcagagag	ccgtgctccg	caatggctgc	cccaagctgc	atgggtcaga	1680
cagcttcccc	tctcggaagg	ccacagggca	gggaagctcg	agagggcatg	tggccctggg	1740
tagggcagct	gcccttcact	catgcccttc	ccaagcacag	gagggaaagg	ctttagtgag	1800
aattctagct	ctgcctcttt	gaccttgcca	agtcaggatc	tgccctctaa	aggagcagag	1860
aaaaccctcc	agatcccttc	gacacccagc	ccctaccac	tgacagagca	caagttagat	1920
ctcagtggtt	gcccttcaga	tttgctgact	ggccttgccc	ccccctccc	tgtgctgcag	1980
cttcattagg	aaaatgaatt	tgatggatc	tgatcccc	gcccagccct	aacctgttct	2040
tctgaggtct	gccctccaac	ggggctgcag	cagcaaaagg	aaagcaagcc	ttgagaaga	2100
ctcatggaag	ggccccaagc	atcctgcacc	catcagttac	tcggaagtta	ggggacaacc	2160
agcagctcga	agagagagct	gtgtgggggc	tgggagagat	gctggagaaa	tttccccatc	2220
agaaggcccc	tacactggcg	gtggaggcag	ggcagtggtg	tgggactcag	ccaacagaca	2280
tagttttcat	tccacctctg	ccttctcagg	ttgtgtgacc	ccagccacat	ggacacccca	2340
gtctgtgaac	taaaaggctg	gtccatggca	ttaacagtgg	agggtgtcca	ggttcttgat	2400
gtcttgaaca	aagaattggg	caaaatgcac	aaagcaagga	aggaaatga	ggttttacc	2460
agaatgaaag	tatactccac	agcatgggag	agggcctgag	catagggaat	caaggacccct	2520
gttacagaat	ttttgggagt	aaataccacc	tagaggattc	catgtgttac	ttgaggtaca	2580
ccctatgtaa	atggaaagga	tgaagtaaat	ttacaatttc	atttacagca	cttaacctat	2640
ggggaggata	ttccctgtta	tagctgaagc	gtgaattggc	cttatgttcc	ctgctccag	2700
acctattttt	cctgcataca	cgggaaaagg	tcagattcac	tgctcagctc	gttttaacctg	2760
tcttggttgc	agcagctcga	gctgggtgtc	aggaccagcc	cgaagctctc	tcctgcctgg	2820
aaggaccagg	cagactgcctg	tctttttcat	gctagagagt	ggttgtgggt	tgctgacttag	2880
cagagaagggt	gcttggcctt	ccctttaatc	ggagaaaaaa	ctttcttaaga	accaggcctg	2940
gttgcagcag	gaactagctt	tcttgggggt	gcagggagcc	taaaagcatac	ctcaggagacg	3000
tcagtggttg	gtccagctctt	ggctggagggt	tctttctact	gaataacttc	tacgggctct	3060
gtcattagca	ggatttgtat	aaattgaagc	agagctgggc	agctcagagc	caatggggaa	3120
gccagccagc	gtgtgtggca	agacctgggc	aacttgggac	cagcctgggc	tgctctctgc	3180
cagcttgtgt	tatcacagca	aggctcttca	cactcagatc	cttggggccc	cagctctgca	3240
atgcgccagt	gtttaaaggga	tgaacctctg	aatttaagt	acttctcagt	gatgtgtgcc	3300
ctctctcgag	gggttcctgt	tcataccatg	tatttactga	ctgctctgta	tatatcgaga	3360
gccaaagagt	ggggccttgt	cttgaacctat	ctcctcatct	gccccctctg	gcacctcctt	3420
ccctcctggc	tctttctctc	aataccgtca	tctctctccc	aactcggtta	atcctgtcct	3480
tcttgccctc	aaatggggac	cttcaaaaaa	aaaaaaaaaa	aa		3522

<210> 3
 <211> 2007
 <212> DNA
 <213> Homo sapiens

<400> 3						
ccagcgctcc	gcgcgcggag	ggcgctggt	gcagcatggg	cgcccgccgg	gcttgggggc	60
tgtctctgct	cggtgctcctg	ctccggggag	gcgcgcgtgc	gtggagacat	ggggcagctc	120
cgtttctccg	acgcaggaaac	tgtgtctcct	atgtgtgtgac	ccgcaccate	tcatgctcatg	180
gtcagaatgc	cacctacctt	cagcgagtgc	tgcagaactg	ccctctggcc	atagctgttc	240
cgaggaagcag	ctacagaaact	gtgttgagac	accatacaaa	ggtgatgtac	aagatagtga	300
ccgcgcctga	gtcgaggctg	tgccctgggc	actcaggagt	gagctgcgag	gaagttgcag	360
cttctcctgc	ctctctgagc	cccatgtggt	cgggcagtat	catgcggcgg	atgtgcctctc	420
ggccccaagc	cttctcaagt	tgtctcaact	gcagcaaatg	gtcagagctc	acagcagcgc	480
tgaaggtgct	ggagggccaag	atgaccatgc	tgaactgtcat	agagcagcca	gtacctccaa	540
ccacagctac	ccctgaggag	cctgccccgc	tctggggctc	ccctcctgcc	caggggcagcc	600
ccggagatgt	aggcctccag	gaccaagtgc	gtgcttgggg	gcttcccgcc	ccaccggccc	660
ccaaaggaga	tgcgcgcagt	cggggcccaa	tggggatgag	aggccccaac	gggtccacagg	720
gcccccagag	gagccctggc	cggtctggag	ctgtggggac	ctctggagag	aggggacctc	780
ctgggccaac	agggcctcct	ggccccctgc	ggcccccagc	ccctgttggg	gcccccctatg	840
ccggatcttc	ccagctcaga	gacccattgc	tgtccaaacac	cttcaactgt	accacaaccc	900
actggcccac	gggacccact	gggcctccag	gccttccagg	gcccatgggt	ccccctgggc	960
ctctcgccgc	cacaggtgtc	cttgggagtc	ctggttaacat	aggaccacca	ggccccaactg	1020
gaccacaagg	aatctctggc	caccagagag	agaaggcgga	gagagagactg	cgtggggcag	1080
ctggcccaca	aggctctgct	gggcagcggg	gggaacctgg	ccctaaggga	gttgggtgtg	1140
agaagagcca	ctggaaccag	agctggggtc	tggggcgggc	cctgcggcga	caggcaccctc	1200
cagcctctct	cggggcgaaga	ggggcggaac	tgcacccaac	taccggatcg	tggccccacg	1260
gagccgggac	gagagagctg	gaggggtggt	gcggccccct	aggcagaccca	ggccagagctt	1320
ccccctccag	cttgaactggc	ccagctgcct	ccagggacgc	cccgctcata	tttataatgtg	1380
tctctcaggt	cccttctgcc	atctaggcct	taggggttaag	caggtctctac	tccctggcac	1440
atgcacatgt	cttgagctga	gcgaaggcctg	agaggagag	cttgggcttc	agttctctctc	1500
tgtgaagtgtg	ggggaggcag	gccttcaagg	agggatagag	gtacaaggct	tctgtctcttc	1560

tgctgtctga	gcattccaggc	ccaaaaggcac	tgaggaggatc	aggagctggg	gctcgcacaa	1620
tcagagagatg	acagggcagg	gggcagctctt	cctccccttc	cccgaccaaa	cctcggggag	1680
ccctctgtgt	ccctctcttc	cttgtgtgtcc	agtgctgggt	ccccaccce	gaagctcaggc	1740
tgcccaatcc	tctgactgga	tcaccggggg	cttcttgcct	cagttctctcc	ctctgagccc	1800
ccaggccctc	ccgcatctca	ggttggggat	ggggacatgg	agaggaagg	ggcgctact	1860
ctctgcaaatg	cttgtgacag	atgccaggag	gtagatgtgt	gctggccaat	aaagcccctc	1920
acctgattcc	ccgcaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	1980
aaaaaaaaaa	aaaaaaaaaa	aaaaaa				2007

<210> 4
 <211> 901
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <222> (872)..(872)
 <223> n equals a,t,g, or c

<400> 4						
ccacgcgtcc	gcccgcgggg	ctgctgcagg	gtctgagccc	cggaacgggt	gtggtggtag	60
ctcccacggc	gtcccactgg	gcccctcacc	tgtctctctc	ccccccagc	gggactctct	120
cggtcccoca	ggacctccag	gtgcagaagt	gaccgcggag	actctgcttc	acgagtttca	180
ggagctgctg	aaagaggcca	cggaagcccg	gttctcaggg	ctcttggaac	cgctgctgcc	240
ccaggggggc	ggcctgcggc	tgttgggcga	ggcctttcac	tgcgggctgc	aggggtcccc	300
ccgggtggac	aagcggacgc	tgttggagct	gcattgtttc	caggctcctg	ctgcccacag	360
tgccttctct	cgaggctcgg	gtctgagcct	ggcctcggtg	cggttcacgg	ccccgtgttc	420
cggcattctc	cagtctctct	ccagtctgca	cgtggaccac	agtgagctgc	agggcaaggc	480
ccggctcgcc	gcccggggag	tgtgtgtgtg	tctcatctgt	attgagctcc	tgtgccagcg	540
ccacacgtgc	ctggaggccg	tctcaggcct	ggagagcaac	agcagggtct	tcacgttaca	600
gggtgcaggc	ctgctgcagg	tgcaggctgg	acagtacgct	tctgtgtttg	tggacaatgg	660
ctccggggcc	gtcctcacc	tccaggcgcc	ctccagcttc	tccgggctgc	ctctggggac	720
gtgagggggc	ccaggggggc	tggcgaggag	ctgcggccgg	atccccggga	ccccctact	780
gatgcccgtg	gtcaccacaa	taaaagagcc	tccaccycga	aaaaaaaaaa	aaaaaaaaaa	840
aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	900
g						901

<210> 5
 <211> 1558
 <212> DNA
 <213> Homo sapiens

<400> 5						
cgagaaacgc	cgcttccgct	tctgtctgca	gagacctcgg	agaccgcgcc	ggggagacgg	60
aggtgctctg	ggtggggggg	acctgtggct	gctcgtaccg	cccccaacc	ctctcttctg	120
cactgcgcgt	ctccgggaag	ccttttcccc	tgtctgtgtt	ccttcaccga	gtctgtgcat	180
cgcccgggac	ctggccggga	ggagccttgg	ccggcgggag	atgctctagg	ggcgcccgccg	240
gaggagcgcc	cgccggggag	gagggcccg	caggaaagat	ggctcccgtg	gacaggagact	300
cttgcctggc	tactgctgc	tccttgcctt	tgcctctggc	ctgttcttga	ctgcgctgcc	360
ccatgtccag	ggggaacagc	aggagtggga	ggggactgag	gagctgcccgt	ccccctcggg	420
ccatgcaggag	agggcttgaag	aaacaatga	aaaatacagg	cccagtcagg	accaggggct	480
ccctgcttcc	cggtgtgttc	gctgctgtga	ccccgtacc	tccatgtacc	cgccgacggc	540
cgctccccag	atcaacatca	ctatcttgaa	aggggagaag	ggtagcccg	gaga tcgagg	600
ctcccaagg	aaatattgca	aaacaggctc	agcaggggcc	agggggcaca	ctggaccacaa	660
agggcagaag	ggctcctcgg	gggcctctgg	ggagcggtgc	aaagagcaact	acgcgcctct	720
ttcgtgtggc	cggaagaagc	ccatgcacag	caaccactac	taccagacgg	tgatcttcga	780
cacggagtct	gtgaaccttc	acgacacttc	caacatgttc	accggcaagt	tctactgcga	840
ctgtcccgcc	ctctacttct	tcagctctca	cgtgcacacc	tggaaaccaga	aggagacata	900
ctctcacatc	atgaagaacg	aggaggaggt	ggcgatcttg	ttcgcgcagg	tggcgacacc	960
cagcatcatc	caaaagccga	gcctgatgct	ggagctgcga	gagcagcagg	aggtgtgggt	1020
acgcctctac	aagggggaac	gtgagaacgc	catcttcagg	gaggagctgg	acacctacat	1080
caaccttcagt	ggctcactgg	tcaagcacgc	caccgagccc	tagctggccg	gccacctctc	1140
ttctctctgc	cactctccac	ccctgcgctg	tgtctgaccc	agggctcacc	agagagctga	1200
ccccacggcc	tcttccccga	tcctctgact	ccgactctct	ggcctttggga	tctacttgaga	1260
cgccctgaac	acacagaaga	ccaaagcgat	cgggtctccc	agatcccga	ctctgtgga	1320
agagctgacg	gcagatgaaa	tcacaggggc	ggggcaccgc	cgagaaacct	ctgggacctt	1380

ccggcgccct	ctctgcacac	atctcgaagt	gaccccgcac	ggcgagacgc	gggtggcgcc	1440
agggcgctcc	aggggtcgcc	accgcggtcc	cagtccttgg	aaataattag	gcaaatctca	1500
aagggtctca	aaggagcaaa	gtaaacctgt	gaggacaaag	aaaaaaaaa	aaaaaaaaa	1558

<210> 6
 <211> 1313
 <212> DNA
 <213> Homo sapiens

<400> 6						
ggcagcagcc	tagagagggc	agactatcac	ggtgccggcg	gtgagaatcc	agggagagga	60
gcggaaacac	aagaggggca	gaagaccggg	gcacttgtgg	gttgacagac	ccctcagcca	120
tgttgggagc	caagccacac	tggtaccag	gtcccttaca	cagtcccggg	gtgcccttgg	180
ttctggtgct	tctggccctg	ggggcggggt	ggggccagga	gggttcagag	ccctcctctg	240
tggaggggga	gtgctgtgtg	gtctgtgagc	ctggccgagc	tgctgcaggg	ggggccgggg	300
gagcagccct	gggagagcca	ccccctgggc	gagtggcatt	tgctgcggtc	cgaagccacc	360
accatgagcc	agcaggggaa	accggcaatg	gcaccagtgg	ggccatctac	ttcgaccagg	420
ttctggtgaa	cgagggcggt	ggctttgacc	gggcctctgg	ctccttcgta	gccctctgtc	480
ggggtgtgta	cagcttccgg	ttccatgtgg	tgaagtgta	caaccgccaa	actgtccagg	540
ttagcctgat	gctgaacacg	tgccctgtca	tctcagcctt	tgccaatgat	cctgacgtga	600
cccgggaggg	agccaccagc	tctgtgttac	tgcccttgga	ccctggggac	cgaatgtctc	660
tcgcgctggc	tcgggggaat	ctactgggtg	gttggaataa	ctcaagtttc	tctggtctcc	720
tcactctccc	tctctgagga	cccaagtctt	tcaagcacaa	gaatccagcc	cttgacaact	780
ttctcttgcc	ctctcttgcc	ccagaaacag	cagaggcagg	agagagactc	cctctggctc	840
ctatcccaac	tctttgcatg	ggaccctgtg	ccaaacaccc	aagtttaaga	gaagagcaga	900
gctgagagca	ggtatataca	gctggaagtg	gaccatggaa	aacatcgata	accatcatc	960
ctctgtgctg	gcacactcct	gaaactgctc	cacctttgaa	glttgaaact	tagtccctcc	1020
acactctgac	tgtcgctccc	ttctctccag	ctctctcact	gagttatctt	cactgtacct	1080
gttccagcat	atcccctccc	tctctcttcc	tctctgatct	tgctgtctta	ttctctctcc	1140
taggtcttct	atatactggg	attccatgat	tcatctcttc	agaccctctc	ctgcagatgt	1200
gctaaacctc	ccctctctct	ttcttatccc	gctgaccat	tgggccagcc	tggatgaatc	1260
tatcaataaa	acaactagag	aatggtgaaa	aaaaaaaaa	aaaaaaaaa	aaa	1313

<210> 7
 <211> 1312
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <222> (27)..(27)
 <223> n equals a,t,g, or c

<220>
 <221> misc_feature
 <222> (1204)..(1204)
 <223> n equals a,t,g, or c

<220>
 <221> misc_feature
 <222> (1225)..(1225)
 <223> n equals a,t,g, or c

<400> 7						
gtggcgccct	ctgtgtgctg	tactgcnccg	ctgctgcccc	gtggcgccgc	agaagcacac	60
ggagccccatc	gtgcttgagg	gcaagtgcct	ggtggtgtgc	gactccagcc	cgtcgccgga	120
cgggcgccgtc	acctctcccc	taggcatctc	cgtgctctcc	ggcagcgcca	aggtggccct	180
ctccgcacag	cgagagacca	accacagacc	gtccgagatg	agcaaccgca	ccatgacctt	240
ctattttcag	caggtatctag	taaatatttg	caaccacttt	gatcttgctt	ccagtatatt	300
tgtagcaccg	agaaaaagga	tttatagctt	cagcttccac	gtggtcaaa	gtgataaacg	360
acaaaccatc	caggtcagtt	taatgcagaa	tggtctacca	gtgatctctg	cctttgcagg	420
agaccaggat	agctccagag	aagctgctag	caatggcgctg	ctgctgctca	tggaaaggga	480
agacaaagtg	catctccaac	ttgagagagg	caacctcatg	gggggctgga	aatactccac	540
attctcgccg	ttcttgggtg	ttctctctata	aacacagagc	ccccatagatg	gtggggggaat	600
ggcgaactgtg	accaggagct	ccggcccttta	aaacaccctg	aacttactgtg	aattggacac	660
ctgttttcca	acctccgtca	gactgttgta	gtagaagaat	gatttccctt	gaaacctcca	720
gtacttttkt	ttttgttttt	tggaaactctg	acaattctct	gggaacctctg	cctctaatta	780

gttttagatg	acaaggtctt	aaggagaaat	gaaattatcg	atttgagcaa	tttgtacctg	840
tgattgtaaa	gtcaatatcg	gattttatcg	ttgggacat	ggacctctt	tggtttgatg	900
ttgtatgttc	gtcccaacgg	aaggagagct	ccgtactcca	ggatgggctg	caggttgacg	960
tacgggcttg	aagttagagc	ccagcaaaag	accactgctt	ggacagtctt	tgcatgtgtg	1020
tctgtgtgtg	tctgtatagc	cttaagaaaa	agaatggctt	cactttcatt	ctgtattctt	1080
ccccccacca	tgtgtgtggg	aggacttggg	agggggatgg	ggacattggg	gaacctgttc	1140
aagaagtgtt	ttatccagag	aagcaaatct	ttgcacgatt	gggactgcaa	tttgtttttt	1200
gtanttgttt	gtgttttttc	cttgnaaaag	ctttactttt	cctttccaca	ctcagctctt	1260
ccctctctca	ccccattttt	aatttttctt	tgccgggggt	tgaaggagag	aa	1312

<210> 8
 <211> 1022
 <212> DNA
 <213> Homo sapiens

<400> 8						
cgacgcaggg	cttgcggggc	cgcatggccc	gacgcggccc	cgacggcgcc	ccccggggctc	60
cgagagagaa	agcgagggcg	gggagggccc	gactgcggcg	acctcgaggg	gacccccgggc	120
cgcgagagaa	ggcgggaccc	ggggggccca	ccgggctctg	cggggagtgc	tcgggtgcctc	180
cgcatctccg	cttcagcgcc	aagcgctccg	agagccgggt	gcctcggcgg	ctcgacgcac	240
ccttgccttt	cgacgcgctg	ctggtgaacg	agcagggaca	ttacgacgcc	gtaccggcca	300
agtctacctc	ccaggtgcct	ggggtctact	acttcggcgt	ccatgccacc	gtctaccggg	360
ccagctctga	gtttgatctg	gtgaagaatg	gcgaatccat	tgctcttttc	ttccagtttt	420
tcgggggggtg	gcccagacca	gcctcgctct	cggggggggg	catggtgagg	ctggagcctg	480
aggaccaaag	gtgggtgacg	gtgggtgtgg	gtgactacat	tggtcatctat	gtgctctgag	540
agacagacag	ccacttctcc	ggattttctg	tgactctcga	ctggcacagc	ccccagctct	600
ttgcttagtg	cacactgcac	agtgaagctc	tgctctcact	ccatagaagg	gggtgtgagg	660
ctgacaccca	ggatcatccg	gagggctggc	ccccctggaa	tatttgtgaat	gactagggag	720
gtggggtagt	gcactctccg	tcctgctgct	ggcaaggaaat	gggaacagtg	ggtgtctgct	780
atcaggtctg	cgacgtccgg	gcagtggtct	gattttctgc	caagaccaga	ggaggtgtgt	840
gtgctggcaa	gtgtgaagtc	ccagtgctct	ctggtccagg	agccccaggt	ggggtgctct	900
cttctgtgtc	ctctgctctt	ctggatctct	ccccccctct	ctctgctctg	gggcccggcc	960
ttttctcaga	gatacctcaa	taaacctaa	aacctctaaa	aaaaaaaaaa	aaaaaaaaaa	1020
aa						1022

<210> 9
 <211> 1254
 <212> DNA
 <213> Homo sapiens

<400> 9						
acgcgtccga	gcagatctga	ggacatctct	gtgcagggcc	agaaaccgcc	cacctgcagt	60
tcctctctcg	ggatggagct	ggggcccgag	tcctgtcccc	cacttgggct	gaagctgctg	120
ctgctctctg	tgtctgtctg	cttcaggggc	caagccaaca	caggctgcta	cggtatccca	180
gggatgcccg	gcctgcggcg	ggcaccaggg	aaggatgggt	acgacggact	ccggggggcc	240
aagggggagc	caggaaatcc	agcaatcccg	gggatccgag	gacccaagg	gcagaaggga	300
gaaccggcgt	taccggcca	tcctgggaaa	aatggcccca	tggaaccccc	tggtatgcca	360
ggggtgcccc	gccccatggg	catccctgga	gagccaggtg	aggaggggag	atacaagcag	420
aaattccagt	cagtgctcac	ggtcactcgg	cagaccacc	agccccctgc	accacaagc	480
ctgatcagat	tcaacggctg	ctcaccacac	ccgcaggagat	attatgacac	gagcaactgg	540
aagtttcacct	gcgaagccc	cggtctctac	tactttgtct	accacgcgtc	gcatacagcc	600
aaactgtgtg	tgtctgtcta	ccgcagcgcc	gtcaaaatgg	tacactttctg	tgccccaacg	660
tccaaaaacca	atcagctcaa	ctcggggcgt	gtgctgctga	gggtgcaggt	ggcgagagg	720
gtgtgtgtgg	gtgtcaatga	ctactacgac	atggtgggca	tcaggggctc	gcacacgctc	780
ttctccgctt	tcctgtctct	ccccgactag	ggcgggcaga	tgctctcgag	ccccacggcg	840
cttccactct	ctccagcttc	ctgcattggc	ccacttact	ggccagcttg	caacttggc	900
tagacacatt	tcocccacag	atggactctt	ctccagggga	gcccacacct	accacacccc	960
actgaacccc	ctcccatggg	gttctctctt	tcctctgaac	ttcttttaga	gtcactgtctt	1020
gtgtgtgtct	tggtgacatt	aaccaatgcc	ttctggtact	gccattcttt	tttttttttt	1080
ttttcaagta	tttgaagggt	tggtggagata	tataaataaa	tcagtgaatt	aaataaataa	1140
aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	1200
aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaa	1254

<210> 10
 <211> 1618
 <212> DNA
 <213> Homo sapiens

```

<400> 10
ccacgcgcgtcc gcaaggagacc agaggccatg cagtggctca gggctcgtga gtgcgcctggg 60
ggagccacag gacacaaggc cacatggggg acagcgccc tgggtcccggt ctgggcacgg 120
ctctctgctct tctctcgtat gtgtgagatc cctatgggtg agctcaacct tgacagagct 180
gtggccagct actgcacacg gtgctgtgac tctgaggacc cctctggatcc tgcctatgta 240
tctccagcct tctctccggg ccgcccccaac gcccctgctt agatcagacc ctacataaat 300
atcaaccaacc tgaagggtgta caaaggggac ccaggcccac tgggcctgcc aggttacatgt 360
ggcagggaagg gtcccacaag ggaagcctgg cctcagggca gcaagggtgta caagggggaag 420
atgggcagcc ccggccccc ccgtgccaaag cgcttctctg ccttctcagt gggccgcaag 480
agggccctgc acagcggcga ggaactccag acgctgctct tcgaaaagggt ctttgtgaac 540
cttgtatgggt gctttgacat ggcgaccggc cagtttgtgt ctccccctgcg tggcatctac 600
ttcttcagcc tcaatgtgca cagctggaaat tacaaggaga cgtacgtgac catatgcat 660
aaccagaaag aggcgtgcat cctgtacgag cagccacgag agcgcagcat catgcagagc 720
cagagtgtga tgctggacct ggccctacggg gaccgcgtct ggggtgcggct cttcaagcgc 780
cagcgcgaga acgacctcta cagcaacgac ttgcacacct acatcacctt cagcgccac 840
ctcataaagg ccgagcagca ctgagggcct ctgggccacc ctcccggctg gagagctcag 900
ctgataccggc atcctgcgag aagacctgcc ctctcactg ggaatccccct cctgcctcct 960
cccagggtct tgccaggggc ttgctcagtc ccttccacca aagtcatctg aacttccgtt 1020
tcccaggggc tccagctgcc ctacagacct gatgtctgtc cccaggtgct ctctgccctt 1080
catgccccct tcacggccc agtgcccga ctctccaggc tttatcaagg tcttaaggcc 1140
cgggtgggga gctctctgct tcagagccct cctccggcct ggtgctgcct ttacaaacct 1200
ctcaggagga agggccacga aagccccagg ctttagagcc ctacagaggt ctggggagct 1260
agagcaaaag atggacctca ggccttccgt ttcttcttcc aggggtgggt ggcctgggtg 1320
tccccatgac ttccaaaccc aggtggcctg ccttcttccc cagaggggag cccctccgc 1380
ccattgggtgc tcatgcagac tctggggcgt aggtgccccg ggggtgtgat tctgggtctc 1440
acagtcgaggg gagccgtgag tccatggcca gatgacggaa acagggctctg accaagtgcc 1500
agggaagacct gtgctataaa ccacctctgc tgatcctgcc cctgcctgac cccgccacgc 1560
cctgcctctc agcatgatta aagaatgctg tctctctgtg gaaaaaaa aaaaaaa 1618

```

```

<210> 11
<211> 1336
<212> DNA
<213> Homo sapiens

```

```

<400> 11
ggcagcagct ggtaccaaa caagtttttc actgagctct catgaaagat cctcagcttc 60
ttgtggattt agaattctgc agcagccacc catctaagag caaagaccac agatgtttgt 120
ctgtctctat gttacaagtt ttgccatttg tgccatggga caaccocggg ctaaatcagtt 180
gaaagagagat aactactccc ccagggttat ctgcagcat cctggcttgc ctggacctcc 240
agggccccct ggagcaaatg gttccccctg gccccatggt cgcactggcc ttccagggaag 300
agatggtaga gacgycagga aaggagagaa aggtgaaaaa ggaactgcag gtttgagagg 360
taagactgga cgcctaggtc tgcgggtgga gaagggggac caagagaga ctgggaaga 420
aggaacctata ggaccagaag gagagaagg aagagagacc ggggtgcctt ggaattggtc cctctggacc 480
aaggggagga aagaatcgct ttctgtttg catcacaaac agctaccacg aagaagaact 540
catctgtctc aaatcgctc ttctgtttg cagggaatct ttacttttat tgatatact cactgtctaa 600
acctattata tttacaagg tctcttcaa cgagggaag catcaaac ctgcacagg 660
gaaagtctatc tgtgctttcc cagggaatct ttacttttat tgatatact cactgtctaa 720
taagcatctg gcaatcgagc tggtagacaa tgggcaatc cggataaaga cctctgacgc 780
caacaacagga aacctatgat tggcttcggg tgcctcagtc atctatctgc agccagaaga 840
tgaagtcttg ctggagattt tcttcacaga ccagaatggt cctctctcag acccagggtg 900
ggcagacagc ttattctccg gttttctctt atacgttgac acagattacc taagtctcat 960
atcagaagat gatgaattgt gatcaggacc aagatccctg ttgtaaaacac tctgatgtga 1020
tctggggttc cagaagtgtg aacaagcagg aatgggattc aaagagactc ccaactcagt 1080
tctaaagcat ttaaagacaa ttctagcaga atttatcaaa acagatgaa acacagaaaa 1140
gttgaaacac caacaaatgt aattctatta aagaatagcc cagagatata attctcttga 1200
aagcaatggt cataaatatt taagcaaat aaagacaagt ttaacaatatt tctattataa 1260
tgccctgagt gataaaacca gttggcaata atattgctt attaaattct caaaaaataa 1320
aaaaaaaaa aaaaaaa 1336

```

```

<210> 12
<211> 1114
<212> DNA
<213> Homo sapiens

```

```

<400> 12
ggcagcagga gcttctttgc tccggagccc cctggagctg gcgggcagcc gcgagggtaa 60

```

```

ccaccatgat cccctgggtg ctectggcct gtgccctccc ctgtgtgtgt gaccactgc 120
ttggcgcttt tgcctgcagg gacttcggga aaggctcccc tcaactggtc tgcagctgc 180
ctggccccca gggccacacc gggccccacc gagccccagg gccctcagga atgatggac 240
gaatggcttt tcttggcaaa gacggccaaag atggacacga cggcgaccgg ggggacagcg 300
gagggaaagt cccactctgc cggacagggt aacgggaaag gccaggacca aagggcaagg 360
cgggggcat tggggcggtt gggcccggtt gggccaaagg ggtcaacggt acccccggga 420
agcatggcac accaggcaag aaggggccca agggcaagaa gggggagcca cgcctccag 480
gccctctcag ctgtggcggt ggcataacca agtcagcttt ctcggtggca gtgaccaaga 540
gtctaccacc ggagcggtgt cccatcaagt ttgacaagat tctgatgaac gagggtggcc 600
actacaatgc ttccagcgcc aagtttgtct gcggcggtgc tgggatctac tacttaacct 660
acgacatacc gctggcccaac aagcacctgg ccatcggtct ggtgcacaa cggcagttacc 720
gcataccgac cttttgctgc aacacggcca accacgatgt ggcctcagge tccaccatcc 780
tggctctcaa cagggggtgac gaagtlttggc tgcagatctt ctactcagag cagaacgggc 840
tcttctatga ccttactggt acagacagcc tctttacggg cttcctaatt tatcgcgacc 900
aggatgacc caacagggtta tagacatgcc acggcggttc tccaggcagg gaacaagctt 960
ctggactgtg gcttacagag caagacccca caactgtagg ctgggggttg ggggtcgagt 1020
gagcgcttct gagctcagcg tcaactcttc tgccctcttt ttccctcttc attaaatcca 1080
aaccttttta tctatcaaaa aaaaaaaaaa aaaa 1114

```

```

<210> 13
<211> 659
<212> DNA
<213> Homo sapiens

```

```

<400> 13
ggcacagcac ggcagctctg gtgggtctgg acgctggccc cggggccggg caccaaccac 60
tcgctcttgc caccaggttc gtcaacattg cgaggcgact cgagcgcggt gccggcggtg 120
tcgctctgct tctgcggcgc gctactctct tctccttcac gctgggcaag ctgcccgcgt 180
agacgtctgc ggttaagctg atgaagaacc gcgacgaggt gacggccaat atttacagac 240
acggcgctgc cggcgccgcg gagatgcaga gccagagcgt gatcttggtc ctgcccggcg 300
gcgacgcgct cggtctgctc agccacgacc acgacggcta cggcgctctc agcaaccacg 360
cgaagtacat caccttctcc ggcttctctg tgtaccccga cctcgccccc cggcgcccgc 420
cgggcctcgg ggctctggag ctactgtgag ccccgggcca gagaagaagg cggcgcccgc 480
agggcgctgc atgcacggcc gggcccgagg ctcgaaagtc ccgcgcgagc gccacggcct 540
cgggcgctgc ctggactctg ccaataaagg ggaagcgagg caccgcgacg ccccgcgacg 600
ccaggaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 659

```

```

<210> 14
<211> 1195
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> misc_feature
<222> (1147)..(1147)
<223> n equals a,t,g, or c

```

```

<400> 14
ccacgcgctc cgggggacag tgaggggacg ggaagggggc cagcctgctg gkccatggga 60
ggggacagctc aggggaaagc ccttcccgcg tctggggaag ggaacttcgc cttcgagcgc 120
agggcagtag gctctcggtc cctgtgtcca ctgctgctca gccacgtggc ctcacaggac 180
accagctctc caggaggcgt ctgacacagt atgatgatga agatcccatg ggcagccatc 240
ccagtaactga tgttctctct gctcctgggc ctaatcgata tctcccaggg ccagctcagc 300
tgcaaccggc ccccgcccat cctggcctcc cggggtatcc ctgggacacc tggcccgcgt 360
ggccaactct ggagcccgag gataaaagga gagaaggggc ttccagggct ggcctggagac 420
cttggtgagt tcggagagaa gggagaccca gggattctct ggaatccagg aaaagtctgc 480
ccaagggccc ccatggggcc taaaggtggc ccagggggccc ctggagcccc agggccccaa 540
ggtgaatcgc gagactacaa ggccaccagc aaaaatcgctt cttctggcac aagaaccatc 600
aacgtccccc tggcccgagg ccagaccatc cgcttctgacc acgtgatcac caacatgaac 660
aacaatttat agcccgcgag tggcaagttc acctgcaagg tgcgggtct ctcactcttc 720
acctaccacg ccagctctctg agggaaacctg tgcgtgaacc tcatcgctgt ccgggagcgt 780
gcacacaggc tggctacctt ctgtgaatat cctctacaac ccttccaggt gaccaccggt 840
ggcatgtgtc tcaagctgga gcagggggag aacgtctctc tcagggccac cgacacgaac 900
tcaactacgg gcatggaggg tgccaacagc atcttttccg ggttctctgt ctttcagat 960
atggagggcct gacctgtggg ctgcttccaa tccaccccgg ctcgccctgc cagcaacgct 1020
cactctacc ccaacaccac ccttgcacca gccaatgcac acagtaggcg cacttgaagt 1080
ctgctgagtg aatgagtaaa taaactcttc aaggccaaaa aaaaaaaaaa cacttaagta 1140

```


ttcatcnaac aatcaccgag tagcgggtgat ccagactgaa aagatgcgag acgcc 1195

<210> 15
<211> 3951
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<222> (3871)..(3871)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (3903)..(3903)
<223> n equals a,t,g, or c

<400> 15
gagctccacc gcggtggcgg ccgctctaga actagtgatg cccccgggct gcaggawttc 60
ggcagcgagag ctgctccgctg ctggaggggaa gtgagagttt tattcaggct cagtacaact 120
gtgctctggaa cgcagtcgcc tgcctgctgg cgcctgggtgta tcgagtgaac tcagagacct 180
gatatgctac taggtataag acagtgcac agttgggaatg gaggtgctgt cctggcttta 240
gaggggggaga ttgccaaaga ggtcccaaaag accccgtgaa gaccctccgc cccacgcccgg 300
ctcgccctcg aaacagcttg aagaagacca cagataatga acccagccaa ttctcagagc 360
ccaggaaagac ttgttcccca actggtacag cacaaaccaag ctgggggggta gatccaaaag 420
aggggccctca ggaactctcag gaaagaaga tacaggtgct agaggagaaag gtctctcgac 480
tcacaaggac ggttcttgac ctccagttct ccttgcctgg agtgagtga aatctcaaac 540
atgccaactca ggtatgatgcc agtagaacac gggcaccagg gctcagcagc cagcaacca 600
agcctgcacac cactgttagt ggagacacag aaacggggcca gagtctctgt gtcttcaaca 660
ctaaggatc tgccatgaag gacatcaagt ctgaattggc tgaagtcaaa gatactctaa 720
agaaacaaag tgacaagctg gaagagctgg atggaaaagt gaagggctac gaagggcagc 780
tcagacagct ccaggagaaga gctcaggggc cgacgggtgac catgacaacc aacgaactct 840
accaagccta tgtggagact aagatcgacg cctcgagaga ggagctcatg gagggtcag 900
acagaaaagt ggcctgacct aaaaactcat gtgagtacaa gctcactggc ctccagcagc 960
agtgctgata ctatggggagc agctacactgg gagtgataga ggtcataagg gagaaggaaa 1020
caagcctgag aaaaagaata aataacctcc gagcccgct acaggagctc tcagcccagg 1080
caaatgtgtg cgcagctgaa aagaattggg acatttggtc acagatcaag acattggacc 1140
agaaaatcga gagattgct gaagccacca gaattgctgaa tggaaactg aatgagtgag 1200
ttgacgccct tatagttcca gagccagatg tggattttga tgcaaaactg aatgacctcg 1260
atgcaggagt caattgtagc gagaagaacg ctgaagaaca ttgcttttac attaggaaa 1320
cccttcgggg ccgcatataat ggagaggtgg gtgacttgaa cgactgtgt aatcagaaa 1380
tcagctctct ggaagaccgt ctggggagcg ttctctctaca gatgaccaat aacactggtg 1440
cagagctcag tcccaccagg gcagcagccc tgccaggagt gtcagggtca ggaatgaac 1500
gggtcatagt ggaattaaac cacttgaagg acaaagtcca agttgtgaa gacatttgcc 1560
tgctgaactc ccagggaagac cctcatggga tggaaaggtgc cttgccaaac agggaaagacc 1620
gcgcagctac gcagcagctg cacttttga aatctctcaa gcacacagat cacaggaagt 1680
ttcagaagaa cgacaacacc atccagaacac ttcaacagga ttttagtttt ctttattctc 1740
aattaaacca cacagaaatc gatgtgactc atcttcaaaa ggaatgtagc aatctgagag 1800
caggtgataa cgtctgcctag ggtaggttca ctaaggtggg tgagcaagaa aggcagatgg 1860
accccggggc gtcccccacg caccocgtgg ctcatgtctg cagtcaagtg gaggagaggt 1920
ggcagagatt gcagagccag gtcatctcgg agctggatgc ttgtaaggaa tgcacgagc 1980
gggtccagag ctggaagctct atggtggagg gcagggtgtc tcataatggc aaaacttgc 2040
cgaagctgga ctctatctca ggaatcttc agaggatcaa ggaggggctc aacaagcatg 2100
tcagcagcct gtgcagctgt gtcagcgaga tgaacggaa gctcaggtcg catctcagag 2160
acattttcgc cctgaagaat tcagttccag agttctacag ccagctcttc cagatttcta 2220
ctgattttga agatctggct caaatttcag catcagcaaa ggcgcctccg ccccccgcgc 2280
ccgacagggc cccgaaggag ccgtgacgc ccgagccggc cccgcccagg cccagcggcc 2340
agagagccct agagagacct gggcgacggc ccgtctgcc ccagcgcccc ccgagaggga 2400
ggccgcccga gccgcagggc tcaccggggc tcacgcggga gacggggcag ccggggcccc 2460
cccgaggcgc aggcgtgtct ggccgggttc tgcgcggggg gcgtggacgg cagacgggga 2520
cgtgacagct ccccgggcga gaaggcttgc cgggcgcacc aggtatcccg aagctacctc 2580
ctgtagcttc cccagagctc ccggtgcctt ctctggtgtc ttcttctgtc ttcttctgtc 2640
aagaagcctt cccagctgat gggggcgctt tctctttaa caaagtgtg gtgaacgagc 2700
gggatgttta caaccacagc accggggtct tcacggctcc ttatgatggg cgtactcgac 2760
tcacggccac cctcaccccc gagagagagc cctacgtgga agcagtgctg tcggttctcca 2820
acgcagcgt ggcccagctg cataccgctg ggtacaggag agactctctg gaataccacc 2880
gccttcagag agctttgcat acctcggggg gccggggggc attccacctc atctgtcacc 2940

```

tgaaggcggg agatgcagtc aacgtcgtgg tgactggggg caagctggct cacacagact 3000
ttagtgaat gtaactccaa ttagtgggg tttcttata tcttttccct tcccaacctct 3060
agggtggctg gggagatgtc aggggaaga yagatagttg taaaaactct aaagctttaa 3120
tatattcgtt ttgtatgtaa tgggaagcac gggctagatt tccacatctg gccccaactc 3180
aaaggcccttc cctcgtgttt gaggccacca tgcccttactg cttccagcca ggcctgcagrg 3240
agtgaggcac accgtgaaca tggccactga cttttctgcc actctaactg gacaactgga 3300
agacttgaa agcctccac ctgtatctac actctgaggg cctggagctg ggcctgagct 3360
tgccacagag gctccgtctg actgtgggct gggaggaggg aggcaggggg gacccggcta 3420
cggtggctgg tctttacac aggcagcac tgtggccagc tgtctgtctg tacactgcat 3480
gcgaagtatt aaacactgaa gtgccgaagt ggcccgctgc gccgcacaga gaccocgact 3540
ttagtttggg ctgtttccac cttggctcac cattggccgc tgggaacttaa cctgctcagg 3600
cgggccctctg cccagctgca aatagggatg cgttagagac tgttcccaaa gcttgttggg 3660
ctccttaaat ggcattgtaca attaaagtgc aaagacaggg agtgcaata aagatggaaa 3720
gccatttcca gttaaaaaaa aaaaaaact cgaggggggg cccggtaccc aattccgctt 3780
atagtggctg gtattacaat tcaactggcg tcgttttaca acgtcgtgac tgggaaaaac 3840
ctggcgctac ccaacttaat cgcttgcagc nacatcccc tttccgcagc tggcgtaata 3900
acnaaaagac ccgcaccgat cgcccttccc aacaggttgc gcaacctgaa t 3951

```

```

<210> 16
<211> 1280
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> misc_feature
<222> (81)..(82)
<223> n equals a,t,g, or c

```

```

<220>
<221> misc_feature
<222> (1271)..(1271)
<223> n equals a,t,g, or c

```

```

<220>
<221> misc_feature
<222> (1279)..(1279)
<223> n equals a,t,g, or c

```

```

<400> 16
ttacaaaag ctatttaggt gacactatag aaggtacgcc tgcaggtagc ggtccggaaat 60
tccgggtcgt acccagcgtg nngggttttg atactatag aggactccct tcaatttcca 120
atggaaatta tagccagctg cagttccaaag ctagagagta tctggagaca ccttatccoc 180
aaagggtata ttccagcagc tgttataagc gaggaggagc atttggttgt ccacgagcaa 240
attcgagagc taactgtctt attatgagaa actcactgtt gctaataaaa cagcagggtg 300
gagtgattct tctcagtgta gcagcccaga aagagacaa gaaaccttta acagtggtga 360
ctctggcaga ggagactccc gtagcatgac cctgtgggat gtgccagta gaaatccagc 420
agccaccata cctgcagtag acgtctaccc tctgcctcag cagatgcgag ttgctctctc 480
agcagccaga accctaatc ttggcccttg aacttttagc caacctattt tgtttgatct 540
tcttctgaac aacttaggag aaacttttga tcttcagctt ggtagattta attgccagtg 600
gaatggcact tacgttttca tttttcacat gctaaaagctg gcagtgaatg tggccactga 660
tgtcaacctc atgaagaagt aagaggctct ggtagcagcc tatgccaatg atgggtctcc 720
agaccatgaa actcgtagca atcatgcaat tcttcagctc tccaggggag accagatattg 780
gttagctgtg cacaggggag caatttatgg aagtagctgg aaataattcta cgttttcagg 840
ctatctcttt tatcaagatt gaaagtcagt acagtatgta agtaaaaaag atggtgttct 900
aattagtggt attgaaggaa aagtagtctt tgccctcatg actgatttgt ttaggaaaaa 960
gtttttgttc ctgaggggag gaggtcctta cttttttgtt tctcttctgt aggtgaaaaa 1020
tcaagctgaa tgacaattag cactaatctg gcactttata aattgtgatg tagcctcgct 1080
agtcaagctg tgaattgata ttgtttgcac ttaatcctta actgtattaa cgttcagctt 1140
actaaactga ctgcctcaag tccaggcaag ttacaatgcc ttgttgtgcc tcaataaaaa 1200
agttacatgc aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1260
aaaaaanaaa nggggggggc 1280

```

```

<210> 17
<211> 3764
<212> DNA
<213> Homo sapiens

```

400> 17						
ctgatactat	ttaaggtagc	cctgcaggta	ccggtccgga	attcgcggcc	gcgtcgagcg	60
atctctcccg	tgggagccag	cgagctcttc	tcctgatctc	tacgtgctca	aggaatccgt	120
ttccctcatg	gaattgagaaa	gttggggaa	aagtcatact	gcgtcttgct	actcaaaagt	180
tgggtccatg	accagacaga	tcagcatcac	ctgggatctt	cttgaagaaa	atgtagaaac	240
tcaggccctca	ccccagaatc	tgctttttta	taagaccccc	agaagctgtt	gtgaaggcag	300
agcagcatct	ctgtgaagaga	cagaaccag	ccccagaggt	gtcacaggaa	gtcacacaga	360
aggacatctt	tcttttgatt	gattcagcag	tcctgtcaag	tataaaagtg	atgctgtguc	420
tgctctggcc	ctgtcagctg	ctgggagtg	tgcttaccat	ttccctgagt	tcactcagcg	480
tcattcagcc	tggttgctac	latgggagta	agccgtgcc	acctcaaat	cctctctaga	540
tgccaccaca	aattccacaa	taccagcccc	tggttcagca	agtacctcac	atgcttttgg	600
ccaaagatgg	cccttgccat	ggcaaggaga	tgccccactt	gcagtatggc	aaagagtatc	660
cacacctcag	ccaataatgt	aaggaaatc	aaccggcgcc	aagaatggcg	atgtggaacg	720
taccacaagaa	agggcaagaa	ataccattag	ccagttttac	aggggaacaa	ggtccccgtg	780
gagagcctgg	ccccagagga	ccacctgggc	ccctgtgttt	gccaggtcat	gggatatactg	840
gaattaaagg	aaaaccaggg	ccacagggat	atccaggagt	tggaagacca	ggtatgcctg	900
gaatgcacgg	gggaagccag	agccatgggc	atgcctgggg	caaaaggaga	aatttggaacg	960
aaagggtgaaa	ttgggctcat	ggggatccca	ggaccacaag	gacctccagg	gctctaatga	1020
ctctctggaa	ttgggaagca	aggtgggcca	gggttaccag	ggcaaccagg	accaaaaggt	1080
gatcgaggag	ccaaaggagc	accaggacct	caaggccttc	gggttctcaa	aggagaagac	1140
ggctctcgga	tgcagaggtc	gccaggtgta	aaggggcctc	cagggaatga	ggccctctcc	1200
ggccctctgt	gactgccagg	agtggggcaa	ccaggagtag	caggctctcc	tgggcccccag	1260
ggccccctgg	gaaagccagg	ggctccagga	gaacctgggc	cacaaggccc	tattggggta	1320
ccgggggttg	aaggaccttc	tgggataccc	ggaattgaaa	agccagggcca	ggatgggagc	1380
ccaggccagc	caggatttcc	aggtggcaaa	ggggagcaag	gactgccagg	gctaacagaga	1440
ccccagagcc	ttccaggagt	tgggaaacca	ggcttccagg	gacccaaagg	tgaccggggc	1500
atgggaggtc	ttctctgggc	tcttggaacca	agaggggaga	aaggacaaat	aggtgccccca	1560
ggaaatagggt	gtctctcagg	agagccaggg	ctgcctggaa	tcccaggtcc	tattgggccc	1620
ccaggttgcta	ttgggttttc	tggaaccaaa	ggagaaggtg	ggatttgtag	gccacagggg	1680
ccacaggatc	ccaagggtga	gccagggctt	caaggcttcc	caggaaagcc	aggtttctct	1740
gtgtgagtag	ggctctctgg	catgaggggt	ttgccaggct	ctacaggggc	aaaggggaaa	1800
gtctgggcaaa	aaggtgtacc	aggactcccc	gggtttccag	gggttctcgg	acctaaagga	1860
gagccaggaa	tccagggtta	tcagggttta	caggggcccc	agggatcccc	agggatgggg	1920
ggcccttagtg	gccccatggg	accactgggg	atccaggccc	ccaaagggga	gcccggccctc	1980
ccaggggccc	ctgggttccc	tggtataggg	aaaccgggag	tggcaggagt	ctatggcccc	2040
ccagggaagc	ctgggtccct	tggttctcaa	ggccagcctg	gccttccagg	acccccaggc	2100
ccctccaggac	ctccaggagc	ccagctgtgt	atgcccccct	caccaccacc	ccagggaagag	2160
tatctggccag	atatggggct	gggaattgat	ggcgtgaacc	cccccctcgc	ctacggggct	2220
agaaaaggca	agaaatggag	gcagctcat	gagatgcctg	catctaccgc	cgagctaac	2280
gcacctttcc	caecygtggg	ggcccaggtg	aagtttaaca	aactcgtcta	ttaacggcaga	2340
cagaactaca	accgcagac	aggcatcttc	acctgtgaag	tccttgggtg	ctactacttt	2400
gcataaccaga	ttcactgcaa	ggggggcaac	gtgtgggttg	ctctatcaa	gaacaacagag	2460
cccgtagtgt	acacgtgaca	cgagtaaaaa	aaagggtctc	tgaccaggag	attctgggag	2520
gcagtgctgc	tgctcagggc	cgagaccggg	gtgttctccc	agatgccctc	agaacaggtc	2580
gcaggactgt	atgccgggca	gtatgtccac	tcctctcttt	caggatattt	atgtatccc	2640
atgtaaaaac	aaaaaaaaca	aaaacaagaa	aaagaaagag	attttataga	agaaaatgac	2700
acaccaaaaa	atccaaatga	aaaacataat	tgcttcaaaa	cacttacaca	gttggaaagt	2760
tatatgtaaa	tgaaaatttg	gaccatttgt	tacaataaaa	aactaagatg	cagtgttaat	2820
actccacaca	cgagcctgta	attgcgaatg	atgggtagaga	gttatgtatc	aagtatctgac	2880
acttggttgt	accacttgga	atcatattag	ctgttttatg	ttatatgctt	ccacagtaac	2940
ctgcttattc	agatcagctca	aaatatatca	gtatgaaaga	tcatagctaa	tgaaggcacc	3000
ctactcatat	tgtttacttt	aaaataattt	taaatatgcc	ttaagaaagt	taattgttga	3060
acaaatcaat	accgattatt	cttgcctaat	ttcctctgta	tttgtgtaga	tactttgaca	3120
tgaaatatat	ggtaggggaga	ccgtagtgtg	taccgcccca	gtgggagggg	gcccctggga	3180
ccctggtgat	ctgtttagtca	aagggatatt	ctctctgtat	cagagctgtc	gtcttttagt	3240
aacaggagtc	ctcgtcagaa	ttgcgtgtct	gttgtctcta	aaagaatggg	tgaaaccaat	3300
ggccttttgt	aatttatctca	gtgcctcttc	tgtaaccaag	actgggtaag	gcacttttgt	3360
ggagcatatg	acagtaaccc	tcaggagctc	agagaaacgg	atgggagaca	tgagcgggtaa	3420
ttactactct	tgtttcccag	agttttctat	tgttttgatt	ttctttttct	tgtaacttat	3480
ttctactatt	ctttctctcca	tgtaattttc	actatggccc	aactaatata	aacacttgga	3540
aattacaagg	aaaaaaaatt	cttctctcaa	taactttcca	aatttgtgga	ttattttatt	3600
gtaatagcag	ttatcagtta	tgcttatata	gcattaaaaa	tttctctctc	ctgactacac	3660
acacaaccac	agtggtgttc	taatcatgga	gatatacgtg	atttttagta	actgaatttt	3720
gaggaacttt	ctctgttttag	catgtatgca	aactgatatg	taat		3760

<210> 18

<211> 2485

<212> DNA
 <213> Homo sapiens
 <220>
 <221> misc_feature
 <222> (2388)..(2388)
 <223> n equals a,t,g, or c
 <220>
 <221> misc_feature
 <222> (2415)..(2415)
 <223> n equals a,t,g, or c
 <220>
 <221> misc_feature
 <222> (2425)..(2425)
 <223> n equals a,t,g, or c
 <220>
 <221> misc_feature
 <222> (2481)..(2481)
 <223> n equals a,t,g, or c

<400> 18
 aggggtccct ggctccctgt gaatacgggc cctccggggc cccggggacc 60
 cctgggtgcc ctgggggcctt cgtatgagact ggcatcgagc gcttgacact gcccaacggy 120
 ggtgtggagc gtgcccgtgt gggcaagggg agtttgggct gggcgagctg 180
 tctgcccattg ccacacccgc ctctactcgt gtgctacact cgcctctccc cgcctcgggc 240
 atgcccgtga aatttgaccg gactctctac aatggccaca ggggctacaa cccagccact 300
 ggcatcttca cctgcccctgt gggcggcgct tactactttg ctaccactgt gcacgtcaag 360
 ggcaccaacg tgtgggtggc cctgtacaag aacaacgtgc cggccacctc tacctacgat 420
 gagtacaaga agggctacct ggaccaggca tctggtgggg ccgtgtctca gctcggggcc 480
 aacgaccagg tctgggtgca gatgccgtcg gaccaggcca acggcctcta ctccacggag 540
 tacatccact cctccttttc aggatctctg ctctgcccca cataaccgcg ggggggtgtc 600
 ctctgcctct ggccctctcc cctttagtgg tagagcgacc ttttcaatta caaagaacct 660
 cctggaaaaa aaaaacaaag ctgaacagag gcggcgctgg ccttggcccg agggagactaa 720
 cttgctttct cctgtcatgc agcctgagat tgtttctgga aggggctggc ctgagtttct 780
 ttccccaaa tgtctgtgca gtgtcagggc tgacccccat aggcctctgag gcacacagcc 840
 cagcccttg tgagtctggt cctctgctgg gccctgaagg agctgagagg gagctcaact 900
 ccccccccg ccacgtgggg agacagccct tcccactggc tcctctgattg cactctgtgg 960
 aggaagggcc cagggcctcc ctcacagccc ttggctgggg tgggtgtggg tcctccaagg ggaagggaga 1020
 acctccagca tatgacagtg gactaaggac tgtggggttt tcctccaagg ggaagggaga 1080
 agaggggacc atcgaggtg cgagtgtgga caccctgcca ggactgcagc ccccatgggt 1140
 atgctgtggc atcagacatg tccgtggtgg gcacagtggc tggttccctg ggaaggggca 1200
 acctcccttt cactgtccca gtggcagcca tgggggaaggc agtttgtgag gcttggggc 1260
 acagacctgg ggcagggagc agctctctac gtctcatcct gtctctcccc ggcctggccc 1320
 gccagctctg gctgttttagc ttgagggcag cacagaggcc cctgggacac ctacagggcc 1380
 gaagatcaaa cctctgtgaa gtgtctagaa gtatctagt cagatgtgg cggagcaga 1440
 atgcacacat agcaaaactg agcaactctc cctttctccc ctcccaactg ctcgggcgtg 1500
 ggtcgggttt ctcaatacaa aattgtaaga ggatcctgt cccccagcc aggtatcccc 1560
 aaggcagag acctctcgtt tggccctctg aacaaggtgc acgcgagctg ggggatgaag 1620
 agcctcccca ctctcctttc cttaataaga accatatgtt ggtgtatgt ggttacaaga 1680
 ggggttcact tgtggggggt tctctcctt ccacctctg gttccaaatt cctgttctaa 1740
 gcaggactag ggcctgagg gctaaggctg ggagagaaag ggtgcccaac ggtcccttgg 1800
 gaatagattg gctctggagc tttctgccct gttccccgat cagagctcct ctgcaggaaa 1860
 caggcagagt gccctcccca acccctcagt ccttaagctc acgggagtg atcgagctga 1920
 gatgagtgct gggagtgggt gacattcctg ctctgtcaca gatggccact tctccccgag 1980
 ctgcaggctg tccgctctgg cctctgcagg gccagcccca ctcttgtac caagtgtgaa 2040
 gctgggtctg tccgtctgtg atctcgttgc actgctccaa gtctggctgt gtccaggcgg 2100
 tccattctga aaatggagga tggctgtgta ctctgtactg gctgagctgt ggttctcttc 2160
 aggttctctt ccaacccctc tccctgtccc acaactcttc caaacaagc aggtctgttt 2220
 cctactcttt caaagaggag aatgataacc caaatctgcc caagtgcac ttgagaaggt 2280
 tttgctgtgg gttcctgtgt grrtttctta ctacctaac cccaaggaaa accaactaag 2340
 ggactctcaa accaytaact ggggtggggg tttttcgtt tcaacntnt ttctcccta 2400
 ggggtcaaa gccantattc atctngatgt tgtttagggg atgggggttc ttgatttggg 2460
 caggaaaatt aattcaggtt nccca

<210> 19
 <211> 1550
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <222> (1547)..(1547)
 <223> n equals a,t,g, or c

<400> 19
 ctgcagctgt tggttctgat tccataccag aggggctcag gatgctgtgt ctgggagctg
 ttctactgct attagctctg cccggtcatg accaggaac cagcactcaa gggcccgag 120
 tctctgttcc cctgcccaag ggggctgca caggttgatg ggcgggcatc ccaggggcatc 180
 cgggccataa tggggcccca ggcctgatg gcagagatgg cacccttgtt gagaagggtg 240
 aaaaaggaga tccaggctct attggtccta agggagacat cggtagaacc ggagtagccg 300
 gggtctgaag tccccgagcc tttccgggaa tccaaggcag gaaaggagaa cctggagaag 360
 gtgctctatg ataccgctca gcattcagtg tgggattgga gacttacgtt actatcccca 420
 acatgcccat tgcctttacc aagatctctt acaatcagca aaaccactat gatggctcca 480
 ctggttaatt ccactgcaac attcctgggc tgtactact tgcctaccac atcacagtct 540
 atatgaagg tgtgaaggtc agcctcttca agaaggacaa ggctatgctc ttcacctatg 600
 atcagtaacca ggaataatatt gtggaccagg cctccggctc tgtgctcctg catctggagg 660
 tggggcacca agtctggctc caggtgtatg ggggaaggaga gcgtaatgga cctctatgctg 720
 ataatacaca tgactccacc ttcacaggct ttcttctcta ccatgacacc aactgatcac 780
 cctaactca gagcctctcy caggccaac agccccaag tcaattaaag cctttcagta 840
 cggttaggaa gttgattatt atttagttgg aggcctttag atattattca ttcatttact 900
 cattcattta ttcattcatt catcaagtaa ctttaaaaaa atcatatgct agtgtccagg 960
 tctctgggag cttcacaaac atgaccagat aactgactag aaagaagtag ttgacagtgc 1020
 tattttgtgc ccaactgtct tctgatgct catatcaatc ctataaggca ctaggaacaa 1080
 gcaattcctc gtttttacag attgtatcct gaggtctaga gagttaagtg aatgtctaac 1140
 gtacacagaa tattaagtga cagtgtctaga aatcaaaccc agagctgtgg actttgttca 1200
 ctgagctgtg cccctttata gaggtacatg ttctctttgg agtgtttgta ggtgtcttgt 1260
 tcccacctca cctgagagcc attgaatttg ccttctctat gaattaaaac tcccccaag 1320
 cagagctccc tcaagagaag tggttctatg atgaagtctc gtcttggagg gaactactact 1380
 caatggtccc tgcactactc tacttctctc taacctatgc ccttctcatg cctttccctc 1440
 caacggggaa agccaactcc atctctaagt gctgaactca tccctgtctc tcaaggccac 1500
 cggccaggga gctctctctga tgtgatctcc actttttttt tttttttaa 1550

<210> 20
 <211> 1518
 <212> DNA
 <213> Homo sapiens

<400> 20
 caacgctgct ggactcactg aatgagctcc agaccactgt ggagggccag ggcgctgac 60
 tggctgactc gggggcaacc aaggaccgta tcattttctg gattaaacag ctgcagcagg 120
 aggccacaga cagatgctaca gagagtgaag agcgcttccg aggcctagag gagggacag 180
 cacaggccgg ccagtcgcccc agcttagagg ggcgattggg ccgtcttgag ggtgtctgtg 240
 aacggttgga cactgtggct gggggactgc agggcctcgc caggggctt tccagacaag 300
 ctgtgggctc ctgggctggg cctccgggaa ccaaccacca ccagccagag caggcagccc 360
 tgttggagaa gctgtgtcgg ggacagcggg gcctgggca ggcgctgggt gcccttaaca 420
 gctcctctga gctcctggag gaccgtctgc accagctcag cctgaaggac ctactgggc 480
 ctgcaggaga ggctggggcc ccaggggctc ctgggctgca gggaccacca ggcctctgct 540
 gacctccagg atccacagggc aaggacgggc aagaggccct gcccacaagt gcaattttag 600
 aagggtgaac gggagtggag ggggaccagg cagccctgt gcccacaagt gcaattttag 660
 ctgctctgag tttgcccggt tctgaaccag gcacggtccc ctctgacaga gtctgtctca 720
 atgatggagg ctattatgat ccagagacag gcgtgttcac agcgccactg gctggagcgt 780
 acttctctag cgcggtgctg actgggaccc ggacagagaa agtgaggccc gtgctgtccc 840
 gctccaacca gggcgtggcc cgcgtagact ccggttgcta cgagcctgag ggcctggaga 900
 ataaagcctt ggcccgggag cagcccagcc caggccacct cggcgctctc agcctcatc 960
 tgcgctgca gggccgggac acggtctgct tcgacctggt catggggcag ctggcgcact 1020
 cggagagacc gctcacctac ttcagcgggg cctgtctcta tggggaccga gtgctgtgaac 1080
 acgctagacc tggggtccgc ccgacgtgt ctactgcgc tgaagagaca cggggggcgg 1140
 cgggctcctg gggctctcgc tgaagcgggg caactagccc tggggcgagc cgcacccagg 1200
 gccgcagcgc gcaaccggcc cagagcgccc tctcccacg cccggggcgc gccgctcag 1260
 gggagctcgg gggccgccat gcagactttt ggccctggcg gatcccccca gacccctcc 1320
 agggcgcgcc tgcgggaggag ccgatcctcg caccctccgc tccctctact ggcctccag 1380

gtcgattccc	tgggctccag	gtccccccgc	cggggcgcgc	ccggccgcga	tactaaacga	1440
tcgaggaata	aagacacttg	gttttttctaa	aaaaaactaa	aaaaaaaaaa	aaaaaaaaaa	1500
aaaaaaaaaa	aaaaaaaaaa					1518

<210> 21
 <211> 1545
 <212> DNA
 <213> Homo sapiens

<400> 21						
ccacgcgtcc	ggtggctcca	tgtataggag	acagtgaaag	agatgggggt	ggcattttct	60
tcacgagagag	tgtgggggag	atgaccgtta	ggtcataaagc	gcgcccttac	tctgactcgg	120
cgagaccagc	atgactctgag	tgaaccaccg	tgaacctggg	ccgcagcagc	cccaggagct	180
ggaggcgctg	cagtcgggaa	acaccaggag	gatggagccc	ttttccctgt	aagcaggagg	240
ccaggatcct	gatctctgag	ccggcttccc	acggacccca	ggccccggca	gggtcctggc	300
ggggaggaaga	acccacggat	tcagagctctg	tcactctgaac	catgaggatc	tgggtgcttc	360
tgcttgccat	tgaaatctgc	acaggggaaca	taaaactaca	ggacacctgc	agggcaaggc	420
acccctggaat	ccctgggaac	cccggtcaca	atggctctgcc	tgggaagagat	ggacgagacg	480
gagcgaagg	tgacaaagcg	gatgcaggag	aaccaggacg	tcctggcagc	ccggggaagg	540
atgggacgag	tggagagaag	ggagaaacag	gagcagatgg	aaaagtgtga	gcacaaaggca	600
tcaaaaggtga	tcaaggctca	agaggaatcc	tgacaaaaaca	tgcccccaag	gggcttgcag	660
ggcccatggg	agagaaagcg	ctccaggagg	agactgggccc	tcaggggcag	aaggggaaata	720
aggggtgacgt	gggtccacct	ggctctgagg	ggccaagggg	caacattggg	cccttggggc	780
caactggttt	acggggcccc	atgggccccta	ttggaaagcc	tggtcccaag	ggagaagctg	840
gaccatgggt	gccccagggt	gagccaggag	tcgggggaat	aagaggctgg	aaaggagatc	900
gaggagagaa	aggggaaatc	ggtagagctc	tagtcttgcc	aaaaagtgtc	tccactgtgg	960
ggctcacggt	gctgagcaag	tttctctctt	cagatgtgcc	cattaaattt	gataagatcc	1020
tgatacaaga	atccacacct	tatgatacag	cagcggggaa	atccactggc	cacattgtcg	1080
gggtctatca	ctctcacctac	cacatcacgt	ttttctccag	gaatgttcag	gtgtctttgg	1140
tccataaagg	agtaaaaaata	ctgcacacca	aagatgctta	catgagctct	gaggaccagg	1200
ccctctggcg	cattgtctctg	cagctgaagc	tcggggaatga	gggtgtggctg	aggtgacacg	1260
gaggagagag	gttcaatctgc	ttgttttgctg	atgaggacga	tgacacaaact	tccacagggt	1320
tcctctctgt	cagcacagag	tgacagagct	gagtttaaaaa	atccgcacaca	ccactccata	1380
gaatcagctt	gggatgaact	tattcagatg	gttttactct	atcaattctc	ccaattatca	1440
caataatcat	aaaaaggtga	aaatggaaaa	gttattccca	aaactgtattc	tgtgtacact	1500
actatttttc	caggagtaaa	tatttaaaaa	aaaaaaaaaa	aaaaa		1545

<210> 22
 <211> 3543
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <222> (3)..(3)
 <223> n equals a,t,g, or c

<400> 22						
ttctcgagc	aattcggcac	gaggttgagc	cttcgagcct	agctgctcgc	acaggactcg	60
gcacactgcc	cttctctgcac	cgactggcca	gctcaagagg	tttggatag	gaactcttct	120
aatctctgcg	cttctctctt	gtctgtcttt	tgtctgggat	gggagccaca	ggcaccttga	180
ggactctccc	ggaccacaagc	ctggagatct	acaagaagat	gtttgagtg	aagcggcggg	240
agcagctggt	ggcactgaag	aaactggcac	agctgaaacga	catccaccag	cagtacaaga	300
tccttgatgt	catgctcaag	gggctcttta	agtgctgga	ggactcccg	acagtctcta	360
ccgctctgta	tgtctccca	gatggggcct	tcgccacaga	cgagaagctg	aagagtgtct	420
ctctccacct	ggtaggagac	acggccttct	tcggcgatgt	ggtgctgcgc	ttcccgagga	480
ttgtctacta	ttactttgac	cacaactcca	actggaacct	ccctcatccg	tggggtatca	540
gtttctgcaa	ccagacagcc	gtcttcaacc	agggggccca	ctcgcccatc	ctcagctcga	600
tgccccagaga	gctggggatg	agtgaagaa	actccaactt	ccagaaccca	tttaaaactg	660
accgcacaga	gttactctcc	agcactgacc	ctttccagaa	ggccctgaga	gaagagagaga	720
aacggccgaa	gaagagaggag	aagcgggaag	agatccgaaa	agggcccaag	atctccagat	780
cccgactgga	gttatagccc	tggagcagct	cagggtctcag	ggggccacaa	ggaggccagrt	840
cgaggaggag	aagagggtga	gggtgtggtt	tgggtgagag	caccagctag	ccctctccag	900
aaggggagag	cacattttgc	cgcccccctg	agactgggtc	tgaagccctg	ctgaaggagac	960
tgagcctcag	atggctggat	tttctctcag	gggcctcctg	ctgaaggggc	cttcagagaga	1020
ttttatctgt	gaatatgtac	cctgtgcaga	cctgtggggg	aggcaggagg	atgcctgcct	1080
ggacctgtt	gggtggctgaa	gacctctgac	cagctgggct	ccgcctctgg	tggggagaga	1140

gcagaactag gttctgagcc acgggtcagg gtgccaccct gctgctggcc ccactgtgtc 1200
acagagctgc ctggcacagg tccagcgcct tctgcagaga cacaataaaa gccagcagac 1250
cctttggacc gaccaaggct ggtgggaaca ctgtgagggg accaggggccc ctgagggatg 1320
tagaacaacg ttggaggtgc cctctgcccc accaggaggg gccccagacc ctggcagggt 1380
agagaaggaa gggggttggc ttgggctctcc tgggtctaac ccatcactgc cctgcagaaa 1440
tgaattggtgt agcaacaatga tccctgtctc ccttgggacc tgggaacact ttagctcaag 1500
aagaccttgc cagcttgttcc tctctggcag cgctggaaga cagctcaacct gtgggtgtgg 1620
acagggaagg ggcctcaggg gacaggcgcc cagccctgca ctcgcgaatg gctgccctaa 1680
gtgtcagtgg ctacagacgt tccctgtctg ggaggccaca gggcagggaa gctgcagagg 1740
gcagtgtggc ctgggtaggg cagctgccct tcaactatgc cctcccaag gagaggagg 1800
aaggccttta gtgagaattc tagctctgcc tctttgacct tgcgaagtca ggaactgtcc 1860
ctcaaggagg cagagaaaac catyccagat cccctcgaca cccagccccc taccactgac 1920
agagcacaa gtagactctga rtgktagccc ttcaraattg ctgactggcc ttggcccacc 1980
cctyctcagt ctgcagcttc attggcaaaa tgaatttgat ggtatctgta tcccctggcc 2040
agccctaacc tgtttctctg aggtggccct yccctacggg ctgcagcagc aaagggaagc 2100
caagctttag aagaagctca tgggaaggcc cagaacatcc tgaccccatc agttactcgg 2160
aagtaagggg ccaagaagca gctggaagag agctgggtgt gggggcttgg argagtgtg 2220
ragaaattgc cccactagaa ggcctctcac tgggcagtg aggcaggscs gtgtgtgtgg 2280
cctgactcaa cagacatagt ttcacttcca ccttgcctt ctgagttgt gtgaccccag 2340
ccactatgaa acccaggtct gtgaactaaa gggctgttcc atggcattam cagtgragg 2400
tgtctcaggt tctgatgtct tgaacaaaag attgggcaaa atgcacaaag caaggaagga 2460
atgaagggtt ttactgagaa tgaaggtata ctcacagca tgggagaggg cctgagctta 2520
gggactcaag gggccgtgta cagaattttt gggagtaaat accactaga ggaactccat 2580
gggttaactg ggtacacct atgtaaatgg aaaggatgaa gtaaatttac aaattcattt 2640
acagcatata ccttatgggg aggtatattc ctgttatagc tgaagcgtga attggtccta 2700
tgttccctgc ctccagacc tattttccgt catcaacggg aaagggtcag attggtcctg 2760
tcagctgttt aaactgtctc ggtgccagca gctggagctg ggtgtcagga ccagcccgca 2820
agctcttccc tgcgggaagg accaggccag ctcgtctcct ttcatgccta tgaagtgtgt 2880
gtggtttgct cctttagcaga gaaggtgctt gggctttccc ttaactggag aaaaaacttt 2940
ctaagaacca ggcctgtgtg gcagcagacc tagctttctt ggggtggcag ctggtgtcgt 3000
gcataactca ggaacagtcag tgggtgggtcc agctttcgtt ggaagttcct tctactgaat 3060
aaactctaga ggcctctgca ttagcaggat ttgtataatt tgaagcagca ctgggcaact 3120
gcagagaggg ggggaagcca gcccagtggt ctgggcaact ctgggcaact tggagcagct 3180
ctgggctgct tcttgccagc tttgtttatc agaacaggc tcttcaactc taactccttg 3240
ggcccccact ctcagaaagc ccagtggtta aaaggatgaa accctggaat taagtgaact 3300
ctcagtgatg tgtgcccctc tctgaocggt ccttgttcat cctcatgtat tctcagcttc 3360
ctgtctatata tgcagagcca aagagtgggg cctggctctg aactatctcc tcatctgccc 3420
ctctctgccc ctccttccc ctgggctctt tctcttaata ccgtcatctc ctctccaaac 3480
tggtaatacc tgtcctttct gccctcaaat ggggcacctc aaaaaaaaaa aaaaaaaaaa 3540
cga 3543

<210> 23
<211> 3522
<212> DNA
<213> Homo sapiens

<400> 23
ggcacagagg ttgacctttg agcctagctg ctgcacagg actcggccac ctgccccttc 60
tgaaccagat ggcacagctca agaggttttg atatggacct tcttcaactc ctggcctctc 120
cttttggctcct gcttttgtct gggatgggag ccacaggcac cttaggagac tccctggacc 180
caagcttgga gatctacaag aagatgtttg aggtgaagcg gcgggagcag ctgttggcac 240
tgaagaacct ggcacagctg aacgacatcc accagcagta caagatccct gatgtcatgc 300
tcaagggtct ctttaagggt ctggaggact cccggacagt gctaccgctg cgtatgtgpc 360
tcccagatgg gccctgcgcc caggacagaga agctgaagga tgettctctc cactgtgtg 420
agaaacaggg cttcttcggc gatgtgtgtg tgcgcttccc gaggatttgg caactatact 480
ttgaccacaa ctccaactg agccttccca tccgctgggg tatcagtttc tgcacccaga 540
ctgagctctt caaccagggg ccccaactgc cctgatggcg cctgatggcg cagagctgg 600
ggatcagtgta gaagactctc aacttccaga accatttaa aatcgaccgc cagaggttca 660
tcccagcac cagctcaggc cagaaaggcc tgagagaaga agagaaaag cagagaagag 720
agggagaagg gaaggagatc cgaaaaggcc caaggaatct cagatccagc tctgagtat 780
agccctggag cagctcaggg ctgagggggc cacaaggagg cagatcggga ggaagaagag 840
gtggagggtt ggttgtgtgt gagagcacca gctagccctc tccagaaggg gaggccacat 900
tgtccccggt ccttgagctc gggctgtgag cccagctgaa gggactgagc ctcagatggc 960
tggattttct ctcaaggggc tcttctgtaa ggggcttcca gaggatttta tgcgtgaaat 1020
atgacccctg gcagacgct gggggaggca ggaggatgc tgcctggacc ctgtgtgggt 1080
ctgaagacct ctggccagct ggcttccgac ctgtgtgggg aagcagcaga actaggttct 1140

```

gagccacggy tccagggtgcc accctgctgc tggccccact gtgtcacaga gctgcctggc 1200
acaggtccca gccctctctg agagacacaa taaaagccag cagacccttt ggagccacca 1260
aggctggttg ggaactgttg aggggacacag ggcctctcag ggtatgagaa acagcttggg 1320
ggatgccctc gcccccacag gggggggccc agggcctcgg aggggacaga aggaaggggg 1380
ttggcttggt cctcctgtgc ctacgccatc actgcccttg acgatgatt ctgttgagaa 1440
aaggactctg aagtgccttg ggaactggga aacatttagc tcaagaagac ctctggagca 1500
catgatccct gtctcagat gtctggggac agtcattgag caagcacagg gaagttagct 1560
tgtctctctc ggcagcgtg gaagacagtc aacctgtggg tggggggctg cagggggaca 1620
ggcgcagccc ctgcaggag ccgtgctccg caatggctgc cctaagctgc atgggtcaga 1680
cagcttcccc gctctggag ccacagggca ggggaagctc agagggcatt tggccctggg 1740
tagggcagct gcccttcact catgccctc ccaagcacag gagggaaggg ctttagttag 1800
aattctagct ctgcctcttt gaccttgcca agtcaggatc tgcctcttaa agggagcagag 1860
aaaacacatc agatccccct gacacccagc ccctaccac tgacagagca caaglgagat 1920
ctcagtggtt gcccttcaga ttgtctgact ggccttggcc caccctctcc tgtgctcgag 1980
cttcattggc aaaaatgaatt tgatggtatc tgtatccct gccccagcct aacctgtttc 2040
ctcagagctg gccctccctac ggggctgcag cagcaaaagg aggccaagcc ttgagaagac 2100
ctcattgaag taccatggca atcctgcacc catcagttac tcgggaagtaa ggggacaaga 2160
agcagctgga agagagctgg gtgtgggggc tggagtgagt gctggagaaa ttccccatc 2220
agaagggccc tcaactgggca gtggaggcag ggcagtgttg tgggactgac tcaacagaca 2280
tagtttcatc tccacctctg ccttctcagg ttgtgtgacc ccagcccatc ggacaccaga 2340
gtctgtgaac taagaggctg gtccatggca ttaacagtgg aggggtgtcca ggttcttgat 2400
gtcttgaaca aagaatttgg caaaatgcac aaagcaagga aggaatgaag ggttttactg 2460
agaaatgaag taaactccac agcatgggag agggcctgag catagggact caagggggccc 2520
gttcacagaa ttttgggagt aaataccccc tagaggatcc cattggttac ttgaggtaca 2580
ccctatgtaa atggaaagga tgaagtaaat ttacaaatc atttacagca taaccctat 2640
ggggaggata ttccctgtta tagctgaagc gtgaattggc cttatgttcc ctgcctccag 2700
acctatttt cctgcataca ogggaaaggg tcagattcac tggctcagct gtttaacctg 2760
tcttggtgcc agcagctgga gctgggtgtc aggaccagcc cgcaagctct tccctgccgg 2820
aaggacagga cagctcgtct tcttttcat gctagagagt ggttgtgtgt gctgacttag 2880
cagagaaggt gcttggcttt ccccttaact ggagaaaaaa ctttctaaga accaggcctg 2940
gttgcagcga gaactagctt tcttggggtg gcagggaagg ctaagcatac ccaggacag 3000
tcagtggttg gtccagcttc ggctggagggt tcttctact gaataacttc tacgggctct 3060
gtcattagca ggaattgtat aatttgaagc agagctgggc aactgcagag caatggggaa 3120
gcagcccgag tgtggtggca agacctgggc aacttgggac cagcctgggc tgtctcttgc 3180
cagctgttgt tatcagaacc aggcctcttca ctctcaagtc ctggggcccc ccatctcaga 3240
atgcccgatg gttaaaagga tgaacctgtg aatttaagt acttctcagt gatgtgtgcc 3300
ctctctgac ggttccctgt tcatcccatg tatttactga gtcctgtctg tatatcgaga 3360
gccaaagagt ggggctctgt ctgaaactat ctctcatct gccctcttct gcaacctctg 3420
ctctctgggc tcttctctct aatacgccta tctctctccc aacctgttga atcctgtctc 3480
ttctgcctc aaatggggcac cttcaaaaaa aaaaaaaaaa aa 3522

```

```

<210> 24
<211> 1969
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> misc_feature
<222> (996)..(996)
<223> n equals a,t,g, or c

```

```

<220>
<221> misc_feature
<222> (1040)..(1040)
<223> n equals a,t,g, or c

```

```

<220>
<221> misc_feature
<222> (1058)..(1058)
<223> n equals a,t,g, or c

```

```

<220>
<221> misc_feature
<222> (1068)..(1068)
<223> n equals a,t,g, or c

```

```

<400> 24

```


ccacgcgctcc	gcgcgcgagg	ggcgccctggt	gcagcatggg	cgcccccggg	gcttgggcgc	60
tgctctgcct	cggtctcctg	ctcccgggag	gcggcgctgc	gtggagcatc	ggggcgagtc	120
cgctctccgg	acgcaggaac	tggtgctcct	atggtgtgac	ccgcaccatc	tcatgacctg	180
tgacagaatgg	cacctacctt	cagcgagtcg	tgcagaactg	cccttgccgc	atgagctgtc	240
cggggagcag	ctacagaaat	gtggtgagac	ccacatacaa	ggtgatgtac	aaagtatgga	300
cgcccgctga	gtggaggtgc	tgccctgggg	actcaggagt	gagctgcgag	gaagctgaga	360
ctctctctgc	ctccttgagg	ccatgtgggt	cgggcagtag	catgcggcgg	atggcctctc	420
ggcccaaggc	ctctctctgc	tgcttcaact	gcagcaaatg	gtcagagctg	acagagcggc	480
tgaagtgct	ggaggccaag	atgaccatgc	tgactgtcat	agagcagcca	tactctccaa	540
ccacagctac	cgctgaggag	ctgcccgcgc	tctggggtcc	ccctcctgcc	caggggcagc	600
ccggagatgg	agggctccag	gaccaagtgc	gtgcttgagg	gcttcccggg	ccacccggcc	660
ccaaaggaga	tgcccgcagt	cggggcccga	tggggatgag	agggcccaca	ggctccacag	720
gccccccagg	gagcccttgc	cggtctggag	ctgtgggcac	ccctggagag	aggggacctc	780
ctaggccacc	agggcctcct	ggccccccctg	ggccccccagc	ccctgttggtg	ccaccccatg	840
cccgatctc	ccagcatgga	gacctattgc	tgtccaaacac	cttcactgag	acccaacaac	900
actggcccca	gggacccact	gggcctccag	gccttccagg	ggccatgggt	ccccctgggc	960
ctctctggcc	cacaggtgtc	cttgggagtc	ctggtnacat	aggaccacca	ggcccactgc	1020
gaccacaaag	aatctcttgn	caccagagag	agaaggngga	gaagaaanga	ctgcgtgtgg	1080
agcctggccc	caacagtgct	gctgggcagc	gggggggaacc	tgcccttaag	ggagacccgt	1140
gtgagaagag	ccaactggaac	cagagctggg	gtctggggcg	gccttgcggg	cacaggcacc	1200
cccgagctcc	acctggactc	ggcagctgct	atgcaaccaa	ctaccgggat	cgtggccccc	1260
aggagccggg	acgagagag	ctgagggctg	tgccggcccc	tgaggcgagc	caggccaggc	1320
ttccctctct	acctggactc	ggcagctgct	ctccagggac	cgcccgctcca	tatttatata	1380
tgctctcagg	gtcccttctg	ccatctaggg	cttaggggta	agcagggtctc	agctctggga	1440
ccatgcacat	gtctgaggct	gagcaagggc	tgagaggaga	ggcttgggcc	tcagtttccc	1500
tctgtgaagt	ggggggagag	agcccttcaa	ggagggaatg	aggtacaagg	cttcgtctca	1560
cttctgtctt	gagcatccag	gcccacaaagc	actgagggag	tcaggagctg	ggccctcgca	1620
catgcagaga	tgacagggca	gggggcagtc	ttcttcccc	ttcccgacca	aaactcgggg	1680
agccctctct	tgcccctccc	ctcttgttgt	ccagtgctgg	gttccccag	cagaggtcag	1740
gctgcaccaat	ctcttgaact	gataaccggg	ggcttcttgc	ctcagttctt	cccttctgag	1800
ccccaggccc	tcccgcattc	caggttgggg	atggggacat	ggagaggaga	ggcccgccca	1860
ctcctgcaaa	tgcttgtgac	agatgccagg	aggtagatgt	gtgctggcca	ataaaggccc	1920
ctactgtatt	ccccgcaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa		1960

```

<210> 25
<211> 2189
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<222> (2)..(2)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (4)..(4)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (7)..(7)
<223> n equals a,t,g, or c

```

<400> 25						
gnancgnggt	acgactcact	atagggaaag	ctggtacgcc	tgcaggtacc	ggtccggaat	60
ttccgggtgc	accacagcgt	ccgcgcggcg	agggcgccgt	gtgcagcatg	ggcgcccgcc	120
gggcttgggg	gctgctctgc	ctcggtctcc	tgctcccggg	agggcgccgt	gcgtggagca	180
tcggggcagc	tcggttctcc	ggacgcagga	actggtgctc	ctatgttggt	accgcacaca	240
ttctatgcca	tgtgcagaat	ggcacctacc	ttcagcgagt	gtgcagaaac	tgccctgggc	300
ccatgagctg	tcgggggagc	agctacagaa	ctgtggtgag	accacatac	aagtgatgt	360
acaagatagt	gaccggccgt	gagtgagggt	gctgcccctg	gcactcagga	gtgagctgcg	420
aggaagtgtc	agcttctctg	gcttctctgg	agcccatgtg	gtcggggcag	accatcggcg	480
ggatggcgct	tcggcccaca	gccttctcag	gttgttctca	ctgcagcaaa	gttgcagagc	540
tgacagatgc	gctgaagggt	ctggagccca	agatgaccat	gctgactgtc	atagagcagc	600
cagtacctcc	aacacacagt	accctgagg	acccctcccc	gctctgggggt	cccctctcctg	660
cccagggcag	ccccggagat	ggaggcctcc	aggaccaagt	cgggtgcttgg	gggcttcccc	720

```

ggccccaccgg ccccaaggga gatgccggca gtcggggccc aatggggatg agagggccac 780
cagggtccaca gggcccccga gggagccctg gccgggctgg agctgtgggc acccctggag 840
agagggggacc tctctgggca ccaggggctc ctggccccc tgggccccc gccctgttg 900
agaccacacaa tgcctgggac tccagcatg gagaccatt gctgtccaa accctteactg 960
gtccccctgg gctctctgac ccacaggtg tccctgggag tcttgggtcac ataggacccc 1020
caggcccccac tggaccacaa ggaatctctg gccaccagg agagaagggg gagagaggac 1140
tgcgtgggga gcttggcccc caaggctctg ctggggcagg gggggaacct ggccttaagg 1200
gagacctgg tgagaagagc cactgggggg aggggttgca ccagctacgc gaggctttga 1260
agattttagc tgagagggtt ttaatcttgg aaacaatgat tgggtctctat gaaccagagc 1320
tggggtctgg ggcggggccct gccggcacag gcaccccag ctcctctgg ggcaagaggg 1380
gcggacatgc aaccacatc cggatcgtgg cccccaggag ccgggacgag agaggctgag 1440
gggtgtgggc gccctgagg cagaccaggc caggcttccc ctctactctg gactcggaca 1500
gtgcctcca gggaccgccc gtccatattt attaatgtcc tcagggtccc tctctgccatc 1560
taggccttag gggttaagcag gtctcagtc tgccaccatg cacatgtctg aggcctagca 1620
agggctgaga ggagaggctt gggcctcagt ttccctctgt gaagtgggg aggcagagcc 1680
ttcacaggag gatagaggta caaggctctg tctcatctgc tgtctgagca tccaggccca 1740
aaggcactga gggagtcagg agctggggct cggcacatgc agagatgaca gggcaggggg 1800
cagttctctc cccctccccc gaccaaacct cctgtgcacc ctccctctct 1860
gtgtctcagt gctgggttcc ccccccagg gtcaggctgc ccaatctctc gactggatca 1920
ccgggggctt cttgcctcag ttcttccctc tgagccccc gccctcccg catctcaggt 1980
tggggatggg gacatggaga ggaaggggcc gcctactcct gcaaatgctt gtgcagatg 2040
ccaggaggtg gatgtgtgct ggccaataaa gggccctacc tgattcccg caaaaaaaa 2100
aaaaaaaaa aaaaaaaaaa aaaggggcgg ccgctctaga ggatccaagc ttacgtacgc 2160
gtgcaygcgr gtcatagtc ttctatagc

```

```

<210> 26
<211> 1236
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<222> (1)..(1)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (6)..(6)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (14)..(14)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (27)..(27)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (39)..(39)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (1230)..(1230)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (1232)..(1232)
<223> n equals a,t,g, or c

```

```

<220>
<221> misc_feature
<222> (1236)..(1236)
<223> n equals a,t,g, or c

<400> 26
ncggngnggca gaangaaat ataaagnaaa ttttctgng cattcggcac ctacctctcag 60
cgagtgtctgc agaactgcc ctggcccacat agctgtccgg ggagcatcta cagaactgtg 120
gtgagaccaca catacaaggt gatgtacaag atagtaccg ccctgtgagt gagggtctgc 180
cttgggacatc caggagtgag ctgcgagaa gttgcagctt cctctgcctc ctctggagccc 240
atgttgtctgc cagttaccat gcggcggatg gcgtcttcgg ccacagcctt ctcaggttgt 300
ctcaactgca gcaaaaggttc agagctgaca gagcggctga aggtgtctgga gggcagaagt 360
acctatgctc ctgtcataga gcagccagta cctccaacac cagctaccct taggagacct 420
gccccctctt ggggtcccc tctgtcccag gccagcccc gagatggagg cctccaggac 480
caagtctgtt ctctggggct tcccgggccc accggcccca agggagatgc cggcagtcgg 540
ggcccaatgg ggtgagagg cccaccaggt ccacagggcc cccaggggag ccttggccgg 600
gctggagctg tgggcacccc tggagagagg ggacctcckg ggccaccagg gctctctggc 660
ccccctgggc cccagcccc tgttgggcca cccatgccg ggtatctcca gcatggagac 720
ccattgtctg ccaacacctt cactgagacc aacaacctt ggccccagg acccaactgg 780
ctccacaggc ctccaggccc catgggtccc cctgggctc ctggccccac aggtgtctct 840
gggagtctct gtcacatagg acccccagg cccactggac ccaaaggaa ctctggccac 900
ccaggagaga agggcgagac aggactgcgt ggggagcctg gcccccagg ctctgtctgg 960
cagcgggggg aacctggccc taaggagagac ctctgtgaga agagccactg ggctctagc 1020
ttacagagct tctctgacga gcaggctcag ctggagctcc tggccagam ggtcamcttc 1080
ctgaaagcca tcatctggcc agaaccagag ctgggggtct gggggcgccc tgcggcgama 1140
ggacccccag cytctctcgg gcaagagggg cggacatgca accaaactac cggatctgtg 1200
gccccagaa cccgggacga agagaagctn annngn 1236

<210> 27
<211> 832
<212> DNA
<213> Homo sapiens

<400> 27
ctgctgggca gcggggggaa cctggcccta aggaagacc ttgtgagaag accctggaac 60
cagagctggg gtcctggggg gccctgtccg gcacaggcac cccagcctc ctctggggga 120
agagggggcg acatgcaacc aactaccgga tctggccccc caggagccgg gacgagagag 180
gtcgagggtg gtggcgggcc ctgaggcaga ccaggccagg ctccctctcc taccctggact 240
cgggcagctg cctccaggga ccgcgcctcc atatttatta agtctctcag ggtctctct 300
gccatctagg ccttaggggt aagcgtctgc cagctctcgg accatgca tgtctgaggc 360
tgagcaagct cttgagggag aggcttgggc ctacgttctc ctctgtgaag tgggggtggc 420
caggctctca agggaggata gaggtacaag gcttctctc atctctgtc tgaacatcca 480
ggcccaaaag cacttgggga gtcaggagct ggggctcggc acatgcagag atgacaggc 540
agggggcagt ctctctccc ctccccgacc aaacctcggg gagcctctt gtccccctc 600
ctctctgttg tcaagtgtct ggttccccac cccagggtca ggtctcccaa tctctgtact 660
ggatcacagg gggctctctg cctcagttct tctctctgag ccccgaggcc ctcccgact 720
tcaggttggg gatggggaca tggagagaa ggggccgctt actctctcaa atgtctgtga 780
cagatgccag gaggtagatg ctgtctctta tacacatctc aacctcatc ga 832

<210> 28
<211> 1967
<212> DNA
<213> Homo sapiens

<400> 28
ccacgcgtcc gcgcgcggag ggcgcctggt gcagcatggg cggcccgagg gcttggggcg 60
tgctctgcct cgggtctcct ctcccgggag gcggcgctgc gtggagcatc tggcgagctc 120
cgtctccggc acgcaggaac ttgtgtctct atgtgtgtgac ccgacgacatc taccgacctg 180
tcagaaatgg cactacacct cagcagatgc tgcagaactg cccctggccc atgagctgtc 240
cggggaatgc ctacagaact ggtgtgagac ccacatacaa ggtgatgtga aagatgtga 300
ccggcctgga cttgaggtgc tgccctgggc actcaggagt gagctgcgag gaagttgcag 360
ctctctctgc ctctctggag cccatgtgtg cgggcagtat catcgcggtc atggcctctc 420
ggcccaagct ctctcaggt tgtctcaact gcagcaaatg ctgagagctc acagagcggc 480
tgaaggtgct ggagggcaga atgacctgc tctactgtcat agagagacca gtacctcaa 540
caccagctac ccttgaggac cctgccccgc tctggggctc cctctctgcc aggggacgcc 600
ccggagatgg aggcctccag gaccaagtgc gtgcttgggg gcttccccgg cccacggcct 660
ccaagggaga tgccggcagt cggggcccaa tggggatgag agggccacca ggtccacagg 720

```

gccccccagg	gagccctggc	cgggctggag	ctgtggggac	ccctggagag	aggggacctc	780
ctggggccacc	agggcctcct	ggccccctg	ggccccccag	ccctgttggg	gccccccatg	840
ccggagatcca	ccagcatgga	gacccattgc	tgctcaaacac	cttacttgag	accacaaccc	900
actggccctca	ggggcccaet	gggctccag	gcccctcagg	gcccattggg	ccccctgggc	960
ctctggggccc	caagggtgtc	cttgggagtc	ctgggtcacat	aggaccccc	ggccccactg	1020
gaccacaagg	aatctctgtc	caccagagag	agaaggggcga	gagaggactg	cgtagggagc	1080
ctgggccccca	aggtctctgt	gggcagcggg	gggaaccttg	ccctaaggga	gacctgtgtg	1140
agaaagagcca	ctggaaacag	agctggggtc	tggggcgggc	cttgcgggca	caggcacccc	1200
cagctctcctt	cggggccaaga	ggggcggaca	tgcaaccaac	taccggatcg	gtggccccag	1260
gagcccgagag	gagagaggct	gagggttggt	gcggccccct	aggcagacca	ggccaggtct	1320
ccccctctac	ctggactcag	ccagctgctt	ccagggaacc	ccctccaat	ttatttaagt	1380
tctctcagagt	cccttctgcc	atctaggcct	taggggttaag	caggtctctag	tctgtccacc	1440
atgacatagt	ctgaggtctg	gcaagggtct	agaaggagag	cttgggacct	agtttccctc	1500
tgtgaagtgt	ggggagggcag	gccttcaagg	agggatagag	gtacaaggct	tcgtctctac	1560
tgtctgtctga	gcattccagg	ccaaaggcac	tgaaggagtc	aggagctggg	gctcgccaca	1620
tgacagagat	acaggggcagg	gggcagctct	ctccccctc	ccccaccaaa	cctcggggag	1680
ccccctctgt	ccccctccct	cttgttcttc	agtgctgggt	tccccacccc	gaggtcaggc	1740
tgcccaatcc	tctgacttga	tcaccggggg	cttcttgcct	cagttctctc	cttcgagccc	1800
ccagccctcc	ccgcatccga	ggttggggat	ggggacatgg	agaggaaggg	gcgcgctaact	1860
ccctgcaaat	cttgtacag	atgccaggag	gtagatgtgt	gctggccaat	aaaggccccct	1920
acctgattcc	ccgcaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaa		1967

<210> 29
 <211> 1967
 <212> DNA
 <213> Homo sapiens

<400> 29						
ccacgcgtcc	gcgcgcggag	ggcgctcgtt	gcagcatggg	cgcccccg	gcttggggcg	60
tgtcctcgtc	cgggctcctg	ctccccggag	gcgcgctcgc	gtggagcatc	ggggcagctc	120
cgttctccgg	acgcaggaaac	tgtgtcctct	atgtggtgac	ccgcaccatc	tcattgcctg	180
tcgagaatgg	caactacctt	cagcgagatgc	tgacagaactg	ccccctggcc	atgagctgtc	240
cggggagcag	ctacagaact	gtggtagagac	ccacatacaa	ggtgagtac	atgagtgta	300
ccgccccgtg	gtggaggtgc	tgccttgggc	actcaggagt	gagctgcgag	gaagttgcag	360
cttctctctg	ctctcttgag	cccatgtggt	cgggcagtac	catcgccggc	atggcgcttc	420
ggccccacag	cttctcagg	tgtctcaact	gcagcaaatg	ctcagagctc	acagagcgcc	480
tgaagggtgt	ggaggcccaag	atgaccatgc	tgaactgtcat	agagcagcca	gtacctccaa	540
caccagctac	ccctgaggac	cctgccccgc	tctggggctc	ccctcctgcc	ccggcagacc	600
ccggagatgg	agggcctccg	gaccaaagtc	gtgcttgggg	gcttccccgg	cacccgctcc	660
ccaaaggaga	tgccggcag	cggggcccaa	tggggatgag	aggccccaca	gggtccacag	720
gccccccagg	gagccctggc	cgggctggag	cttggggcac	ccctggagag	aggggacctc	780
ctggggccacc	agggcctcct	ggccccctg	ggccccccag	ccctgttggg	caacccatgc	840
cccgagatctc	cagcatcggg	gaacctatgc	tgtccaacac	cttacttgag	accacaaccc	900
ctctggggccc	gggacccaet	gggctccag	gcccctcagg	gcccattggg	ccccctgggc	960
gaccacaagg	aatctctgtc	caccagagag	ctgggtcacat	aggaccccc	ggccccactg	1020
gtggcccccca	aggtctctgt	gggcagcggg	gggaaccttg	ccctaaggga	gacctgtgtg	1080
agaaagagcca	ctggaaacag	agctggggtc	tggggcgggc	cttgcgggca	caggcacccc	1140
cagctctcctt	cggggccaaga	ggggcggaca	tgcaaccaac	taccggatcg	gtggccccag	1200
gagcccgagag	gagagaggct	gagggttggt	gcggccccct	aggcagacca	ggccaggtct	1260
ccccctctac	ctggactcag	ccagctgctt	ccagggaacc	ccctccaat	ttatttaagt	1320
tctctcagagt	cccttctgcc	atctaggcct	taggggttaag	caggtctctag	tctgtccacc	1380
atgacatagt	ctgaggtctga	gcaagggtct	agaaggagag	cttggggctc	agtttccctc	1440
tgtgaagtgt	ggggagggcag	gccttcaagg	agggatagag	gtacaaggct	tcgtctctac	1500
tgtctgtctga	gcattccagg	ccaaaggcac	tgaaggagtc	aggagctggg	gctcgccaca	1560
tgacagagat	acaggggcagg	gggcagctct	ctccccctc	ccccaccaaa	cctcggggag	1620
ccccctctgt	ccccctccct	cttgttcttc	agtgctgggt	tccccacccc	gaggtcaggc	1680
tgcccaatcc	tctgacttga	tcaccggggg	cttcttgcct	cagttctctc	cttcgagccc	1740
ccagggccctc	ccgcatccga	ggttggggat	ggggacatgg	agaggaaggg	gcgcgctaact	1800
ccctgcaaat	cttgtacag	atgccaggag	gtagatgtgt	gctggccaat	aaaggccccct	1860
acctgattcc	ccgcaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaa		1920

<210> 30
 <211> 2006
 <212> DNA
 <213> Homo sapiens

```

<400> 30
ccacgcgctcc ggcgcgcggag ggcgcctggg gcagcattgg cggccgcggg gcttggggcg 60
tgctctgect ggcgtctctg ctcccgggag cggcgctctg gtggagcctc ggggcagctc 120
cgctctccgg acgcaggaaac ttgtgctctc atgtgggtgac cgcgaccatc tcatgctcat 180
tgcagaattg cacctacct cagcgagtg cgcagactat ggtgatgtac atgagctgtc 240
cggggagcag clacagaact gtggtagagc actcaggagt gactgcggag gaagtgtcag 360
ccgccgttga gtggaggtgc tgccttgggc cccatgtggg cgggcagtat catcgccgg atggccttc 420
cttctcttgc ctctctggag cccatgtggg cgggcagtat catcgccgg acagagcggc 480
ggccacagc ctctcgaagt tgtctcaact gcagcaaat gtactgtcat agagcagcca gtacctcaa 540
cagagagatg aggcctccag gaccaagtgc ttgtggggcc cctctctgcc cggggcagcc 600
ccaggaggaga tggccgcagt cggggcccaa tggggatgag agggccacca ggtccacagg 720
gcceccagag gacgccttgc cgggctggag ctgtgggcac cctggagag aggggacctc 780
ctgggcacac agggcctctc ggcctccctg ggcctccagg cctgttggg ccacctcagg 840
cccgatcttc cccgatggga gacctattgc tgtccaacac ctctactgag accaacaacc 900
actggcccca gggaccactc ggcctccag gccctccagg gccatgggt cccctggggc 960
ctcttggccc cacaggtgtc cctgggagtc ctgggtcacat aggaccccca gggccactgc 1020
gacccaaaag aatctctgct caccaggag agaaaggcga gagaggactc gttggggagc 1080
ctggccccea aggccttctc gggcagcggg gggaaacttg ccttaaggga gacctgggtg 1140
aagaagacca ctggaaaccag agctggggtc tgggcgggcc ctgcggccac aggcaccccc 1200
agcctctctc ggggcaagag ggcggacatg caaccaccta ccgggatctg ggcctccagg 1260
agccgggacg agagaggctg aggggtgttg cggcccttga ggcagaccag gccaggcttc 1320
ccctctaac ttgactcggc cagctgcctc cagggaacgc cgtctcat tttatagt 1380
cctcagggtc cctctgcca tctaggcctt aggggtaagc aggtctcagt cctggacca 1440
tgcaactgtc ttaggcttag caaggctga gaggagagc ttgggctcgt gtttctctc 1500
gtgaagtggg gggaggcagg ccttcaaggga gggatagagg tacaaggctc cgtctcatc 1560
gtgtcttggg catccagccc caaaggcact gaggagtgca ggaagtgggg ctgcggacat 1620
gcagagatga cagggcaggg ggcagttctc ctccccctcc cgcgccaacc ctcggggagc 1680
ctctcttggc cctctctccc ttgttgtcca gtgctgggtt ccccaaccgc aggtcaggct 1740
gcceaatctc ctgactggat caccgggggc ttcttgcctc agttcttccc tctgagcccc 1800
caggccctcc cgcactccag gttggggatg gggacatgga gaggaaaggg ccgcctactc 1860
ctgcaaatgc ttgtgacaga tgcaggagg tagatgtgtg ctggccaata aaggccctca 1920
cctgat tccc cgcataaaaaa aaaaaaaa aaaaaaaa aaaaaaaa 1980
aaaaaaaaa aaaaaaaaaa aaaaaa 2006

```

```

<210> 31
<211> 897
<212> DNA
<213> Homo sapiens

```

```

<400> 31
ccacgcgctcc ggcgcgcggg ctgctgaggg gtctgagccc cggcagagggt gtgtgggtag 60
ctccaccagg gtccactcag gccctcaacc tgcctctctc tccccccagg gggactctct 120
cggctcccca ggaactccag gtcgagaagt gaccgcggag actctgcttc acgagtttca 180
ggagctgctg aaagaggcca cggagcccg gtctctcagg ctcttggaac cgtctgtgcc 240
caggggggcg cagctcggc tggtagggga ggccttccac tgcgggtgc cggctcccg 300
tgctctctg agagctccg gtctgagcct ggcttgcagg cggcttgcagg ctgccctgtc 420
cggcactctc cagtctctc ccagtctgca cgtggaccac agtgagctgc agggcaaggc 480
cggctcggg cccgggagc ttgtgtgtgt tctcatctgt attgagctcc tggccagcg 540
ccacactgtc ctggaggcgc tctcaggcct ggagagcaac agcagggtct tgcagctaca 600
ggttgcaggg ctgctccagc tgcaggctgg acagtacgct tctgtgtttg tggacaatgg 660
ctccggggcc ctctccacca tccaggcggg ctccagcttc tccgggtgc tcttgggacc 720
gtgaggggc caggggggcg tggcgaggag ctcccgcg atccccggg cctctctact 780
gatgcccggt gtaccaccaa taaagagccc tccacctca aaaaaaaaaa aaaaaaaaaa 840
aaaaaaaaa aaaaaaaaaa aaaaaa 897

```

```

<210> 32
<211> 990
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> misc_feature
<222> (751) .. (751)

```

<223> n equals a,t,g, or c

<220>

<221> misc_feature

<222> (879)..(879)

<223> n equals a,t,g, or c

<220>

<221> misc_feature

<222> (888)..(888)

<223> n equals a,t,g, or c

<220>

<221> misc_feature

<222> (897)..(897)

<223> n equals a,t,g, or c

<220>

<221> misc_feature

<222> (899)..(899)

<223> n equals a,t,g, or c

<220>

<221> misc_feature

<222> (901)..(901)

<223> n equals a,t,g, or c

<400> 32

ggggaactgc	agtacacgca	ggagtaagag	tggggaggcag	gacagagctg	ggacacaggt	60
atggagaggg	ggttcacgca	gcctagagag	ggcagactat	cagggtgccc	gcccgtgagaa	120
tcaggaggaga	ggagcggaaa	cagaagaggg	gcagaagacc	ggggcaactg	tgggttgacg	180
agccctccag	ccatgttgga	agccaagcca	cactggctac	caggctccct	acacagctccc	240
gggctgcctc	tggtttctggt	gcttctggcc	ctgggggccc	ggtgggcccc	ggagggggtca	300
gagcccgctc	tgctggaggg	ggagtgcctg	gtggtctgtg	agcctggccc	agctgctgca	360
ggggggcccc	ggggagcagc	cctgggagag	gcaccccctg	ggcgagtggc	atttgytgcg	420
gtccgaagcc	accaccaatga	gccagcaggg	gaaccgcgca	atggcaccag	tggggccctc	480
tacttcagacc	aggttcctggt	gaacgagggc	gggtggcttg	acccgggccc	tggtctcttc	540
gtagccctcg	tcgggggtgt	ctacagcttc	cggttcctat	tggtgaaggt	gtacaaccgc	600
caaatctgctc	aggttgagcct	gatgctgaac	acgtggcctg	tcactctcagc	ctttgccaat	660
gatacctgacg	tgacccggga	ggcagccacc	agctctgtgc	tactgcccct	ggacccctggg	720
gaccgaagtgt	ctctgcgcct	gcgtcggggg	naactctactg	ggtgggttggg	aatactcaag	780
ttctctctggc	ttctctcatct	tcctctctctg	aaggacccaa	gtctttcaag	cacaagaatc	840
cagccctctga	caactttctct	ctgcctctctc	ttgccccana	aacagcanaa	ccggaganana	900
naectccctct	ggctcctatc	ccactctctt	gcattgggaac	ctgtgccaaa	cacccaaggt	960
taagaaaaaaa	ataaaactgt	ggcatctcca				990

<210> 33

<211> 1384

<212> DNA

<213> Homo sapiens

<400> 33

tcgagttttt	tttttttttt	tttgaccacc	attctctagt	tgttttattg	atagattcat	60
ccaggctggg	ccaatgggac	agcgggataa	gaagaagaga	gggaggggtt	agcatactgg	120
caggagaggg	tctgaaggaa	tgaatcatgg	aatcccaagt	aataggaagc	ctaaggagga	180
gaataagaca	gcacagatca	ggagaagag	agatagtggg	gatatgctgg	aacaggtaca	240
gtgaaratata	ctcagtgaga	gagctgggag	gaaggaggca	gcagtcaag	tttgaggagga	300
ctaagaattca	aacttcaag	gtggacagtt	tcaggaggtg	gccaaagca	argatgcatg	360
gttatcsatg	ttttccatgg	tccacttcca	gctctgtata	cctgcwcag	ytirytytt	420
ytcttaaatc	tggtgttttg	gcacaggktc	ccatgcaaac	argtgggata	ggarccagag	480
ggagtctctc	tcctgcctcg	gctgtttctg	gggcaagaga	gggcagaaga	aagtgttcag	540
ggctctgaat	cttgtgtctg	aaaracttgg	gtcctcagag	aggggaagat	ggaaagccag	600
agaaacttga	gtatttccaa	ccaccacgta	gattcccccg	acgcaggcgc	agagacactc	660
gtgtccccag	gtccaaggcc	agtagcacag	agctgggtgg	tgctcccgg	gtcactgcag	720
gatcatgtgc	aaagcctcag	atgacaggcc	acgtgttcag	catcaggctc	acctggaacg	780
tttggcggtt	gtacacatga	accacatgga	accggaaagt	gtagacaccc	ccggacaggg	840
ctacgaagga	gccagagggc	cgggtcaaac	caccgcctcc	gttcaccagg	acctggtcga	900

```

agtagatggc cccamtgggt ccattgcccgt tttcccctgc tggctcatgg tghtggcttc 960
ggaccgcagc aaatgccact cgcaccagggg gtgcctctcc cagggctgct ccccggggcc 1020
ccoctgcagc agctcgggca ggctcacaga ccaccaggga ctcccctcct agcaggagcg 1080
gctctgaccc gtctcggggc caccggggcc caggggccag aagcaccaga actaagggca 1140
gcccgggact gtgtagggga cctggtagcc agtgtggctt ggctcccaac atggctgaag 1200
ggctctcaaa ccgcaaggag ccccggtctt ctgccctctc tctgtttccg ctctctcccc 1260
tggattctca ccgcggggcg cctgtagtgc tggcctctct aggctcgcgt aaccccctct 1320
cctacctgtg gtcccagctc tgtcctgctt cccactctta ctctcgtgtt cactgcagtt 1380
cccc
<210> 34
<211> 809
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<222> (307)..(307)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (751)..(751)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (756)..(756)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (804)..(804)
<223> n equals a,t,g, or c

<400> 34
ccctgtcgtc cccgtgcggg cgcagaacga caccggagccc atcgtgctgg agggcgaagt 60
ctcgggtggt tgcgactcca gccctgcggc ggcaggcgcc gtcacctctc ccttaggcat 120
ctcgtgcgcg tcgggcagcg ccaagggtggc ctctccgcc acgcggagca ccaaccacga 180
gcgctccgag atgagcaacc gcaccatgac catctatttc gaccagggtat tagtaaatat 240
tggcaaccac ttgatcttg ctccagtat atttgtagca ccgagaaaag ggaattatag 300
cttcagnttc cacgtgggtca aagtgtataa cagacaaaacc atccaggtca gtttaagtca 360
gaatggctac ccagtgatct cggcctttgc aggagaccag gatgtcacca gagaagctgc 420
tagcaatagg tgcgtcgtgc tcatggaaaag ggaagacaaa gtgcattcca aacttgagag 480
aggcaacctc atgggggggt ggaatactc cacattctcg ggcctcttgg tgtttctctc 540
ataaacacag agccccctag atggtggggg aatggcaaac tggaccacag actccgccct 600
ttaaacacac ctggaaactta ctggaattgg acaccttgtt tccaacctcc gttcagactg 660
tttgcagtag gaaggaaatga ttctctttgg aaacctccag tacttttgtt ttgttttttg 720
ggattattga catttctcgc ggaaccgggc ntttnttag ttttttagat gacaaggctc 780
ttaagggaga attgaatttt tcgntttga
<210> 35
<211> 1215
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<222> (1212)..(1212)
<223> n equals a,t,g, or c

<400> 35
ggggcgcgag ctccagctcc cgggtgccgg gactcgggtc tcccgccagg gggcgccact 60
cccgcgctt tgcagccctg agcgggggag ggcgccaggc ggcgggagcc cctttggcca 120
gccccccaga tctgccctgc ggggaaggggt ggaggaggta cccgtgcggg aggaagcgct 180
ggcgaaqct caggcagggg cggggagggg tacggtgacc ttagagtcgc gcgccgctg 240
cgggctgagc cgcgcgtact ctcamctcgc cgcgccgctt accccgcagg actgccggga 300

```

```

cctcgagggg accccggggc gcgaggagag gggggaccgg cggggcccac cggggcctgcc 360
ggggagtgct cgggtgccct gggatccgcc ttacggccca agcgtctccg gagccgggtg 420
cctccgcgct ctgagccacc ctgccccttc gaccggtgac tggtagaaca gcaaggacat 480
taagagcgcc tctacgggca gttcaccctg caggtgctcg ggggtacta ctctccgcgc 540
catgccaccg tctacgggca cagcctgcag ttgatctgg tgaagaatgg gcaatccatt 600
gcctctttct tccagctttt cgggggggtg cccaagccag cctcgtctct gkgggggggc 660
atgggttcgg tgagccctga ggaccaagtg tgggtgcagg tgggtgtggg tgactacatt 720
ggcatctatg cccagcatca gacagacagc accttctccg gatttctggt gtactccgac 780
tggcacagct cccagctctt tgcttagtgc ccactgcaaa gtgagctact cctctcactc 840
ctagaagagc ggtgtgaggg tgacaaccag gtcatccagg agggctggcc cccctggaat 900
attgtgaatg actaggggag tggggtagag cactctccgt cctgctgtcg ccaagggaatg 960
ggaaacagtgg ctgtctctga tcaggtctgg cagcatgggg cagtggctgg atttctgcc 1020
aaagaccagag gagtgtgtct tgctggcaag tgaagtccc ccagtgtctc tgattccagg 1080
gccaccggtg ggtgtgtctc ttctgtgtcc tetgtctctc tggatcctcc ccaacccctc 1140
ctgctcctgg ggcgcgccct ttcttcagag atcactcaat aaaccttaaga accctcaaaa 1200
aaaaaaaaa anggy 1215

```

```

<210> 36
<211> 1311
<212> DNA
<213> Homo sapiens

```

```

<400> 36
ggtcgaccga cgcgtccgca ctcagacacc gtgtcctctt gcctgggaga ggggaagcag 60
atctgaggac atctctgtgc caggccagaa accgcccacc tgcagttcct tctccgggat 120
ggacgtgggg cccagctccc tgccccacct tgggtggaag ctgctgtctg tctgtgtgt 180
gtgccccttc agggggccaag ctgctacggg atccccagga tgcccggcct 240
gcccggggga ccagggaagg atgggtacga cggactgccg gggcccaagg gggagccagg 300
aatcccagcc attcccggga tccgaggacc caaagggcag aagggagaa cggcttacc 360
gcgccatctt gggaaaaaat gcccatggg acccctggg atgccagggg tgcccggccc 420
catgggcatc catggtagag caggtgagga gggcagatac aagcagaaat tccagtcagt 480
gttccaggtc actcggcaga cccaccagcc ccttgcaacc aacagcctga tcagattcaa 540
cgcggtctct accaaccggc agggagatta tgacacgagc actggcaagt tgcactgcaa 600
agtccccgct ctctactact ttgtctacca cgcgtcgcat acagccaacc tgtcgtgtgt 660
gctgtaccgc agcggggtca aagtgtgtac ctctgtggc cacacgtcca aaacaaata 720
ggtcaactcg ggcgggtgtc tgctgaggtt gcaggtgggc gaggaggtgt ggtcgtgtgt 780
caatgactac tacgacatgt tgggcatcca gggtctgac agcgtctctt cggcttctct 840
gtcttctccc gactaggggc ggcagatgag ctgcagcccc accggcccttc cactctctct 900
agcttctctg atggacccca ctacttgccc agtctgcatc ctgtcctaga ccatctctct 960
caccagatgg acttctcttc caggagagcc accctgacc accccaactg caccctctct 1020
coattgggtc tctcctctct ctgaactctc ttaggagtc ctgctgtgtg ggtctctggg 1080
acactaacac aatgcctctt ggtactgcca ttctttttt aaattttt aaattttt 1140
aggggtgggg agatatataa ataaatcatg aaatcaatc aaaaaaaaaa aaaaaaaaaa 1200
aaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa a 1260
aaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1311

```

```

<210> 37
<211> 350
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> misc_feature
<222> (4)..(4)
<223> n equals a,t,g, or c

```

```

<220>
<221> misc_feature
<222> (7)..(7)
<223> n equals a,t,g, or c

```

```

<220>
<221> misc_feature
<222> (9)..(9)
<223> n equals a,t,g, or c

```

```

<400> 37

```



```

gggnatnang ctctctgctc ttccccgact agggcgggca gatgcgctcg agaccacagg      60
gccttccacc tccctcagct tcctgcacgg acccacctta ctggccagtc tgcacctctg      120
cctagaccat tctccctctc agggagccca cctcgaccca ccccaactgc accccctccc      180
catgggttct tctctctctc tgaactttct taggagtcac tgcttggtg tgctctggga      240
cacttaacca atgctctctg gtactgccat tcttttttt ttttttcaa gttattggaag      300
gggtggggag atatataaat aaatcatgaa atcaaaaaaa aaaaaaaaag      350

<210> 38
<211> 622
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<222> (316)..(316)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (511)..(511)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (525)..(525)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (578)..(578)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (582)..(582)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (599)..(599)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (614)..(614)
<223> n equals a,t,g, or c

<400> 38
ggggagcaga tctgaggaca tctctgtgcc agggcagaaa cgcgccacct gcagtttctt      60
ctccgggatg gaactggggc ccagctccct gccccacctt gggtggaagc tgctgtgctg      120
cctgtctgtg ctgcccctca ggggccaagg caacacaggc tgctacggga tcccagggat      180
gcccgccctg ccgggggcac cagggaagga tgggtacgac ggactgccgg ggcccaaggg      240
ggagccagga atccagccat tccgggatcc gaggacccaa arggcagaag ggagaacccg      300
gcttacccgg ccatcttggg aaaawtgggc catggkaccc cctgggatgc caggggtgoc      360
ggcccatagg catcccttga gagcaggtga gragggcaga tacaagcaga aattccagtc      420
aktgttcagg cactcggaga ccacagcccc tgaccaaca gctgatagat caacgcggtc      480
taacaaccga aggagatata cacgacactg naagtcaact aaagncgggc ttacacttgc      540
tacacgcgtg ataacgaact ggctgtgtga cgaacggnta angggcactt tgggcaacnc      600
aaacataggc aatnccgggg ct                                     622

<210> 39
<211> 1333
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature

```

```

<222> (485)..(486)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (493)..(493)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (496)..(496)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (587)..(587)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (633)..(633)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (1330)..(1330)
<223> n equals a,t,g, or c

<400> 39
agctgggtacc aaagcaagatt ttctactgag ctctcatgaa agatcctcag tctcttggg 60
atttgaatc tcgcagcagc ccaccatcta agagcaagar ccaagatgt ttgtcttgc 120
ctatgttaca agttttgcca ttgtgtccag tggacaaccc cggggtaatc agttgaaagg 180
agagaactac tcgccagggt atatctgcag catctctggc ttgcctggac ctccagggcc 240
ccctggagca aatggttccc ctggggccca tggctgcctc ggcttccag gaagagatgg 300
tagagacggc aggaaggagg agaaagggtg aaagggaact gcaggtttga gaggtaaagc 360
tgagacgccta ggtcttgcgc gtgagaaaagg ggaccaagga gagactggga agaaaaggacc 420
cataggacca gagggaagaga aaggagaagt aggtccaatt ggtctcctg gaccaaaggg 480
agacnnatga tancntnagg acccggggct gcctggagtt tcgagatgtg gaagcatcgt 540
gctcaaatcc gccctttctg ttggcatcac aaccagctac ccagaanaaa gactacatct 600
tatatttaac aaggtctccc ttccacgagg ganagcacta caacctctgc acagggggaag 660
ttcatctgtg ctttcccagg ggaatctatta cttttcttat gatatcacat tggctaataa 720
gcactctggca atcggagctgg tacacaattgg gcaataccgg ataaagacct tgcagcccaa 780
cacaggaaac catgatgtgg cttcgggggtc cacagtcctc tatctgcagc cagaagatga 840
agctctggctg gagattttct tcacagacca gaatggcctc ttctcagacc cagggttgggc 900
agacagccta tctctcgggt ttctcttata cgttgacaca gattacctag attccatcc 960
agaagatgat gaattgtgat caggaccaag atccctgtgg taaacactct gattgaatct 1020
gggggttcag aaggtgggac aacgaggaat gggatccaaa gagactccca ctgagattct 1080
aaagcattta aagacaattc tagcagaatt tatcaaaaaa agatgaacaa cagaaaagtt 1140
gaaaccacaa caaaatgaat tctattaagg aatagcccca gatataaatt ctcttgaagg 1200
caatgttcat aaatatttaa gcaaatataa gacaatgtta acaaattttc tattaaattgc 1260
cctgagtgat aaaaaccagt ggcaataata ttgccttatt aatcttccaa aaaaataaaa 1320
aaattaaaaa aaa 1333

<210> 40
<211> 1211
<212> DNA
<213> Homo sapiens

<400> 40
tcgagttttt tttttttttt ttgatgaat aaaaaggttt ggatttaatt aaggggaaaa 60
aaagagcgrg agggagtgag cctgaggcta gaacgcgtca ctcgaccccc cacccccagc 120
ctacagttgt ggggtctctgc tctgtaagcc caagtcacaga agcttgttcc ctgcctggag 180
gaccgcctgg gcattgtctat acctcgttgg ggtcatctcg gtcggcatag attaggaagc 240
ccgtaaaagg gctgtctctgc cagtaagggt catagaagag ctcgttctgc ttgctgtaga 300
agatctcgag ccaaacctcg tcacctgtct tgagagccag gatgtgtgag cctgagacca 360
catcgtgggt ccgggtgttg gcatcaagg tcggatgcgc gtactggcgc ttgtgcacca 420
ggccgatggc caggtgtctg ttggccagcg tgatgtcgta ggtgaagtga tagatccag 480

```

```

gcacgcgcga gacgaacttg ccgctggaag cattgtagt ggcaccctcg ttcacatgaa 540
tctgttcaaa ctgtgatggc agccgctccc gtgggtagct ctgtgtcact gccaccgaga 600
aaagctgactt ggtatggcca ctgccacagc tgcaggggcc tggggaggcc ggcctccccc 660
tcttgcccttt gggccctctc ttgcttggtg tggcatgctt ccggggggtg ccgttgacc 720
tcttggggccc acggggccga gccgcgccaa tggcccgccg ttggcccttt ggtctggct 780
ttcccggtt acctgtccgg ccaggtggag ctctctctcc gctgtccccc cgttccggt 840
cgtgtccatc ttggcgctct ttgccaagaa agcccaatcg tcccatcatt cctgagggc 900
ctggggctcc tggggggccc ggtgggccc gggggccagg caggctgcag accagttag 960
gggagccttt ccggaagctc ctgcgagcaa aggcgccaa cagtgggtca cgcacacag 1020
ggagggcaga gccccaggag acccagggga tcatgtgggt tacctctcgc gctcccgc 1080
acgtccaggg gcgtccggag caaagaagct cctcgtgccg aatctctgca ccgccgggga 1140
tcactagtgt cttagagcgc cgccaccgcg gtggagctcc agcttttgtt ccwtttagga 1200
ggaagattcc c

```

```

<210> 41
<211> 616
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> misc_feature
<222> (262)..(262)
<223> n equals a,t,g, or c

```

```

<220>
<221> misc_feature
<222> (536)..(536)
<223> n equals a,t,g, or c

```

```

<400> 41
ggcacagcgc acgcaacttg gtgggctcgg acgttgcccc cgggcgccgc accaaccact 60
cgccctcgac accgagttcg tcaacattgg cggcgacttc gacgcgrcgg ccggcgtggt 120
ccgctgcgct cctcccggcg cctacttctt ctcttcacg ctgggcaagc tgccgcgttaa 180
gacgctgtcg gttaaagctga tgaagaaccg cgacgaggtg caggccatga ttacgacga 240
cgccgcgtcg cgccgcgcgc angatgcaga gccagagcgt gatgctggcc ctgcgcgcgc 300
gcgacgctc ttgctgtcca gccacgacca cgacggctac ggcgcctaca gcaacacagg 360
caagtacatc accttctccg gcttctcggt gtaccocagc ctgcgcccgcc gcgcccgccg 420
ggcctcgggg cctcggagct actgtgagcc ccggggcaga gaagagcccg ggaggccag 480
gggcgtgcat gccaggccgg gcccgaggct gcaaaagtcc gcgcgagccc caccgntccc 540
ggcgccgctt ggaactctgc aataaagcgg aaagcgggca cggcaggccc ggmagccag 600
gmaaaaaaaaa
616

```

```

<210> 42
<211> 1161
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> misc_feature
<222> (1113)..(1113)
<223> n equals a,t,g, or c

```

```

<400> 42
gccagcctgc tgggtccatgg gaggggaccg tcaggggaaa gcccttccc cctctgggga 60
aggaaacttc cgcttcggac cgagggcagc aggcctctcg ctctgtgtcc cactgtgct 120
gaccgccagg gcctcacagg acaccagctt cccaggagcg gtctgacaca gtatgatgat 180
gaagatccca tggggcagca tcccagttact gatgtgtct ctgctctcgg ccttaacga 240
tatctccagc gccccagctc gctgcaccgg gcccccagcc atccctggca gccctgggat 300
ccctgggaca cctggccccg atggccaacc tgggacccca gggataaaa gagagaaagg 360
gcttccaggc ctgctggcag acctaggtga gtccggagag aaggagagacc cagggtatcc 420
tgggaatcca ggaaaagtgc gccccaaggc ccccatggg cctaaagtg gccccaggcg 480
ccctggagcc ccaggcccca aaggtgaatc gggagactac aaggccacc agaaaatcgc 540
cttctctgcc acaagaacca tcaactctcc cctgcgcgg gaccagacca tccgtctga 600
ccacgtgcat accaactaga acaacaatta tgagcccgcc agtggcaagt tcacctgcaa 660
cctgcgccgt cctactactc tcacctacca cgcagctct cgagggaacc tgtcgtgaa 720
ggatctcgt gggccgggagc gtgcacagaa ggtggtcacc ttctgtgact atgcctacaa 780
caccctccag gtcaccaccg gtggcatggt cctcaagctg gaggcgggg agaagctct 840

```

cctgcaggcc	accgacaaga	actcactact	gggcatggag	ggcgccaaca	gcattcttttc	900
cgggttccctg	ctctttccag	atatggaggc	ctgacctctg	ggctgcttca	catccacccc	960
ggctccccct	gccagcaaac	ctcactctac	ccccaacacc	accctctgac	cagccaatgc	1020
acacagtagg	gcttgggtga	tgctgctgag	tgaatgagta	aataaactct	taagagccaa	1080
aaaaaanaaa	aaaaagcact	taagtattca	tcnaacaatc	accagtagtc	gggtgatccag	1140
actgaaaaga	tgcgagagcg	c				1161

<210> 43
 <211> 687
 <212> DNA
 <213> Homo sapiens

<400> 43	
ccggggccccc	cccccgagtt
tcacttcagca	gcattcacca
ggggttagagc	gagcgttgct
caggccctcca	tatctggaaa
cccatagtg	agttcttgct
aggaccactgc	caccggtggt
acctctgtgtg	cacgctcccg
cggtgtgtagg	tgaagtakta
tcataatgt	tgkcatgtt
agggggacgt	tgatggktct
cgattcacct	ttgggctggg
tggggcccgc	ttttcctgat
tttttttttt	tttttggcct
tgtaaragttt	atttactcat
ctgggcaagg	ggkkgkgttg
atgtgaagca	gccacacagt
tgctgttgcc	accctccagt
tctccccctg	ctccagcttg
catagtcaca	gaagggtgacc
acaggttccc	tcgagagctg
tgaaacttgc	ctgacgggac
ggatgggtctg	gtccscggcg
tctgggkqgc	ctgagctctcc
ccttaggccc	atggggggcct
	687

<210> 44
 <211> 1194
 <212> DNA
 <213> Homo sapiens

<400> 44	
ttggtccatg	ggagggggacc
ccgcttcgga	ccgagggcag
ggccttcacag	gacacagct
atggggcagc	atcccagtag
ggcccagctc	agctgcacgt
acctggccccc	gatggccaac
cgctggctgga	gaccatgggt
aggaaaagct	ggccccaagg
cccaggccccc	aaagggtgaat
cacaagaagc	atcaacgttc
caccacacatg	aacaaagatt
tctctactac	ttcacctaac
tgacccggag	cgtgcacaga
ggctaccacc	ggtggccatg
caccgacacg	aactcactac
gctctttcca	gatatggagg
tgccagcagc	gctcactcta
ggcttgggtga	atgctgtctg
gtctaatcca	actctgtgtc
tggttacatg	aatgaatgaa
ccatgaatga	atgaaaaaaa
agcccttccc	gcctctgggg
gctcctggtc	ccactgtctg
cgcttgacac	agtatgatga
cctgctcctg	ggcctaactg
catccctggc	atcccgggta
agggataaaa	ggagagaaaag
gaaggggagac	caggggattc
ccctaaaggt	ggcccagggg
caaggccacc	cagaaaaatg
ggaccagacc	atccgcttcc
cagtgccaag	ttcaactgca
tcgagggaac	ctgtgcgtga
cttctgtgac	tatgcttaca
ggagcagggg	gagaacgtct
gggtgccaat	agcatctttt
ggctgcttc	acatccaccc
caccctctgc	ccagccaatg
aaataaaact	ttcaaggcca
gcacaccaga	agtgcacatg
aaaaa	aaaaa
	1194

<210> 45
 <211> 1792
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <222> (19)..(19)
 <223> n equals a,t,g, or c
 <220>
 <221> misc_feature
 <222> (132)..(132)
 <223> n equals a,t,g, or c

<220>
 <221> misc_feature
 <222> (185)..(185)
 <223> n equals a,t,g, or c

<400> 45
 tccgccccat tgcgcgaant ggcgcgtagc cgtgtacggt ggaaggtcta tataascaga 60
 gcttcggtta gtaaccgtca gatcgctgga agcgccatcc acgctgtttt gacctccata 120
 gaagaccggg gmcgcagcca gcytcggagc tctagcttag ccgcgggacg gataccawtt 180
 tcaencagga accagctatg accactaggg ttttgcaaaa agctatlttag gtcacactat 240
 agaaggtacg cctgcgggta ccgggtccgga atccccgggt cgaccacagc gtccggtcct 300
 gccccagtag cccccggagg agaggccgcc ccagcccgca ggtcccaocg gggtcaatcg 360
 ggagacgggc caggccgggc ccccgcgagg cgcaggcggt tctggggcgg gttcgcccg 420
 gggcggtgac ggcagaccg ggagcgccac cgtccccggc gcagaagcct tcggggcgcc 480
 accaggtatc ccgaagtcac ctctgtagc ttccccagga gctccggtgc ctctctctgt 540
 gtctttttct cgggggtcca ccagaagcc ttccccagt gatggggcgg tgtctctct 600
 taacaaagt cgtgtgaacg acggggtgt ttacaacccc agcaccgggg tcttcacggc 660
 tccttatgat gggcgctacc tgatcacggc caccctcacc ccgagagag acgctacgt 720
 ggaagcagtg ctgtcggtct ccaacggcag cgtggccag ctgcataccg ctgggtacag 780
 gagagagttc cgggaatacc accgccctcc agggagcttg catacctgag gggggccggg 840
 ggcatctcac ctcatctgac acctgaaggg gggagatgca gtcaacgtcg tggtagactgg 900
 gggcaagctg gctcacacag actttgatga aatgtactcc acatttagtg gggttttct 960
 atatctttc ttttccacc tctaaggtgg ctggggagat gtcaggggaa agayagatat 1020
 ttgtaaaac tctaaagctt taatatatc gggttctgt taatggaaag cggggccgtag 1080
 agtttccaca taggccccaa cataaagggc ttccctcgct gttgagggca ccatgctcta 1140
 ctgcaccagc caggctgca gragtgagg acacgggtga acatggccac gacttttct 1200
 gccactctaa ctgggacaat ggaagactg gaaaggcctc cactgtatc tactactgga 1260
 gggccctgga gcttgccaca gggctcgt ctgactgtgt ctgggagga 1320
 gggagggcag ggagagccgg tcacgggtggc tgggtcttac tgcagggcag gctgtggcc 1380
 agctgtctgt ctttacctg catgcagaag ttttaacact gaagtgcgca agtggcgtct 1440
 gcgcgcgac agagaccctc actttagtt ttgccagact cggctgttcc acgcttggt 1500
 gctcggaact taacctgct aggggggact tggccagact acaatttaag atcgcttaga 1560
 gactgtctcc aaagctgtt gggctctta aatggcatg acaatttaag tgcaagacga 1620
 cggagtgtca ataaagatt aaagccatt ccagttttaa ccagttttaa aaaaaaaaaa 1680
 aaaaaaaaaa aaaaaagggc ggcgcgtcta gaggatccct cgagggggcc acgcttacgc 1740
 gtgcatgca cgtcatagct ctctccctat ctctccgta ttataagtag ct 1792

<210> 46
 <211> 1412
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <222> (1363)..(1363)
 <223> n equals a,t,g, or c

<400> 46
 ccacggcttc ggtcctgcc cagcggcccc ccgaggagag gccgccccag ccgcagaggt 60
 ccacgggggt catcgaggag acgggcccag ccggggcccc ccgaggcgca ggggtgtctg 120
 gccggggtct gccgcggggc gtggacggcc agaccgggag ccgcacggat ccggcgcgag 180
 aaggctctgc gggcgaccca ggatacccca agtcaactcc ttagtcttcc ccaggagctc 240
 cgtgtccttc tctggtctc tttttctgg ggctcaccca gaagccttgc ccagtgtatg 300
 ggggggtgt cctctttaac aaagtgtgg tgaacgacg ggaatgttac aacccagca 360
 cgggtgtctt caggctcct tatgatgggc gctacctgat gctacggcacc ctacccccg 420
 agagagagc ctacgtggaa gcagtctgt cgtgtccaa ccgcagcgtg gccacgtgc 480
 ataccgtgc gtacaggaga gagtctctgg aataccacc cctccaggga gctttgcata 540
 cctgcccggg ccggggggca ttccacctca tctgcaact caagggcgga gatcgactca 600
 acgtgtgtgt gactgggggc aagctggctc acacagact ttagtgaagt tactccacat 660
 ttagtgggt tttctatata cctttctctt cccactctta agtggctgg ggagatgta 720
 ggggaaagag agatagtgt aaaaactcta atactcgtt atattcggt ttgtatgtaat 780
 ggaagcagcg ggttagagtt tccacatagg cccaacata aaggccttcc ctgtgtgtg 840
 aggtcacact gcttactcgc atccagccag atccagaga gctgagaga ctgcagcaca 900
 ggcactgac tttctgcca ctctaactg acaactggaa gacttgaaaa ggcctccacc 960
 tgtatctaca cttcaggggc cctggaactg gctgagctt gcacagagtg ctccgtgtca 1020
 ctgtgggctg ggaggaggga ggcaggggag accgggtcac ggtggtcgt ctttactgca 1080

gggcagcact	gtggccagct	gtctgtcttt	acactgcatg	cagaagtta	aacactgaag	1140
tgccgaagt	gcccgtgccg	ccgcacagag	acccgactt	tagtttgggc	tgttccacgc	1200
ttgggtcacc	atgtccgcct	gggacttaac	ctgctcagcg	gggccttcgc	ccagctgcaa	1260
atagggatgc	gttagagact	gttcccaag	gtctgtgggc	tctctaaatg	gcagtacaaa	1320
ttcaagtgc	aagacagggg	gtgtcaataa	agatggaaag	ccntttccag	ttaaaaaaa	1380
aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aa			1412

<210> 47
 <211> 646
 <212> DNA
 <213> Homo sapiens

<400> 47						
cgatcctctc	cggtggagcc	agcgagcctc	tctcctgat	cttacgtgct	caaggatcca	60
gtttcaccta	tggaatgaga	aagttgggga	agaagtcatc	tagcgtcttg	ctactcaag	120
ttgtgtccat	ggaccagcag	catcagcatc	acctgggact	ttcttggaag	aaatgtagaa	180
actcagcgct	accaccaaaa	tctgcctttt	tataagaccc	ccagaagctg	ttgtgaagcg	240
agagcagcat	ctgtcgaaga	gacagaaaac	agccccagag	gtgtcacagg	aagtccaccg	300
caaggacatt	ggcttttgat	ttgattcagc	agtcctgtca	agtataaatg	tgtgtcgctg	360
gtctgcctgg	cctctgcagc	tgctgggagt	gctgcttacc	atttccctga	gttccatcag	420
gctcttaccg	gctgtgtcct	actatgggat	caagccgctg	ccacctcaaa	ttctctccga	480
gatgcaccaca	caaatcccaa	aataccagcc	cctgggtcag	caagtacctc	acatgccttt	540
ggccaaagat	ggcctttgcc	tgggcaagga	gatgccccac	ttgcagtatg	gcataagatg	600
tcacacaccta	ccccaatata	tgaaggaaat	tcaaccggcg	gtcgac		646

<210> 48
 <211> 2536
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <222> (2)..(3)
 <223> n equals a,t,g, or c

<400> 48						
gnntgacacc	cagcgccctc	gagcgatgga	gaagctgctg	gcctcggttg	aggagcggtt	60
cgccacccct	cagggtctgg	gggtgggcgc	agggccccc	aggaatgctg	ctctccacag	120
ctggccgcgc	gactgcgcga	gctggagcgc	aggtctggatg	tcgtggccgg	ctcagtgcac	180
gtgctgagtg	ggcgccgagg	cacagagctg	ggaggagcgc	cggggcaggg	agggccaccc	240
ccaggctaca	ccagcttgcc	ctccgcctg	tctcgctctg	aggaccgctt	caactccacc	300
ctgggcccct	cggaggagca	ggaggagagc	tggtctgggg	ctctgggggg	gctgagccac	360
tggtctgctg	ctgcccgggg	ccgactagag	cagttggggg	ggctgctggc	caatgtgagc	420
gggkagctgg	ggggggcggt	ggatctgttg	gaggagcagc	tgccaggggc	catcgagcca	480
agtgcccttg	agcgccctgg	ggcccccctg	gagcaggact	ctcaagtcat	cgagatcttc	540
ctgcacacgg	tggagacagc	ggggagggcc	cgccagggca	cgctggaggg	attacaagag	600
ttgtgtgggc	ggcttcagga	tcgtgtggat	gcccaggatg	agacagctgc	agagtccaca	660
ctacggctga	attctactgc	ggcccggcta	ggccaactgc	aggggctctg	cgaggcccat	720
gggatgatgg	gctgtggggc	ctgtggcgga	gtccaagagg	aactagccgc	ccttcgggat	780
ggtgtggagc	gctgctctct	ccccctgttg	ctctctcggg	gtcctggggc	tggtccaggt	840
ttgtgggggc	caagccgtgg	gcccctggac	ggcttcagcg	gttttggggg	cagctcagcg	900
tcagccctgc	agggccctga	aggagagctc	tctgaggtta	tctcagctct	caetctccct	960
aatgactcac	tgaatgagct	ccagaccact	gtggagggcc	agggcgctga	ttgtgctgac	1020
ggagggccaa	ccaaggacgc	tatcatctct	gagattaaac	ggctcgagca	ggagggcaca	1080
cagcatctgc	cagagagtga	agagcgcttc	cgaggcctag	aggagggcca	gagcacaggc	1140
ggccagtgctg	ccagctctaga	ggggcgatgt	ggccgtcttg	agggtgtctg	tgaacgggtg	1200
gacacttgcc	cttgggggag	cgaggggcctg	cgcgaggggc	tttcagagca	tgagctcttg	1260
ctctgggctg	ggctccggga	aaaccaacac	accagccaga	tcaggggcag	ccctgttgag	1320
aaagctgtctg	ggggacagcg	gggcttgggc	agccgctctg	gtgcccttaa	gccttccttg	1380
cagctcctgg	aggacgctct	gcaccagctc	agcctgaagg	acctcaactg	gccttcaggga	1440
gaggtctggc	ccccagggcc	tctgtggcgt	cagggacccc	caggccctgc	tggaactcca	1500
ggatcaccag	gcaaggagcg	gcaaggaggg	cccatcgggc	caccaggttc	tcaaggtgaa	1560
cagggagctg	agggggccac	agcagccctc	gtgccccaag	gtgcattttg	ctactgtctg	1620
agtttgcgcc	ggctctgaac	aggcagcgct	cccttcgaca	gagtcctctg	caatgatgat	1680
gctctatgat	atccagagag	agggctgttc	acagcgccac	tggtctggag	ctactgtctg	1740
agcgcggtgc	tgactgggca	ccggcacgag	aaagtgaggg	ccgtgctgtc	ccgtcccaac	1800

```

caggcgctgg cccgcgtaga ctcgggtggc taaggagcctg agggcctgga gaataagccg 1920
gtggccgaga ccagagccag ccggggcaacc ctgggcgtct tcagcctcat cctgcgcgtg 1980
caggccgggg acacgggtctg cgtcgacctg gtcatggggc agctggcgca ctccggaggag 2040
ccgctcacca tcttcagcgg ggccctgtct tatggggacc cagagcttga acacgcgtag 2100
actggggctc cgcccgacgt gtctacgtct gctgaagaga cagcgggggc ggccggctcc 2160
tggggtctcg cctcagacgg ggcacctagc cctgggcgag cgcgcgaacc ggccggcgag 2220
cggcacccgc cccagagcgg atcgagactt ttggcctggc ggcgcggctc agggagagctc 2280
ggggcgaggg agcgagctc cgcacccctc cgtccctcca ctggccctcc aggtcgattc 2340
cctgggtccc agcgagctc cgcacccctc cgcgccacgc catactaaac gatcgagaaa 2400
taaaagacac tgggttttct aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 2460
aaaaaaaaag ggcgcg 2520
2536

```

```

<210> 49
<211> 1530
<212> DNA
<213> Homo sapiens

```

```

<400> 49
tccatgtata ggagacagtg aaagagatgg ggggtggcatt ttcttccagg agagtgtggg 60
ggagatgacc gttaggtcat aagcgcgcgc ctactctgca ctggcgagac cagcaaaagt 120
ggagtgaacc cagctgaacc tgggcccgcag cagcccgcga ggcctggaggc gctcgagctg 180
ggaaacacca ggaggatgga gcccttttcc ctgtaagcag gaggccagga tcttgattcc 240
tgagccggct tcccacggac ccagggcccc ggcagggtcc tggcgggagg aagaacccac 300
ggattccagg tctgtcatct gaaccatgag gatctgggtg cttctgcttg ccatgaaat 360
ctgcacaggg aacataaact cacaggacac ctgcaggcaa gggcacccctg gaatccctgg 420
gaaccccggt cacaatggtc tgccctggaag agatggagca gacggagcga agggtagaca 480
aggggatgca ggagaaaccg gacgtcctgg cagcccgggg aaggaaggga cgagtggaga 540
gaaggggaga cgaggagcag atggaaaagt tgaagcaaaa ggcatacaag gtgatcaagg 600
ctcaagagaa tcccagagaa aacatggccc caaggggctt gcaaggccca tgggagagaa 660
agggctccga gagagacgtg ggccctcagg caggaagggg aataaagggtt acgtgggttc 720
cactggtctc gaggggcca ggggcaacat tgggcctttg ggcccaactg gtttaccggg 780
ccccatggg cctattggaa agcctggtcc caaggagaaa gctggaccca cggggcccca 840
gggtgagcca ggagtccggg gaataagagg ctggaaaggga gatcgaggag agaaagggaa 900
aatcggtgag actctagtct tgccaaaaag tgctttactg gtggggctca cgggtctgag 960
caagtttctc tcttcagatg tgcccattaa atttgataag atctctgata acgaattcaa 1020
ccattatgat acagcagcgg ggaattccac gtgccacatt ctgggggtct attacttcac 1080
ctaccacatc actgttttct ccaggaatgt tcaggtgtct ttggtcaaaa atggagttaa 1140
aatactgcac accaagatg cttacatgag cctcgaggac caggccctcg cggcgattgt 1200
cctgcagctg aagctcgggg atgaggtgtg gctgcaggtg acaggaggag agaggttcaa 1260
tggcttgttt gctgatgagg acgatgacac aactttcaca ggggtctctc tcttcagcag 1320
cccgtagacg agggaggttt aaaaatccgc cacaccatcc atcagaatca cctctgggatg 1380
aactatcaca gatggtttta ctttattaat tcttccaatt attacaataa tcataaaaag 1440
gtgaaaatcg aaaaagtatt cccaaaactg attctgtgta acttactatt tttccaggag 1500
taaatattta aataaaaaaa aaaaaaaaag 1530

```

```

<210> 50
<211> 229
<212> PRT
<213> Homo sapiens

```

```

<400> 50
Met Asp Leu Leu Gln Phe Leu Ala Phe Leu Phe Val Leu Leu Leu Ser
1 5 10 15
Gly Met Gly Ala Thr Gly Thr Leu Arg Thr Ser Leu Asp Pro Ser Leu
20 25 30
Glu Ile Tyr Lys Lys Met Phe Glu Val Lys Arg Arg Glu Gln Leu Leu
35 40 45
Ala Leu Lys Asn Leu Ala Gln Leu Asn Asp Ile His Gln Gln Tyr Lys
50 55 60
Ile Leu Asp Val Met Leu Lys Gly Leu Phe Lys Val Leu Glu Asp Ser
65 70 75 80

```

Arg Thr Val Leu Thr Ala Ala Asp Val Leu Pro Asp Gly Pro Cys Pro
 85 90 95
 Gln Asp Glu Lys Leu Lys Asp Ala Phe Ser His Val Val Glu Asn Thr
 100 105 110
 Ala Phe Phe Gly Asp Val Val Leu Arg Phe Pro Arg Ile Val His Tyr
 115 120 125
 Tyr Phe Asp His Asn Ser Asn Trp Asn Leu Leu Ile Arg Trp Gly Ile
 130 135 140
 Ser Phe Cys Asn Gln Thr Gly Val Phe Asn Gln Gly Pro His Ser Pro
 145 150 155 160
 Ile Leu Ser Leu Met Ala Gln Glu Leu Gly Ile Ser Glu Lys Asp Ser
 165 170 175
 Asn Phe Gln Asn Pro Phe Lys Ile Asp Arg Thr Glu Phe Ile Pro Ser
 180 185 190
 Thr Asp Pro Phe Gln Lys Ala Leu Arg Glu Glu Glu Lys Arg Arg Lys
 195 200 205
 Lys Glu Glu Lys Arg Lys Glu Ile Arg Lys Gly Pro Arg Ile Ser Arg
 210 215 220
 Ser Gln Ser Glu Leu
 225

<210> 51
 <211> 421
 <212> PRT
 <213> Homo sapiens

<400> 51
 Met Gly Gly Pro Arg Ala Trp Ala Leu Leu Cys Leu Gly Leu Leu Leu
 1 5 10 15
 Pro Gly Gly Gly Ala Ala Trp Ser Ile Gly Ala Ala Pro Phe Ser Gly
 20 25 30
 Arg Arg Asn Trp Cys Ser Tyr Val Val Thr Arg Thr Ile Ser Cys His
 35 40 45
 Val Gln Asn Gly Thr Tyr Leu Gln Arg Val Leu Gln Asn Cys Pro Trp
 50 55 60
 Pro Met Ser Cys Pro Gly Ser Ser Tyr Arg Thr Val Val Arg Pro Thr
 65 70 75 80
 Tyr Lys Val Met Tyr Lys Ile Val Thr Ala Arg Glu Trp Arg Cys Cys
 85 90 95
 Pro Gly His Ser Gly Val Ser Cys Glu Glu Val Ala Ala Ser Ala
 100 105 110
 Ser Leu Glu Pro Met Trp Ser Gly Ser Thr Met Arg Arg Met Ala Leu
 115 120 125
 Arg Pro Thr Ala Phe Ser Gly Cys Leu Asn Cys Ser Lys Val Ser Glu
 130 135 140
 Leu Thr Glu Arg Leu Lys Val Leu Glu Ala Lys Met Thr Met Leu Thr
 145 150 155 160

Val Ile Glu Gln Pro Val Pro Pro Thr Pro Ala Thr Pro Glu Asp Pro
 165 170 175
 Ala Pro Leu Trp Gly Pro Pro Ala Gln Gly Ser Pro Gly Asp Gly
 180 185 190
 Gly Leu Gln Asp Gln Val Gly Ala Trp Gly Leu Pro Gly Pro Thr Gly
 195 200 205
 Pro Lys Gly Asp Ala Gly Ser Arg Gly Pro Met Gly Met Arg Gly Pro
 210 215 220
 Pro Gly Pro Gln Gly Pro Pro Gly Ser Pro Gly Arg Ala Gly Ala Val
 225 230 235 240
 Gly Thr Pro Gly Glu Arg Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly
 245 250 255
 Pro Pro Gly Pro Pro Ala Pro Val Gly Pro Pro His Ala Arg Ile Ser
 260 265 270
 Gln His Gly Asp Pro Leu Leu Ser Asn Thr Phe Thr Glu Thr Asn Asn
 275 280 285
 His Trp Pro Gln Gly Pro Thr Gly Pro Pro Gly Pro Pro Gly Pro Met
 290 295 300
 Gly Pro Pro Gly Pro Pro Gly Pro Thr Gly Val Gly Ser Pro Gly
 305 310 315 320
 His Ile Gly Pro Pro Gly Pro Thr Gly Pro Lys Gly Ile Ser Gly His
 325 330 335
 Pro Gly Glu Lys Gly Glu Arg Gly Leu Arg Gly Glu Pro Gly Pro Gln
 340 345 350
 Gly Ser Ala Gly Gln Arg Gly Glu Pro Gly Pro Lys Gly Asp Pro Gly
 355 360 365
 Glu Lys Ser His Trp Asn Gln Ser Trp Gly Leu Gly Arg Ala Leu Pro
 370 375 380
 Ala Gln Ala Pro Pro Ala Ser Phe Gly Ala Arg Gly Ala Asp Met Gln
 385 390 395 400
 Pro Thr Thr Gly Ser Trp Pro Pro Gly Ala Gly Thr Arg Glu Ala Glu
 405 410 415
 Gly Gly Gly Gly Pro
 420

<210> 52
 <211> 240
 <212> PRT
 <213> Homo sapiens

<400> 52
 His Ala Ser Ala Ala Arg Ala Ala Ala Gly Ser Glu Pro Arg Thr Gly
 1 5 10 15
 Cys Gly Gly Ser Ser His Arg Val Pro Leu Gly Pro Ser Pro Ala Ser
 20 25 30

Leu Ser Pro Gln Arg Asp Leu Phe Gly Pro Pro Gly Pro Pro Gly Ala
 35 40 45
 Glu Val Thr Ala Glu Thr Leu Leu His Glu Phe Gln Glu Leu Leu Lys
 50 55 60
 Glu Ala Thr Glu Arg Arg Phe Ser Gly Leu Leu Asp Pro Leu Leu Pro
 65 70 75 80
 Gln Gly Ala Gly Leu Arg Leu Val Gly Glu Ala Phe His Cys Arg Leu
 85 90 95
 Gln Gly Pro Arg Arg Val Asp Lys Arg Thr Leu Val Glu Leu His Gly
 100 105 110
 Phe Gln Ala Pro Ala Ala Gln Gly Ala Phe Leu Arg Gly Ser Gly Leu
 115 120 125
 Ser Leu Ala Ser Gly Arg Phe Thr Ala Pro Val Ser Gly Ile Phe Gln
 130 135 140
 Phe Ser Ala Ser Leu His Val Asp His Ser Glu Leu Gln Gly Lys Ala
 145 150 155 160
 Arg Leu Arg Ala Arg Asp Val Val Cys Val Leu Ile Cys Ile Glu Ser
 165 170 175
 Leu Cys Gln Arg His Thr Cys Leu Glu Ala Val Ser Gly Leu Glu Ser
 180 185 190
 Asn Ser Arg Val Phe Thr Leu Gln Val Gln Gly Leu Leu Gln Leu Gln
 195 200 205
 Ala Gly Gln Tyr Ala Ser Val Phe Val Asp Asn Gly Ser Gly Ala Val
 210 215 220
 Leu Thr Ile Gln Ala Gly Ser Ser Phe Ser Gly Leu Leu Leu Gly Thr
 225 230 235 240

<210> 53

<211> 281

<212> PRT

<213> Homo sapiens

<400> 53

Met Gly Ser Arg Gly Gln Gly Leu Leu Ala Tyr Cys Leu Leu Leu
 1 5 10 15
 Ala Phe Ala Ser Gly Leu Val Leu Ser Arg Val Pro His Val Gln Gly
 20 25 30
 Glu Gln Gln Glu Trp Glu Gly Thr Glu Glu Leu Pro Ser Pro Pro Asp
 35 40 45
 His Ala Glu Arg Ala Glu Glu Gln His Glu Lys Tyr Arg Pro Ser Gln
 50 55 60
 Asp Gln Gly Leu Pro Ala Ser Arg Cys Leu Arg Cys Cys Asp Pro Gly
 65 70 75 80
 Thr Ser Met Tyr Pro Ala Thr Ala Val Pro Gln Ile Asn Ile Thr Ile
 85 90 95
 Leu Lys Gly Glu Lys Gly Asp Arg Gly Asp Arg Gly Leu Gln Gly Lys
 100 105 110

Tyr Gly Lys Thr Gly Ser Ala Gly Ala Arg Gly His Thr Gly Pro Lys
 115 120
 Gly Gln Lys Gly Ser Met Gly Ala Pro Gly Glu Arg Cys Lys Ser His
 130 135
 Tyr Ala Ala Phe Ser Val Gly Arg Lys Lys Pro Met His Ser Asn His
 145 150 155 160
 Tyr Tyr Gln Thr Val Ile Phe Asp Thr Glu Phe Val Asn Leu Tyr Asp
 165 170 175
 His Phe Asn Met Phe Thr Gly Lys Phe Tyr Cys Tyr Val Pro Gly Leu
 180 185 190
 Tyr Phe Phe Ser Leu Asn Val His Thr Trp Asn Gln Lys Glu Thr Tyr
 195 200 205
 Leu His Ile Met Lys Asn Glu Glu Val Ala Ile Leu Phe Ala Gln
 210 215 220
 Val Gly Asp Arg Ser Ile Met Gln Ser Gln Ser Leu Met Leu Glu Leu
 225 230 235 240
 Arg Glu Gln Asp Gln Val Trp Val Arg Leu Tyr Lys Gly Glu Arg Glu
 245 250 255
 Asn Ala Ile Phe Ser Glu Glu Leu Asp Thr Tyr Ile Thr Phe Ser Gly
 260 265 270
 Tyr Leu Val Lys His Ala Thr Glu Pro
 275 280

<210> 54

<211> 205

<212> PRT

<213> Homo sapiens

<400> 54

Met Leu Gly Ala Lys Pro His Trp Leu Pro Gly Pro Leu His Ser Pro
 1 5 10 15
 Gly Leu Pro Leu Val Leu Val Leu Leu Ala Leu Gly Ala Gly Trp Ala
 20 25 30
 Gln Glu Gly Ser Glu Pro Val Leu Leu Glu Gly Glu Cys Leu Val Val
 35 40 45
 Cys Glu Pro Gly Arg Ala Ala Ala Gly Gly Pro Gly Gly Ala Ala Leu
 50 55 60
 Gly Glu Ala Pro Pro Gly Arg Val Ala Phe Ala Val Arg Ser His
 65 70 75 80
 His His Glu Pro Ala Gly Glu Thr Gly Asn Gly Thr Ser Gly Ala Ile
 85 90 95
 Tyr Phe Asp Gln Val Leu Val Asn Glu Gly Gly Gly Phe Asp Arg Ala
 100 105 110
 Ser Gly Ser Phe Val Ala Pro Val Arg Gly Val Tyr Ser Phe Arg Phe
 115 120 125
 His Val Val Lys Val Tyr Asn Arg Gln Thr Val Gln Val Ser Leu Met
 130 135 140

Leu Asn Thr Trp Pro Val Ile Ser Ala Phe Ala Asn Asp Pro Asp Val
 145 150 155 160
 Thr Arg Glu Ala Ala Thr Ser Ser Val Leu Leu Pro Leu Asp Pro Gly
 165 170 175
 Asp Arg Val Ser Leu Arg Leu Arg Arg Gly Asn Leu Leu Gly Gly Trp
 180 185 190
 Lys Tyr Ser Ser Phe Ser Gly Phe Leu Ile Phe Pro Leu
 195 200 205

<210> 55
 <211> 189
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (9)
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 55
 Leu Ala Leu Leu Leu Leu Leu Xaa Ala Cys Cys Pro Val Arg Ala
 1 5 10 15
 Gln Asn Asp Thr Glu Pro Ile Val Leu Glu Gly Lys Cys Leu Val Val
 20 25 30
 Cys Asp Ser Ser Pro Ser Ala Asp Gly Ala Val Thr Ser Ser Leu Gly
 35 40 45
 Ile Ser Val Arg Ser Gly Ser Ala Lys Val Ala Phe Ser Ala Thr Arg
 50 55 60
 Ser Thr Asn His Glu Pro Ser Glu Met Ser Asn Arg Thr Met Thr Ile
 65 70 75 80
 Tyr Phe Asp Gln Val Leu Val Asn Ile Gly Asn His Phe Asp Leu Ala
 85 90 95
 Ser Ser Ile Phe Val Ala Pro Arg Lys Gly Ile Tyr Ser Phe Ser Phe
 100 105 110
 His Val Val Lys Val Tyr Asn Arg Gln Thr Ile Gln Val Ser Leu Met
 115 120 125
 Gln Asn Gly Tyr Pro Val Ile Ser Ala Phe Ala Gly Asp Gln Asp Val
 130 135 140
 Thr Arg Glu Ala Ala Ser Asn Gly Val Leu Leu Met Glu Arg Glu
 145 150 155 160
 Asp Lys Val His Leu Lys Leu Glu Arg Gly Asn Leu Met Gly Gly Trp
 165 170 175
 Lys Tyr Ser Thr Phe Ser Gly Phe Leu Val Phe Pro Leu
 180 185

<210> 56
 <211> 201
 <212> PRT

<213> Homo sapiens

<400> 56

```

Ser  Gln  Gly  Leu  Pro  Gly  Arg  Asp  Gly  Arg  Asp  Gly  Arg  Asp  Gly  Ala
 1          5          10          15

Pro  Gly  Ala  Pro  Gly  Glu  Lys  Gly  Glu  Gly  Gly  Arg  Pro  Gly  Leu  Pro
          20          25          30

Gly  Pro  Arg  Gly  Asp  Pro  Gly  Pro  Arg  Gly  Glu  Ala  Gly  Pro  Ala  Gly
          35          40          45

Pro  Thr  Gly  Pro  Ala  Gly  Glu  Cys  Ser  Val  Pro  Pro  Arg  Ser  Ala  Phe
          50          55          60

Ser  Ala  Lys  Arg  Ser  Glu  Ser  Arg  Val  Pro  Pro  Pro  Ser  Asp  Ala  Pro
65          70          75          80

Leu  Pro  Phe  Asp  Arg  Val  Leu  Val  Asn  Glu  Gln  Gly  His  Tyr  Asp  Ala
          85          90          95

Val  Thr  Gly  Lys  Phe  Thr  Cys  Gln  Val  Pro  Gly  Val  Tyr  Tyr  Phe  Ala
          100         105         110

Val  His  Ala  Thr  Val  Tyr  Arg  Ala  Ser  Leu  Gln  Phe  Asp  Leu  Val  Lys
          115         120         125

Asn  Gly  Glu  Ser  Ile  Ala  Ser  Phe  Phe  Gln  Phe  Phe  Gly  Gly  Trp  Pro
130         135         140

Lys  Pro  Ala  Ser  Leu  Ser  Gly  Gly  Ala  Met  Val  Arg  Leu  Glu  Pro  Glu
145         150         155         160

Asp  Gln  Val  Trp  Val  Gln  Val  Gly  Val  Gly  Asp  Tyr  Ile  Gly  Ile  Tyr
          165         170         175

Ala  Ser  Ile  Lys  Thr  Asp  Ser  Thr  Phe  Ser  Gly  Phe  Leu  Val  Tyr  Ser
          180         185         190

Asp  Trp  His  Ser  Ser  Pro  Val  Phe  Ala
          195         200

```

<210> 57

<211> 245

<212> PRT

<213> Homo sapiens

<400> 57

```

Met  Asp  Val  Gly  Pro  Ser  Ser  Leu  Pro  His  Leu  Gly  Leu  Lys  Leu  Leu
 1          5          10          15

Leu  Leu  Leu  Leu  Leu  Leu  Pro  Leu  Arg  Gly  Gln  Ala  Asn  Thr  Gly  Cys
          20          25          30

Tyr  Gly  Ile  Pro  Gly  Met  Pro  Gly  Leu  Pro  Gly  Ala  Pro  Gly  Lys  Asp
          35          40          45

Gly  Tyr  Asp  Gly  Leu  Pro  Gly  Pro  Lys  Gly  Glu  Pro  Gly  Ile  Pro  Ala
          50          55          60

Ile  Pro  Gly  Ile  Arg  Gly  Pro  Lys  Gly  Gln  Lys  Gly  Glu  Pro  Gly  Leu
65          70          75          80

Pro  Gly  His  Pro  Gly  Lys  Asn  Gly  Pro  Met  Gly  Pro  Pro  Gly  Met  Pro
          85          90          95

```

Gly Val Pro Gly Pro Met Gly Ile Pro Gly Glu Pro Gly Glu Glu Gly
 100 105 110
 Arg Tyr Lys Gln Lys Phe Gln Ser Val Phe Thr Val Thr Arg Gln Thr
 115 120 125
 His Gln Pro Pro Ala Pro Asn Ser Leu Ile Arg Phe Asn Ala Val Leu
 130 135 140
 Thr Asn Pro Gln Gly Asp Tyr Asp Thr Ser Thr Gly Lys Phe Thr Cys
 145 150 155 160
 Lys Val Pro Gly Leu Tyr Tyr Phe Val Tyr His Ala Ser His Thr Ala
 165 170 175
 Asn Leu Cys Val Leu Leu Tyr Arg Ser Gly Val Lys Val Val Thr Phe
 180 185 190
 Cys Gly His Thr Ser Lys Thr Asn Gln Val Asn Ser Gly Gly Val Leu
 195 200 205
 Leu Arg Leu Gln Val Gly Glu Glu Val Trp Leu Ala Val Asn Asp Tyr
 210 215 220
 Tyr Asp Met Val Gly Ile Gln Gly Ser Asp Ser Val Phe Ser Gly Phe
 225 230 235 240
 Leu Leu Phe Pro Asp
 245

<210> 58
 <211> 278
 <212> PRT
 <213> Homo sapiens

<400> 58
 Met Gln Trp Leu Arg Val Arg Glu Ser Pro Gly Glu Ala Thr Gly His
 1 5 10 15
 Arg Val Thr Met Gly Thr Ala Ala Leu Gly Pro Val Trp Ala Ala Leu
 20 25 30
 Leu Leu Phe Leu Leu Met Cys Glu Ile Pro Met Val Glu Leu Thr Phe
 35 40 45
 Asp Arg Ala Val Ala Ser Asp Cys Gln Arg Cys Cys Asp Ser Glu Asp
 50 55 60
 Pro Leu Asp Pro Ala His Val Ser Ser Ala Ser Ser Ser Gly Arg Pro
 65 70 75 80
 His Ala Leu Pro Glu Ile Arg Pro Tyr Ile Asn Ile Thr Ile Leu Lys
 85 90 95
 Gly Asp Lys Gly Asp Pro Gly Pro Met Gly Leu Pro Gly Tyr Met Gly
 100 105 110
 Arg Glu Gly Pro Gln Gly Glu Pro Gly Pro Gln Gly Ser Lys Gly Asp
 115 120 125
 Lys Gly Glu Met Gly Ser Pro Gly Ala Pro Cys Gln Lys Arg Phe Phe
 130 135 140
 Ala Phe Ser Val Gly Arg Lys Thr Ala Leu His Ser Gly Glu Asp Phe

145 150 155 160
 Gln Thr Leu Leu Phe Glu Arg Val Phe Val Asn Leu Asp Gly Cys Phe
 165 170 175
 Asp Met Ala Thr Gly Gln Phe Ala Ala Pro Leu Arg Gly Ile Tyr Phe
 180 185 190
 Phe Ser Leu Asn Val His Ser Trp Asn Tyr Lys Glu Thr Tyr Val His
 195 200 205
 Ile Met His Asn Gln Lys Glu Ala Val Ile Leu Tyr Ala Gln Pro Ser
 210 215 220
 Glu Arg Ser Ile Met Gln Ser Gln Ser Val Met Asn Asp Leu Ala Tyr
 225 230 235 240
 Gly Asp Arg Val Trp Val Arg Leu Phe Lys Arg Gln Arg Glu Asn Ala
 245 250 255
 Ile Tyr Ser Asn Asp Phe Asp Thr Tyr Ile Thr Phe Ser Gly His Leu
 260 265 270
 Ile Lys Ala Glu Asp Asp
 275

 <210> 59
 <211> 289
 <212> PRT
 <213> Homo sapiens

 <400> 59
 Met Phe Val Leu Leu Tyr Val Thr Ser Phe Ala Ile Cys Ala Ser Gly
 1 5 10 15
 Gln Pro Arg Gly Asn Gln Leu Lys Gly Glu Asn Tyr Ser Pro Arg Tyr
 20 25 30
 Ile Cys Ser Ile Pro Gly Leu Pro Gly Pro Pro Gly Pro Pro Gly Ala
 35 40 45
 Asn Gly Ser Pro Gly Pro His Gly Arg Ile Gly Leu Pro Gly Arg Asp
 50 55 60
 Gly Arg Asp Gly Arg Lys Gly Glu Lys Gly Glu Lys Gly Thr Ala Gly
 65 70 75 80
 Leu Arg Gly Lys Thr Gly Pro Leu Gly Leu Ala Gly Glu Lys Gly Asp
 85 90 95
 Gln Gly Glu Thr Gly Lys Lys Gly Pro Ile Gly Pro Glu Gly Glu Lys
 100 105 110
 Gly Glu Val Gly Pro Ile Gly Pro Gly Pro Lys Gly Asp Arg Gly
 115 120 125
 Glu Gln Gly Asp Pro Gly Leu Pro Gly Val Cys Arg Cys Gly Ser Ile
 130 135 140
 Val Leu Lys Ser Ala Phe Ser Val Gly Ile Thr Thr Ser Tyr Pro Glu
 145 150 155 160
 Glu Arg Leu Pro Ile Ile Phe Asn Lys Val Leu Phe Asn Glu Gly Glu
 165 170 175

His Tyr Asn Pro Ala Thr Gly Lys Phe Ile Cys Ala Phe Pro Gly Ile
 180 185 190
 Tyr Tyr Phe Ser Tyr Asp Ile Thr Leu Ala Asn Lys His Leu Ala Ile
 195 200 205
 Gly Leu Val His Asn Gly Gln Tyr Arg Ile Lys Thr Phe Asp Ala Asn
 210 215 220
 Thr Gly Asn His Asp Val Ala Ser Gly Ser Thr Val Ile Tyr Leu Gln
 225 230 235 240
 Pro Glu Asp Glu Val Trp Leu Glu Ile Phe Phe Thr Asp Gln Asn Gly
 245 250 255
 Leu Phe Ser Asp Pro Gly Trp Ala Asp Ser Leu Phe Ser Gly Phe Leu
 260 265 270
 Leu Tyr Val Asp Thr Asp Tyr Leu Asp Ser Ile Ser Glu Asp Asp Glu
 275 280 285
 Leu

<210> 60
 <211> 285
 <212> PRT
 <213> Homo sapiens

<400> 60
 Met Ile Pro Trp Val Leu Leu Ala Cys Ala Leu Pro Cys Ala Ala Asp
 1 5 10 15
 Pro Leu Leu Gly Ala Phe Ala Arg Arg Asp Phe Arg Lys Gly Ser Pro
 20 25 30
 Gln Leu Val Cys Ser Leu Pro Gly Pro Gln Gly Pro Pro Gly Pro Pro
 35 40 45
 Gly Ala Pro Gly Pro Ser Gly Met Met Gly Arg Met Gly Phe Pro Gly
 50 55 60
 Lys Asp Gly Gln Asp Gly His Asp Gly Asp Arg Gly Asp Ser Gly Glu
 65 70 75 80
 Glu Gly Pro Pro Gly Arg Thr Gly Asn Arg Gly Lys Pro Gly Pro Lys
 85 90 95
 Gly Lys Ala Gly Ala Ile Gly Arg Ala Gly Pro Arg Gly Pro Lys Gly
 100 105 110
 Val Asn Gly Thr Pro Gly Lys His Gly Thr Pro Gly Lys Lys Gly Pro
 115 120 125
 Lys Gly Lys Lys Gly Glu Pro Gly Leu Pro Gly Pro Cys Ser Cys Gly
 130 135 140
 Ser Gly His Thr Lys Ser Ala Phe Ser Val Ala Val Thr Lys Ser Tyr
 145 150 155 160
 Pro Arg Glu Arg Leu Pro Ile Lys Phe Asp Lys Ile Leu Met Asn Glu
 165 170 175
 Gly Gly His Tyr Asn Ala Ser Ser Gly Lys Phe Val Cys Gly Val Pro
 180 185 190

Gly Ile Tyr Tyr Phe Thr Tyr Asp Ile Thr Leu Ala Asn Lys His Leu
 195 200 205
 Ala Ile Gly Leu Val His Asn Gly Gln Tyr Arg Ile Arg Thr Phe Asp
 210 215 220
 Ala Asn Thr Gly Asn His Asp Val Ala Ser Gly Ser Thr Ile Leu Ala
 225 230 235 240
 Leu Lys Gln Gly Asp Glu Val Trp Leu Gln Ile Phe Tyr Ser Glu Gln
 245 250 255
 Asn Gly Leu Phe Tyr Asp Pro Tyr Trp Thr Asp Ser Leu Phe Thr Gly
 260 265 270
 Phe Leu Ile Tyr Ala Asp Gln Asp Asp Pro Asn Glu Val
 275 280 285

<210> 61
 <211> 146
 <212> PRT
 <213> Homo sapiens

<400> 61
 Thr Arg Ser Leu Val Gly Ser Asp Ala Gly Pro Gly Pro Arg His Gln
 1 5 10 15
 Pro Leu Ala Phe Asp Thr Glu Phe Val Asn Ile Gly Gly Asp Phe Asp
 20 25 30
 Ala Ala Ala Gly Val Phe Arg Cys Arg Leu Pro Gly Ala Tyr Phe Phe
 35 40 45
 Ser Phe Thr Leu Gly Lys Leu Pro Arg Lys Thr Leu Ser Val Lys Leu
 50 55 60
 Met Lys Asn Arg Asp Glu Val Gln Ala Met Ile Tyr Asp Asp Gly Ala
 65 70 75 80
 Ser Arg Arg Arg Glu Met Gln Ser Gln Ser Val Met Leu Ala Leu Arg
 85 90 95
 Arg Gly Asp Ala Val Trp Leu Leu Ser His Asp His Asp Gly Tyr Gly
 100 105 110
 Ala Tyr Ser Asn His Gly Lys Tyr Ile Thr Phe Ser Gly Phe Leu Val
 115 120 125
 Tyr Pro Asp Leu Ala Pro Ala Ala Pro Pro Gly Leu Gly Ala Ser Glu
 130 135 140
 Leu Leu
 145

<210> 62
 <211> 251
 <212> PRT
 <213> Homo sapiens

<400> 62
 Met Lys Ile Pro Trp Gly Ser Ile Pro Val Leu Met Leu Leu Leu Leu
 1 5 10 15

Leu Gly Leu Ile Asp Ile Ser Gln Ala Gln Leu Ser Cys Thr Gly Pro
 20 25 30
 Pro Ala Ile Pro Gly Ile Pro Gly Ile Pro Gly Thr Pro Gly Pro Asp
 35 40 45
 Gly Gln Pro Gly Thr Pro Gly Ile Lys Gly Glu Lys Gly Leu Pro Gly
 50 55 60
 Leu Ala Gly Asp His Gly Glu Phe Gly Glu Lys Gly Asp Pro Gly Ile
 65 70 75 80
 Pro Gly Asn Pro Gly Lys Val Gly Pro Lys Gly Pro Met Gly Pro Lys
 85 90 95
 Gly Gly Pro Gly Ala Pro Gly Ala Pro Gly Pro Lys Gly Glu Ser Gly
 100 105 110
 Asp Tyr Lys Ala Thr Gln Lys Ile Ala Phe Ser Ala Thr Arg Thr Ile
 115 120 125
 Asn Val Pro Leu Arg Arg Asp Gln Thr Ile Arg Phe Asp His Val Ile
 130 135 140
 Thr Asn Met Asn Asn Asn Tyr Glu Pro Arg Ser Gly Lys Phe Thr Cys
 145 150 155 160
 Lys Val Pro Gly Leu Tyr Tyr Phe Thr Tyr His Ala Ser Ser Arg Gly
 165 170 175
 Asn Leu Cys Val Asn Leu Met Arg Gly Arg Glu Arg Ala Gln Lys Val
 180 185 190
 Val Thr Phe Cys Asp Tyr Ala Tyr Asn Thr Phe Gln Val Thr Thr Gly
 195 200 205
 Gly Met Val Leu Lys Leu Glu Gln Gly Glu Asn Val Phe Leu Gln Ala
 210 215 220
 Thr Asp Lys Asn Ser Leu Leu Gly Met Glu Gly Ala Asn Ser Ile Phe
 225 230 235 240
 Ser Gly Phe Leu Leu Phe Pro Asp Met Glu Ala
 245 250

<210> 63

<211> 975

<212> PRT

<213> Homo sapiens

<400> 63

Met Pro Cys Pro Ser Ala Leu Val Tyr Arg Val Asn Phe Arg Pro Arg
 1 5 10 15

Tyr Val Thr Arg Tyr Lys Thr Val Thr Gln Leu Glu Trp Arg Cys Cys
 20 25 30

Pro Gly Phe Arg Gly Gly Asp Cys Gln Glu Gly Pro Lys Asp Pro Val
 35 40 45

Lys Thr Leu Arg Pro Thr Pro Ala Arg Pro Arg Asn Ser Leu Lys Lys
 50 55 60

Ala Thr Asp Asn Glu Pro Ser Gln Phe Ser Glu Pro Arg Lys Thr Leu

65	70					75					80				
Ser	Pro	Thr	Gly	Thr	Ala	Gln	Pro	Ser	Trp	Gly	Val	Asp	Pro	Lys	Glu
				85					90					95	
Gly	Pro	Gln	Glu	Leu	Gln	Glu	Lys	Lys	Ile	Gln	Val	Leu	Glu	Glu	Lys
			100					105					110		
Val	Leu	Arg	Leu	Thr	Arg	Thr	Val	Leu	Asp	Leu	Gln	Ser	Ser	Leu	Ala
		115					120					125			
Gly	Val	Ser	Glu	Asn	Leu	Lys	His	Ala	Thr	Gln	Asp	Asp	Ala	Ser	Arg
		130				135					140				
Thr	Arg	Ala	Pro	Gly	Leu	Ser	Ser	Gln	His	Pro	Lys	Pro	Asp	Thr	Thr
					150					155					160
Val	Ser	Gly	Asp	Thr	Glu	Thr	Gly	Gln	Ser	Pro	Gly	Val	Phe	Asn	Thr
				165						170					175
Lys	Glu	Ser	Gly	Met	Lys	Asp	Ile	Lys	Ser	Glu	Leu	Ala	Glu	Val	Lys
			180					185					190		
Asp	Thr	Leu	Lys	Asn	Lys	Ser	Asp	Lys	Leu	Glu	Glu	Leu	Asp	Gly	Lys
		195					200					205			
Val	Lys	Gly	Tyr	Glu	Gly	Gln	Leu	Arg	Gln	Leu	Gln	Glu	Ala	Ala	Gln
		210				215					220				
Gly	Pro	Thr	Val	Thr	Met	Thr	Thr	Asn	Glu	Leu	Tyr	Gln	Ala	Tyr	Val
					230					235					240
Asp	Ser	Lys	Ile	Asp	Ala	Leu	Arg	Glu	Glu	Leu	Met	Glu	Gly	Met	Asp
				245					250					255	
Arg	Lys	Leu	Ala	Asp	Leu	Lys	Asn	Ser	Cys	Glu	Tyr	Lys	Leu	Thr	Gly
		260						265					270		
Leu	Gln	Gln	Gln	Cys	Asp	Asp	Tyr	Gly	Ser	Ser	Tyr	Leu	Gly	Val	Ile
			275				280					285			
Glu	Leu	Ile	Gly	Glu	Lys	Glu	Thr	Ser	Leu	Arg	Lys	Glu	Ile	Asn	Asn
		290					295				300				
Leu	Arg	Ala	Arg	Leu	Gln	Glu	Pro	Ser	Ala	Gln	Ala	Asn	Cys	Cys	Asp
					310					315					320
Ser	Glu	Lys	Asn	Gly	Asp	Ile	Gly	Gln	Gln	Ile	Lys	Thr	Leu	Asp	Gln
			325						330					335	
Lys	Ile	Glu	Arg	Val	Ala	Glu	Ala	Thr	Arg	Met	Leu	Asn	Gly	Arg	Leu
			340					345				350			
Asp	Asn	Glu	Phe	Asp	Arg	Leu	Ile	Val	Pro	Glu	Pro	Asp	Val	Asp	Phe
		355					360					365			
Asp	Ala	Lys	Trp	Asn	Glu	Leu	Asp	Ala	Arg	Ile	Asn	Val	Thr	Glu	Lys
			370				375				380				
Asn	Ala	Glu	Glu	His	Cys	Phe	Tyr	Ile	Glu	Glu	Thr	Leu	Arg	Gly	Ala
					390					395					400
Ile	Asn	Gly	Glu	Val	Gly	Asp	Leu	Lys	Gln	Leu	Val	Asp	Gln	Lys	Ile
				405					410					415	
Gln	Ser	Leu	Glu	Asp	Arg	Leu	Gly	Ser	Val	Leu	Leu	Gln	Met	Thr	Asn
			420					425					430		

Asn Thr Gly Ala Glu Leu Ser Pro Pro Gly Ala Ala Ala Leu Pro Gly
 435 440 445
 Val Ser Gly Ser Gly Asp Glu Arg Val Met Met Glu Leu Asn His Leu
 450 455 460
 Lys Asp Lys Val Gln Val Val Glu Asp Ile Cys Leu Leu Asn Ile Gln
 465 470 475 480
 Gly Lys Pro His Gly Met Glu Gly Ala Leu Pro Asn Arg Glu Asp Arg
 485 490 495
 Ala Val Arg Asp Ser Leu His Leu Leu Lys Ser Leu Asn Asp Thr Met
 500 505 510
 His Arg Lys Phe Gln Glu Thr Glu Gln Thr Ile Gln Lys Leu Gln Gln
 515 520 525
 Asp Phe Ser Phe Leu Tyr Ser Gln Leu Asn His Thr Glu Asn Asp Val
 530 535 540
 Thr His Leu Gln Lys Glu Met Ser Asn Cys Arg Ala Gly Glu Asn Ala
 545 550 555 560
 Gly Met Gly Arg Phe Thr Lys Val Gly Glu Gln Glu Arg Thr Val Asp
 565 570 575
 Thr Leu Pro Ser Pro Gln His Pro Val Ala His Cys Cys Ser Gln Leu
 580 585 590
 Glu Glu Arg Trp Gln Arg Leu Gln Ser Gln Val Ile Ser Glu Leu Asp
 595 600 605
 Ala Cys Lys Glu Cys Thr Gln Gly Val Gln Arg Glu Val Ser Met Val
 610 615 620
 Glu Gly Arg Val Ser His Met Glu Lys Thr Cys Ser Lys Leu Asp Ser
 625 630 635 640
 Ile Ser Gly Asn Leu Gln Arg Ile Lys Glu Gly Leu Asn Lys His Val
 645 650 655
 Ser Ser Leu Trp Asn Cys Val Arg Gln Met Asn Gly Thr Leu Arg Ser
 660 665 670
 His Ser Arg Asp Ile Ser Gly Leu Lys Asn Ser Val Gln Gln Phe Tyr
 675 680 685
 Ser His Val Phe Gln Ile Ser Thr Asp Leu Gln Asp Leu Val Lys Phe
 690 695 700
 Gln Pro Ser Ala Lys Ala Pro Ser Pro Pro Pro Ala Glu Ala Pro
 705 710 715 720
 Lys Glu Pro Leu Gln Pro Glu Pro Ala Pro Pro Arg Pro Ser Gly Pro
 725 730 735
 Ala Thr Ala Glu Asp Pro Gly Arg Arg Pro Val Leu Pro Gln Arg Pro
 740 745 750
 Pro Glu Glu Arg Pro Pro Gln Pro Pro Gly Ser Thr Gly Val Ile Ala
 755 760 765
 Glu Thr Gly Gln Ala Gly Pro Pro Ala Gly Ala Gly Val Ser Gly Arg
 770 775 780

Gly Leu Pro Arg Gly Val Asp Gly Gln Thr Gly Ser Gly Thr Val Pro
 785 790 795 800
 Gly Ala Glu Gly Phe Ala Gly Ala Pro Gly Tyr Pro Lys Ser Pro Pro
 805 810 815
 Val Ala Ser Pro Gly Ala Pro Val Pro Ser Leu Val Ser Phe Ser Ala
 820 825 830
 Gly Leu Thr Gln Lys Pro Phe Pro Ser Asp Gly Gly Val Val Leu Phe
 835 840 845
 Asn Lys Val Leu Val Asn Asp Gly Asp Val Tyr Asn Pro Ser Thr Gly
 850 855 860
 Val Phe Thr Ala Pro Tyr Asp Gly Arg Tyr Leu Ile Thr Ala Thr Leu
 865 870 875 880
 Thr Pro Glu Arg Asp Ala Tyr Val Glu Ala Val Leu Ser Val Ser Asn
 885 890 895
 Ala Ser Val Ala Gln Leu His Thr Ala Gly Tyr Arg Arg Glu Phe Leu
 900 905 910
 Glu Tyr His Arg Pro Pro Gly Ala Leu His Thr Cys Gly Gly Pro Gly
 915 920 925
 Ala Phe His Leu Ile Val His Leu Lys Ala Gly Asp Ala Val Asn Val
 930 935 940
 Val Val Thr Gly Gly Lys Leu Ala His Thr Asp Phe Asp Glu Met Tyr
 945 950 955 960
 Ser Thr Phe Ser Gly Val Phe Leu Tyr Pro Phe Leu Ser His Leu
 965 970 975

<210> 64
 <211> 158
 <212> PRT
 <213> Homo sapiens

<400> 64
 Met Thr Pro Val Asp Val Pro Val Thr Asn Pro Ala Ala Thr Ile Leu
 1 5 10 15
 Pro Val His Val Tyr Pro Leu Pro Gln Gln Met Arg Val Ala Phe Ser
 20 25 30
 Ala Ala Arg Thr Ser Asn Leu Ala Pro Gly Thr Leu Asp Gln Pro Ile
 35 40 45
 Val Phe Asp Leu Leu Leu Asn Asn Leu Gly Glu Thr Phe Asp Leu Gln
 50 55 60
 Leu Gly Arg Phe Asn Cys Pro Val Asn Gly Thr Tyr Val Phe Ile Phe
 65 70 75 80
 His Met Leu Lys Leu Ala Val Asn Val Pro Leu Tyr Val Asn Leu Met
 85 90 95
 Lys Asn Glu Glu Val Leu Val Ser Ala Tyr Ala Asn Asp Gly Ala Pro
 100 105 110
 Asp His Glu Thr Ala Ser Asn His Ala Ile Leu Gln Leu Phe Gln Gly
 115 120 125

Asp Gln Ile Trp Leu Arg Leu His Arg Gly Ala Ile Tyr Gly Ser Ser
 130 135 140

Trp Lys Tyr Ser Thr Phe Ser Gly Tyr Leu Leu Tyr Gln Asp
 145 150 155

<210> 65
 <211> 605
 <212> PRT
 <213> Homo sapiens

<400> 65
 Met Gly Tyr Leu Glu Leu Lys Glu Asn Gln Gly His Arg Asp Ile Gln
 1 5 10 15
 Glu Leu Glu Ser Gln Val Cys Leu Glu Cys Gln Gly Lys Pro Gly Ala
 20 25 30
 Met Gly Met Pro Gly Ala Lys Gly Glu Ile Gly Gln Lys Gly Glu Ile
 35 40 45
 Gly Pro Met Gly Ile Pro Gly Pro Gln Gly Pro Pro Gly Pro His Gly
 50 55 60
 Leu Pro Gly Ile Gly Lys Pro Gly Gly Pro Gly Leu Pro Gly Gln Pro
 65 70 75 80
 Gly Pro Lys Gly Asp Arg Gly Pro Lys Gly Leu Pro Gly Pro Gln Gly
 85 90 95
 Leu Arg Gly Pro Lys Gly Asp Lys Gly Phe Gly Met Pro Gly Ala Pro
 100 105 110
 Gly Val Lys Gly Pro Pro Gly Met His Gly Pro Pro Gly Pro Val Gly
 115 120 125
 Leu Pro Gly Val Gly Lys Pro Gly Val Thr Gly Phe Pro Gly Pro Gln
 130 135 140
 Gly Pro Leu Gly Lys Pro Gly Ala Pro Gly Glu Pro Gly Pro Gln Gly
 145 150 155 160
 Pro Ile Gly Val Pro Gly Val Gln Gly Pro Pro Gly Ile Pro Gly Ile
 165 170 175
 Gly Lys Pro Gly Gln Asp Gly Ile Pro Gly Gln Pro Gly Phe Pro Gly
 180 185 190
 Gly Lys Gly Glu Gln Gly Leu Pro Gly Leu Pro Gly Pro Pro Gly Leu
 195 200 205
 Pro Gly Ile Gly Lys Pro Gly Phe Pro Gly Pro Lys Gly Asp Arg Gly
 210 215 220
 Met Gly Gly Val Pro Gly Ala Leu Gly Pro Arg Gly Glu Lys Gly Pro
 225 230 235 240
 Ile Gly Ala Pro Gly Ile Gly Gly Pro Pro Gly Glu Pro Gly Leu Pro
 245 250 255
 Gly Ile Pro Gly Pro Met Gly Pro Pro Gly Ala Ile Gly Phe Pro Gly
 260 265 270
 Pro Lys Gly Glu Gly Gly Ile Val Gly Pro Gln Gly Pro Pro Gly Pro

275					280					285					
Lys	Gly	Glu	Pro	Gly	Leu	Gln	Gly	Phe	Pro	Gly	Lys	Pro	Gly	Phe	Leu
290					295					300					
Gly	Glu	Val	Gly	Pro	Pro	Gly	Met	Arg	Gly	Leu	Pro	Gly	Pro	Ile	Gly
305					310					315					320
Pro	Lys	Gly	Glu	Ala	Gly	Gln	Lys	Gly	Val	Pro	Gly	Leu	Pro	Gly	Val
				325					330					335	
Pro	Gly	Leu	Leu	Gly	Pro	Lys	Gly	Glu	Pro	Gly	Ile	Pro	Gly	Asp	Gln
		340						345					350		
Gly	Leu	Gln	Gly	Pro	Pro	Gly	Ile	Pro	Gly	Ile	Gly	Gly	Pro	Ser	Gly
		355					360					365			
Pro	Ile	Gly	Pro	Pro	Gly	Ile	Pro	Gly	Pro	Lys	Gly	Glu	Pro	Gly	Leu
	370					375					380				
Pro	Gly	Pro	Pro	Gly	Phe	Pro	Gly	Ile	Gly	Lys	Pro	Gly	Val	Ala	Gly
	385					390					395				400
Leu	His	Gly	Pro	Pro	Gly	Lys	Pro	Gly	Ala	Leu	Gly	Pro	Gln	Gly	Gln
			405						410					415	
Pro	Gly	Leu	Pro	Gly	Pro	Pro	Gly	Pro	Pro	Gly	Pro	Pro	Gly	Pro	Pro
		420						425					430		
Ala	Val	Met	Pro	Pro	Thr	Pro	Pro	Gln	Gly	Glu	Tyr	Leu	Pro	Asp	
	435						440					445			
Met	Gly	Leu	Gly	Ile	Asp	Gly	Val	Lys	Pro	Pro	His	Ala	Tyr	Gly	Ala
	450					455					460				
Lys	Lys	Gly	Lys	Asn	Gly	Gly	Pro	Ala	Tyr	Glu	Met	Pro	Ala	Phe	Thr
	465			470							475				480
Ala	Glu	Leu	Thr	Ala	Pro	Phe	Pro	Pro	Val	Gly	Ala	Pro	Val	Lys	Phe
			485						490					495	
Asn	Lys	Leu	Leu	Tyr	Asn	Gly	Arg	Gln	Asn	Tyr	Asn	Pro	Gln	Thr	Gly
		500						505					510		
Ile	Phe	Thr	Cys	Glu	Val	Pro	Gly	Val	Tyr	Tyr	Phe	Ala	Tyr	His	Val
		515					520					525			
His	Cys	Lys	Gly	Gly	Asn	Val	Trp	Val	Ala	Leu	Phe	Lys	Asn	Asn	Glu
	530					535					540				
Pro	Val	Met	Tyr	Thr	Tyr	Asp	Glu	Tyr	Lys	Lys	Gly	Phe	Leu	Asp	Gln
	545					550					555				560
Ala	Ser	Gly	Ser	Ala	Val	Leu	Leu	Leu	Arg	Pro	Gly	Asp	Arg	Val	Phe
			565						570					575	
Leu	Gln	Met	Pro	Ser	Glu	Gln	Ala	Ala	Gly	Leu	Tyr	Ala	Gly	Gln	Tyr
		580					585						590		
Val	His	Ser	Ser	Phe	Ser	Gly	Tyr	Leu	Leu	Tyr	Pro	Met			
		595					600					605			

<210> 66
 <211> 194
 <212> PRT

<213> Homo sapiens

<400> 66

Arg Gly Pro Trp Leu₅ Pro Trp Asn Thr Gly₁₀ Pro Pro Gly Pro Pro Gly
 1 15
 Pro Pro Gly Pro Pro Gly Ala Pro Gly₂₅ Ala Phe Asp Glu Thr Gly Ile
 20 30
 Ala Gly Leu His Leu Pro Asn Gly₄₀ Gly Val Glu Gly Ala Val Leu Gly
 35 45
 Lys Gly Gly Lys Pro Gln Phe Gly Leu Gly Glu Leu Ser Ala His Ala
 50 55 60
 Thr Pro Ala Phe Thr Ala Val Leu Thr Ser Pro Phe Pro Ala Ser Gly
 65 70 75 80
 Met Pro Val Lys Phe Asp Arg Thr Leu Tyr₉₀ Asn Gly His Ser Gly Tyr
 85 95
 Asn Pro Ala Thr Gly Ile Phe Thr Cys₁₀₅ Pro Val Gly Gly Val Tyr Tyr
 100 110
 Phe Ala Tyr His Val His Val Lys Gly Thr Asn Val Trp Val Ala Leu
 115 120 125
 Tyr Lys Asn Asn Val Pro Ala Thr Tyr Thr Tyr Asp Glu Tyr Lys Lys
 130 135 140
 Gly Tyr Leu Asp Gln Ala Ser Gly Gly Ala Val Leu Gln Leu Arg Pro
 145 150 155 160
 Asn Asp Gln Val Trp Val Gln Met Pro Ser Asp Gln Ala Asn Gly Leu
 165 170 175
 Tyr Ser Thr Glu Tyr Ile His Ser Ser Phe Ser Gly Phe Leu Leu Cys
 180 185 190
 Pro Thr

<210> 67

<211> 244

<212> PRT

<213> Homo sapiens

<400> 67

Met Leu Leu Leu Gly₅ Ala Val Leu Leu Leu₁₀ Leu Ala Leu Pro Gly His
 1 15
 Asp Gln Glu Thr Thr Thr Gln Gly Pro Gly Val Leu Leu Pro Leu Pro
 20 25 30
 Lys Gly Ala Cys Thr Gly Trp Met Ala Gly Ile Pro Gly His Pro Gly
 35 40 45
 His Asn Gly Ala Pro Gly Arg Asp Gly Arg Asp Gly Thr Pro Gly Glu
 50 55 60
 Lys Gly Glu Lys Gly Asp Pro Gly Leu Ile Gly Pro Lys Gly Asp Ile
 65 70 75 80
 Gly Glu Thr Gly Val Pro Gly Ala Glu Gly Pro Arg Gly Phe Pro Gly
 85 90 95

Ile Gln Gly Arg Lys Gly Glu Pro Gly Glu Gly Ala Tyr Val Tyr Arg
 100 105 110
 Ser Ala Phe Ser Val Gly Leu Glu Thr Tyr Val Thr Ile Pro Asn Met
 115 120 125
 Pro Ile Arg Phe Thr Lys Ile Phe Tyr Asn Gln Gln Asn His Tyr Asp
 130 135 140
 Gly Ser Thr Gly Lys Phe His Cys Asn Ile Pro Gly Leu Tyr Tyr Phe
 145 150 155 160
 Ala Tyr His Ile Thr Val Tyr Met Lys Asp Val Lys Val Ser Leu Phe
 165 170 175
 Lys Lys Asp Lys Ala Met Leu Phe Thr Tyr Asp Gln Tyr Gln Glu Asn
 180 185 190
 Asn Val Asp Gln Ala Ser Gly Ser Val Leu Leu His Leu Glu Val Gly
 195 200 205
 Asp Gln Val Trp Leu Gln Val Tyr Gly Glu Gly Glu Arg Asn Gly Leu
 210 215 220
 Tyr Ala Asp Asn Asp Asn Asp Ser Thr Phe Thr Gly Phe Leu Leu Tyr
 225 230 235 240
 His Asp Thr Asn

<210> 68

<211> 361

<212> PRT

<213> Homo sapiens

<400> 68

Thr Arg Pro Asp Ser Leu Asn Glu Leu Gln Thr Thr Val Glu Gly Gln
 1 5 10 15
 Gly Ala Asp Leu Ala Asp Leu Gly Ala Thr Lys Asp Arg Ile Ile Ser
 20 25 30
 Glu Ile Asn Arg Leu Gln Gln Glu Ala Thr Glu His Ala Thr Glu Ser
 35 40 45
 Glu Glu Arg Phe Arg Gly Leu Glu Glu Gly Gln Ala Gln Ala Gly Gln
 50 55 60
 Cys Pro Ser Leu Glu Gly Arg Leu Gly Arg Leu Glu Gly Val Cys Glu
 65 70 75 80
 Arg Leu Asp Thr Val Ala Gly Gly Leu Gln Gly Leu Arg Glu Gly Leu
 85 90 95
 Ser Arg His Val Ala Gly Leu Trp Ala Gly Leu Arg Glu Thr Asn Thr
 100 105 110
 Thr Ser Gln Met Gln Ala Ala Leu Glu Lys Leu Val Gly Gly Gln
 115 120 125
 Ala Gly Leu Gly Arg Arg Leu Gly Ala Leu Asn Ser Ser Leu Gln Leu
 130 135 140
 Leu Glu Asp Arg Leu His Gln Leu Ser Leu Lys Asp Leu Thr Gly Pro

145 150 155 160
 Ala Gly Glu Ala Gly Pro Pro Gly Pro Pro Gly Leu Gln Gly Pro Pro
 165 170 175
 Gly Pro Ala Gly Pro Pro Gly Ser Pro Gly Lys Asp Gly Gln Glu Gly
 180 185 190
 Pro Ile Gly Pro Pro Gly Pro Gln Gly Glu Gln Gly Val Glu Gly Ala
 195 200 205
 Pro Ala Ala Pro Val Pro Gln Val Ala Phe Ser Ala Ala Leu Ser Leu
 210 215 220
 Pro Arg Ser Glu Pro Gly Thr Val Pro Phe Asp Arg Val Leu Leu Asn
 225 230 235 240
 Asp Gly Gly Tyr Tyr Asp Pro Glu Thr Gly Val Phe Thr Ala Pro Leu
 245 250 255
 Ala Gly Arg Tyr Leu Leu Ser Ala Val Leu Thr Gly His Arg His Glu
 260 265 270
 Lys Val Glu Ala Val Leu Ser Arg Ser Asn Gln Gly Val Ala Arg Val
 275 280 285
 Asp Ser Gly Gly Tyr Glu Pro Glu Gly Leu Glu Asn Lys Pro Val Ala
 290 295 300
 Glu Ser Gln Pro Ser Pro Gly Thr Leu Gly Val Phe Ser Leu Ile Leu
 305 310 315
 Pro Leu Gln Ala Gly Asp Thr Val Cys Val Asp Leu Val Met Gly Gln
 325 330 335
 Leu Ala His Ser Glu Glu Pro Leu Thr Ile Phe Ser Gly Ala Leu Leu
 340 345 350
 Tyr Gly Asp Pro Glu Leu Glu His Ala
 355 360

<210> 69
 <211> 333
 <212> PRT
 <213> Homo sapiens

<400> 69
 Met Arg Ile Trp Trp Leu Leu Leu Ala Ile Glu Ile Cys Thr Gly Asn
 1 5 10 15
 Ile Asn Ser Gln Asp Thr Cys Arg Gln Gly His Pro Gly Ile Pro Gly
 20 25 30
 Asn Pro Gly His Asn Gly Leu Pro Gly Arg Asp Gly Arg Asp Gly Ala
 35 40 45
 Lys Gly Asp Lys Gly Asp Ala Gly Glu Pro Gly Arg Pro Gly Ser Pro
 50 55 60
 Gly Lys Asp Gly Thr Ser Gly Glu Lys Gly Glu Arg Gly Ala Asp Gly
 65 70 75 80
 Lys Val Glu Ala Lys Gly Ile Lys Gly Asp Gln Gly Ser Arg Gly Ser
 85 90 95

Pro Gly Lys His Gly Pro Lys Gly Leu Ala Gly Pro Met Gly Glu Lys
 100 105 110
 Gly Leu Arg Gly Glu Thr Gly Pro Gln Gly Gln Lys Gly Asn Lys Gly
 115 120 125
 Asp Val Gly Pro Thr Gly Pro Glu Gly Pro Arg Gly Asn Ile Gly Pro
 130 135 140
 Leu Gly Pro Thr Gly Leu Pro Gly Pro Met Gly Pro Ile Gly Lys Pro
 145 150 155 160
 Gly Pro Lys Gly Glu Ala Gly Pro Thr Gly Pro Gln Gly Glu Pro Gly
 165 170 175
 Val Arg Gly Ile Arg Gly Trp Lys Gly Asp Arg Gly Glu Lys Gly Lys
 180 185 190
 Ile Gly Glu Thr Leu Val Leu Pro Lys Ser Ala Phe Thr Val Gly Leu
 195 200 205
 Thr Val Leu Ser Lys Phe Pro Ser Ser Asp Val Pro Ile Lys Phe Asp
 210 215 220
 Lys Ile Leu Tyr Asn Glu Phe Asn His Tyr Asp Thr Ala Ala Gly Lys
 225 230 235 240
 Phe Thr Cys His Ile Ala Gly Val Tyr Tyr Phe Thr Tyr His Ile Thr
 245 250 255
 Val Phe Ser Arg Asn Val Gln Val Ser Leu Val Lys Asn Gly Val Lys
 260 265 270
 Ile Leu His Thr Lys Asp Ala Tyr Met Ser Ser Glu Asp Gln Ala Ser
 275 280 285
 Gly Gly Ile Val Leu Gln Leu Lys Leu Gly Asp Glu Val Trp Leu Gln
 290 295 300
 Val Thr Gly Gly Glu Arg Phe Asn Gly Leu Phe Ala Asp Glu Asp Asp
 305 310 315 320
 Asp Thr Thr Phe Thr Gly Phe Leu Leu Phe Ser Ser Pro
 325 330

<210> 70
 <211> 229
 <212> PRT
 <213> Homo sapiens

<400> 70
 Met Asp Leu Leu Gln Phe Leu Ala Phe Leu Phe Val Leu Leu Leu Ser
 1 5 10 15
 Gly Met Gly Ala Thr Gly Thr Leu Arg Thr Ser Leu Asp Pro Ser Leu
 20 25 30
 Glu Ile Tyr Lys Lys Met Phe Glu Val Lys Arg Arg Glu Gln Leu Leu
 35 40 45
 Ala Leu Lys Asn Leu Ala Gln Leu Asn Asp Ile His Gln Gln Tyr Lys
 50 55 60
 Ile Leu Asp Val Met Leu Lys Gly Leu Phe Lys Val Leu Glu Asp Ser
 65 70 75 80

Ala Pro Leu Trp Gly Pro Pro Pro Ala Gln Gly Ser Pro Gly Asp Gly
 180 185 190
 Gly Leu Gln Asp Gln Val Gly Ala Trp Gly Leu Pro Gly Pro Thr Gly
 195 200 205
 Pro Lys Gly Asp Ala Gly Ser Arg Gly Pro Met Gly Met Arg Gly Pro
 210 215 220
 Pro Gly Pro Gln Gly Pro Pro Gly Ser Pro Gly Arg Ala Gly Ala Val
 225 230 235 240
 Gly Thr Pro Gly Glu Arg Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly
 245 250 255
 Pro Pro Gly Pro Pro Ala Pro Val Gly Pro Pro His Ala Arg Ile Ser
 260 265 270
 Gln His Gly Asp Pro Leu Leu Ser Asn Thr Phe Thr Glu Thr Asn Asn
 275 280 285
 His Trp Pro Gln Gly Pro Thr Gly Pro Pro Gly Pro Pro Gly Pro Met
 290 295 300
 Gly Pro Pro Gly Pro Pro Gly Pro Thr Gly Val Pro Gly Ser Pro Gly
 305 310 315 320
 Xaa Ile Gly Pro Pro Gly Pro Thr Gly Pro Lys Gly Ile Ser Gly His
 325 330 335
 Pro Gly Glu Lys Gly Glu Lys Lys Xaa Leu Arg Gly Glu Pro Gly Pro
 340 345 350
 Gln Gly Ser Ala Gly Gln Arg Gly Glu Pro Gly Pro Lys Gly Asp Pro
 355 360 365
 Gly Glu Lys Ser His Trp Asn Gln Ser Trp Gly Leu Gly Gly Pro Cys
 370 375 380
 Arg His Arg His Pro Gln Pro Pro Ser Gly Gln Glu Gly Gly His Ala
 385 390 395 400
 Thr Asn Tyr Arg Asp Arg Gly Pro Gln Glu Pro Gly Arg Glu Arg Leu
 405 410 415
 Arg Val Val Ala Ala Pro Glu Ala Asp Gln Ala Arg Leu Pro Leu Leu
 420 425 430
 Pro Gly Leu Gly Gln Leu Pro Pro Gly Thr Ala Arg Pro Tyr Leu Leu
 435 440 445
 Met Ser Ser Gly Ser Leu Leu Pro Ser Arg Pro
 450 455

<210> 73
 <211> 443
 <212> PRT
 <213> Homo sapiens

<400> 73
 Met Gly Gly Pro Arg Ala Trp Ala Leu Leu Cys Leu Gly Leu Leu Leu
 1 5 10 15
 Pro Gly Gly Gly Ala Ala Trp Ser Ile Gly Ala Ala Pro Phe Ser Gly

20					25					30					
Arg	Arg	Asn	Trp	Cys	Ser	Tyr	Val	Val	Thr	Arg	Thr	Ile	Ser	Cys	His
		35					40					45			
Val	Gln	Asn	Gly	Thr	Tyr	Leu	Gln	Arg	Val	Leu	Gln	Asn	Cys	Pro	Trp
	50					55					60				
Pro	Met	Ser	Cys	Pro	Gly	Ser	Ser	Tyr	Arg	Thr	Val	Val	Arg	Pro	Thr
	65					70					75				80
Tyr	Lys	Val	Met	Tyr	Lys	Ile	Val	Thr	Ala	Arg	Glu	Trp	Arg	Cys	Cys
				85					90						95
Pro	Gly	His	Ser	Gly	Val	Ser	Cys	Glu	Glu	Val	Ala	Ala	Ser	Ser	Ala
			100					105					110		
Ser	Leu	Glu	Pro	Met	Trp	Ser	Gly	Ser	Thr	Met	Arg	Arg	Met	Ala	Leu
		115					120					125			
Arg	Pro	Thr	Ala	Phe	Ser	Gly	Cys	Leu	Asn	Cys	Ser	Lys	Val	Ser	Glu
		130				135					140				
Leu	Thr	Glu	Arg	Leu	Lys	Val	Leu	Glu	Ala	Lys	Met	Thr	Met	Leu	Thr
	145					150					155				160
Val	Ile	Glu	Gln	Pro	Val	Pro	Pro	Thr	Pro	Ala	Thr	Pro	Glu	Asp	Pro
				165					170					175	
Ala	Pro	Leu	Trp	Gly	Pro	Pro	Pro	Ala	Gln	Gly	Ser	Pro	Gly	Asp	Gly
			180					185					190		
Gly	Leu	Gln	Asp	Gln	Val	Gly	Ala	Trp	Gly	Leu	Pro	Gly	Pro	Thr	Gly
		195					200					205			
Pro	Lys	Gly	Asp	Ala	Gly	Ser	Arg	Gly	Pro	Met	Gly	Met	Arg	Gly	Pro
		210					215				220				
Pro	Gly	Pro	Gln	Gly	Pro	Pro	Gly	Ser	Pro	Gly	Arg	Ala	Gly	Ala	Val
		225					230				235				240
Gly	Thr	Pro	Gly	Glu	Arg	Gly	Pro	Pro	Gly	Pro	Pro	Gly	Pro	Pro	Gly
			245						250					255	
Pro	Pro	Gly	Pro	Pro	Ala	Pro	Val	Gly	Pro	Pro	His	Ala	Arg	Ile	Ser
			260					265					270		
Gln	His	Gly	Asp	Pro	Leu	Leu	Ser	Asn	Thr	Phe	Thr	Glu	Thr	Asn	Asn
		275					280					285			
His	Trp	Pro	Gln	Gly	Pro	Thr	Gly	Pro	Pro	Gly	Pro	Pro	Gly	Pro	Met
	290					295					300				
Gly	Pro	Pro	Gly	Pro	Pro	Gly	Pro	Thr	Gly	Val	Pro	Gly	Ser	Pro	Gly
	305					310					315				320
His	Ile	Gly	Pro	Pro	Gly	Pro	Thr	Gly	Pro	Lys	Gly	Ile	Ser	Gly	His
			325					330						335	
Pro	Gly	Glu	Lys	Gly	Glu	Arg	Gly	Leu	Arg	Gly	Glu	Pro	Gly	Pro	Gln
			340				345					350			
Gly	Ser	Ala	Gly	Gln	Arg	Gly	Glu	Pro	Gly	Pro	Lys	Gly	Asp	Pro	Gly
		355					360					365			
Glu	Lys	Ser	His	Trp	Gly	Glu	Gly	Leu	His	Gln	Leu	Arg	Glu	Ala	Leu
		370				375					380				

Lys Ile Leu Ala Glu Arg Val Leu Ile Leu Glu Thr Met Ile Gly Leu
 385 390 395 400
 Tyr Glu Pro Glu Leu Gly Ser Gly Ala Gly Pro Ala Gly Thr Gly Thr
 405 410 415
 Pro Ser Leu Leu Arg Gly Lys Arg Gly Gly His Ala Thr Asn Tyr Arg
 420 425 430
 Ile Val Ala Pro Arg Ser Arg Asp Glu Arg Gly
 435 440

<210> 74
 <211> 12
 <212> PRT
 <213> Homo sapiens

<400> 74
 Gly Arg Pro Arg Pro Pro Ala Leu Val Leu Ala Arg
 1 5 10

<210> 75
 <211> 19
 <212> PRT
 <213> Homo sapiens

<400> 75
 Gly Thr Ala Arg Pro Tyr Leu Leu Met Ser Ser Gly Ser Leu Leu Pro
 1 5 10 15

Ser Arg Pro

<210> 76
 <211> 421
 <212> PRT
 <213> Homo sapiens

<400> 76
 Met Gly Gly Pro Arg Ala Trp Ala Leu Leu Cys Leu Gly Leu Leu Leu
 1 5 10 15

Pro Gly Gly Gly Ala Ala Trp Ser Ile Gly Ala Ala Pro Phe Ser Gly
 20 25 30

Arg Arg Asn Trp Cys Ser Tyr Val Val Thr Arg Thr Ile Ser Cys His
 35 40 45

Val Gln Asn Gly Thr Tyr Leu Gln Arg Val Leu Gln Asn Cys Pro Trp
 50 55 60

Pro Met Ser Cys Pro Gly Ser Ser Tyr Arg Thr Val Val Arg Pro Thr
 65 70 75 80

Tyr Lys Val Met Tyr Lys Ile Val Thr Ala Arg Glu Trp Arg Cys Cys
 85 90 95

Pro Gly His Ser Gly Val Ser Cys Glu Glu Val Ala Ala Ser Ser Ala
 100 105 110

Ser Leu Glu Pro Met Trp Ser Gly Ser Thr Met Arg Arg Met Ala Leu
 115 120
 Arg Pro Thr Ala Phe Ser Gly Cys Leu Asn Cys Ser Lys Val Ser Glu
 130 135 140
 Leu Thr Glu Arg Leu Lys Val Leu Glu Ala Lys Met Thr Met Leu Thr
 145 150 155 160
 Val Ile Glu Gln Pro Val Pro Ser Thr Pro Ala Thr Pro Glu Asp Pro
 165 170 175
 Ala Pro Leu Trp Gly Pro Pro Pro Ala Gln Gly Ser Pro Gly Asp Gly
 180 185 190
 Gly Leu Gln Asp Gln Val Gly Ala Trp Gly Leu Pro Gly Pro Thr Gly
 195 200 205
 Pro Lys Gly Asp Ala Gly Ser Arg Gly Pro Met Gly Met Arg Gly Pro
 210 215 220
 Pro Gly Pro Gln Gly Pro Pro Gly Ser Pro Gly Arg Ala Gly Ala Val
 225 230 235 240
 Gly Thr Pro Gly Glu Arg Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly
 245 250 255
 Pro Pro Gly Pro Pro Ala Pro Val Gly Pro Pro His Ala Arg Ile Ser
 260 265 270
 Gln His Gly Asp Pro Leu Leu Ser Asn Thr Phe Thr Glu Thr Asn Asn
 275 280 285
 His Trp Pro Gln Gly Pro Thr Gly Pro Pro Gly Pro Pro Gly Pro Met
 290 295 300
 Gly Pro Pro Gly Pro Pro Gly Pro Thr Gly Val Pro Gly Ser Pro Gly
 305 310 315 320
 His Ile Gly Pro Pro Gly Pro Thr Gly Pro Lys Gly Ile Ser Gly His
 325 330 335
 Pro Gly Glu Lys Gly Glu Arg Gly Leu Arg Gly Glu Pro Gly Pro Gln
 340 345 350
 Gly Ser Ala Gly Gln Arg Gly Glu Pro Gly Pro Lys Gly Asp Pro Gly
 355 360 365
 Glu Lys Ser His Trp Asn Gln Ser Trp Gly Leu Gly Arg Ala Leu Pro
 370 375 380
 Ala Gln Ala Pro Pro Ala Ser Phe Gly Ala Arg Gly Ala Asp Met Gln
 385 390 395 400
 Pro Thr Thr Gly Ser Trp Pro Pro Gly Ala Gly Thr Arg Glu Ala Glu
 405 410 415
 Gly Gly Gly Gly Pro
 420

<210> 77
 <211> 421
 <212> PRT
 <213> Homo sapiens

<400> 77

Met Gly Gly Pro Arg Ala Trp Ala Leu Leu Cys Leu Gly Leu Leu Leu
 1 5 10 15

Pro Gly Gly Gly Ala Ala Trp Ser Ile Gly Ala Ala Pro Phe Ser Gly
 20 25 30

Arg Arg Asn Trp Cys Ser Tyr Val Val Thr Arg Thr Ile Ser Cys His
 35 40 45

Val Gln Asn Gly Thr Tyr Leu Gln Arg Val Leu Gln Asn Cys Pro Trp
 50 55 60

Pro Met Ser Cys Pro Gly Ser Ser Tyr Arg Thr Val Val Arg Pro Thr
 65 70 75 80

Tyr Lys Val Met Tyr Lys Ile Val Thr Ala Arg Glu Trp Arg Cys Cys
 85 90 95

Pro Gly His Ser Gly Val Ser Cys Glu Glu Val Ala Ala Ser Ser Ala
 100 105 110

Ser Leu Glu Pro Met Trp Ser Gly Ser Thr Met Arg Arg Met Ala Leu
 115 120 125

Arg Pro Thr Ala Phe Ser Gly Cys Leu Asn Cys Ser Lys Val Ser Glu
 130 135 140

Leu Thr Glu Arg Leu Lys Val Leu Glu Ala Lys Met Thr Met Leu Thr
 145 150 155 160

Val Ile Glu Gln Pro Val Pro Pro Thr Pro Ala Thr Pro Glu Asp Pro
 165 170 175

Ala Pro Leu Trp Gly Pro Pro Pro Ala Gln Gly Ser Pro Gly Asp Gly
 180 185 190

Gly Leu Gln Asp Gln Val Gly Ala Trp Gly Leu Pro Gly Pro Thr Gly
 195 200 205

Pro Lys Gly Asp Ala Gly Ser Arg Gly Pro Met Gly Met Arg Gly Pro
 210 215 220

Pro Gly Pro Gln Gly Pro Pro Gly Ser Pro Gly Arg Ala Gly Ala Val
 225 230 235 240

Gly Thr Pro Gly Glu Arg Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly
 245 250 255

Pro Pro Gly Pro Pro Ala Pro Val Gly Pro Pro His Ala Arg Ile Ser
 260 265 270

Gln His Gly Asp Pro Leu Leu Ser Asn Thr Phe Thr Glu Thr Asn Asn
 275 280 285

His Trp Pro Gln Gly Pro Thr Gly Pro Pro Gly Pro Gly Pro Met
 290 295 300

Gly Pro Pro Gly Pro Pro Gly Pro Thr Gly Val Pro Gly Ser Pro Gly
 305 310 315 320

His Ile Gly Pro Pro Gly Pro Thr Gly Pro Lys Gly Ile Ser Gly His
 325 330 335

Pro Gly Glu Lys Gly Glu Arg Gly Leu Arg Gly Glu Pro Gly Pro Gln
 340 345 350

Gly Ser Ala Gly Gln Arg Gly Glu Pro Gly Pro Lys Gly Asp Pro Gly
 355 360 365
 Glu Lys Ser His Trp Asn Gln Ser Trp Gly Leu Gly Arg Ala Leu Pro
 370 375 380
 Ala Gln Ala Pro Pro Ala Ser Phe Gly Ala Arg Gly Ala Asp Met Gln
 385 390 395 400
 Pro Thr Thr Gly Ser Trp Pro Pro Gly Ala Gly Thr Arg Glu Ala Glu
 405 410 415
 Gly Gly Gly Gly Pro
 420

<210> 78
 <211> 458
 <212> PRT
 <213> Homo sapiens

<400> 78
 Met Gly Gly Pro Arg Ala Trp Ala Leu Leu Cys Leu Gly Leu Leu Leu
 1 5 10 15
 Pro Gly Gly Gly Ala Ala Trp Ser Ile Gly Ala Ala Pro Phe Ser Gly
 20 25 30
 Arg Arg Asn Trp Cys Ser Tyr Val Val Thr Arg Thr Ile Ser Cys His
 35 40 45
 Val Gln Asn Gly Thr Tyr Leu Gln Arg Val Leu Gln Asn Cys Pro Trp
 50 55 60
 Pro Met Ser Cys Pro Gly Ser Ser Tyr Arg Thr Val Val Arg Pro Thr
 65 70 75 80
 Tyr Lys Val Met Tyr Lys Ile Val Thr Ala Arg Glu Trp Arg Cys Cys
 85 90 95
 Pro Gly His Ser Gly Val Ser Cys Glu Glu Val Ala Ala Ser Ser Ala
 100 105 110
 Ser Leu Glu Pro Met Trp Ser Gly Ser Thr Met Arg Arg Met Ala Leu
 115 120 125
 Arg Pro Thr Ala Phe Ser Gly Cys Leu Asn Cys Ser Lys Val Ser Glu
 130 135 140
 Leu Thr Glu Arg Leu Lys Val Leu Glu Ala Lys Met Thr Met Leu Thr
 145 150 155 160
 Val Ile Glu Gln Pro Val Pro Pro Thr Pro Ala Thr Pro Glu Asp Pro
 165 170 175
 Ala Pro Leu Trp Gly Pro Pro Pro Ala Gln Gly Ser Pro Gly Asp Gly
 180 185 190
 Gly Leu Gln Asp Gln Val Gly Ala Trp Gly Leu Pro Gly Pro Thr Gly
 195 200 205
 Pro Lys Gly Asp Ala Gly Ser Arg Gly Pro Met Gly Met Arg Gly Pro
 210 215 220
 Pro Gly Pro Gln Gly Pro Pro Gly Ser Pro Gly Arg Ala Gly Ala Val
 225 230 235 240

Gly Thr Pro Gly Glu Arg Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly
 245 250 255
 Pro Pro Gly Pro Pro Ala Pro Val Gly Pro Pro His Ala Arg Ile Ser
 260 265 270
 Gln His Gly Asp Pro Leu Leu Ser Asn Thr Phe Thr Glu Thr Asn Asn
 275 280 285
 His Trp Pro Gln Gly Pro Thr Gly Pro Pro Gly Pro Gly Pro Met
 290 295 300
 Gly Pro Pro Gly Pro Pro Gly Pro Thr Gly Val Pro Gly Ser Pro Gly
 305 310 315 320
 His Ile Gly Pro Pro Gly Pro Thr Gly Pro Lys Gly Ile Ser Gly His
 325 330 335
 Pro Gly Glu Lys Gly Glu Arg Gly Leu Arg Gly Glu Pro Gly Pro Gln
 340 345 350
 Gly Ser Ala Gly Gln Arg Gly Glu Pro Gly Pro Lys Gly Asp Pro Gly
 355 360 365
 Glu Lys Ser His Trp Asn Gln Ser Trp Gly Leu Gly Gly Pro Cys Arg
 370 375 380
 His Arg His Pro Gln Pro Pro Ser Gly Gln Glu Gly Gly His Ala Thr
 385 390 395 400
 Asn Tyr Arg Asp Arg Gly Pro Gln Glu Pro Gly Arg Glu Arg Leu Arg
 405 410 415
 Val Val Ala Ala Pro Glu Ala Asp Gln Ala Arg Leu Pro Leu Leu Pro
 420 425 430
 Gly Leu Gly Gln Leu Pro Pro Gly Thr Ala Arg Pro Tyr Leu Leu Met
 435 440 445
 Ser Ser Gly Ser Leu Leu Pro Ser Arg Pro
 450 455

<210> 79
 <211> 240
 <212> PRT
 <213> Homo sapiens

<400> 79
 His Ala Ser Ala Ala Arg Ala Ala Ala Gly Ser Glu Pro Arg Thr Gly
 1 5 10 15
 Cys Gly Gly Ser Ser His Arg Val Pro Leu Gly Pro Ser Pro Ala Ser
 20 25 30
 Leu Ser Pro Gln Arg Asp Leu Phe Gly Pro Pro Gly Pro Pro Gly Ala
 35 40 45
 Glu Val Thr Ala Glu Thr Leu Leu His Glu Phe Gln Glu Leu Leu Lys
 50 55 60
 Glu Ala Thr Glu Arg Arg Phe Ser Gly Leu Leu Asp Pro Leu Leu Pro
 65 70 75 80
 Gln Gly Ala Gly Leu Arg Leu Val Gly Glu Ala Phe His Cys Arg Leu

85					90					95					
Gln	Gly	Pro	Arg	Arg	Val	Asp	Lys	Arg	Thr	Leu	Val	Glu	Leu	His	Gly
			100					105					110		
Phe	Gln	Ala	Pro	Ala	Ala	Gln	Gly	Ala	Phe	Leu	Arg	Gly	Ser	Gly	Leu
	115					120						125			
Ser	Leu	Ala	Ser	Gly	Arg	Phe	Thr	Ala	Pro	Val	Ser	Gly	Ile	Phe	Gln
	130					135					140				
Phe	Ser	Ala	Ser	Leu	His	Val	Asp	His	Ser	Glu	Leu	Gln	Gly	Lys	Ala
	145					150				155					160
Arg	Leu	Arg	Ala	Arg	Asp	Val	Val	Cys	Val	Leu	Ile	Cys	Ile	Glu	Ser
			165					170						175	
Leu	Cys	Gln	Arg	His	Thr	Cys	Leu	Glu	Ala	Val	Ser	Gly	Leu	Glu	Ser
			180					185					190		
Asn	Ser	Arg	Val	Phe	Thr	Leu	Gln	Val	Gln	Gly	Leu	Leu	Gln	Leu	Gln
			195				200					205			
Ala	Gly	Gln	Tyr	Ala	Ser	Val	Phe	Val	Asp	Asn	Gly	Ser	Gly	Ala	Val
	210					215				220					
Leu	Thr	Ile	Gln	Ala	Gly	Ser	Ser	Phe	Ser	Gly	Leu	Leu	Leu	Gly	Thr
	225					230				235					240

<210> 80

<211> 256

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (75)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (187)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (229)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (232)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (235)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (236)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE
 <222> (237)
 <223> Xaa equals any of the naturally occurring L-amino acids

 <400> 80
 Met Leu Gly Ala Lys Pro His Trp Leu Pro Gly Pro Leu His Ser Pro
 1 5 10 15
 Gly Leu Pro Leu Val Leu Val Leu Leu Ala Leu Gly Ala Gly Trp Ala
 20 25 30
 Gln Glu Gly Ser Glu Pro Val Leu Leu Glu Gly Glu Cys Leu Val Val
 35 40 45
 Cys Glu Pro Gly Arg Ala Ala Ala Gly Gly Pro Gly Gly Ala Ala Leu
 50 55 60
 Gly Glu Ala Pro Pro Gly Arg Val Ala Phe Xaa Ala Val Arg Ser His
 65 70 75 80
 His His Glu Pro Ala Gly Glu Thr Gly Asn Gly Thr Ser Gly Ala Ile
 85 90 95
 Tyr Phe Asp Gln Val Leu Val Asn Glu Gly Gly Gly Phe Asp Arg Ala
 100 105 110
 Ser Gly Ser Phe Val Ala Pro Val Arg Gly Val Tyr Ser Phe Arg Phe
 115 120 125
 His Val Val Lys Val Tyr Asn Arg Gln Thr Val Gln Val Ser Leu Met
 130 135 140
 Leu Asn Thr Trp Pro Val Ile Ser Ala Phe Ala Asn Asp Pro Asp Val
 145 150 155 160
 Thr Arg Glu Ala Ala Thr Ser Ser Val Leu Leu Pro Leu Asp Pro Gly
 165 170 175
 Asp Arg Val Ser Leu Arg Leu Arg Arg Gly Xaa Ser Thr Gly Trp Leu
 180 185 190
 Glu Ile Leu Lys Phe Leu Trp Leu Pro His Leu Pro Ser Leu Lys Asp
 195 200 205
 Pro Ser Leu Ser Ser Thr Arg Ile Gln Pro Leu Thr Thr Phe Phe Cys
 210 215 220
 Pro Leu Leu Pro Xaa Lys Gln Xaa Lys Gln Xaa Xaa Ser Leu Trp
 225 230 235 240
 Leu Leu Ser His Leu Phe Ala Trp Glu Pro Val Pro Asn Thr Gln Val
 245 250 255

 <210> 81
 <211> 205
 <212> PRT
 <213> Homo sapiens

 <220>
 <221> SITE
 <222> (80)
 <223> Xaa equals any of the naturally occurring L-amino acids

 <220>
 <221> SITE
 <222> (93)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 81

```
Met Leu Gly Ala Lys Pro His Trp Leu Pro Gly Pro Leu His Ser Pro
 1          5          10          15

Gly Leu Pro Leu Val Leu Val Leu Leu Ala Leu Gly Ala Gly Trp Ala
          20          25          30

Gln Glu Gly Ser Glu Pro Val Leu Leu Glu Gly Glu Cys Leu Val Val
          35          40          45

Cys Glu Pro Gly Arg Ala Ala Ala Gly Gly Pro Gly Gly Ala Ala Leu
          50          55          60

Gly Glu Ala Pro Pro Gly Arg Val Ala Phe Ala Ala Val Arg Ser Xaa
 65          70          75          80

His His Glu Pro Ala Gly Glu Thr Gly Asn Gly Thr Xaa Gly Ala Ile
          85          90          95

Tyr Phe Asp Gln Val Leu Val Asn Glu Gly Gly Gly Phe Asp Arg Ala
          100          105          110

Ser Gly Ser Phe Val Ala Pro Val Arg Gly Val Tyr Ser Phe Arg Phe
          115          120          125

His Val Val Lys Val Tyr Asn Arg Gln Thr Val Gln Val Ser Leu Met
          130          135          140

Leu Asn Thr Trp Pro Val Ile Ser Ala Phe Ala Asn Asp Pro Asp Val
          145          150          155          160

Thr Arg Glu Ala Ala Thr Ser Ser Val Leu Leu Pro Leu Asp Pro Gly
          165          170          175

Asp Arg Val Ser Leu Arg Leu Arg Arg Gly Asn Leu Leu Gly Gly Trp
          180          185          190

Lys Tyr Ser Ser Phe Ser Gly Phe Leu Ile Phe Pro Leu
          195          200          205
```

<210> 82

<211> 180

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (102)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 82

```
Ala Cys Cys Pro Val Arg Ala Gln Asn Asp Thr Glu Pro Ile Val Leu
 1          5          10          15

Glu Gly Lys Cys Leu Val Val Cys Asp Ser Ser Pro Ser Ala Asp Gly
          20          25          30

Ala Val Thr Ser Ser Leu Gly Ile Ser Val Arg Ser Gly Ser Ala Lys
          35          40          45

Val Ala Phe Ser Ala Thr Arg Ser Thr Asn His Glu Pro Ser Glu Met
          50          55          60
```

Ser Asn Arg Thr Met Thr Ile Tyr Phe Asp Gln Val Leu Val Asn Ile
 65 70 75 80

Gly Asn His Phe Asp Leu Ala Ser Ser Ile Phe Val Ala Pro Arg Lys
 85 90 95

Gly Ile Tyr Ser Phe Xaa Phe His Val Val Lys Val Tyr Asn Arg Gln
 100 105 110

Thr Ile Gln Val Ser Leu Met Gln Asn Gly Tyr Pro Val Ile Ser Ala
 115 120 125

Phe Ala Gly Asp Gln Asp Val Thr Arg Glu Ala Ala Ser Asn Gly Val
 130 135 140

Leu Leu Leu Met Glu Arg Glu Asp Lys Val His Leu Lys Leu Glu Arg
 145 150 155 160

Gly Asn Leu Met Gly Gly Trp Lys Tyr Ser Thr Phe Ser Gly Phe Leu
 165 170 175

Val Phe Pro Leu
 180

<210> 83
 <211> 241
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (62)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (191)
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 83
 Ala Gly Glu Gly Pro Arg Arg Arg Glu Pro Pro Trp Pro Ala Pro Gln
 1 5 10 15

Ile Cys Pro Ala Gly Arg Gly Gly Gly Thr Arg Ala Gly Gly Gly
 20 25 30

Ala Gly Arg Ser Ser Gly Arg Gly Glu Gly Tyr Gly Asp Leu Arg
 35 40 45

Val Ala Ala Pro Leu Arg Ala Glu Pro Pro Leu Leu Ser Xaa Cys Arg
 50 55 60

Pro Ala Tyr Pro Ala Gly Leu Pro Gly Pro Arg Gly Asp Pro Gly Pro
 65 70 75 80

Arg Gly Glu Ala Gly Pro Ala Gly Pro Thr Gly Pro Ala Gly Glu Cys
 85 90 95

Ser Val Pro Pro Arg Ser Ala Phe Ser Ala Lys Arg Ser Glu Ser Arg
 100 105 110

Val Pro Pro Pro Ser Asp Ala Pro Leu Pro Phe Asp Arg Val Leu Val
 115 120 125

Asn Glu Gln Gly His Tyr Asp Ala Val Thr Gly Lys Phe Thr Cys Gln

130 135 140
Val Pro Gly Val Tyr Tyr Phe Ala Val His Ala Thr Val Tyr Arg Ala
145 150 155 160
Ser Leu Gln Phe Asp Leu Val Lys Asn Gly Glu Ser Ile Ala Ser Phe
165 170 175
Phe Gln Phe Phe Gly Gly Trp Pro Lys Pro Ala Ser Leu Ser Xaa Gly
180 185 190
Ala Met Val Arg Leu Glu Pro Glu Asp Gln Val Trp Val Gln Val Gly
195 200 205
Val Gly Asp Tyr Ile Gly Ile Tyr Ala Ser Ile Lys Thr Asp Ser Thr
210 215 220
Phe Ser Gly Phe Leu Val Tyr Ser Asp Trp His Ser Ser Pro Val Phe
225 230 235 240
Ala

<210> 84
<211> 245
<212> PRT
<213> Homo sapiens

<400> 84
Met Asp Val Gly Pro Ser Ser Leu Pro His Leu Gly Leu Lys Leu Leu
1 5 10 15
Leu Leu Leu Leu Leu Leu Pro Leu Arg Gly Gln Ala Asn Thr Gly Cys
20 25 30
Tyr Gly Ile Pro Gly Met Pro Gly Leu Pro Gly Ala Pro Gly Lys Asp
35 40 45
Gly Tyr Asp Gly Leu Pro Gly Pro Lys Gly Glu Pro Gly Ile Pro Ala
50 55 60
Ile Pro Gly Ile Arg Gly Pro Lys Gly Gln Lys Gly Glu Pro Gly Leu
65 70 75 80
Pro Gly His Pro Gly Lys Asn Gly Pro Met Gly Pro Pro Gly Met Pro
85 90 95
Gly Val Pro Gly Pro Met Gly Ile Pro Gly Glu Pro Gly Glu Glu Gly
100 105 110
Arg Tyr Lys Gln Lys Phe Gln Ser Val Phe Thr Val Thr Arg Gln Thr
115 120 125
His Gln Pro Pro Ala Pro Asn Ser Leu Ile Arg Phe Asn Ala Val Leu
130 135 140
Thr Asn Pro Gln Gly Asp Tyr Asp Thr Ser Thr Gly Lys Phe Thr Cys
145 150 155 160
Lys Val Pro Gly Leu Tyr Tyr Phe Val Tyr His Ala Ser His Thr Ala
165 170 175
Asn Leu Cys Val Leu Leu Tyr Arg Ser Gly Val Lys Val Val Thr Phe
180 185 190
Cys Gly His Thr Ser Lys Thr Asn Gln Val Asn Ser Gly Gly Val Leu

[illegible]

```
<210> 85
<211> 76
<212> PRT
<213> Homo sapiens
```

```

<400> 85
Ala Leu Pro Arg Leu Gly Arg Ala Asp Ala Leu Glu Thr His Gly Pro
 1          5          10          15
Ser Thr Ser Leu Ser Phe Leu His Gly Pro Thr Leu Leu Ala Ser Leu
          20          25          30
His Pro Cys Leu Asp His Ser Pro Leu Gln Gly Ala His Pro Asp Pro
          35          40          45
Pro Pro Leu His Pro Leu Pro Met Gly Ser Leu Leu Pro Leu Asn Phe
          50          55          60
Phe Arg Ser His Cys Leu Cys Gly Ser Trp Asp Thr
65          70          75

```

```
<210> 86
<211> 185
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (72)
<223> Xaa equals any of the naturally occurring L-amino acids
```

```
<220>
<221> SITE
<222> (86)
<223> Xaa equals any of the naturally occurring L-amino acids
```

```
<220>
<221> SITE
<222> (88)
<223> Xaa equals any of the naturally occurring L-amino acids
```

```
<220>
<221> SITE
<222> (90)
<223> Xaa equals any of the naturally occurring L-amino acids
```

```
<220>
<221> SITE
<222> (109)
<223> Xaa equals any of the naturally occurring L-amino acids
```

<220>

<221> SITE
 <222> (119)
 <223> Xaa equals any of the naturally occurring L-amino acids

 <220>
 <221> SITE
 <222> (148)
 <223> Xaa equals any of the naturally occurring L-amino acids

 <220>
 <221> SITE
 <222> (153)
 <223> Xaa equals any of the naturally occurring L-amino acids

 <220>
 <221> SITE
 <222> (171)
 <223> Xaa equals any of the naturally occurring L-amino acids

 <220>
 <221> SITE
 <222> (172)
 <223> Xaa equals any of the naturally occurring L-amino acids

 <220>
 <221> SITE
 <222> (178)
 <223> Xaa equals any of the naturally occurring L-amino acids

 <220>
 <221> SITE
 <222> (183)
 <223> Xaa equals any of the naturally occurring L-amino acids

 <400> 86
 Met Asp Val Gly Pro Ser Ser Leu Pro His Leu Gly Leu Lys Leu Leu
 1 5 10 15
 Leu Leu Leu Leu Leu Leu Pro Leu Arg Gly Gln Ala Asn Thr Gly Cys
 20 25 30
 Tyr Gly Ile Pro Gly Met Pro Gly Leu Pro Gly Ala Pro Gly Lys Asp
 35 40 45
 Gly Tyr Asp Gly Leu Pro Gly Pro Lys Gly Glu Pro Gly Ile Gln Pro
 50 55 60
 Phe Arg Asp Pro Arg Thr Gln Xaa Ala Glu Gly Arg Thr Arg Leu Thr
 65 70 75 80
 Arg Pro Ser Trp Glu Xaa Trp Xaa Met Xaa Pro Pro Gly Met Pro Gly
 85 90 95
 Val Pro Ala His Gly His Pro Trp Arg Ala Gly Glu Xaa Gly Arg Tyr
 100 105 110
 Lys Gln Lys Phe Gln Ser Xaa Ser Arg His Ser Glu Thr Thr Ala Pro
 115 120 125
 Asp Pro Thr Ala Asp Arg Ser Thr Arg Ser Asn Asn Arg Arg Arg Tyr
 130 135 140
 Thr Arg His Xaa Lys Ser Leu Lys Xaa Arg Leu Thr Leu Ala Thr Arg
 145 150 155 160
 Val Ile Ser Asn Trp Leu Cys Asp Glu Arg Xaa Xaa Gly Thr Leu Gly
 165 170 175

Asn Xaa Asn Ile Gly Asn Xaa Gly Ala
 180 185

<210> 87
 <211> 127
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (127)
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 87
 Met Phe Val Leu Leu Tyr Val Thr Ser Phe Ala Ile Cys Ala Ser Gly
 1 5 10 15
 Gln Pro Arg Gly Asn Gln Leu Lys Gly Glu Asn Tyr Ser Pro Arg Tyr
 20 25 30
 Ile Cys Ser Ile Pro Gly Leu Pro Gly Pro Gly Pro Gly Ala
 35 40 45
 Asn Gly Ser Pro Gly Pro His Gly Arg Ile Gly Leu Pro Gly Arg Asp
 50 55 60
 Gly Arg Asp Gly Arg Lys Gly Glu Lys Gly Lys Gly Thr Ala Gly
 65 70 75 80
 Leu Arg Gly Lys Thr Gly Pro Leu Gly Leu Ala Gly Glu Lys Gly Asp
 85 90 95
 Gln Gly Glu Thr Gly Lys Lys Gly Pro Ile Gly Pro Glu Gly Glu Lys
 100 105 110
 Gly Glu Val Gly Pro Ile Gly Pro Pro Gly Pro Lys Gly Asp Xaa
 115 120 125

<210> 88
 <211> 285
 <212> PRT
 <213> Homo sapiens

<400> 88
 Met Ile Pro Trp Val Leu Leu Ala Cys Ala Leu Pro Cys Ala Ala Asp
 1 5 10 15
 Pro Leu Leu Gly Ala Phe Ala Arg Arg Asp Phe Arg Lys Gly Ser Pro
 20 25 30
 Gln Leu Val Cys Ser Leu Pro Gly Pro Gln Gly Pro Pro Gly Pro Pro
 35 40 45
 Gly Ala Pro Gly Pro Ser Gly Met Met Gly Arg Met Gly Phe Pro Gly
 50 55 60
 Lys Asp Gly Gln Asp Gly His Asp Gly Asp Arg Gly Asp Ser Gly Glu
 65 70 75 80
 Glu Gly Pro Pro Gly Arg Thr Gly Asn Arg Gly Lys Pro Gly Pro Lys
 85 90 95

Gly Lys Ala Gly Ala Ile Gly Arg Ala Gly Pro Arg Gly Pro Lys Gly
 100 105 110
 Val Asn Gly Thr Pro Gly Lys His Gly Thr Pro Gly Lys Lys Gly Pro
 115 120 125
 Lys Gly Lys Lys Gly Glu Pro Gly Leu Pro Gly Pro Cys Ser Cys Gly
 130 135 140
 Ser Gly His Thr Lys Ser Ala Phe Ser Val Ala Val Thr Lys Ser Tyr
 145 150 155 160
 Pro Arg Glu Arg Leu Pro Ile Lys Phe Asp Lys Ile Leu Met Asn Glu
 165 170 175
 Gly Gly His Tyr Asn Ala Ser Ser Gly Lys Phe Val Cys Gly Val Pro
 180 185 190
 Gly Ile Tyr Tyr Phe Thr Tyr Asp Ile Thr Leu Ala Asn Lys His Leu
 195 200 205
 Ala Ile Gly Leu Val His Asn Gly Gln Tyr Arg Ile Arg Thr Phe Asp
 210 215 220
 Ala Asn Thr Gly Asn His Asp Val Ala Ser Gly Ser Thr Ile Leu Ala
 225 230 235 240
 Leu Lys Gln Gly Asp Glu Val Trp Leu Gln Ile Phe Tyr Ser Glu Gln
 245 250 255
 Asn Gly Leu Phe Tyr Asp Pro Tyr Trp Thr Asp Ser Leu Phe Thr Gly
 260 265 270
 Phe Leu Ile Tyr Ala Asp Gln Asp Asp Pro Asn Glu Val
 275 280 285

<210> 89
 <211> 205
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (5)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (27)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (104)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (119)
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 89
 Phe Phe Phe Phe Xaa Pro Gly Leu Pro Gly Leu Pro Cys Pro Leu Ser
 1 5 10 15

Ala Leu Leu Ala Glu Ser Arg Arg Ala Arg Xaa Pro Trp Arg Ser Arg
 20 25 30
 Gly Thr Phe Glu Pro Arg Ala Arg Pro Gly Met His Ala Pro Gly Pro
 35 40 45
 Pro Gly Leu Phe Ser Gly Pro Gly Leu Thr Val Ala Pro Arg Pro Arg
 50 55 60
 Gly Pro Ala Gly Gly Gly Gly Glu Val Gly Val His Gln Glu Ala Gly
 65 70 75 80
 Glu Gly Asp Val Leu Ala Val Val Ala Val Gly Ala Val Ala Val Val
 85 90 95
 Val Val Ala Glu Gln Pro Glu Xaa Ser Pro Arg Arg Arg Ala Ser Ile
 100 105 110
 Thr Leu Trp Leu Cys Ile Xaa Ala Ala Pro Arg Arg Ala Val Val Val
 115 120 125
 Asn His Gly Leu His Leu Val Ala Val Leu His Gln Leu Asn Arg Gln
 130 135 140
 Arg Leu Thr Arg Gln Leu Ala Gln Arg Glu Gly Glu Glu Val Gly Ala
 145 150 155 160
 Gly Gln Thr Ala Ala Glu His Ala Gly Arg Val Glu Val Ala Ala
 165 170 175
 Asn Val Asp Glu Leu Gly Val Glu Gly Glu Trp Leu Val Pro Arg Pro
 180 185 190
 Gly Pro Ala Ser Glu Pro Thr Lys Leu Arg Ala Leu Cys
 195 200 205

<210> 90

<211> 251

<212> PRT

<213> Homo sapiens

<400> 90

Met Lys Ile Pro Trp Gly Ser Ile Pro Val Leu Met Leu Leu Leu Leu
 1 5 10 15
 Leu Gly Leu Ile Asp Ile Ser Gln Ala Gln Leu Ser Cys Thr Gly Pro
 20 25 30
 Pro Ala Ile Pro Gly Ile Pro Gly Ile Pro Gly Thr Pro Gly Pro Asp
 35 40 45
 Gly Gln Pro Gly Thr Pro Gly Ile Lys Gly Glu Lys Gly Leu Pro Gly
 50 55 60
 Leu Ala Gly Asp His Gly Glu Phe Gly Glu Lys Gly Asp Pro Gly Ile
 65 70 75 80
 Pro Gly Asn Pro Gly Lys Val Gly Pro Lys Gly Pro Met Gly Pro Lys
 85 90 95
 Gly Gly Pro Gly Ala Pro Gly Ala Pro Gly Pro Lys Gly Glu Ser Gly
 100 105 110
 Asp Tyr Lys Ala Thr Gln Lys Ile Ala Phe Ser Ala Thr Arg Thr Ile
 115 120 125

```

Asn Val Pro Leu Arg Arg Asp Gln Thr Ile Arg Phe Asp His Val Ile
  130          135          140

Thr Asn Met Asn Asn Asn Tyr Glu Pro Arg Ser Gly Lys Phe Thr Cys
  145          150          155          160

Lys Val Pro Gly Leu Tyr Tyr Phe Thr Tyr His Ala Ser Ser Arg Gly
  165          170          175

Asn Leu Cys Val Asn Leu Met Arg Gly Arg Glu Arg Ala Gln Lys Val
  180          185          190

Val Thr Phe Cys Asp Tyr Ala Tyr Asn Thr Phe Gln Val Thr Thr Gly
  195          200          205

Gly Met Val Leu Lys Leu Glu Gln Gly Glu Asn Val Phe Leu Gln Ala
  210          215          220

Thr Asp Lys Asn Ser Leu Leu Gly Met Glu Gly Ala Asn Ser Ile Phe
  225          230          235          240

Ser Gly Phe Leu Leu Phe Pro Asp Met Glu Ala
      245          250

```

```

<210> 91
<211> 168
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (34)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (40)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (44)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (51)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (57)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (62)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (65)
<223> Xaa equals any of the naturally occurring L-amino acids

```

<220>

<221> SITE

<222> (83)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 91

Pro Gly Ile Arg Lys Arg Arg Pro Gln Gly Pro His Gly Pro Lys Val
 1 5 10 15
 Ala Gln Gly Pro Glu Ala Pro Ser Pro Lys Val Asn Arg Glu Thr Gln
 20 25 30
 Ala Xaa Gln Lys Met Pro Phe Xaa Ala Thr Arg Xaa Ile Asn Val Pro
 35 40 45
 Leu Arg Xaa Asp Gln Thr Ile Arg Xaa Asp His Val Ile Xaa Asn Met
 50 55 60
 Xaa Asn Asn Tyr Glu Pro Arg Ser Gly Lys Phe Thr Cys Lys Val Pro
 65 70 75 80
 Gly Leu Xaa Tyr Phe Thr Tyr His Ala Ser Arg Gly Asn Leu Cys
 85 90 95
 Val Asn Leu Met Arg Gly Arg Glu Arg Ala Gln Lys Val Val Thr Phe
 100 105 110
 Cys Asp Tyr Ala Tyr Asn Thr Phe Gln Val Thr Thr Gly Gly Met Val
 115 120 125
 Leu Lys Leu Glu Gln Gly Glu Asn Val Phe Leu Gln Ala Thr Asp Lys
 130 135 140
 Asn Ser Leu Leu Gly Met Glu Gly Ala Asn Ser Ile Phe Ser Gly Phe
 145 150 155 160
 Leu Leu Phe Pro Asp Met Glu Ala
 165

<210> 92

<211> 255

<212> PRT

<213> Homo sapiens

<400> 92

His Ser Met Met Met Lys Ile Pro Trp Gly Ser Ile Pro Val Leu Met
 1 5 10 15
 Leu Leu Leu Leu Leu Gly Leu Ile Asp Ile Ser Gln Ala Gln Leu Ser
 20 25 30
 Cys Thr Gly Pro Pro Ala Ile Pro Gly Ile Pro Gly Ile Pro Gly Thr
 35 40 45
 Pro Gly Pro Asp Gly Gln Pro Gly Thr Pro Gly Ile Lys Gly Glu Lys
 50 55 60
 Gly Leu Pro Gly Leu Ala Gly Asp His Gly Glu Phe Gly Glu Lys Gly
 65 70 75 80
 Asp Pro Gly Ile Pro Gly Asn Pro Gly Lys Val Gly Pro Lys Gly Pro
 85 90 95
 Met Gly Pro Lys Gly Gly Pro Gly Ala Pro Gly Ala Pro Gly Lys
 100 105 110

Gly Glu Ser Gly Asp Tyr Lys Ala Thr Gln Lys Ile Ala Phe Ser Ala
 115 120 125
 Thr Arg Thr Ile Asn Val Pro Leu Arg Arg Asp Gln Thr Ile Arg Phe
 130 135 140
 Asp His Val Ile Thr Asn Met Asn Asn Tyr Lys Glu Pro Arg Ser Gly
 145 150 155 160
 Lys Phe Thr Cys Lys Val Pro Gly Leu Tyr Tyr Phe Thr Tyr His Ala
 165 170 175
 Ser Ser Arg Gly Asn Leu Cys Val Asn Leu Met Arg Gly Arg Glu Arg
 180 185 190
 Ala Gln Lys Val Val Thr Phe Cys Asp Tyr Ala Tyr Asn Thr Phe Gln
 195 200 205
 Val Thr Thr Gly Gly Met Val Leu Lys Leu Glu Gln Gly Glu Asn Val
 210 215 220
 Phe Leu Gln Ala Thr Asp Lys Asn Ser Leu Leu Gly Met Glu Gly Ala
 225 230 235 240
 Asn Ser Ile Phe Ser Gly Phe Leu Leu Phe Pro Asp Met Glu Ala
 245 250 255

<210> 93
 <211> 258
 <212> PRT
 <213> Homo sapiens

<400> 93
 Ala Phe Ala Lys Ser Tyr Leu Gly Asp Thr Ile Glu Gly Thr Pro Ala
 1 5 10 15
 Gly Thr Gly Pro Glu Phe Pro Gly Arg Pro Thr Arg Pro Val Leu Pro
 20 25 30
 Gln Arg Pro Pro Glu Glu Arg Pro Pro Gln Pro Pro Gly Ser Thr Gly
 35 40 45
 Val Ile Ala Glu Thr Gly Gln Ala Gly Pro Pro Ala Gly Ala Gly Val
 50 55 60
 Ser Gly Arg Gly Leu Pro Arg Gly Val Asp Gly Gln Thr Gly Ser Gly
 65 70 75 80
 Thr Val Pro Gly Ala Glu Gly Phe Ala Gly Ala Pro Gly Tyr Pro Lys
 85 90 95
 Ser Pro Pro Val Ala Ser Pro Gly Ala Pro Val Pro Ser Leu Val Ser
 100 105 110
 Phe Ser Ala Gly Leu Thr Gln Lys Pro Phe Pro Ser Asp Gly Gly Val
 115 120 125
 Val Leu Phe Asn Lys Val Leu Val Asn Asp Gly Asp Val Tyr Asn Pro
 130 135 140
 Ser Thr Gly Val Phe Thr Ala Pro Tyr Asp Gly Arg Tyr Leu Ile Thr
 145 150 155 160
 Ala Thr Leu Thr Pro Glu Arg Asp Ala Tyr Val Glu Ala Val Leu Ser
 165 170 175

Val Ser Asn Ala Ser Val Ala Gln Leu His Thr Ala Gly Tyr Arg Arg
 180 185 190
 Glu Phe Leu Glu Tyr His Arg Pro Pro Gly Ala Leu His Thr Cys Gly
 195 200 205
 Gly Pro Gly Ala Phe His Leu Ile Val His Leu Lys Ala Gly Asp Ala
 210 215 220
 Val Asn Val Val Val Thr Gly Gly Lys Leu Ala His Thr Asp Phe Asp
 225 230 235 240
 Glu Met Tyr Ser Thr Phe Ser Gly Val Phe Leu Tyr Pro Phe Leu Ser
 245 250 255
 His Leu

<210> 94
 <211> 232
 <212> PRT
 <213> Homo sapiens

<400> 94
 Thr Arg Pro Val Leu Pro Gln Arg Pro Pro Glu Glu Arg Pro Pro Gln
 1 5 10 15
 Pro Pro Gly Ser Thr Gly Val Ile Ala Glu Thr Gly Gln Ala Gly Pro
 20 25 30
 Pro Ala Gly Ala Gly Val Ser Gly Arg Gly Leu Pro Arg Gly Val Asp
 35 40 45
 Gly Gln Thr Gly Ser Gly Thr Val Pro Gly Ala Glu Gly Phe Ala Gly
 50 55 60
 Ala Pro Gly Tyr Pro Lys Ser Pro Pro Val Ala Ser Pro Gly Ala Pro
 65 70 75 80
 Val Pro Ser Leu Val Ser Phe Ser Ala Gly Leu Thr Gln Lys Pro Phe
 85 90 95
 Pro Ser Asp Gly Gly Val Val Leu Phe Asn Lys Val Leu Val Asn Asp
 100 105 110
 Gly Asp Val Tyr Asn Pro Ser Thr Gly Val Phe Thr Ala Pro Tyr Asp
 115 120 125
 Gly Arg Tyr Leu Ile Thr Ala Thr Leu Thr Pro Glu Arg Asp Ala Tyr
 130 135 140
 Val Glu Ala Val Leu Ser Val Ser Asn Ala Ser Val Ala Gln Leu His
 145 150 155 160
 Thr Ala Gly Tyr Arg Arg Glu Phe Leu Glu Tyr His Arg Pro Pro Gly
 165 170 175
 Ala Leu His Thr Cys Gly Gly Pro Gly Ala Phe His Leu Ile Val His
 180 185 190
 Leu Lys Ala Gly Asp Ala Val Asn Val Val Val Thr Gly Gly Lys Leu
 195 200 205
 Ala His Thr Asp Phe Asp Glu Met Tyr Ser Thr Phe Ser Gly Val Phe

210 215 220

Leu Tyr Pro Phe Leu Ser His Leu
225 230

<210> 95
<211> 98
<212> PRT
<213> Homo sapiens

<400> 95
Met Ala Val Leu Pro Gly Pro Leu Gln Leu Leu Gly Val Leu Leu Thr
1 5 10 15
Ile Ser Leu Ser Ser Ile Arg Leu Ile Gln Ala Gly Ala Tyr Tyr Gly
20 25 30
Ile Lys Pro Leu Pro Pro Gln Ile Pro Pro Gln Met Pro Gln Ile
35 40 45
Pro Gln Tyr Gln Pro Leu Gly Gln Gln Val Pro His Met Pro Leu Ala
50 55 60
Lys Asp Gly Leu Ala Met Gly Lys Glu Met Pro His Leu Gln Tyr Gly
65 70 75 80
Lys Glu Tyr Pro His Leu Pro Gln Tyr Met Lys Glu Ile Gln Pro Ala
85 90 95
Val Asp

<210> 96
<211> 542
<212> PRT
<213> Homo sapiens

<400> 96
Met Gln Ala Cys Gly Gln Leu Cys Ser Gly Ala Pro Gly Glu Gln Asp
1 5 10 15
Ser Gln Val Ser Glu Ile Leu Ser Ala Leu Glu Arg Arg Val Leu Asp
20 25 30
Ser Glu Gly Gln Leu Arg Leu Val Gly Ser Gly Leu His Thr Val Glu
35 40 45
Ala Ala Gly Glu Ala Arg Gln Ala Thr Leu Glu Gly Leu Gln Glu Val
50 55 60
Val Gly Arg Leu Gln Asp Arg Val Asp Ala Gln Asp Glu Thr Ala Ala
65 70 75 80
Glu Phe Thr Leu Arg Leu Asn Leu Thr Ala Ala Arg Leu Gly Gln Leu
85 90 95
Glu Gly Leu Leu Gln Ala His Gly Asp Glu Gly Cys Gly Ala Cys Gly
100 105 110
Gly Val Gln Glu Glu Leu Gly Arg Leu Arg Asp Gly Val Glu Arg Cys
115 120 125
Ser Cys Pro Leu Leu Pro Pro Arg Gly Pro Gly Ala Gly Pro Gly Val

130					135					140					
Gly 145	Gly	Pro	Ser	Arg	Gly 150	Pro	Leu	Asp	Gly	Phe 155	Ser	Val	Phe	Gly 160	Gly
Ser	Ser	Gly	Ser	Ala 165	Leu	Gln	Ala	Leu	Gln 170	Gly	Glu	Leu	Ser	Glu 175	Val
Ile	Leu	Ser	Phe 180	Ser	Ser	Leu	Asn	Asp 185	Ser	Leu	Asn	Glu	Leu 190	Gln	Thr
Thr	Val	Glu 195	Gly	Gln	Gly	Ala	Asp 200	Leu	Ala	Asp	Leu	Gly 205	Ala	Thr	Lys
Asp	Arg	Ile 210	Ile	Ser	Glu	Ile 215	Asn	Arg	Leu	Gln	Gln 220	Glu	Ala	Thr	Glu
His	Ala	Thr	Glu	Ser	Glu 230	Glu	Arg	Phe	Arg	Gly 235	Leu	Glu	Glu	Gly	Gln 240
Ala	Gln	Ala	Gly	Gln 245	Cys	Pro	Ser	Leu	Glu 250	Gly	Arg	Leu	Gly	Arg 255	Leu
Glu	Gly	Val	Cys 260	Glu	Arg	Leu	Asp	Thr 265	Val	Ala	Gly	Gly	Leu 270	Gln	Gly
Leu	Arg	Glu 275	Gly	Leu	Ser	Arg	His 280	Val	Ala	Gly	Leu 285	Trp	Ala	Gly	Leu
Arg	Glu 290	Thr	Asn	Thr	Thr	Ser	Gln 295	Met	Gln	Ala	Ala 300	Leu	Leu	Glu	Lys
Leu	Val	Gly 305	Gly	Gln	Ala 310	Gly	Leu	Gly	Arg	Arg 315	Leu	Gly	Ala	Leu	Asn 320
Ser	Ser	Leu	Gln 325	Leu	Glu	Asp	Arg	Leu 330	His	Gln	Leu	Ser	Leu	Lys 335	
Asp	Leu	Thr	Gly 340	Pro	Ala	Gly	Glu	Ala 345	Gly	Pro	Pro	Gly	Pro 350	Pro	Gly
Leu	Gln	Gly 355	Pro	Pro	Gly	Pro	Ala 360	Gly	Pro	Pro	Gly	Ser 365	Pro	Gly	Lys
Asp	Gly 370	Gln	Glu	Gly	Pro	Ile 375	Gly	Pro	Pro	Gly	Pro 380	Gln	Gly	Glu	Gln
Gly	Val	Glu	Gly	Ala	Pro 390	Ala	Ala	Pro	Val	Pro 395	Gln	Val	Ala	Phe	Ser 400
Ala	Ala	Leu	Ser	Leu 405	Pro	Arg	Ser	Glu	Pro 410	Gly	Thr	Val	Pro	Phe	Asp 415
Arg	Val	Leu	Leu 420	Asn	Asp	Gly	Gly	Tyr 425	Tyr	Asp	Pro	Glu	Thr 430	Gly	Val
Phe	Thr	Ala 435	Pro	Leu	Ala	Gly	Arg 440	Tyr	Leu	Leu	Ser	Ala 445	Val	Leu	Thr
Gly	His	Arg	His	Glu	Lys 455	Val	Glu	Ala	Val	Leu	Ser 460	Arg	Ser	Asn	Gln
Gly	Val	Ala	Arg	Val	Asp 470	Ser	Gly	Gly	Tyr	Glu 475	Pro	Glu	Gly	Leu	Glu 480
Asn	Lys	Pro	Val	Ala 485	Glu	Ser	Gln	Pro	Ser 490	Pro	Gly	Thr	Leu	Gly 495	Val

Phe Ser Leu Ile Leu Pro Leu Gln Ala Gly Asp Thr Val Cys Val Asp
 500 505 510
 Leu Val Met Gly Gln Leu Ala His Ser Glu Glu Pro Leu Thr Ile Phe
 515 520 525
 Ser Gly Ala Leu Leu Tyr Gly Asp Pro Glu Leu Glu His Ala
 530 535 540

<210> 97
 <211> 333
 <212> PRT
 <213> Homo sapiens

<400> 97
 Met Arg Ile Trp Trp Leu Leu Leu Ala Ile Glu Ile Cys Thr Gly Asn
 1 5 10 15
 Ile Asn Ser Gln Asp Thr Cys Arg Gln Gly His Pro Gly Ile Pro Gly
 20 25 30
 Asn Pro Gly His Asn Gly Leu Pro Gly Arg Asp Gly Arg Asp Gly Ala
 35 40 45
 Lys Gly Asp Lys Gly Asp Ala Gly Glu Pro Gly Arg Pro Gly Ser Pro
 50 55 60
 Gly Lys Asp Gly Thr Ser Gly Glu Lys Gly Glu Arg Gly Ala Asp Gly
 65 70 75 80
 Lys Val Glu Ala Lys Gly Ile Lys Gly Asp Gln Gly Ser Arg Gly Ser
 85 90 95
 Pro Gly Lys His Gly Pro Lys Gly Leu Ala Gly Pro Met Gly Glu Lys
 100 105 110
 Gly Leu Arg Gly Glu Thr Gly Pro Gln Gly Gln Lys Gly Asn Lys Gly
 115 120 125
 Asp Val Gly Pro Thr Gly Pro Glu Gly Pro Arg Gly Asn Ile Gly Pro
 130 135 140
 Leu Gly Pro Thr Gly Leu Pro Gly Pro Met Gly Pro Ile Gly Lys Pro
 145 150 155 160
 Gly Pro Lys Gly Glu Ala Gly Pro Thr Gly Pro Gln Gly Glu Pro Gly
 165 170 175
 Val Arg Gly Ile Arg Gly Trp Lys Gly Asp Arg Gly Glu Lys Gly Lys
 180 185 190
 Ile Gly Glu Thr Leu Val Leu Pro Lys Ser Ala Phe Thr Val Gly Leu
 195 200 205
 Thr Val Leu Ser Lys Phe Pro Ser Ser Asp Val Pro Ile Lys Phe Asp
 210 215 220
 Lys Ile Leu Tyr Asn Glu Phe Asn His Tyr Asp Thr Ala Ala Gly Lys
 225 230 235 240
 Phe Thr Cys His Ile Ala Gly Val Tyr Tyr Phe Thr Tyr His Ile Thr
 245 250 255
 Val Phe Ser Arg Asn Val Gln Val Ser Leu Val Lys Asn Gly Val Lys

	260		265		270
Ile Leu His Thr Lys Asp Ala Tyr Met Ser Ser Glu Asp Gln Ala Ser	275	280		285	
Gly Gly Ile Val Leu Gln Leu Lys Leu Gly Asp Glu Val Trp Leu Gln	290	295	300		
Val Thr Gly Gly Glu Arg Phe Asn Gly Leu Phe Ala Asp Glu Asp Asp	305	310	315	320	
Asp Thr Thr Phe Thr Gly Phe Leu Leu Phe Ser Ser Pro	325	330			

<210> 98
 <211> 159
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (43)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (155)
 <223> Xaa equals any of the naturally occurring L-amino acids

Gln Glu Gly Ser Glu Pro Val Leu Leu Glu Gly Glu Cys Leu Val Val	1	5	10	15
Cys Glu Pro Gly Arg Ala Ala Ala Gly Gly Pro Gly Gly Ala Ala Leu	20	25	30	
Gly Glu Ala Pro Pro Gly Arg Val Ala Phe Xaa Ala Val Arg Ser His	35	40	45	
His His Glu Pro Ala Gly Glu Thr Gly Asn Gly Thr Ser Gly Ala Ile	50	55	60	
Tyr Phe Asp Gln Val Leu Val Asn Glu Gly Gly Gly Phe Asp Arg Ala	65	70	75	80
Ser Gly Ser Phe Val Ala Pro Val Arg Gly Val Tyr Ser Phe Arg Phe	85	90	95	
His Val Val Lys Val Tyr Asn Arg Gln Thr Val Gln Val Ser Leu Met	100	105	110	
Leu Asn Thr Trp Pro Val Ile Ser Ala Phe Ala Asn Asp Pro Asp Val	115	120	125	
Thr Arg Glu Ala Ala Thr Ser Ser Val Leu Leu Pro Leu Asp Pro Gly	130	135	140	
Asp Arg Val Ser Leu Arg Leu Arg Arg Gly Xaa Ser Thr Gly Trp	145	150	155	

<210> 99
 <211> 27
 <212> DNA

<213> Homo sapiens

<400> 99

gcggcaagct ttttgcaaag cctaggc

27

<210> 100

<211> 287

<212> PRT

<213> Homo sapiens

<400> 100

Pro Arg Val Arg Lys Glu Pro Glu Ala Met Gln Trp Leu Arg Val Arg
1 5 10 15Glu Ser Pro Gly Glu Ala Thr Gly His Arg Val Thr Met Gly Thr Ala
20 25 30Ala Leu Gly Pro Val Trp Ala Ala Leu Leu Leu Phe Leu Leu Met Cys
35 40 45Glu Ile Pro Met Val Glu Leu Thr Phe Asp Arg Ala Val Ala Ser Asp
50 55 60Cys Gln Arg Cys Cys Asp Ser Glu Asp Pro Leu Asp Pro Ala His Val
65 70 75 80Ser Ser Ala Ser Ser Ser Gly Arg Pro His Ala Leu Pro Glu Ile Arg
85 90 95Pro Tyr Ile Asn Ile Thr Ile Leu Lys Gly Asp Lys Gly Asp Pro Gly
100 105 110Pro Met Gly Leu Pro Gly Tyr Met Gly Arg Glu Gly Pro Gln Gly Glu
115 120 125Pro Gly Pro Gln Gly Ser Lys Gly Asp Lys Gly Glu Met Gly Ser Pro
130 135 140Gly Ala Pro Cys Gln Lys Arg Phe Phe Ala Phe Ser Val Gly Arg Lys
145 150 155 160Thr Ala Leu His Ser Gly Glu Asp Phe Gln Thr Leu Leu Phe Glu Arg
165 170 175Val Phe Val Asn Leu Asp Gly Cys Phe Asp Met Ala Thr Gly Gln Phe
180 185 190Ala Ala Pro Leu Arg Gly Ile Tyr Phe Phe Ser Leu Asn Val His Ser
195 200 205Trp Asn Tyr Lys Glu Thr Tyr Val His Ile Met His Asn Gln Lys Glu
210 215 220Ala Val Ile Leu Tyr Ala Gln Pro Ser Glu Arg Ser Ile Met Gln Ser
225 230 235 240Gln Ser Val Met Leu Asp Leu Ala Tyr Gly Asp Arg Val Trp Val Arg
245 250 255Leu Phe Lys Arg Gln Arg Glu Asn Ala Ile Tyr Ser Asn Asp Phe Asp
260 265 270Thr Tyr Ile Thr Phe Ser Gly His Leu Ile Lys Ala Glu Asp Asp
275 280 285

<210> 101
 <211> 162
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (1)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (33)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (48)
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 101
 Xaa Leu Trp Asp Pro Gly Leu Pro Gly Val Cys Arg Cys Gly Ser Ile
 1 5 10 15
 Val Leu Lys Ser Ala Phe Ser Val Gly Ile Thr Thr Ser Tyr Pro Glu
 20 25 30
 Xaa Arg Leu Pro Ile Ile Phe Asn Lys Val Leu Leu Pro Arg Gly Xaa
 35 40 45
 Ala Leu Gln Pro Cys His Arg Gly Ser Ser Ser Val Leu Ser Gln Gly
 50 55 60
 Ile Tyr Tyr Phe Ser Tyr Asp Ile Thr Leu Ala Asn Lys His Leu Ala
 65 70 75 80
 Ile Gly Leu Val His Asn Gly Gln Tyr Arg Ile Lys Thr Phe Asp Ala
 85 90 95
 Asn Thr Gly Asn His Asp Val Ala Ser Gly Ser Thr Val Ile Tyr Leu
 100 105 110
 Gln Pro Glu Asp Glu Val Trp Leu Glu Ile Phe Phe Thr Asp Gln Asn
 115 120 125
 Gly Leu Phe Ser Asp Pro Gly Trp Ala Asp Ser Leu Phe Ser Gly Phe
 130 135 140
 Leu Leu Tyr Val Asp Thr Asp Tyr Leu Asp Ser Ile Ser Glu Asp Asp
 145 150 155 160
 Glu Leu

<210> 102
 <211> 15
 <212> PRT
 <213> Homo sapiens

<400> 102
 Gly Ser Ile Val Leu Lys Ser Ala Phe Ser Val Gly Ile Thr Thr
 1 5 10 15

<210> 103
 <211> 14
 <212> PRT
 <213> Homo sapiens

<400> 103
 Gly Ile Tyr Tyr Phe Ser Tyr Asp Ile Thr Leu Ala Asn Lys
 1 5 10

<210> 104
 <211> 13
 <212> PRT
 <213> Homo sapiens

<400> 104
 Asp Ser Leu Phe Ser Gly Phe Leu Leu Tyr Val Asp Thr
 1 5 10

<210> 105
 <211> 13
 <212> PRT
 <213> Homo sapiens

<400> 105
 Asn His Asp Val Ala Ser Gly Ser Thr Val Ile Tyr Leu
 1 5 10

<210> 106
 <211> 126
 <212> PRT
 <213> Homo sapiens

<400> 106
 Ser Ala Phe Thr Val Ile Leu Ser Lys Ala Tyr Pro Ala Val Gly Ala
 1 5 10 15
 Pro Ile Pro Phe Asp Glu Ile Leu Tyr Asn Arg Gln Gln His Tyr Asp
 20 25 30
 Pro Arg Ser Gly Ile Phe Thr Cys Lys Ile Pro Gly Ile Tyr Tyr Phe
 35 40 45
 Ser Tyr His Ile His Val Lys Gly Thr His Val Trp Val Gly Leu Tyr
 50 55 60
 Lys Asn Gly Thr Pro Thr Met Tyr Thr Tyr Asp Glu Tyr Ser Lys Gly
 65 70 75 80
 Tyr Leu Asp Gln Ala Ser Gly Ser Ala Ile Met Glu Leu Thr Glu Asn
 85 90 95
 Asp Gln Val Trp Leu Gln Leu Pro Asn Ala Glu Ser Asn Gly Leu Tyr
 100 105 110
 Ser Ser Glu Tyr Val His Ser Ser Phe Ser Gly Phe Leu Val
 115 120 125

<210> 107
 <211> 126

<212> PRT

<213> Homo sapiens

<400> 107

```

Ser Ala Phe Ser Val Ala Val Thr Lys Ser Tyr Pro Arg Glu Arg Leu
 1           5           10           15
Pro Ile Lys Phe Asp Lys Ile Leu Met Asn Glu Gly Gly His Tyr Asn
          20           25           30
Ala Ser Ser Gly Lys Phe Val Cys Gly Val Pro Gly Ile Tyr Tyr Phe
          35           40           45
Thr Tyr Asp Ile Thr Leu Ala Asn Lys His Leu Ala Ile Gly Leu Val
          50           55           60
His Asn Gly Gln Tyr Arg Ile Arg Thr Phe Asp Ala Asn Thr Gly Asn
          65           70           75           80
His Asp Val Ala Ser Gly Ser Thr Ile Leu Ala Leu Lys Gln Gly Asp
          85           90           95
Glu Val Trp Leu Gln Ile Phe Tyr Ser Glu Gln Asn Gly Leu Phe Tyr
          100          105          110
Asp Pro Tyr Trp Thr Asp Ser Leu Phe Thr Gly Phe Leu Ile
          115          120          125

```